<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease - Abdelhamid, AS - 2020 | Cochrane Library</title> <meta content="Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease - Abdelhamid, AS - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease - Abdelhamid, AS - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003177.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease" name="citation_title"/> <meta content="Asmaa S Abdelhamid" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Tracey J Brown" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Julii S Brainard" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Priti Biswas" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Gabrielle C Thorpe" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Helen J Moore" name="citation_author"/> <meta content="Teesside University" name="citation_author_institution"/> <meta content="Katherine HO Deane" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Carolyn D Summerbell" name="citation_author"/> <meta content="Durham University" name="citation_author_institution"/> <meta content="Helen V Worthington" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="Fujian Song" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Lee Hooper" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="l.hooper@uea.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD003177.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/02/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003177.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Dietary Supplements; *Primary Prevention; *Secondary Prevention; Adiposity; Arrhythmias, Cardiac [epidemiology]; Cardiovascular Diseases [diet therapy, mortality, *prevention &amp; control]; Cause of Death; Coronary Disease [mortality]; Docosahexaenoic Acids [therapeutic use]; Eicosapentaenoic Acid [therapeutic use]; Fatty Acids, Omega‐3 [adverse effects, *therapeutic use]; Hemorrhage [epidemiology]; Pulmonary Embolism [epidemiology]; Randomized Controlled Trials as Topic; Regression Analysis; Stroke [epidemiology]; Treatment Outcome; alpha‐Linolenic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003177.pub5&amp;doi=10.1002/14651858.CD003177.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="sogqpCtr";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003177\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003177\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","fr","de","pt","ko","ja","hr","fa","pl","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003177.pub5",title:"Omega\\u20103 fatty acids for the primary and secondary prevention of cardiovascular disease",firstPublishedDate:"Feb 29, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003177.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003177.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003177.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003177.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003177.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003177.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003177.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003177.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003177.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003177.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>55606 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003177.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0167"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0056"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0057"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0085"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-sec-0161"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/appendices#CD003177-sec-0172"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/table_n/CD003177StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/table_n/CD003177StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0002">Asmaa S Abdelhamid</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0003">Tracey J Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0004">Julii S Brainard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0005">Priti Biswas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0006">Gabrielle C Thorpe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0007">Helen J Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0008">Katherine HO Deane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0009">Carolyn D Summerbell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0010">Helen V Worthington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0011">Fujian Song</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information#CD003177-cr-0012"><i class="icon corresponding-author fa fa-envelope"></i>Lee Hooper</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information/en#CD003177-sec-0193">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 February 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003177.pub5">https://doi.org/10.1002/14651858.CD003177.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003177-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003177-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003177-abs-0009">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003177-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003177-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003177-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003177-abs-0013">한국어</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003177-abs-0011">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003177-abs-0020">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003177-abs-0001" lang="en"> <section id="CD003177-sec-0001"> <h3 class="title" id="CD003177-sec-0001">Background</h3> <p>Omega‐3 polyunsaturated fatty acids from oily fish (long‐chain omega‐3 (LCn3)), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), as well as from plants (alpha‐linolenic acid (ALA)) may benefit cardiovascular health. Guidelines recommend increasing omega‐3‐rich foods, and sometimes supplementation, but recent trials have not confirmed this. </p> </section> <section id="CD003177-sec-0002"> <h3 class="title" id="CD003177-sec-0002">Objectives</h3> <p>To assess the effects of increased intake of fish‐ and plant‐based omega‐3 fats for all‐cause mortality, cardiovascular events, adiposity and lipids. </p> </section> <section id="CD003177-sec-0003"> <h3 class="title" id="CD003177-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE and Embase to February 2019, plus ClinicalTrials.gov and World Health Organization International Clinical Trials Registry to August 2019, with no language restrictions. We handsearched systematic review references and bibliographies and contacted trial authors. </p> </section> <section id="CD003177-sec-0004"> <h3 class="title" id="CD003177-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that lasted at least 12 months and compared supplementation or advice to increase LCn3 or ALA intake, or both, versus usual or lower intake. </p> </section> <section id="CD003177-sec-0005"> <h3 class="title" id="CD003177-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion, extracted data and assessed validity. We performed separate random‐effects meta‐analysis for ALA and LCn3 interventions, and assessed dose‐response relationships through meta‐regression. </p> </section> <section id="CD003177-sec-0006"> <h3 class="title" id="CD003177-sec-0006">Main results</h3> <p>We included 86 RCTs (162,796 participants) in this review update and found that 28 were at low summary risk of bias. Trials were of 12 to 88 months' duration and included adults at varying cardiovascular risk, mainly in high‐income countries. Most trials assessed LCn3 supplementation with capsules, but some used LCn3‐ or ALA‐rich or enriched foods or dietary advice compared to placebo or usual diet. LCn3 doses ranged from 0.5 g a day to more than 5 g a day (19 RCTs gave at least 3 g LCn3 daily). </p> <p>Meta‐analysis and sensitivity analyses suggested <b>little or no effect of increasing LCn3</b> on <b>all‐cause mortality</b> (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.93 to 1.01; 143,693 participants; 11,297 deaths in 45 RCTs; high‐certainty evidence), <b>cardiovascular mortality</b> (RR 0.92, 95% CI 0.86 to 0.99; 117,837 participants; 5658 deaths in 29 RCTs; moderate‐certainty evidence), <b>cardiovascular events</b> (RR 0.96, 95% CI 0.92 to 1.01; 140,482 participants; 17,619 people experienced events in 43 RCTs; high‐certainty evidence), <b>stroke</b> (RR 1.02, 95% CI 0.94 to 1.12; 138,888 participants; 2850 strokes in 31 RCTs; moderate‐certainty evidence) or <b>arrhythmia</b> (RR 0.99, 95% CI 0.92 to 1.06; 77,990 participants; 4586 people experienced arrhythmia in 30 RCTs; low‐certainty evidence). Increasing LCn3 may <b>slightly reduce coronary heart disease mortality (number needed to treat for an additional beneficial outcome (NNTB) 334</b> , RR 0.90, 95% CI 0.81 to 1.00; 127,378 participants; 3598 coronary heart disease deaths in 24 RCTs, low‐certainty evidence) and <b>coronary heart disease events</b> (<b>NNTB 167</b>, RR 0.91, 95% CI 0.85 to 0.97; 134,116 participants; 8791 people experienced coronary heart disease events in 32 RCTs, low‐certainty evidence). Overall, effects did not differ by trial duration or LCn3 dose in pre‐planned subgrouping or meta‐regression. There is little evidence of effects of eating fish. </p> <p><b>Increasing ALA</b> intake probably makes <b>little or no difference to all‐cause mortality</b> (RR 1.01, 95% CI 0.84 to 1.20; 19,327 participants; 459 deaths in 5 RCTs, moderate‐certainty evidence),<b>cardiovascular mortality</b> (RR 0.96, 95% CI 0.74 to 1.25; 18,619 participants; 219 cardiovascular deaths in 4 RCTs; moderate‐certainty evidence), <b>coronary heart disease mortality</b> (RR 0.95, 95% CI 0.72 to 1.26; 18,353 participants; 193 coronary heart disease deaths in 3 RCTs; moderate‐certainty evidence) and <b>coronary heart disease events</b> (RR 1.00, 95% CI 0.82 to 1.22; 19,061 participants; 397 coronary heart disease events in 4 RCTs; low‐certainty evidence). However, increased ALA may slightly <b>reduce risk of cardiovascular disease events</b> (<b>NNTB 500</b> , RR 0.95, 95% CI 0.83 to 1.07; but RR 0.91, 95% CI 0.79 to 1.04 in RCTs at low summary risk of bias; 19,327 participants; 884 cardiovascular disease events in 5 RCTs; low‐certainty evidence), and probably slightly reduces risk of <b>arrhythmia</b> (<b>NNTB 91</b> , RR 0.73, 95% CI 0.55 to 0.97; 4912 participants; 173 events in 2 RCTs; moderate‐certainty evidence). Effects on <b>stroke are unclear</b>. </p> <p>Increasing LCn3 and ALA had little or no effect on serious adverse events, adiposity, lipids and blood pressure, except increasing LCn3 reduced triglycerides by ˜15% in a dose‐dependent way (high‐certainty evidence). </p> </section> <section id="CD003177-sec-0007"> <h3 class="title" id="CD003177-sec-0007">Authors' conclusions</h3> <p>This is the most extensive systematic assessment of effects of omega‐3 fats on cardiovascular health to date. Moderate‐ and low‐certainty evidence suggests that increasing LCn3 slightly reduces risk of coronary heart disease mortality and events, and reduces serum triglycerides (evidence mainly from supplement trials). Increasing ALA slightly reduces risk of cardiovascular events and arrhythmia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003177-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003177-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003177-abs-0010">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003177-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003177-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003177-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003177-abs-0016">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003177-abs-0015">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003177-abs-0014">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003177-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003177-abs-0019">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003177-abs-0012">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003177-abs-0021">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003177-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003177-abs-0004" lang="en"> <h3>Omega‐3 intake for cardiovascular disease</h3> <p><b>Review question</b> </p> <p>We reviewed randomised trials (where participants have an equal chance of being assigned to either treatment) examining effects of increasing fish‐ and plant‐based omega‐3 fats on heart and circulatory disease (called cardiovascular diseases, which include heart attacks and stroke), fatness and blood fats (lipids, including cholesterol, triglycerides, high‐density lipoprotein (HDL – 'good' cholesterol) and low‐density lipoprotein (LDL – 'bad' cholesterol)). </p> <p><b>Background</b> </p> <p>The main types of omega‐3 fats are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both found in fish, and alpha‐linolenic acid (ALA) found in plant foods. Many people believe that taking omega‐3 supplements reduces risk of heart disease, stroke and death. </p> <p><b>Trial characteristics</b> </p> <p>The evidence is current to February 2019. The review included 86 trials involving 162,796 people. These trials assessed effects of greater omega‐3 intake versus lower omega‐3 intake for at least a year on heart and circulatory disease. Twenty‐eight trials were very trustworthy (well‐designed so as not to give biased results). Participants were adults, some with existing illness and some healthy, living in North America, Europe, Australia and Asia. Most EPA and DHA trials provided capsules, few gave oily fish. </p> <p><b>Key results</b> </p> <p>Increasing EPA and DHA has little or no effect on deaths and cardiovascular events (high‐certainty evidence) and probably makes little or no difference to cardiovascular death, stroke, or heart irregularities (moderate‐certainty evidence). However, increasing EPA and DHA may slightly reduce risk of coronary death and coronary events (low‐certainty evidence, coronary events are illnesses of arteries supplying the heart). To prevent one person having a coronary event, 167 people would need to increase their EPA and DHA, and 334 people would need to increase their EPA and DHA to prevent one person dying from coronary disease. EPA and DHA reduce triglycerides by about 15% but do not affect fatness or other lipids (high‐certainty evidence). </p> <p>Eating more ALA (for example, by increasing walnuts or enriched margarine) probably makes little or no difference to all‐cause, cardiovascular or coronary deaths or coronary events but probably slightly reduces cardiovascular events and heart irregularities (moderate‐ or low‐certainty evidence). To prevent one person having a coronary event, 500 people would need to increase their ALA, 91 people to prevent one person having arrhythmia. </p> <p>There is little evidence of effects of eating fish. EPA and DHA reduce triglycerides. EPA, DHA and ALA may be slightly protective of some heart and circulatory diseases. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003177-sec-0167" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003177-sec-0167"></div> <h3 class="title" id="CD003177-sec-0168">Implications for practice</h3> <section id="CD003177-sec-0168"> <p>We found high‐certainty evidence that long‐chain omega‐3 fats (LCn3) do not have important positive or negative effects on mortality or cardiovascular events and moderate‐certainty evidence that they have little or no effect on cardiovascular disease mortality, stroke or arrhythmia in primary or secondary prevention. However, we found low‐certainty evidence that LCn3 slightly reduces risk of coronary heart disease mortality (number needed to treat for an additional beneficial outcome (NNTB) 334, NNTB 200 in secondary prevention, NNTB 1000 in primary prevention), and coronary heart disease events (NNTB 167, NNTB 143 in secondary prevention, NNTB 200 in primary prevention). As these effects are very small (and numbers needed to treat for an additional benefit high), supplemental LCn3 fats are probably not useful for preventing or treating cardiovascular disease. LCn3 fats can help to reduce serum triglycerides, though they do not appear to affect body fatness or other lipid fractions. </p> <p>An NNTB of 167 means that 167 people will need to take LCn3 supplements for around four years each so that one of those people avoids a coronary heart disease event. The other 166 people receive no benefit. Similarly, an NNTB of 334 means that 334 people need to take LCn3 supplements for around four years each for one person to avoid death from coronary heart disease, the other 333 people do not benefit. </p> <p>How does an NNTB of 143 or 500 compare with effective medications in cardiovascular disease prevention? Could we compare, for example, with the use of statins in secondary prevention of myocardial infarction or ezetimibe added to statins after acute coronary syndrome? In the 4S trial (<a href="./references#CD003177-bbs2-0275" title="Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383‐9. ">Scandinavian Simvastatin Survival Study Group 1994</a>), 8% of the participants taking simvastatin died, and 12% of those taking the placebo died, a difference of 4%, so the NNTB was 25. Twenty‐five people needed to take simvastatin for around five years to prevent one person dying. Most of us decide to take statins post‐myocardial infarction. Ten‐year NNTBs for statins in primary prevention when used according to appropriate guidance are around 30, to prevent one case of atherosclerotic cardiovascular disease (<a href="./references#CD003177-bbs2-0266" title="MortensenMB , NordestgaardBG . Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat. JAMA Cardiology [Epub ahead of print]2019. [DOI: 10.1001/jamacardio.2019.3665] ">Mortensen 2019</a>). The IMPROVE‐IT trial showed that giving ezetimibe in addition to statin to 50 people with acute coronary syndrome for seven years each prevents one person from having a cardiovascular event (<a href="./references#CD003177-bbs2-0285" title="TurgeonRD , ZarnkeKB , AllanGM . Does ezetimibe modify clinical outcomes?. Canadian Family Physician Medecin de Famille Canadien2015;61(3):251. [PMC4369637] ">Turgeon 2015</a>). </p> <p>Individuals may make differing decisions about whether an NNTB of 143 is useful. Perhaps NNTBs should be noted on fish oil supplement packages: “If 143 people with existing cardiovascular disease take this supplement for 5 years each then one of those 143 people will avoid a coronary event (such as a heart attack). If 1000 people without existing cardiovascular disease take this supplement for 5 years each then one person will avoid dying from coronary heart disease”. Then each of us could decide whether this is the way we wish to spend our money, on omega‐3 supplements or a different cardiovascular treat such as a pair of running shoes, healthy fruit or fish, or a relaxation class. </p> <p>Most evidence on LCn3 fats came from trials of capsules of fish oil or eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) mixtures. While we did not see important differences between trials of supplemental capsules and trials of oily fish, there were few trials of oily fish. Fish and seafood are nutrient‐dense and rich in a variety of other nutrients (such as vitamin D, calcium, iodine, selenium) so are useful foods even without cardiovascular benefits. In light of the evidence in this review it would be appropriate to review official recommendations supporting supplemental LCn3 fatty acid intake. </p> <p>We found low‐certainty evidence that increasing ALA may slightly reduce risk of cardiovascular disease events (NNTB 500) and moderate‐certainty evidence that increasing ALA probably reduces risk of arrhythmia (NNTB 91). However, there is probably little or no effect on all‐cause or cardiovascular mortality, coronary heart disease mortality or coronary heart disease events (low‐ and moderate‐certainty evidence). As with LCn3, effects of ALA were very small; 91 people would need to increase their ALA intake to prevent one person developing arrhythmia, and 500 would need to take more ALA to prevent one person experiencing a cardiovascular disease event. We found no evidence that ALA affected adiposity or serum lipids. Trials of ALA gave ALA‐rich or enriched foods such as walnuts or ALA‐enriched margarine. </p> </section> <h3 class="title" id="CD003177-sec-0169">Implications for research</h3> <section id="CD003177-sec-0169"> <p>There are several large ongoing trials of supplemental LCn3 fats (see <a href="./references#CD003177-sec-0202" title="">Characteristics of ongoing studies</a>, and large parts of <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a> are ongoing). We suggest that given the minimal protective effects suggested for omega‐3 fats in the large number of trials to date, no further trials should be initiated until the ongoing trials have reported. Ongoing and completed trials should make data on baseline LCn3 intake, and details of deaths, cardiovascular outcomes, lipids, adiposity and blood pressure available, as well as other key health outcomes, regardless of their primary outcomes. </p> <p>Further large and high‐certainty trials of ALA carried out in lower‐ and higher‐income countries, and that assess baseline ALA intake and use biomarkers to assess compliance would be helpful to clarify the cardiovascular effects of ALA. Similarly trials of dietary fish would be helpful. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003177-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003177-sec-0050"></div> <div class="table" id="CD003177-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : adults with or without existing CVD<br/> <b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle‐income countries (Argentina, Iran, Turkey and China). No trials took place wholly in low‐ or low‐middle income countries.<br/> <b>Intervention</b> : higher intake of LCn3 fats<br/> <b>Comparison</b>: lower intake of LCn3 fats </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish or fish oils as a food, oil, made into a spreading fat, or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils, were also accepted. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lower LCn3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with higher LCn3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> – deaths<br/> Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/> (74 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.93 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143,693</p> <p>(45 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake makes little or no difference to risk of all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> – cardiovascular deaths<br/> Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/> (43 to 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117,837<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake probably makes little or no difference to risk of cardiovascular death</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular events</b> </p> <p>Assessed with number of participants experiencing any cardiovascular event</p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/> (118 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.92 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140,482<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake makes little or no difference to risk of cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality</b> – CHD deaths<br/> Assessed with coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (24 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.81 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127,378<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may slightly reduce CHD mortality (<b>NNTB 334</b>, 95% CI 200 to infinity; NNTB 1000 for primary prevention; NNTB 200 for secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease events</b> – CHD events<br/> Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (58 to 66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.85 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134,116<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may slightly reduce the risk of CHD events (<b>NNTB 167</b>, 95% CI 100 to 500; NNTB 200 for primary prevention; NNTB 143 for secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> <p>Assessed with number of participants experiencing at least 1 fatal or non‐fatal, ischaemic or haemorrhagic stroke </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (19 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.94 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138,888<br/> (31 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmias</b> </p> <p>Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (52 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.92 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,990<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may make little or no difference to risk of arrhythmia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: bleeding</b> </p> <p>Assessed with number of participants experiencing bleeding events</p> <p>Duration: range 12‐72 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per</b> 1000<br/> (14 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/> (0.91 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80,147<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of LCn3 fat intake on bleeding is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: pulmonary embolus or DVT</b> </p> <p>Assessed with number of participants experiencing pulmonary embolus or DVT</p> <p>Duration: range 18‐36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per</b> 1000<br/> (2 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/> (0.44 to 2.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3546<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of LCn3 fat intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CHD</b> : coronary heart disease; <b>CI</b> : confidence interval; <b>CVD:</b> cardiovascular disease; <b>DHA:</b> docosahexaenoic acid; <b>DVT</b> : deep vein thrombosis; <b>EPA:</b> eicosapentaenoic acid; <b>IHD</b> : ischaemic heart disease; <b>LCn3:</b> long‐chain omega‐3; <b>MI</b> : myocardial infarction; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><b>All‐cause mortality, long‐chain omega‐3 (LCn3)</b> </p> <p> <ul id="CD003177-list-0001"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (risk ratio (RR) 1.0) when analysis was limited to trials at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed‐effect meta‐analysis or results in the analysis limited to larger trials. It was further noted by the World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health that although many of the trials had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: tight confidence intervals, very large numbers of participants took part in long‐term randomised controlled trials (RCTs) with consistent results. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Cardiovascular mortality, LCn3</b> </p> <p> <ul id="CD003177-list-0002"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias and with fixed‐effect analysis (adding weight to the suggestion of little or no effect) but did not alter when the analyses were limited to trials at low risk of compliance bias or larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude important benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Cardiovascular events, LCn3</b> </p> <p> <ul id="CD003177-list-0003"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias (adding weight to the suggestion of little or no effect) but did not alter with fixed‐effect meta‐analysis or results in the analysis limited to larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: very large numbers of participants took part in long‐term RCTs with consistent results. Given the lack of an important effect in this very large set of participants, any effect appears too small to be individually relevant. The 95% confidence intervals excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Coronary heart disease mortality, LCn3</b> </p> <p> <ul id="CD003177-list-0004"> <li> <p><b>Risk of bias</b>: effect size more than 8% was retained when analysis was limited to trials at low summary risk of bias, low risk of compliance bias and larger trials. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. As 95% confidence intervals did not exclude lack of effect we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in the RR would rise. This weakens the suggestion of an effect. Downgraded once. </p> </li> </ul> </p> <p><sup>e</sup><b>Coronary heart disease events, LCn3</b> </p> <p> <ul id="CD003177-list-0005"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias, but increased when limiting trials to those at low risk of compliance problems and larger trials. There was a small protective effect in the main analysis and some sensitivity analyses, but not in sensitivity analyses limiting to RCTs at low summary risk of bias or using fixed‐effect analysis. The suggestion of a dose response in meta‐regression was lost when <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> data were omitted. We summarised this as suggesting a true effect of around 8%. This is on the borderline of little or no effect and a more than 8% effect. Downgraded twice. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence interval did not include the null. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: no suggestion from the funnel plot of publication bias. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Stroke, LCn3</b> </p> <p> <ul id="CD003177-list-0006"> <li> <p><b>Risk of bias</b>: effect size consistently suggested little or no effect for all sensitivity analyses. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: very large numbers of participants took part in long‐term RCTs with consistent results. Given the lack of a statistically significant effect in this very large set of participants any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important harms, we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot did not suggest any small trial bias. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Arrhythmias, LCn3</b> </p> <p> <ul id="CD003177-list-0007"> <li> <p><b>Risk of bias</b>: effect size remained similar in most sensitivity analyses, but suggested harm when limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals of the sensitivity analysis excluding trials at higher risk of bias included both harm and no effect, and there was a statistically significant difference in effect size between trials at low summary risk of bias and other trials, we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot not interpretable as trials all of a similar size and weight. Not downgraded. </p> </li> </ul> </p> <p><sup>h</sup><b>Bleeding, LCn3</b> </p> <p> <ul id="CD003177-list-0008"> <li> <p><b>Risk of bias</b>: effect size changed direction (from harmful to protective) when analysis limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude large and important benefits or harms. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>i</sup><b>Pulmonary embolus or DVD, LCn3</b> </p> <p> <ul id="CD003177-list-0009"> <li> <p><b>Risk of bias</b>: effect size suggested greater harm when analysis limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude large benefits or large harms. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003177-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High versus low alpha‐linolenic acid omega‐3 fats for preventing cardiovascular disease (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High versus low alpha‐linolenic omega‐3 fats for preventing cardiovascular disease (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adults with or without existing CVD </p> <p><b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle‐income countries (Argentina, Iran, Turkey and China). No trials took place in low‐ or low‐ to middle‐income countries.<br/> <b>Intervention</b> : higher intake of ALA<br/> <b>Comparison</b>: lower intake of ALA </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been refined ALA: linseed (flax); canola (rapeseed); perilla; purslane; mustard seed; candlenut; stillingia; or walnut, as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega‐3 fat content of at least 10% of the total fat content. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lower ALA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with higher ALA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> – deaths<br/> Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (20 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.84 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to risk of all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> – cardiovascular deaths<br/> Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known. </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (9 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.74 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,619<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to risk of cardiovascular mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular events</b> </p> <p>Assessed with number of participants experiencing any cardiovascular event</p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (39 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing ALA intake may slightly reduce the risk of cardiovascular events. (<b>NNTB 500</b>, 95% CI 125 to −334; NNTB 500 in primary prevention; NNTB 84 in secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality</b> – CHD deaths<br/> Assessed with: coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (8 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.72 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,353<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on risk of CHD mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease events</b><br/> Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (17 to 26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.82 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,061<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake may make little or no difference to CHD events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> <p>Assessed with: number of participants experiencing at least one fatal or non‐fatal, ischaemic or haemorrhagic stroke </p> <p>Duration: range 12 to 40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15<br/> (0.66 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on stroke is unclear as the evidence is of very low certainty</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmias</b> </p> <p>Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (22 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.55 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4912<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably slightlyreduces the risk of arrhythmias. (<b>NNTB 91</b>, 95% CI 56 to 1000; assessment by primary or secondary prevention not possible) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: bleeding</b> </p> <p>Assessed with number of participants experiencing bleeding events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The effect of ALA intake on bleeding is unclear as no trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: pulmonary embolus or DVT</b> </p> <p>Assessed with number of participants experiencing pulmonary embolus or DVT</p> <p>Duration: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per</b> 1000<br/> (0 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b><br/> (0.01 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>708<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALA</b> : alpha‐linolenic acid; <b>CHD</b> : coronary heart disease; <b>CI</b> : confidence interval; <b>DVT</b> : deep vein thrombosis; <b>IHD</b> : ischaemic heart disease; <b>MI</b> : myocardial infarction; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><b>All‐cause mortality, alpha‐linolenic acid (ALA)</b> </p> <p> <ul id="CD003177-list-0010"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main meta‐analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Cardiovascular mortality, ALA</b> </p> <p> <ul id="CD003177-list-0011"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis, or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in RCTs in long‐term trials with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Cardiovascular events, ALA</b> </p> <p> <ul id="CD003177-list-0012"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis, with larger trials and in fixed‐effect analysis, and a 9%‐10% reduction in risk when data were limited to RCTs at low summary risk of bias or at low risk from compliance problems. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals do not exclude important benefits we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Coronary heart disease mortality, ALA</b> </p> <p> <ul id="CD003177-list-0013"> <li> <p><b>Risk of bias</b>: all sensitivity analyses suggested little or no effect. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>e</sup><b>Coronary heart disease events, ALA</b> </p> <p> <ul id="CD003177-list-0014"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analyses, in fixed‐effect meta‐analysis, in larger trials or when limiting to trials at low risk of compliance bias, but some risk reduction (9%) when data were limited to RCTs at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Stroke, ALA</b> </p> <p> <ul id="CD003177-list-0015"> <li> <p><b>Risk of bias</b>: the main analysis, fixed‐effect analysis, and larger trials suggest increased risk of stroke with more ALA, but there was little or no effect when data were limited to RCTs at low summary risk of bias, and a suggestion of benefit when limited to trials with low risk of compliance problems. Downgraded twice. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: only 49 participants experienced strokes in the included trials; 95% confidence intervals do not exclude important benefits or harms, downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Arrhythmias, ALA</b> </p> <p> <ul id="CD003177-list-0016"> <li> <p><b>Risk of bias</b>: increasing ALA reduced the risk of arrhythmia in the main analysis, and also in all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: two trials, which included adults with previous myocardial infarction or successful cardioversion in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: as 95% confidence intervals do not exclude little or no effect we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>h</sup><b>Pulmonary embolus or DVD, ALA</b> </p> <p> <ul id="CD003177-list-0017"> <li> <p><b>Risk of bias</b>: the single trial was not at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: with one trial no inconsistency. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: healthy men and women, no participants with CVD risk factors or previous CVD; low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: only one event included in a single trial. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003177-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low omega‐3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>High versus low omega‐3 fats for modification of CVD risk factors (adiposity and lipids)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b>: adults with or without existing CVD </p> <p><b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle income countries. No trials took place in low‐ or low‐middle income countries. </p> <p><b>Intervention</b> : higher omega‐3 intake (LCn3 or ALA)<br/> <b>Comparison</b>: lower omega‐3 intake (LCn3 or ALA) </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish; fish oils; linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega‐3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or ALAs, or concentrated fish or algal oils, were also accepted. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> <p><b>All in trials of 12 to 72 months' duration</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low omega‐3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high omega‐3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, LCn3 ‐ weight, kg </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean body weight was 81.2 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 kg lower<br/> (0.69 lower to 0.70 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,000<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to body weight</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, LCn3 ‐ BMI, kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BMI was 27.3 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/> (0.14 lower to 0.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,474<br/> (15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to BMI</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum total cholesterol,</b> LCn3 – TC, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TC was 5.61 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/> (0.05 lower to 0.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,469<br/> (30 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to serum TC</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum triglyceride</b>,LCn3 ‐ fasting TG, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TG was 1.59 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.24 lower<br/> (0.31 lower to 0.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,998<br/> (27 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 intake reduces serum TG by about 0.24 mmol/L or 15%</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum high‐density lipoprotein</b>, LCn3 – HDL, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HDL was 1.32 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (0.01 to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46,604<br/> (30 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 intake has little or no effect on serum HDL</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum low‐density lipoprotein</b>, LCn3 – LDL, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean LDL was 3.27 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/> (0.01 lower to 0.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,454<br/> (25 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to serum LDL.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, ALA – weight, kg </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean weight was 80.9 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.49 lower<br/> (4.17 lower to 1.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>664<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> Very low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on body weight is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, ALA – BMI, kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BMI was 27.4 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.42 lower<br/> (1.53 lower to 0.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1581<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on BMI is unclear as the evidence is of very low certainty</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum total cholesterol</b>, ALA – TC, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TC was 5.02 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/> (0.23 lower to 0.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2164<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake may make little or no difference to serum TC</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum triglyceride</b>, ALA ‐ fasting TG, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TG was 1.48 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 lower<br/> (0.11 lower to 0.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1776<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to serum TG</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum high‐density lipoprotein</b>, ALA – HDL, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HDL was 1.49 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 lower<br/> (0.08 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1776<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on serum HDL</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum low‐density lipoprotein</b>, ALA – LDL, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean LDL was 2.88 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 lower<br/> (0.15 lower to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2201<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on serum LDL</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALA</b> : alpha‐linolenic acid; <b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>DHA:</b> docosahexaenoic acid; <b>EPA:</b> eicosapentaenoic acid; <b>HDL</b> : high‐density lipoprotein; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>LDL</b> : low‐density lipoprotein; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>TC</b> : total cholesterol; <b>TG</b>: triglycerides </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup><b>Measures of adiposity, weight, long‐chain omega‐3 (LCn3)</b> </p> <p> <ul id="CD003177-list-0018"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term randomised controlled trials (RCTs) with consistent results; 95% confidence intervals exclude important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Measures of adiposity, body mass index (BMI), LCn3</b> </p> <p> <ul id="CD003177-list-0019"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. 95% confidence intervals exclude important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Lipids, serum total cholesterol, LCn3</b> </p> <p> <ul id="CD003177-list-0020"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: the 95% CI excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot did not suggest clear small trial bias. However, we are aware of several trials whose data could not be included; not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Lipids, serum triglycerides, LCn3</b> </p> <p> <ul id="CD003177-list-0021"> <li> <p><b>Risk of bias</b>: there was a greater than 5% (and statistically significant) effect overall and in all sensitivity analyses, including when data were limited to RCTs at low summary risk of bias. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. 95% confidence intervals exclude harm and lack of effect. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but results of fixed‐effect and random‐effects analyses were similar, suggesting little small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>e</sup><b>Lipids, high‐density lipoprotein (HDL), LCn3</b> </p> <p> <ul id="CD003177-list-0022"> <li> <p><b>Risk of bias</b>: the suggested little or no effect (less than 5% increase) in HDL with increased LCn3 was apparent in all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals exclude harms or benefits. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot suggested no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Lipids, low‐density lipoprotein (LDL), LCn3</b> </p> <p> <ul id="CD003177-list-0023"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot did not suggest clear small trial bias, and results of fixed‐effect and random‐effects analyses were similar. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Measures of adiposity, weight, alpha‐linolenic acid (ALA)</b> </p> <p> <ul id="CD003177-list-0024"> <li> <p><b>Risk of bias</b>: no included trials were at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals included both benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but effects in fixed‐effect and random‐effects meta‐analysis were different suggesting that small trial bias may be present. We are aware of several trials whose data could not be included. Downgraded once. </p> </li> </ul> </p> <p><sup>h</sup><b>Measures of adiposity, BMI, ALA</b> </p> <p> <ul id="CD003177-list-0025"> <li> <p><b>Risk of bias</b>: the main analysis and some sensitivity analyses suggested that ALA reduced BMI, but this was not seen when trials were limited to those at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals include benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but effects of fixed‐effect and random‐effects analyses were distinct, suggesting some small trial bias. We are aware of several trials whose data could not be included. Downgraded once. </p> </li> </ul> </p> <p><sup>i</sup><b>Lipids, serum total cholesterol, ALA</b> </p> <p> <ul id="CD003177-list-0026"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: the main analysis included both benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias, fixed‐effect and random‐effects meta‐analysis suggested similar effects. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>j</sup><b>Lipids, serum triglycerides, ALA</b> </p> <p> <ul id="CD003177-list-0027"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals included benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias and fixed‐effect and random‐effects analysis results were similar. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>k</sup><b>Lipids, HDL, ALA</b> </p> <p> <ul id="CD003177-list-0028"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis and all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence interval includes harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, effects of fixed‐effect and random‐effects meta‐analysis was very similar suggesting lack of small trial bias. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>l</sup><b>Lipids, LDL, ALA</b> </p> <p> <ul id="CD003177-list-0029"> <li> <p><b>Risk of bias</b>: little or no effect in main analysis and all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: for main analysis 95% confidence interval included benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, effects of fixed‐effect and random‐effects meta‐analysis were similar suggesting no small trial bias. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003177-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003177-sec-0051"></div> <section id="CD003177-sec-0052"> <h3 class="title" id="CD003177-sec-0052">Description of the condition</h3> <p>Cardiovascular diseases are disorders of the heart and blood vessels. They comprise cerebrovascular disease (including stroke and transient ischaemic attack), coronary heart disease (including heart attack or myocardial infarction and angina), peripheral arterial disease (diseases of the blood vessels to the arms and legs), deep vein thrombosis and pulmonary embolism (blood clots formed in the legs which can move to the heart and lungs), as well as rheumatic and congenital heart disease (<a href="./references#CD003177-bbs2-0289" title="World Health Organization. Cardiovascular Diseases (CVDs). Fact sheets; May 2017. www.who.int/mediacentre/factsheets/fs317/en (accessed 24 November 2017). ">WHO 2017</a>); these last two are not discussed in this review. Globally, 31% of all deaths are due to cardiovascular disease, more than from any other cause (<a href="./references#CD003177-bbs2-0289" title="World Health Organization. Cardiovascular Diseases (CVDs). Fact sheets; May 2017. www.who.int/mediacentre/factsheets/fs317/en (accessed 24 November 2017). ">WHO 2017</a>). Of the estimated 17.7 million people who died from cardiovascular diseases in 2015, around 7.4 million were due to coronary heart disease and 6.7 million due to stroke. Of 17 million premature deaths in 2015 caused by non‐communicable diseases, 82% were in low‐ and middle‐income countries, and 37% were caused by cardiovascular diseases (<a href="./references#CD003177-bbs2-0289" title="World Health Organization. Cardiovascular Diseases (CVDs). Fact sheets; May 2017. www.who.int/mediacentre/factsheets/fs317/en (accessed 24 November 2017). ">WHO 2017</a>). </p> </section> <section id="CD003177-sec-0053"> <h3 class="title" id="CD003177-sec-0053">Description of the intervention</h3> <p>Omega‐3 fats (also called Ω3 or n‐3 fats) from fish sources include eicosapentaenoic acid (EPA, or 20:5), docosahexaenoic acid (DHA, 22:6) and docosapentaenoic acid (DPA, 22:5); these are long‐chain omega‐3 fats (LCn3). Alpha‐linolenic acid (ALA or α‐linolenic, 18:3) is the short‐chain omega‐3 fat found in plants and grass‐fed meat, which is partially converted to LCn3 fatty acids within our bodies. There is some debate about the effectiveness of this conversion, which may differ depending on whether it is assessed over the short or long term as well as on other dietary factors (<a href="./references#CD003177-bbs2-0262" title="LiD , SinclairA , WilsonA , NakkoteS , KellyF , AbedinL , et al. Effect of dietary alpha‐linolenic acid on thrombotic risk factors in vegetarian men. American Journal of Clinical Nutrition1999;69:872‐82. ">Li 1999</a>; <a href="./references#CD003177-bbs2-0271" title="PawloskyRJ , HibbelnJR , NovotnyJA , SalemNJr . Physiological compartmental analysis of alpha‐linolenic acid metabolism in adult humans. Journal of Lipid Research2001;42:1257‐65. ">Pawlosky 2001</a>). For this reason the effectiveness of ALA may differ from that of the LCn3 fats. </p> <p>Since Bang and colleagues first suggested that the abundance of omega‐3 fatty acids in the diet of the Greenland Inuit people was responsible for their low mortality from ischaemic heart disease (<a href="./references#CD003177-bbs2-0220" title="BangHO , DyerbergJ . Plasma lipids and lipoproteins in Greenlandic West Coast Eskimos. Acta Medica Scandinavica1972;192:85‐94. ">Bang 1972</a>; <a href="./references#CD003177-bbs2-0221" title="BangHO , DyerbergJ , HjorneN . The composition of food consumed by Greenland Eskimos. Acta Medica Scandinavica1976;200:69‐73. ">Bang 1976</a>), there has been considerable interest in the protective role and possible mechanism of action of marine unsaturated fats. This interest has spread to encompass plant seeds and oils rich in ALA, including chia seed, flax (linseed) and rapeseed (canola) oils (<a href="./references#CD003177-bbs2-0267" title="NettletonJA . Omega‐3 fatty acids: comparison of plant and seafood sources in human nutrition. Journal of the American Dietetic Association1991;91:331‐7. ">Nettleton 1991</a>), their derivatives (e.g. margarines), purslane leaves (<a href="./references#CD003177-bbs2-0280" title="SimopoulosAP , NormanHA , GillaspyJE , DukeJA . Common purslane: a source of omega‐3 fatty acids and antioxidants. Journal of the American College of Nutrition1992;11(4):374‐82. ">Simopoulos 1992</a>), and nuts (especially walnuts). </p> </section> <section id="CD003177-sec-0054"> <h3 class="title" id="CD003177-sec-0054">How the intervention might work</h3> <p>Proposed mechanisms for the protective role of omega‐3 fats against cardiovascular diseases include: lowering the blood pressure; altering the lipid profile, especially reduced serum triglyceride concentration; modulating arterial lipoprotein lipase levels; reducing thrombotic tendency; producing anti‐inflammatory effects and anti‐arrhythmic effects; improving vascular endothelial function and insulin sensitivity; and increasing plaque stability and paraoxonase levels (<a href="./references#CD003177-bbs2-0223" title="BhatnagarD , DurringtonPN . Omega‐3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. International Journal of Clinical Practice2003;57(4):305‐14. ">Bhatnagar 2003</a>; <a href="./references#CD003177-bbs2-0225" title="British Nutrition Foundation. N‐3 fatty acids and health. London: British Nutrition Foundation; 1999. Briefing paper. ">BNF 1999</a>; <a href="./references#CD003177-bbs2-0232" title="CalabresiL , VillaB , CanavesiM , SirtoriCR , JamesRW , BerniniF , et al. An omega‐3 polyunsaturated fatty acid concentrate increases plasma high‐density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism2004;53(2):153‐8. ">Calabresi 2004</a>; <a href="./references#CD003177-bbs2-0234" title='ChangCL , DeckelbaumRJ . Omega‐3 fatty acids: mechanisms underlying "protective effects" in atherosclerosis. Current Opinion in Lipidology2013;24(4):345‐50. [DOI: 10.1097/MOL.0b013e3283616364] '>Chang 2013</a>; <a href="./references#CD003177-bbs2-0241" title="GeelenA , BrouwerIA , ZockPL , KatanMB . Antiarrhythmic effects of n‐3 fatty acids: evidence from human studies. Current Opinion in Lipidology2004;15:25‐30. ">Geelen 2004</a>). </p> <p>Given that most omega‐3 fats are ingested in the form of oily fish or fish oil (often fish liver) capsules, reports of high levels of various toxic compounds such as mercury, dioxins and polychlorinated biphenyls (PCBs) in oily fish and fish oils are concerning (<a href="./references#CD003177-bbs2-0226" title="BourdonJA , BazinetTM , ArnasonTT , KimpeLE , BlaisJM , WhitePA . Polychlorinated biphenyls (PCBs) contamination and aryl hydrocarbon receptor (AhR) agonist activity of omega‐3 polyunsaturated fatty acid supplements: implications for daily intake of dioxins and PCBs. Food and Chemical Toxicology2010;48(11):3093‐7. ">Bourdon 2010</a>; <a href="./references#CD003177-bbs2-0240" title="Food Standards Agency UK. Dioxins and PCBs in the UK diet: 1997 total diet study samples. Food Surveillance Information Sheet. Number 4/00; 2000. [FSIS 4/00] ">FSA 2000</a>; <a href="./references#CD003177-bbs2-0261" title="LevineKE , LevineMA , WeberFX , HuY , PerlmutterJ , GrohsePM . Determination of mercury in an assortment of dietary supplements using an inexpensive combustion atomic absorption spectrometry technique. Journal of Automated Methods &amp; Management in Chemistry2005;2005(4):211‐6. ">Levine 2005</a>; <a href="./references#CD003177-bbs2-0263" title="LiemAK , TheelenRM . Dioxins: Chemical Analysis, Exposure and Risk Assessment. Utrecht: Universiteit Utrecht, 1997. [ISBN 90 393 2012 8] ">Liem 1997</a>; <a href="./references#CD003177-bbs2-0264" title="MAFFUK . Concentrations of metals and other elements in marine fish and shellfish. Food Surveillance Information Sheet no.151; 1998. [FSIS 151] ">MAFF 1998A</a>; <a href="./references#CD003177-bbs2-0273" title="Scientific Advisory Committee on Nutrition, Committee on Toxicity. Advice on fish consumption: benefits &amp; risks. London, United Kingdom: Her Majesty's Stationary Office, 2004. ">SACN COT 2004</a>; <a href="./references#CD003177-bbs2-0286" title="USFood , DrugAdministration . What you need to know about mercury in fish and shellfish. www.fda.gov/food/foodborneillnesscontaminants/metals/ucm351781.htm(accessed May 2018). ">USFDA 1995</a>). These are all fat soluble and accumulate over time in the body, so harm may be exhibited only after long‐term fish consumption or supplementation with fish oils. Animal intervention trials and human cohorts who have suffered accidental exposure to dioxins and PCBs suggest that pre‐natal exposure may cause sub‐fertility problems, and adult exposures may lead to an excess of total cancers (<a href="./references#CD003177-bbs2-0254" title="Joint FAO/WHO Expert Committee on Food Additives. Summary of the fifty‐seventh meeting of JEFCA, 2001. apps.who.int/iris/bitstream/handle/10665/42578/WHO_TRS_909.pdf?sequence=1. ">JECFA 2001</a>). Human cohorts exposed to high levels of mercury exhibit neurological problems (<a href="./references#CD003177-bbs2-0286" title="USFood , DrugAdministration . What you need to know about mercury in fish and shellfish. www.fda.gov/food/foodborneillnesscontaminants/metals/ucm351781.htm(accessed May 2018). ">USFDA 1995</a>). As many people eat oily fish once or twice a week or take fish oil supplements, it is important to explore the potentially harmful effects of fish‐associated omega‐3 intake. It is also possible that omega‐3 fats themselves may exhibit harm, for example through extension of bleeding times or suppression of normal immune responses (<a href="./references#CD003177-bbs2-0287" title="USFood , DrugAdministration . Center for Food Safety and Applied Nutrition, Office of Nutritional Products. Labeling, and dietary supplements: letter regarding dietary supplement health claim for omega‐3 fatty acids and coronary heart disease (docket No. 91N‐0103). www.fda.gov/Food/LabelingNutrition/ucm073992.htm#cardio2004. ">USFDA 2000</a>). </p> <p>Cardiovascular effects of eating more oily fish may differ from those of taking a fish oil supplement because fish (not fish oil) is a rich source of nutrients including selenium, iodine, zinc, calcium and protein. Fish in the diet may also displace a variety of other foods including sources of saturated or trans fats, so it could alter cardiovascular disease risk in other ways. </p> </section> <section id="CD003177-sec-0055"> <h3 class="title" id="CD003177-sec-0055">Why it is important to do this review</h3> <p>There is a great deal of public belief in the cardiovascular benefits of omega‐3 fats. Analysis of US National Health and Nutrition Examination Survey data from 2003 to 2008 suggests that in the USA, adults' mean LCn3 intakes were greater from dietary supplements (0.72 g/d EPA and DHA) than from foods (0.41 g/d, <a href="./references#CD003177-bbs2-0270" title="PapanikolaouY , BrooksJ , ReiderC , FulgoniVL . U.S. adults are not meeting recommended levels for fish and omega‐3 fatty acid intake: results of an analysis using observational data from NHANES 2003–2008. Nutrition Journal2014;13:31. [DOI: 10.1186/1475‐2891‐13‐31] ">Papanikolaou 2014</a>). But public health advice differs across countries. For example, the National Institute for Health and Clinical Excellence in the UK now encourages fish intake but discourages supplementation: "people with or at high risk of CVD [cardiovascular disease] should be advised to consume at least 2 portions of fish per week, including a portion of oily fish". However, it advises that omega‐3 fatty acid compounds "should not be offered for primary or secondary prevention of CVD [cardiovascular disease]" (<a href="./references#CD003177-bbs2-0268" title="NICE . Cardiovascular disease: risk assessment and reduction, including lipid modification clinical guideline [CG181]. www.nice.org.uk/guidance/cg181 July 2014, last updated September 2016. ">NICE 2016</a>). The American Heart Association (AHA) also "recommends eating fish (particularly fatty fish) at least two times (two servings) a week". Although the AHA suggests that omega‐3 intake via foods is preferable, it is more positive about omega‐3 supplements: "those with coronary artery disease may not get enough omega‐3 by diet alone. These people may want to talk to their doctor about supplements" (<a href="./references#CD003177-bbs2-0216" title="American Heart Association. Fish and Omega‐3 Fatty Acids. www.heart.org/HEARTORG/HealthyLiving/HealthyEating/HealthyDietGoals/Fish‐and‐Omega‐3‐Fatty‐Acids_UCM_303248_Article.jsp#.WhfuRzenzIU (accessed 24 November 2017). ">AHA 2016</a>). These recommendations are balanced with a warning about potential excessive bleeding in those taking doses of more than 3 g/d omega‐3 fatty acids (presumably LCn3 fats). The AHA have issued updated guidelines on use of omega‐3 fats to treat raised triglycerides, suggesting that "prescription n‐3 FAs [fatty acids, meaning LCn3] (EPA+DHA or EPA‐only) at a dose of 4 g/d (&gt;3 g/d total EPA+DHA) are an effective and safe option for reducing triglycerides as monotherapy or as an adjunct to other lipid‐lowering agents" (<a href="./references#CD003177-bbs2-0281" title="Skulas‐RayAC , WilsonPW , HarrisWS , BrintonEA , Kris‐EthertonPM , RichterCK , et al. Omega‐3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation2019;140:e673‐e691. [DOI: 10.1161/CIR.0000000000000709] ">Skulas‐Ray 2019</a>). Such recommendations, and resulting increased fish consumption, have potentially negative long‐term consequences for our marine ecosystems (<a href="./references#CD003177-bbs2-0229" title="BrunnerEJ , JonesPJ , FrielS , BartleyM . Fish, human health and marine ecosystem health: policies in collision. International Journal of Epidemiology2009;38(1):93‐100. [DOI: 10.1093/ije/dyn157] ">Brunner 2009</a>). </p> <p>Epidemiological trials have supported the relationship between high omega‐3 intake and lower cardiovascular disease rates (<a href="./references#CD003177-bbs2-0219" title="Ballard‐BarbashR , CallawayCW . Marine fish oils: role in prevention of coronary artery disease. Mayo Clinic Proceedings1987;62:113‐8. ">Ballard‐Barbash 1987</a>; <a href="./references#CD003177-bbs2-0230" title="BurrML . Fish and ischaemic heart disease. World Review of Nutrition and Dietetics1993;72:49‐60. ">Burr 1993</a>; <a href="./references#CD003177-bbs2-0257" title="Kris‐EthertonPM , HarrisWS , AppelLJ , for the Nutrition Committee of the American Heart Association. Fish consumption, fish oil, omega 3 fatty acids, and cardiovascular disease. Circulation2002;106:2747‐57. ">Kris‐Etherton 2002</a>). However, these associations could be due to other characteristics of people who choose to eat fish. In many societies eating fish is associated with better social status and a health‐conscientious life view (<a href="./references#CD003177-bbs2-0231" title="CadeJE , BurleyVJ , GreenwoodDC , UK Women's Cohort Study Steering Group. The UK Women's Cohort Study: comparison of vegetarians, fish‐eaters and meat‐eaters. Public Health Nutrition2007;7(7):871‐8. [DOI: 10.1079/PHN2004620] ">Cade 2007</a>), so eating fish is highly confounded by dietary quality, socioeconomic status and other markers of healthy lifestyles. As an example, the global attributable burden of eating a diet low in seafood omega‐3 fats was estimated as 1.1% of global disability‐adjusted life‐years (DALYs; 95% confidence interval (CI) 0.8 to 1.5), "with 22% of ischaemic heart disease DALYs attributable to low seafood intake" (<a href="./references#CD003177-bbs2-0239" title="EngellRE , SanmanE , LimSS , MozaffarianD . Seafood omega‐3 intake and risk of coronary heart disease death: an updated meta‐analysis with implications for attributable burden. Lancet2013;381(Special Issue):S45. [DOI: 10.1016/S0140‐6736(13)61299‐4] ">Engell 2013</a>). The data sources are not described, but when the estimate was derived from randomised controlled trials (RCTs) alone, rather than cohort trials and RCTs combined, the estimated global attributable burden was much smaller, 0.5% (95% CI −0.5 to 1.4). Information concerning cause and effect is more reliably supplied by intervention trials in which participants are randomly allocated to receive fish oil or advice to eat more fish. </p> <p>Systematic reviews of RCTs have had various findings. A recent version of this review (<a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>), included 79 long‐term RCTs and more than 112,000 participants, finding no effects of omega‐3 fats on all‐cause mortality or cardiovascular outcomes. Other systematic reviews have suggested a lack of effect for omega‐3 fats on all‐cause mortality or a variety of cardiovascular diseases (<a href="./references#CD003177-bbs2-0233" title="CampbellA , PriceJ , HiattWR . Omega‐3 fatty acids for intermittent claudication. Cochrane Database of Systematic Reviews2013, Issue 7. [DOI: 10.1002/14651858.CD003833.pub4] ">Campbell 2013</a>; <a href="./references#CD003177-bbs2-0235" title="ChowdhuryR , StevensS , GormanD , PanA , WarnakulaS , ChowdhuryS , et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta‐analysis. BMJ2012;345(7881):e6698. ">Chowdhury 2012</a>; <a href="./references#CD003177-bbs2-0255" title="KhoueiryG , Abi RafehN , SullivanE , SaifulF , JafferyZ , KenigsbergDN , et al. Do omega‐3 polyunsaturated fatty acids reduce risk of sudden cardiac death and ventricular arrhythmias? A meta‐analysis of randomized trials. Heart &amp; Lung2013;42(4):251‐6. ">Khoueiry 2013</a>; <a href="./references#CD003177-bbs2-0256" title="KotwalS , JunM , SullivanD , PerkovicV , NealB . Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta‐analysis. Circulation. Cardiovascular Quality and Outcomes2012;5(6):808‐18. ">Kotwal 2012</a>; <a href="./references#CD003177-bbs2-0258" title="KwakSM , MyungSK , LeeYJ , SeoHG . Efficacy of omega‐3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials. Archives of Internal Medicine2012;172(9):686‐94. ">Kwak 2012</a>; <a href="./references#CD003177-bbs2-0265" title="MarianiJ , DovalHC , NulD , VariniS , GrancelliH , FerranteD , et al. N‐3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta‐analysis of randomized controlled trials. Journal of the American Heart Association2013;2(1):e005033. ">Mariani 2013</a>; <a href="./references#CD003177-bbs2-0272" title="RizosEC , NtzaniEE , BikaE , KostapanosMS , ElisafMS . Association between omega‐3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta‐analysis. JAMA2012;308(10):1024‐33. ">Rizos 2012</a>; <a href="./references#CD003177-bbs2-0293" title="ZhengT , ZhaoJ , WangY , LiuW , WangZ , ShangY , et al. The limited effect of omega‐3 polyunsaturated fatty acids on cardiovascular risk in patients with impaired glucose metabolism: a meta‐analysis. Clinical Biochemistry2014;47(6):369‐77. ">Zheng 2014</a>). However, some reviews have highlighted particular outcomes or circumstances in which cardiovascular disease prevention was evident: after heart surgery (<a href="./references#CD003177-bbs2-0246" title="HeZ , YangL , TianJ , YangK , WuJ , YaoY . Efficacy and safety of omega‐3 fatty acids for the prevention of atrial fibrillation: a meta‐analysis. Canadian Journal of Cardiology2013;29(2):196‐203. ">He 2013</a>), for preventing sudden cardiac death (<a href="./references#CD003177-bbs2-0292" title="ZhaoYT , ChenQ , SunYX , LiXB , ZhangP , XuY , et al. Prevention of sudden cardiac death with omega‐3 fatty acids in patients with coronary heart disease: a meta‐analysis of randomized controlled trials. Annals of Medicine2009;41(4):301‐10. ">Zhao 2009</a>), for reducing cardiovascular disease mortality and sudden cardiac death, although with no effect on all‐cause mortality (<a href="./references#CD003177-bbs2-0284" title="TrikalinosTA , MoorthyD , ChungM , YuWW , LeeJ , LichtensteinAH , et al. Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient‐disease associations. Journal of Clinical Epidemiology2012;65(1):16‐29. ">Trikalinos 2012</a>), for cardiovascular disease mortality (<a href="./references#CD003177-bbs2-0278" title="SethiA , BajajA , KhoslaS , AroraRR . Statin use mitigate the benefit of omega‐3 fatty acids supplementation: a meta‐regression of randomized trials. American Journal of Therapeutics2016;23(3):e737‐48. ">Sethi 2016</a>), and for reducing the risk of stroke in women, albeit with no effect on stroke overall (<a href="./references#CD003177-bbs2-0259" title="LarssonSC , OrsiniN , WolkA . Long‐chain omega‐3 polyunsaturated fatty acids and risk of stroke: a meta‐analysis. European Journal of Epidemiology2012;27(12):895‐901. ">Larsson 2012</a>). <a href="./references#CD003177-bbs2-0258" title="KwakSM , MyungSK , LeeYJ , SeoHG . Efficacy of omega‐3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta‐analysis of randomized, double‐blind, placebo‐controlled trials. Archives of Internal Medicine2012;172(9):686‐94. ">Kwak 2012</a> reported marginal effects on cardiovascular death, though these were lost when a poor‐quality trial was removed, and a few others have reported only positive effects in their abstracts (reductions in cardiovascular events, cardiac death and coronary events) (<a href="./references#CD003177-bbs2-0237" title="Delgado‐ListaJ , Perez‐MartinezP , Lopez‐MirandaJ , Perez‐JimenezF . Long chain omega‐3 fatty acids and cardiovascular disease: a systematic review. British Journal of Nutrition2012;107(Suppl 2):S201‐13. ">Delgado‐Lista 2012</a>). These disparate findings have fuelled both debate and confusion. A recent extensive Agency for Healthcare Research and Quality review meta‐analysed risk factors extensively but suggested there was only limited RCT data to assess the effects of omega‐3 fats on clinical cardiovascular disease outcomes (<a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>). The publication recently of a suite of large‐scale and long‐term trials of LCn3 (<a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>), has prompted the need to update <a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>. </p> <p>This systematic review and meta‐analysis aimed to assess the evidence on the effects of omega‐3 fats (LCn3 and ALA separately) on all‐cause mortality and cardiovascular diseases. It also aimed to assess potentially harmful effects of omega‐3 fats or compounds associated with consuming LCn3 fats, such as excessive bleeding. A related review has formally systematically reviewed potential harms such as excessive cancers, rather than simply examining trials included in this review for cancer outcomes (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>). We assessed mechanisms of action such as lipid and body weight changes and antiarrhythmic effects as primary or secondary outcomes in this review, and we have systematically reviewed these outcomes in a formal way by including trials that assessed adiposity, lipids and arrhythmic events, even where no cardiovascular disease events occurred or were reported. The World Health Organization (WHO) is currently updating its guidance on polyunsaturated fatty acid (PUFA) intake in adults and children. This is one of a set of systematic reviews commissioned by WHO in order to inform and contribute to the development of updated WHO recommendations. Sister systematic reviews have assessed effects of omega‐3, omega‐6 and total polyunsaturated fats on inflammation and inflammatory bowel disease (<a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>), diabetes and glucose metabolism (<a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>), depression and anxiety (<a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>), cognition and dementia (<a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>), cancers (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>) and functional status (<a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>). Separate reviews assess effects of omega‐6 fats and total polyunsaturated fat on mortality and cardiovascular outcome (<a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>; <a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a>), and provide a detailed database of the relevant trials for use by others (<a href="./references#CD003177-bbs2-0251" title="HooperL , AbdelhamidAS , BrainardJ , DeaneKH , SongF , the PUFAH Group. Creation of a database to assess effects of omega‐3, omega‐6 and total polyunsaturated fats on health: methodology for a set of systematic reviews. BMJ Open2019;9:e029554. [DOI: 10.1136/bmjopen‐2019‐029554] ">Hooper 2019</a>). </p> <p>The results of this review including GRADE assessments were discussed and reviewed by the WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health as part of WHO’s guideline development process. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003177-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003177-sec-0056"></div> <p>To assess the effects of increased intake of fish‐ and plant‐based omega‐3 for all‐cause mortality, cardiovascular events, adiposity and lipids. </p> <p>The primary review question was, 'Do long‐chain omega‐3 fats (LCn3, fish‐based omega‐3 fats) or ALA (plant‐based omega‐3 fats) alter risk of all‐cause mortality, cardiovascular deaths, cardiovascular events, coronary heart disease deaths, coronary heart disease events, stroke, arrhythmia, adiposity and lipids?' </p> <p>Secondary questions include the following.</p> <p> <ul id="CD003177-list-0030"> <li> <p>If omega‐3 fatty acids confer protection:</p> <ul id="CD003177-list-0031"> <li> <p>does protection occur equally in those at low and at high risk of cardiovascular disease?</p> </li> <li> <p>does protection depend on the dose of omega‐3 fats taken per day?</p> </li> <li> <p>do effects differ between dietary and supplemental omega‐3 sources?</p> </li> <li> <p>does protection depend on trial summary risk of bias?</p> </li> </ul> </li> <li> <p>Is protection or harm stronger with longer trial duration?</p> </li> <li> <p>Are effects of omega‐3 fatty acids dependent on baseline triglyceride levels or diabetic status? </p> </li> </ul> </p> <p>The latter was suggested by WHO NUGAG and added post‐hoc specifically for this update.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003177-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003177-sec-0057"></div> <section id="CD003177-sec-0058"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003177-sec-0059"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled clinical trials that included diet advice or dietary supplementation to promote omega‐3 fatty acid intake versus placebo, no supplementation, usual diet or lower‐dose omega‐3. One of our outcomes had to be measured and available (through publications or contact with trial authors), and trials had to follow participants for at least 12 months (52 weeks or 360 days). For advice trials, follow‐up must have been at least 12 months following advice, and for trials where participants received food or supplementation, provision must have continued for at least 12 months. We accepted randomisation of individuals or of clusters as long as there were at least six clusters randomised. </p> <p>Careful work by Browning suggests that supplements of EPA and DHA equivalent to one weekly portion of oily fish results in 95% of maximal incorporation by 5 days for EPA in plasma phosphatidylcholine (95% CI 0 to 18 days) to 273 days for DHA into blood mononuclear cells (95% CI 0 to 670 days; <a href="./references#CD003177-bbs2-0110" title="BrowningLM , WalkerCG , ManderAP , WestAL , MaddenJ , GambellJM , et al. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. American Journal of Clinical Nutrition2012;96(4):748‐58. [PUBMED: 22932281] WalkerCG , BrowningLM , ManderAP , MaddenJ , WestAL , CalderPC , et al. Age and sex differences in the incorporation of EPA and DHA into plasma fractions, cells and adipose tissue in humans. British Journal of Nutrition2014;111(4):679‐89. [PUBMED: 24063767] WalkerCG , BrowningLM , StecherL , WestAL , MaddenJ , JebbSA , et al. Fatty acid profile of plasma NEFA does not reflect adipose tissue fatty acid profile. British Journal of Nutrition2015;114(5):756‐62. [PUBMED: 26205910] WalkerCG , WestAL , BrowningLM , MaddenJ , GambellJM , JebbSA , et al. The pattern of fatty acids displaced by EPA and DHA following 12 months supplementation varies between blood cell and plasma fractions. Nutrients2015;7(8):6281‐93. [PUBMED: 26247960] ">FISH 2012</a>). While this suggests individual variability, on average all compartments except blood mononuclear cells had equilibrated by 117 days (both EPA and DHA into plasma phosphatidylcholine, plasma cholesteryl esters, plasma nonesterified fatty acids, plasma triglycerides, erythrocytes and platelets). The authors stated, "EPA and DHA reached a maximum in platelets in 3–4 weeks and 1–2 months, respectively, and in blood mononuclear cells in 6–9 months". For this reason we chose 12 months as the minimum duration of intervention, as it allows equilibration of most body compartments with EPA and DHA as well as time for this change in body composition to have some effect on cardiovascular risk or mortality. </p> <p>In previous reviews of dietary effects on cardiovascular outcomes, we limited trials to at least two years' duration (<a href="./references#CD003177-bbs2-0249" title="HooperL , MartinN , AbdelhamidA , Davey SmithG . Reduction in saturated fat intake for cardiovascular disease. Cochrane Database of Systematic Reviews2015, Issue 6. [DOI: 10.1002/14651858.CD011737] ">Hooper 2015</a>), as the proposed mechanism of effects was via LDL cholesterol, atherosclerosis and its sequelae, and this takes time to develop. The 4S trial showed separation of the survival curves at around two years (<a href="./references#CD003177-bbs2-0275" title="Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet1994;344(8934):1383‐9. ">Scandinavian Simvastatin Survival Study Group 1994</a>). Potential mechanisms for effects of PUFAs are broader, including what could be rapid effects on arrhythmias or inflammation, so we decided to include trials of at least 12 months to ensure we did not miss these effects. </p> </section> <section id="CD003177-sec-0060"> <h4 class="title">Types of participants</h4> <p>Trials in adults (18 years or older, men and women) at any risk of cardiovascular disease (with or without existing cardiovascular disease) were eligible, including those in participants with increased risk of cancer, those undergoing or who have undergone coronary artery bypass grafting or angioplasty, and those with current or previous cardiovascular disease, nephritis in systemic lupus erythematosus, breast cysts, diabetes mellitus, rheumatoid arthritis, multiple sclerosis, psoriasis, hay fever, asthma or ulcerative colitis. Including these populations allows us to understand both development and progression of cardiovascular disease (primary and secondary prevention). We excluded participants who were pregnant or acutely ill (with acute‐stage cancer, undergoing heart or renal transplantation, with HIV or AIDS, on haemodialysis, with IgA glomerulonephritis, or any other renal problem except in diabetes). </p> </section> <section id="CD003177-sec-0061"> <h4 class="title">Types of interventions</h4> <p>The intervention must have been dietary supplementation, a provided diet or advice on diet. The foodstuffs or supplements must have been: oily fish (including mackerel, dogfish, salmon, herring, trout, tuna, sturgeon, stablefish, anchovy, sprat, coho, capelin, sardines, swordfish, sild, pilchard, brisling, menhaden, bloater, whitebait, crab and conger eel); fish oils (made from any of the above or a mixture of fish, or cod liver oil); linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, capsule, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega‐3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or ALAs, or concentrated fish or algal oils, were also accepted. Supplementation may have been in oil or capsule form or as foodstuffs provided to be consumed by mouth (excluding enteral and parenteral feeds and enemas). </p> <p>We excluded trials using multiple risk factor interventions on lifestyle factors (such as weight reduction, smoking or physical activity goals), or differential dietary interventions not involving dietary fats, except where that other intervention was a direct replacement for polyunsaturated fats or the effect of diet or supplementation could be separated out from the other interventions. </p> <p>Trials were eligible if they compared the effect of dietary advice or supplementation to increase omega‐3 fats with the usual diet, no advice, no supplementation, placebo or lower‐dose omega‐3. </p> </section> <section id="CD003177-sec-0062"> <h4 class="title">Types of outcome measures</h4> <section id="CD003177-sec-0063"> <h5 class="title">Primary outcomes</h5> <p>Primary outcomes included numbers of participants experiencing:</p> <p> <ul id="CD003177-list-0032"> <li> <p>all‐cause mortality (deaths);</p> </li> <li> <p>cardiovascular mortality (cardiovascular deaths);</p> </li> <li> <p>cardiovascular events (cardiovascular events);</p> </li> <li> <p>coronary heart disease mortality (coronary heart disease deaths);</p> </li> <li> <p>coronary heart disease events;</p> </li> <li> <p>stroke; and</p> </li> <li> <p>arrhythmia (atrial fibrillation).</p> </li> </ul> </p> <p>We analysed coronary heart disease using the first of the following to be reported: number of participants experiencing coronary heart disease or coronary events, total myocardial infarction, acute coronary syndrome or angina (stable and unstable). This meant that if trial authors reported coronary heart disease events, we used these in analysis; where trials did not report coronary heart disease events but did report total myocardial infarction, we used that (and so on). Combined cardiovascular events included fatal and non‐fatal myocardial infarction, angina, stroke, heart failure, peripheral arterial disease, sudden death and non‐scheduled cardiovascular interventions – coronary artery bypass surgery or angioplasty. We included all available outcomes where we could be sure that the same participant was not being counted twice. </p> <p>At the request of WHO NUGAG Subgroup on Diet and Health, we added coronary heart disease mortality post hoc as a primary outcome. Data used were the first of the following list reported: coronary death, ischaemic heart disease death, fatal myocardial infarction, cardiac death. We only used cardiac death when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death. The reason for excluding cardiac death in sensitivity analysis was that it goes slightly outside our area of interest, including other causes of death in addition to coronary heart disease, such as cardiomyopathies and congenital and valvular heart diseases. We wanted to include cardiac death in the main analysis as we felt that otherwise we would be missing some important cases of coronary heart mortality, but we decided to exclude it in sensitivity analysis as we were potentially including a few outcomes that coronary heart disease mortality did not encompass. </p> </section> <section id="CD003177-sec-0064"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included:</p> <p> <ul id="CD003177-list-0033"> <li> <p>major adverse cerebrovascular or cardiovascular events (MACCEs) or individual cardiovascular events (total, fatal or non‐fatal myocardial infarction, sudden cardiac death, angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome); </p> </li> <li> <p>body weight and other measures of adiposity; and</p> </li> <li> <p>lipids (total, LDL or HDL cholesterol and triglycerides).</p> </li> </ul> </p> <p>We defined MACCEs as participants experiencing myocardial infarction, unstable angina, stroke or death. We did not consider trials that did not provide data on all these health events for this outcome. </p> <p>The review included trials if any of their participants experienced or were assessed for any primary or secondary outcome. These could have been reported in publications (as outcomes or reasons for dropout or adverse events), supplied by trial authors, or which clearly happened even if exact numbers were not available. However, as almost all trials note if a death or cardiovascular event occurs in a trial participant (so all trials assessed for our primary outcomes) we only included trials where at least one event occurred, or where a continuous outcome was measured. </p> <section id="CD003177-sec-0065"> <h6 class="title">Tertiary outcomes</h6> <p>We extracted the following outcomes where available within included trials.</p> <p> <ul id="CD003177-list-0034"> <li> <p>Blood pressure</p> </li> <li> <p>Serious adverse events (any other reported illnesses)</p> </li> <li> <p>Side effects</p> </li> <li> <p>Dropouts</p> </li> <li> <p>Quality‐of‐life measures</p> </li> <li> <p>Economic costs</p> </li> </ul> </p> <p>We originally intended to assess type 2 diabetes diagnoses, measures of glucose metabolism, cancers, breast cancer, neurocognitive outcomes such as dementia, depression and anxiety within included trials. However, as part of the larger set of reviews we formally systematically reviewed effects of omega‐3 fats on type 2 diabetes diagnoses and measures of glucose metabolism (<a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>), cancers including breast cancer (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>), neurocognitive outcomes such as dementia (<a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>), irritable bowel disease (IBD) and inflammatory factors (<a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>), depression and anxiety (<a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>), and functional outcomes (<a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>), so a partial assessment within this review would be unhelpful and potentially misleading. For this reason we exclude these specific outcomes from our reporting of serious adverse events. </p> </section> <section id="CD003177-sec-0066"> <h6 class="title">Key outcomes</h6> <p>When the World Health Organization (WHO) NUGAG Subgroup on Diet and Health requested this review update they named the following as key outcomes to inform their planned dietary guidance. </p> <p> <ul id="CD003177-list-0035"> <li> <p>All‐cause mortality</p> </li> <li> <p>Cardiovascular disease mortality</p> </li> <li> <p>Cardiovascular disease events</p> </li> <li> <p>Coronary heart disease mortality</p> </li> <li> <p>Coronary heart disease events</p> </li> <li> <p>Stroke</p> </li> <li> <p>Arrhythmia (atrial fibrillation)</p> </li> <li> <p>Serum lipids including total cholesterol, fasting triglycerides, high‐density lipoprotein (HDL) and low‐density lipoprotein (LDL) </p> </li> <li> <p>Measures of adiposity (body weight and body mass index (BMI)</p> </li> </ul> </p> <p>We were not able to make all of these outcomes into primary outcomes (as the number of primary outcomes are restricted for Cochrane Reviews). However, because WHO NUGAG Subgroup on Diet and Health will use these outcomes to underpin guidance, we carried out sensitivity analyses, subgroup analyses and GRADE assessment of certainty of evidence for them, even when they were not primary outcomes. </p> </section> </section> </section> </section> <section id="CD003177-sec-0067"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003177-sec-0068"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases on 13 February 2019 to identify reports of relevant randomised clinical trials: </p> <p> <ul id="CD003177-list-0036"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 2) in the Cochrane Library; </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily and MEDLINE (Ovid, 1946 to 12 February 2019); </p> </li> <li> <p>Embase Classic and Embase (Ovid, 1947 to 2019 week 6).</p> </li> </ul> </p> <p>We applied date limits to the terms from the original strategies so that the search included only new records (<a href="./appendices#CD003177-sec-0173">Appendix 1</a>). The RCT filter for MEDLINE was the Cochrane sensitivity and precision‐maximising RCT filter, and for Embase, we applied the terms as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003177-bbs2-0260" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). </p> <p><a href="./appendices#CD003177-sec-0174">Appendix 2</a> shows the MEDLINE search strategy for the original version of this review (<a href="./references#CD003177-bbs2-0295" title="HooperL , HarrisonRA , SummerbellCD , MooreH , WorthingtonHV , NessA , et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD003177.pub2] ">Hooper 2004</a>), <a href="./appendices#CD003177-sec-0175">Appendix 3</a> and <a href="./appendices#CD003177-sec-0176">Appendix 4</a> show searches used to update the previous version of this review (<a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>). </p> <p>For the previous (27 April 2017) update we also ran searches for a new systematic review of the effects of polyunsaturated fats on cardiovascular disease (<a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>), as well as updating and extending a Cochrane Review of the effects of omega‐6 polyunsaturated fats on health outcomes (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a>). We ran searches for these reviews using the same RCT filters (<a href="./appendices#CD003177-sec-0176">Appendix 4</a>). The results of these searches were de‐duplicated against the omega‐3 searches, and all the titles and abstracts assessed as a single set for all three reviews. We created a data set of RCTs that lasted at least six months and compared higher versus lower omega‐6, omega‐3 or total PUFA in adults. We used this data set as the wider study pool from which we selected included trials for all reviews (<a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>; <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>; <a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>; <a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>; <a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>; <a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>; <a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>; <a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a>; <a href="./references#CD003177-bbs2-0251" title="HooperL , AbdelhamidAS , BrainardJ , DeaneKH , SongF , the PUFAH Group. Creation of a database to assess effects of omega‐3, omega‐6 and total polyunsaturated fats on health: methodology for a set of systematic reviews. BMJ Open2019;9:e029554. [DOI: 10.1136/bmjopen‐2019‐029554] ">Hooper 2019</a>; <a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>). We did not repeat these additional searches in 2019. </p> <p>We also searched two trials registers, ClinicalTrials.gov (<a href="https://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>), and the WHO International Clinical Trials Registry Platform (ICTRP, <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>), to 31 July 2019 for registry entries for relevant completed and ongoing trials. </p> </section> <section id="CD003177-sec-0069"> <h4 class="title">Searching other resources</h4> <p>We assessed titles and abstracts retrieved during these electronic searches for relevant RCTs and also relevant systematic reviews. We handsearched the included trials in all relevant systematic reviews up to April 2017 for new trials and additional publications of included trials. We contacted authors of all large included trials (at least 100 participants) included up to April 2017 and some smaller trials for further trial data, methodological details and references to trials not yet identified, including published, unpublished or ongoing trials. </p> <p>For all included trials we carefully searched and data‐extracted trials registry entries, protocols, supplementary materials, letters, conference abstracts and additional publications to help us locate complete data sets. </p> </section> </section> <section id="CD003177-sec-0070"> <h3 class="title" id="CD003177-sec-0070">Data collection and analysis</h3> <section id="CD003177-sec-0071"> <h4 class="title">Selection of studies</h4> <p>At least two review authors independently assessed titles and abstracts resulting from the electronic and bibliographic searches. We rejected titles and abstracts on initial screen only if the review author could determine from the title and abstract that the article was not a report of a RCT; did not address omega‐3 intake (or total polyunsaturated fat or omega‐6 fat for the other two reviews); were exclusively in children or young adults (less than 18 years old), pregnant women or the critically ill; were of less than 12 months' duration; or if the intervention was multi‐factorial and we could not separate out the effect of dietary fat. </p> <p>We rejected trials only when it was certain that no primary or secondary outcome events occurred, and none of the secondary outcome risk factors were measured. When we could not reject a title or abstract with certainty, we obtained the full text of the article for further evaluation. We made attempts to obtain full‐text translations or evaluations, or both, of all potentially relevant non‐English articles. </p> <p>We used an in/out form to assess full‐text papers and trials for inclusion (or otherwise) into the review. We contacted the authors of all potentially included RCTs for further information on trial methodology and outcomes. Two review authors independently decided on inclusion of full‐text RCTs, resolving any differences by discussion and, when necessary, in consultation with the review author team. </p> </section> <section id="CD003177-sec-0072"> <h4 class="title">Data extraction and management</h4> <p>We designed a data extraction form for this review, which each of the review authors tested on a common 'training' trial (<a href="./references#CD003177-bbs2-0072" title="AngererP , KothnyW , StorkS , vonSchackyC . Effect of dietary supplementation with omega‐3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovascular Research2002;54(1):183‐90. vonSchackyC , AngererP , KothnyW , TheisenK , MudraH . The effect of dietary omega‐3 fatty acids on coronary atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine1999;130(7):554‐62. vonSchackyC , BaumannK , AngererP . The effect of n‐3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids2001;36(Suppl):S99‐102. ">SCIMO 1999</a>), and we adapted the form as needed. We extracted data concerning participants, interventions, and outcomes, as described above in the selection criteria section. We extracted dichotomous data from dietary advice trials at the latest point available in the trial (regardless of the amount of reinforcement of the original dietary message), while for supplement trials, we extracted dichotomous data to the point that supplementation or the trial ended, whichever was earlier. We extracted continuous data at the nearest time point to 12 months and also the latest point available in fixed‐term trials, but in trials where participants were followed up for varying durations (aside from dropouts), we extracted the participants' data from the first time point following the mean trial duration. We never used data from periods following the end of a trial in meta‐analysis. </p> <p>We also extracted data on risk of bias, assessed using the Cochrane 'Risk of bias' tool, along with data on potential effect modifiers, including existing cardiovascular disease (primary or secondary prevention), trial duration, intensity of intervention (dietary advice, diet provided, supplemental foods, supplements (capsules) and any combination), LCn3 fats or ALA and dose, replacement, medications used (including statins, antihypertensive, antiarrhythmic or antithrombotic medication), fatty acid data (from plasma, platelets or adipose tissue) and smoking status. </p> <p>For primary and secondary dichotomous outcomes, we extracted numbers of participants experiencing an outcome and total numbers of participants randomised (or in whom the outcome was assessed where known) for each trial arm. For continuous outcomes, we extracted the number of participants assessed, means and standard deviations of the final readings in each treatment arm; we calculated standard deviations from other variance data where appropriate. Where data were available on both change and final readings, we used data on change. </p> <p>Two review authors independently extracted original reports of trial results. We resolved differences between review authors' results by discussion and, when necessary, in consultation with a third review author or the review author team. </p> </section> <section id="CD003177-sec-0073"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias for each included trial, using Cochrane criteria (<a href="./references#CD003177-bbs2-0248" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), including in the domains of sequence generation; allocation concealment; blinding of participants and personnel, blinding of outcome assessors; incomplete outcome data; and selective outcome reporting. Additional review‐specific criteria included similarity of type and intensity of intervention in both arms (attention) and evidence of appropriate moderate to high compliance (to establish that the intervention group were receiving a different intake of omega‐3 fats than the control group). <a href="#CD003177-tbl-0004">Table 1</a> presents specific details of how we interpreted these criteria for this review. </p> <div class="table" id="CD003177-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment methods in greater detail</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias element</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for low risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for unclear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for high risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias: random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. For example "the randomisation sequence was computer generated". We allowed that a good method of randomisation was strongly implied if the authors discussed stratification and/or blocking. Therefore, if the authors were not explicit about their randomisation method but did describe stratification or blocking we assessed this as corresponding to low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors have not described their method in sufficient detail for the assessment of whether it would produce comparable groups. For example, the authors state "the trial was randomised" and provide no further information. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The randomisation method was assessed as not truly random, and may not produce comparable groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias: allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described the method used to conceal allocation sequence in sufficient detail to determine whether the allocations could have been foreseen in advance of, or during, enrolment. Good methods included putting allocation codes in opaque sealed envelopes (ideally prepared by someone outside the treatment or assessment teams and sequentially numbered), using a telephone allocation system after the participants had consented to participate or providing a random number that links to a specific set of capsules prepared and distributed centrally or by an arms‐length pharmacist. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors gave insufficient detail as to method.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The allocation was known in advance of participants consenting to take part in the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance bias: blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described all measures used, if any, to blind trial participants and personnel from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "both the intervention and placebo capsules looked and tasted the same." However, if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding, then we assumed that the blinding was effective and the risk of bias was low. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient methodological details were provided e.g. "the trial was blinded."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was unblinded or where blinding was broken, e.g. "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detection bias: blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial authors needed to have described measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "the outcome assessors had no knowledge of the group allocation, and both the intervention and placebo capsules looked and tasted the same so the self‐assessment scales were also blinded." However if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding of the assessors, then we assumed that the blinding was effective and the risk of bias is low. All biochemical assessment (lipids, glucose, CRP, insulin, PSA, etc.) were considered at low risk of detection bias if outcome assessor blinding or double‐blinding was stated. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient methodological details were provided e.g. "the trial was blinded."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was unblinded or blinding was broken, e.g. for a self‐assessment measure "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only." </p> <p>Because the level of blinding could vary by outcome, assessment of risk of bias was based on blinding of the review's primary outcome(s). Where primary outcomes had different assessments we opted for the higher risk of bias but noted that risk of bias was lower for other outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition bias: incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. They needed to report the number of attrition/exclusions, the numbers in each group at each time point, reasons for attrition/exclusion and any re‐inclusions in analyses. Ideally, they would report how they imputed any missing data e.g. last observation carried forward. There needed to be a reasonable balance of attrition/exclusions between trial arms and ≤ 20% of the sample should be lost over a year. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors didn't state reasons for attrition/exclusion, or were unclear about the numbers lost to attrition/exclusion in each trial arm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors demonstrated a substantial difference in the rates of attrition/exclusions between the trial arms and/or &gt; 20% of the baseline sample was lost over a year (&gt; 10% over 6 months). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias: selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have published their trial protocol or trials registry entry before the end of the trial's recruitment period, i.e. prospectively. They needed to have reported on all of the primary and secondary outcomes listed in the protocol/registry entry. We deemed reporting additional secondary outcomes in the results paper(s), although not ideal, to still be low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial protocol or trials registry entry was found, it was registered retrospectively, or the dates of registration and participant recruitment were unclear. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors did not report at least one primary or secondary outcome listed in the protocol/registry entry or the results paper(s) reported a primary outcome that was not listed at all in the protocol or not listed as a primary outcome in the protocol. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: attention bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have reported that participants in all trial arms received the same amount of attention and time from researchers and clinical teams. For example, "All participants attended the clinic for a baseline assessment which took 2 hours. They were then followed with monthly telephone calls, and finally attended for a 6 month assessment at the clinic which took 1 hour." If the trial only differed by the content of the capsules, and the assessment schedule was not stated to differ between the two arms, we assumed it to be at low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors did not state the attention each arm received.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in different arms received different amounts of attention. For example "the intervention group only attended for additional assessments at months 2, 4, and 6" or "the rates of relapse differed substantially between the groups which led to differing amounts of treatment time and attention," or "the intervention group received a 40 minute dietary education session." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: limited compliance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have reported on the level of compliance in all arms in sufficient detail to determine whether the trial results were robust. We followed a flow chart to make this determination. A statistically significant difference between the intervention and control groups in a body measure of at least 50% of the test fatty acids. Where no body measures were reported then estimated compliance needed to be greater than 64% (proportion complying multiplied by compliance threshold). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance not reported or not in a way that could be interpreted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measures of compliance were reported but fell below the appropriate thresholds.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the absence of any additional issues this item was coded "low risk of bias"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If fraud concerns had been raised and the paper had been withdrawn, or the author had been found guilty of fraud by a legal or medical entity the paper was excluded from the review. However if fraud concerns were raised, but the journal had not withdrawn the paper, and the author had not been formally sanctioned; then the trial was included in the review, but concerns were raised here, and the risk of bias for this item was high. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CRP</b> : C‐reactive protein; <b>PSA</b>: prostate specific antigen </p> </td> </tr> </tbody> </table> </div> <p>In brief, we considered a trial to be at low risk of attention bias when participants were given the same amount of time and attention from trial staff and health professionals whether they were in the intervention or control arms, and at low risk of compliance bias when adherence was assessed, results of that assessment were clearly reported for both intervention and control arms, and where most participants appeared to have taken at least 75% of the intended PUFA dose. </p> <section id="CD003177-sec-0074"> <h5 class="title">Summary risk of bias</h5> <p><a href="./references#CD003177-bbs2-0276" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273:408‐12. ">Schulz 1995</a> found that poorly concealed allocation was associated with a 40% greater effect size, so randomisation and allocation concealment are core issues for all trials. Lack of blinding is associated with bias, though smaller levels of bias than lack of allocation concealment (<a href="./references#CD003177-bbs2-0274" title="SavovicJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16:1‐82. ">Savovic 2012</a>), especially in trials with objectively measured outcomes (<a href="./references#CD003177-bbs2-0290" title="WoodL , EggerM , GluudLL , SchulzK , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336:601‐5. ">Wood 2008</a>), such as those we primarily used in our review. Although we originally planned to assess summary risk of bias for all included trials in the same way across the whole set of reviews (<a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>; <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>; <a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>; <a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>; <a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>; <a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>; <a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>; <a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a>; <a href="./references#CD003177-bbs2-0251" title="HooperL , AbdelhamidAS , BrainardJ , DeaneKH , SongF , the PUFAH Group. Creation of a database to assess effects of omega‐3, omega‐6 and total polyunsaturated fats on health: methodology for a set of systematic reviews. BMJ Open2019;9:e029554. [DOI: 10.1136/bmjopen‐2019‐029554] ">Hooper 2019</a>; <a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>), we adopted a different approach after discussing the different nature of supplement trials compared to dietary advice or food provision trials with the WHO NUGAG Subgroup on Diet and Health. </p> <p>We considered supplement or capsule type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, blinding of participants and personnel, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category). </p> <p>We considered dietary advice or all‐food‐provided type trials to be at low summary risk of bias where we judged randomisation, allocation concealment, and blinding of outcome assessors to be adequate. We considered all other trials to be at moderate or high risk of bias (a single category). </p> </section> </section> <section id="CD003177-sec-0075"> <h4 class="title">Measures of treatment effect</h4> <p>We pooled dichotomous data using risk ratios (RR) to describe effect sizes and continuous data using mean differences (MD). Where effects were described by different but comparable measures or scales in different trials, we planned to combine them using standardised mean difference (SMD), but this was not needed in this review. </p> </section> <section id="CD003177-sec-0076"> <h4 class="title">Unit of analysis issues</h4> <p>We considered that we could reduce patient numbers in cluster‐randomised trials to an effective sample size, as described by <a href="./references#CD003177-bbs2-0245" title="HauckWW , GillissCL , DonnerA , GortnerS . Randomisation by cluster. Nursing Research1991;40(6):356‐8. ">Hauck 1991</a>, however, we identified no such trials. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within trials, but only where we could be certain that we were not counting individual participants more than once within any one of our review outcome categories. </p> <p>For trials with intervention arms providing different omega‐3 doses, we combined data for the intervention groups for binary outcomes and used higher‐dose data versus control for continuous outcomes. We used arms with different doses separately when subgrouping by dose. Where factorial trials ran more than one intervention included in this review (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>), we did not pool both comparisons in the same meta‐analysis. </p> </section> <section id="CD003177-sec-0077"> <h4 class="title">Dealing with missing data</h4> <p>We sought trials registry entries and trial protocols to help us assess which trials measured each outcome. Where trials appeared to have collected – but did not report – data, we wrote to trial authors to ask for information. We wrote to authors of all trials that randomised at least 100 participants as well as to those of many smaller trials (although not to all due to limited resources), prioritising our efforts on larger trials that would tend to provide more information to the review. For larger trials where we found no trials registry entry or protocol, we wrote to trial authors to ask whether they had collected information on any outcomes of interest that we had not yet located. Where it was clear that data existed but could not be located to use within the review, we noted this and assessed the potential effect of this missing data on effect sizes narratively. </p> <p>A recent meta‐analysis of effects of omega‐3 fats on cardiovascular outcomes, <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>, worked with 10 large RCTs in depth to formulate their outcome data to match precisely between trials. It is difficult as a reviewer to access complex outcomes (such as 'cardiovascular events') where we need to count people experiencing events, rather than counting events ‐ events are additive, but people experiencing events are not (a participant experiencing a stroke, non‐fatal myocardial infarction and angina must be counted as only one person experiencing cardiovascular events, rather than three events). As the review had worked with trial authors to optimise their data, we used data from this review to both fill in missing data (some data had not been previously published) and also to update our data where the data in <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> differed from previously reported data for any outcome. The trials that this applies to, those included in <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>, were <a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0022" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BerstadP , SeljeflotI , VeierodMB , HjerkinnEM , ArnesenH , PedersenJI . Supplementation with fish oil affects the association between very long‐chain n‐3 polyunsaturated fatty acids in serum non‐esterified fatty acids and soluble vascular cell adhesion molecule‐1. Clinical Science2003;105(1):13‐20. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition &amp; Metabolism2006;3:4. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism2006;3:1‐10. EinvikG , EkebergO , KlemsdalTO , SandvikL , HjerkinnEM . Physical distress is associated with cardiovascular events in a high risk population of elderly men. BMC Cardiovascular Disorders2009;9:14. [PUBMED: 19331677] EinvikG , EkebergO , LavikJG , EllingsenI , KlemsdalTO , HjerkinnEM . The influence of long‐term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. Journal of Psychosomatic Research2010;68(6):567‐72. EinvikG , KlemsdalTO , SandvikL , HjerkinnEM . A randomized clinical trial on n‐3 polyunsaturated fatty acids supplementation and all‐cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention &amp; Rehabilitation2010;17(5):588‐92. EllingsenI , HjerkinnEM , ArnesenH , SeljeflotI , HjermannI , TonstadS . Follow‐up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. European Journal of Clinical Nutrition2006;60(3):378‐85. FurenesEB , SeljeflotI , SolheimS , HjerkinnEM , ArnesenH , FurenesEB . Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation2008;68(3):177‐84. HjerkinnEM , AbdelnoorM , BreivikL , BergengenL , EllingsenI , SeljeflotI , et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention &amp; Rehabilitation2006;13(3):325‐33. HjerkinnEM , SeljeflotI , EllingsenI , BerstadP , HjermannI , SandvikL , et al. Influence of long‐term intervention with dietary counselling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. American Journal of Clinical Nutrition2005;81(3):583‐9. LindmanAS , PedersenJI , HjerkinnEM , ArnesenH , VeierodMB , EllingsenI , et al. The effects of long‐term diet and omega‐3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis and Haemostasis2004;91(6):1097‐104. TroseidM , ArnesenH , HjerkinnEM , SeljeflotI . Serum levels of interleukin‐18 are reduced by diet and n‐3 fatty acid intervention in elderly high‐risk men. Metabolism: Clinical and Experimental2009;58(11):1543‐9. TroseidM , SeljeflotI , WeissTW , KlemsdalTO , HjerkinnEM , ArnesenH . Arterial stiffness is independently associated with interleukin‐18 and components of the metabolic syndrome. Atherosclerosis2010;209(2):337‐9. ">DO IT 2010</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>. </p> </section> <section id="CD003177-sec-0078"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity using the I<sup>2</sup> test and assumed it to be important when I<sup>2</sup> test value was more than 60% (<a href="./references#CD003177-bbs2-0247" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). </p> </section> <section id="CD003177-sec-0079"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to assess for evidence of bias for primary outcomes where at least 10 trials contributed to the meta‐analysis (<a href="./references#CD003177-bbs2-0238" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). We also compared effects from random‐effects and fixed‐effect meta‐analyses to understand whether small study effects may be important (<a href="./references#CD003177-bbs2-0269" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. Draft version (29th January 2019). In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA editor(s). Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane, 2019. ">Page 2019</a>), alongside reporting known missing data (above). </p> </section> <section id="CD003177-sec-0080"> <h4 class="title">Data synthesis</h4> <p>Primary measures of interest were effects of dietary advice or supplementation of fish‐based (LCn3) fats, and ALAs, on primary outcomes. We separated out effects of LCn3 and ALA in all analyses and thus present two separate sets of results: one for LCn3 and one for ALA. </p> <p>We combined treatment/control differences in the outcomes across trials using risk ratios (RR) or mean differences (MD) in random‐effects meta‐analysis. For combined outcomes (e.g. combined cardiovascular events), we made attempts to add numbers of individuals experiencing specific outcomes within trials, but only where we were certain that we were not counting individual participants more than once within any one of our review outcome categories. However, individuals may have been counted for more than one of the review outcomes (in separate forest plots). </p> </section> <section id="CD003177-sec-0081"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We explored the effects of LCn3 and ALA separately on all primary review outcomes and also on key review outcomes where these were secondary outcomes in our review and included at least six trials by subgrouping. The planned subgroup analyses were as follows. </p> <p> <ul id="CD003177-list-0037"> <li> <p>Type of intervention: dietary advice, supplemental foods (for example margarine fortified with rapeseed, tins of sardines or oils to use in cooking) provided by the trial, supplements (capsules or oils) provided to take as medicine or any combination </p> </li> <li> <p>Replacement of saturated fatty acids, mono‐unsaturated fatty acids (MUFA), omega‐6 fats, fat mixture, carbohydrates or sugars, non‐fat or no placebo, or unclear, with LCn3 or ALA </p> </li> <li> <p>Primary prevention versus secondary prevention of cardiovascular disease (where trials that recruited participants for cardiovascular disease at baseline were considered secondary prevention trials, and trials that did not recruit on the basis of cardiovascular disease, so may include some or no people with existing cardiovascular disease, were considered primary prevention trials) </p> </li> <li> <p>LCn3 dose: at least 150 mg/d, 250 mg/d, 400 mg/d from all sources including supplements (above or below each threshold); low dose 0.4 g/d to 2.4 g/d, medium dose 2.5 g/d to 4.4 g/d, and high dose ≥ 4.5 g/d of combined LCn3 fats; </p> </li> <li> <p>ALA dose: higher versus lower levels of intake (≥ 5 g/d versus &lt; 5 g/d);</p> </li> <li> <p>Trial duration: trials with medium follow‐up (12 to 23 months), medium follow‐up (24 to 47 months) and long follow‐up (≥ 48 months) </p> </li> <li> <p>Statin use (&lt; 50% of control group on statins, ≥ 50% of control group on statins, use of statins unclear) </p> </li> <li> <p>Baseline LCn3 intake, and baseline ALA intake</p> </li> </ul> </p> <p>There were insufficient data on baseline omega‐3 or ALA intake (or intake in control groups, which could have been used as a proxy) to subgroup by baseline omega‐3 or ALA intake. </p> <p>Post‐hoc, WHO NUGAG asked us to assess whether effects of omega‐3 fats differed by baseline triglyceride or diabetes status. We carried out post‐hoc subgroups on primary outcomes whenever the other subgroups were created, including the following. </p> <p> <ul id="CD003177-list-0038"> <li> <p>Triglyceride status: raised triglycerides at baseline (inclusion criteria relate to triglycerides and mean triglycerides in control group at baseline were &gt; 200 mg/dL or &gt; 2.26 mmol/L) versus normal triglycerides (triglycerides did not relate to inclusion criteria, or mean triglycerides in control group at baseline was &lt; 200 mg/dL or &lt; 2.26 mmol/L) </p> </li> <li> <p>Diabetes status: diabetic at baseline (at least half of participants had diabetes) versus diabetes risk factors at baseline (insulin resistance, non‐alcoholic fatty liver disease, non‐alcoholic steatohepatitis or obesity) versus inclusion criteria that did not relate to diabetic status. </p> </li> </ul> </p> <section id="CD003177-sec-0082"> <h5 class="title">Meta‐regression</h5> <p>We used meta‐regression to further explore effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose (looking for evidence of dose response for each), trial duration, primary or secondary prevention, food or capsule intervention (food included dietary advice and supplemental foods), and risk of bias (summary risk of bias low or moderate to high) on primary outcomes. We performed random‐effects meta‐regression using the STATA 16 command meta regress (<a href="./references#CD003177-bbs2-0222" title="BerkleyCS , HoaglinDC , MostellerF , ColditzGA . A random‐effects regression model for meta‐analysis. Statistics in Medicine1995;14:395‐411. ">Berkley 1995</a>; <a href="./references#CD003177-bbs2-0279" title="SharpS . Meta‐analysis regression. Stata Technical Bulletin1998;42:16‐22. ">Sharp 1998</a>): log(e) risk ratio versus (dose or primary/secondary prevention or type of intervention or risk of bias or duration), weighted by the standard error of the log(e) risk ratio. Where there were no events in one arm, we added 0.1 to the numbers for both groups (so a trial with 10 people experiencing stroke in one arm but none in the other arm would be entered as 10.1 and 0.1). We analysed all included trials (of at least 12 months' duration) that reported each outcome from this review and its sister reviews (omega‐3 trials from this review, omega‐6 trials from <a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a>, and total PUFA trials from <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). We carried out meta‐regression of each variable singly, then a multivariate meta‐regression of the three variables with lowest P values in single regression for each outcome. Given that we generally included data from fewer than 40 trials and there were some missing data for some trials, we did not run meta‐regressions with more than three variables at one time. </p> </section> </section> <section id="CD003177-sec-0083"> <h4 class="title">Sensitivity analysis</h4> <p>We carried out sensitivity analyses on all primary outcomes (regardless of the number of included trials) and on key outcomes that were secondary outcomes in this review. </p> <p>We used sensitivity analyses to assess robustness of results to:</p> <p> <ul id="CD003177-list-0039"> <li> <p>trial quality (removing trials at moderate or high summary risk of bias);</p> </li> <li> <p>trial size (retaining only trials that randomised at least 100 participants across all trial arms); </p> </li> <li> <p>fixed‐effect analysis; and</p> </li> <li> <p>compliance (retaining only trials where we assessed compliance as conferring low risk of bias). </p> </li> </ul> </p> <p>We tabulated the type and frequency of side effects and adverse effects (with the other extracted data on adverse effects) and compared between different trials and designs. </p> <section id="CD003177-sec-0084"> <h5 class="title">'Summary of findings' tables</h5> <p>We interpreted outcome data as follows.</p> <p> <ol id="CD003177-list-0040"> <li> <p>Is there an effect? (options were ‘increased risk’, ‘decreased risk’, or ‘little or no effect’). Our main outcome measure was RR so we decided on existence of an effect using RR. RR more than 8% (RR &lt; 0.92 or &gt; 1.08) for the highest‐certainty evidence suggested increased or decreased risk (otherwise little or no effect). The presence or not of an effect was decided on the RR for the main analysis and sensitivity analyses, the highest‐certainty evidence (the main analysis, the sensitivity analyses of trials at low summary risk of bias and at low risk of compliance problems). </p> </li> <li> <p>For continuous outcomes, we considered increasing ALA or LCn3 to have little or no effect unless effect sizes represented at least 5% change from baseline (or 2% in the case of cumulative outcomes such as adiposity). </p> </li> <li> <p>We assessed certainty of evidence using GRADE assessment (<a href="./references#CD003177-bbs2-0242" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE Working Group 2004</a>), for key outcomes. We used the five GRADE considerations (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence as it related to the trials that contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Section 8.5 (<a href="./references#CD003177-bbs2-0248" title="HigginsJP , AltmanDG , SterneJA , editor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), and Chapter 11 (<a href="./references#CD003177-bbs2-0277" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , AklE , et al. on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Schünemann 2017</a>), of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, plus GRADEpro GDT software (<a href="./references#CD003177-bbs2-0243" title="McMaster University (developed by Evidence Prime, Inc). GRADEpro GDT. Version accessed 30 September 2017. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc), 2015. ">GRADEpro GDT</a>). We justified all decisions to downgrade the certainty of trials using footnotes and made comments to aid readers' understanding of the review. </p> </li> <li> <p>Where there was a suggested effect, we assessed the size of effect using the number needed to treat for an additional beneficial outcome (NNTB), number needed to treat for an additional harmful outcome (NNTH) or absolute risk reduction (ARR). </p> </li> </ol> </p> <p>We included three 'Summary of findings' tables: for effects of LCn3 on primary outcomes (<a href="./full#CD003177-tbl-0001">summary of findings Table for the main comparison</a>), effects of ALA on primary outcomes (<a href="./full#CD003177-tbl-0002">summary of findings Table 2</a>), and for key outcomes that were not included in the review primary outcomes (measures of adiposity and serum lipids, <a href="./full#CD003177-tbl-0003">summary of findings Table 3</a>). </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003177-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003177-sec-0085"></div> <section id="CD003177-sec-0086"> <h3 class="title">Description of studies</h3> <section id="CD003177-sec-0087"> <h4 class="title">Results of the search</h4> <p>During the 2019 update, we assessed a further 2419 publications for inclusion and included another seven trials (<a href="#CD003177-fig-0001">Figure 1</a>). We found that six previously ongoing trials had published relevant results (<a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0023" title="AsbellPA , MaguireMG , PeskinE , BunyaVY , KuklinskiEJ . Dry Eye Assessment and Management (DREAM) Study: study design and baseline characteristics. Contemporary Clinical Trials2018;71:70‐9. [DOI: https://doi.org/10.1016/j.cct.2018.06.002] NCT02128763 . Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014). The Dry Eye Assessment and Management Study Research Group. n−3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine2018;378(18):1681‐90. [DOI: 10.1056/NEJMoa1709691] ">DREAM Asbell 2018</a>; <a href="./references#CD003177-bbs2-0024" title="CauleyJA , ManiniTM , LovatoL , TaltonJ , AntonSD , DomanchukK , et al. ENRGISE Investigators. The enabling reduction of low‐grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(8):1296‐302. [DOI: 10.1093/gerona/gly204] ManiniTM , AntonSD , BeaversDP , CauleyJA , EspelandMA , FieldingRA , et al. ENRGISE pilot study investigators. Eabling reduction of low‐grade inflammation in seniors pilot study: concept, rationale, and design. Journal of the American Geriatrics Society2017;65:1961‐68. [DOI: 10.1111/jgs.14965] NCT02676466 . The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low‐grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016). PahorM , AntonSD , BeaversDP , CauleyJA , FieldingRA , KritchevskySB , et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL‐6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(10):1612–19. [DOI: 10.1093/gerona/gly277] ">ENRGISE 2018</a>; <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>), so we included them in the review, and we included a further trial (not previously ongoing, <a href="./references#CD003177-bbs2-0039" title="AlfaddaghA , ElajamiTK , AshfaqueH , SalehM , BistrianBR , WeltyFK . Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. Journal of the American Heart Association2017;6(12):e006981. [DOI: 10.1161/JAHA.117.006981] AlfaddaghA , ElajamiTK , WeltyFK . Abstract 16294: Omega‐3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. Circulation2016;134:A16294. AlfaddaghA , MohebaliD , ElajamiTK , SalehM , WeltyFK . Abstract 17391: Omega‐3 fatty acid index &gt;= 4% prevents progression of coronary artery plaque in non‐diabetic subjects on statin therapy. Circulation2017;136 (Suppl 1):A17391. AlfaddaghA , WeltyFK . Abstract 17689: Omega‐3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short. ElajamiTK , AlfaddaghA , LakshminarayanD , SolimanM , ChandnaniM , WeltyFK . Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American Heart Association2017;6(7):e004740. [DOI: 10.1161/JAHA.116.004740] ElajamiTK , AlfaddaghA , WeltyFK . Abstract 16353: Triglyceride reduction with omega‐3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. Circulation2016;134:A16353. LakshminarayanDK , ElajamiTK , SolimanM , AlfaddaghA , WeltyFK . Omega‐3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. Circulation2015;132:A15530. ">HEARTS 2017</a>). We assessed 29 registry entries from ClinicalTrials.gov and 88 entries from WHO ICTRP, of which seven were newly included as ongoing trials (<a href="./references#CD003177-bbs2-0207" title="NCT03806426 . Effect of EPA‐FFA on polypectomy in familial adenomatous polyposis. clinicaltrials.gov/show/NCT03806426(first received January 2019). ">NCT03806426</a>; <a href="./references#CD003177-bbs2-0197" title="NCT02926027 . Effect of Vascepa on improving coronary atherosclerosis in people with high triglycerides taking statin therapy (EVAPORATE). clinicaltrials.gov/ct2/show/NCT02926027 (first posted 6 October 2016). ">EVAPORATE 2016</a>; <a href="./references#CD003177-bbs2-0200" title="NCT03448185 . Improving betabolic health in patients with diastolic dysfunction (MTG). clinicaltrials.gov/ct2/show/NCT03448185 (first posted 28 February 2018). ">MTG 2018</a>; <a href="./references#CD003177-bbs2-0206" title="NCT03784963 . Efficacy of omega‐3 fatty acid therapy in preventing gastrointestinal bleeding in patients with CF‐LVAD. clinicaltrials.gov/ct2/show/NCT03784963 (first posted 24 December 2018). ">NCT03784963</a>; <a href="./references#CD003177-bbs2-0198" title="NCT03691519 . Prevention of cognitive decline in older adults with low DHA/EPA index in red blood cells (LO‐MAPT). clinicaltrials.gov/show/NCT03691519 (added to registry 1 October 2018). ">LO‐MAPT 2018</a>; <a href="./references#CD003177-bbs2-0209" title="NCT03406897 . Pilot study of omega‐3 and vitamin D in high‐dose in type I diabetic patients (POSEIDON). clinicaltrials.gov/show/NCT03406897 (added to register 28 January 2018). ">POSEIDON 2018</a>; <a href="./references#CD003177-bbs2-0190" title="ACTRN12618000761268 . A 56 week, double‐blind, randomised study to evaluate the efficacy of testosterone, with and without DHA supplementation on cerebral amyloid load in known brain amyloid‐PET positive men with subjective memory complaints. www.anzctr.org.au/ACTRN12618000761268.aspx (added to register 7 May 2018). ">ACTRN12618000761268 2018</a>), and one is awaiting assessment, as it appears to fulfil all inclusion criteria, except that trial duration is unclear (<a href="./references#CD003177-bbs2-0188" title="IRCT20100123003140N21 . Effect of omega 3 fatty acids supplement on inflammatory factors (IL‐1ß, IL‐6, TNF‐a, IL‐10) and lipid profile in Parkinson disease. en.irct.ir/trial/29861 (added to register 18 April 2017). ">IRCT20100123003140N21</a>). <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a> had a number of substudies registered with different trial registration numbers, which we included as part of the included <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a> trial (noted in the <a href="./references#CD003177-sec-0199" title="">Characteristics of included studies</a>), even though most are ongoing. This provided 86 RCTs (over 421 documents) included in this review. </p> <div class="figure" id="CD003177-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD003177-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Of these 86 RCTs, we included 83 in meta‐analyses. Three trials clearly collected relevant data but did not report them in a format that we could use in meta‐analyses (<a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012</a>; <a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a>; <a href="./references#CD003177-bbs2-0068" title="OlendzkiBC , LeungK , VanBuskirkS , ReedG , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evidence‐based Complementary and Alternative Medicine : ECAM2011;2011:827286. ReedGW , LeungK , RossettiRG , VanbuskirkS , SharpJT , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: an 18‐month, randomized, and double‐blind trial. Evidence‐based Complementary and Alternative Medicine : ECAM2014;2014:857456. ">Reed 2014</a>; <a href="#CD003177-fig-0001">Figure 1</a>). </p> <p>Using the data provided in <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>, we updated the data for 10 trials already included in this review (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0022" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BerstadP , SeljeflotI , VeierodMB , HjerkinnEM , ArnesenH , PedersenJI . Supplementation with fish oil affects the association between very long‐chain n‐3 polyunsaturated fatty acids in serum non‐esterified fatty acids and soluble vascular cell adhesion molecule‐1. Clinical Science2003;105(1):13‐20. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition &amp; Metabolism2006;3:4. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism2006;3:1‐10. EinvikG , EkebergO , KlemsdalTO , SandvikL , HjerkinnEM . Physical distress is associated with cardiovascular events in a high risk population of elderly men. BMC Cardiovascular Disorders2009;9:14. [PUBMED: 19331677] EinvikG , EkebergO , LavikJG , EllingsenI , KlemsdalTO , HjerkinnEM . The influence of long‐term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. Journal of Psychosomatic Research2010;68(6):567‐72. EinvikG , KlemsdalTO , SandvikL , HjerkinnEM . A randomized clinical trial on n‐3 polyunsaturated fatty acids supplementation and all‐cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention &amp; Rehabilitation2010;17(5):588‐92. EllingsenI , HjerkinnEM , ArnesenH , SeljeflotI , HjermannI , TonstadS . Follow‐up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. European Journal of Clinical Nutrition2006;60(3):378‐85. FurenesEB , SeljeflotI , SolheimS , HjerkinnEM , ArnesenH , FurenesEB . Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation2008;68(3):177‐84. HjerkinnEM , AbdelnoorM , BreivikL , BergengenL , EllingsenI , SeljeflotI , et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention &amp; Rehabilitation2006;13(3):325‐33. HjerkinnEM , SeljeflotI , EllingsenI , BerstadP , HjermannI , SandvikL , et al. Influence of long‐term intervention with dietary counselling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. American Journal of Clinical Nutrition2005;81(3):583‐9. LindmanAS , PedersenJI , HjerkinnEM , ArnesenH , VeierodMB , EllingsenI , et al. The effects of long‐term diet and omega‐3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis and Haemostasis2004;91(6):1097‐104. TroseidM , ArnesenH , HjerkinnEM , SeljeflotI . Serum levels of interleukin‐18 are reduced by diet and n‐3 fatty acid intervention in elderly high‐risk men. Metabolism: Clinical and Experimental2009;58(11):1543‐9. TroseidM , SeljeflotI , WeissTW , KlemsdalTO , HjerkinnEM , ArnesenH . Arterial stiffness is independently associated with interleukin‐18 and components of the metabolic syndrome. Atherosclerosis2010;209(2):337‐9. ">DO IT 2010</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>). This has allowed us to include additional outcomes for some trials, and use updated numbers for others. </p> </section> <section id="CD003177-sec-0088"> <h4 class="title">Included studies</h4> <p>The 86 included RCTs randomised 162,796 participants, adding 31% to the number of participants with this update (we included 112,059 participants in the previous version of this review, <a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>). Fifteen trials (16 comparisons) randomised at least 1000 participants (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0054" title="NatvigH . The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. Tidsskrift for Den Norske Laegeforening1967;87(11):1033‐41. NatvigH , BorchgrevinkCF , DedichenJ , OwrenPA , SchiotzEH , WestlundK . A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965‐66. Scandinavian Journal of Clinical and Laboratory Investigation1968;105(Suppl):1‐20. ">Norwegian 1968</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>), of which one was a 2x2 factorial trial, which included both interventions (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>). Most of these larger trials assessed effects of LCn3 fats, but two trials/arms assessed effects of ALA (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0054" title="NatvigH . The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. Tidsskrift for Den Norske Laegeforening1967;87(11):1033‐41. NatvigH , BorchgrevinkCF , DedichenJ , OwrenPA , SchiotzEH , WestlundK . A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965‐66. Scandinavian Journal of Clinical and Laboratory Investigation1968;105(Suppl):1‐20. ">Norwegian 1968</a>). </p> <p>Participants had cardiovascular disease at baseline in 35 of the trials (secondary prevention), and the remaining 50 trials were of primary prevention, while one was mixed (<a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>). </p> <p>Most trials assessed effects of LCn3 fats.</p> <p> <ul id="CD003177-list-0041"> <li> <p>Sixty‐nine trials increased LCn3 intake using supplementary capsules or medicinal oils (<a href="./references#CD003177-bbs2-0001" title="QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. ">ADCS 2010</a>; <a href="./references#CD003177-bbs2-0002" title="NigamA , TalajicM , RoyD , NattelS , LambertJ , NozzaA , et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. Journal of the American College of Cardiology2014;64(14):1441‐8. NigamA , TalajicM , RoyD , NattelS , LambertJ , NozzaA , et al. Multicentre trial of fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress: the atrial fibrillation fish oil research study. Canadian Journal of Cardiology2013;1:S383. ">AFFORD 2013</a>; <a href="./references#CD003177-bbs2-0003" title="AhnJ , ParkSK , ParkTS , KimJH , YunE , KimSP , et al. Effect of n‐3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. Korean Circulation Journal2016;46(4):481‐9. [PUBMED: 27482256] ">Ahn 2016</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0008" title="BaldassarreD , AmatoM , EliginiS , BarbieriSS , MussoniL , FrigerioB , et al. Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double‐blind pilot study in primary prevention. Annals of Medicine2006;38(5):367‐75. [DOI: 10.1080/07853890600852880] ">Baldassarre 2006</a>; <a href="./references#CD003177-bbs2-0009" title="BatesD , CartlidgeNE , FrenchJM , JacksonMJ , NightingaleS , ShawDA , et al. A double‐blind controlled trial of long chain n‐3 polyunsaturated fatty acids in the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry1989;52(1):18‐22. ">Bates 1989</a>; <a href="./references#CD003177-bbs2-0010" title="BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Archives of Ophthalmology2004;122(9):1297‐305. BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Archives of Ophthalmology2004;122(9):1306‐14. ">Berson 2004</a>; <a href="./references#CD003177-bbs2-0012" title="BroxJ , OlaussenK , OsterudB , ElvevollEO , BjornstadE , BrattebogG , et al. A long‐term seal‐ and cod‐liver‐oil supplementation in hypercholesterolemic subjects. Lipids2001;36(1):7‐13. ">Brox 2001</a>; <a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0016" title="DerosaG , CiceroAF , D'AngeloA , BorghiC , MaffioliP . Effects of n‐3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors (Oxford, England)2016;42(3):316‐22. [PUBMED: 27040503] ">Derosa 2016</a>; <a href="./references#CD003177-bbs2-0017" title="BlokWL , DeslypereJP , DemackerPN , Van derVen‐JongekrijgJ , HectorsMP , Van derMeerJW , et al. Pro‐ and anti‐inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. European Journal of Clinical Investigation1997;27(12):1003‐8. [PUBMED: 9466128] DeslypereJP . Influence of supplementation with n‐3 fatty acids on different coronary risk factors in men: a placebo controlled study. Verhandelingen ‐ Koninklijke Academie voor Geneeskunde van Belgie1992;54(3):189‐216. [PUBMED: 1413984] KatanMB , DeslypereJP , VanBirgelenAP , PendersM , ZegwaardM . Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18‐month controlled study. Journal of Lipid Research1997;38(10):2012‐22. [PUBMED: 9374124] ">Deslypere 1992</a>; <a href="./references#CD003177-bbs2-0021" title="DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome. European Heart Journal2014;35(Abstract Suppl):1156. DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. International Journal of Cardiology2014;176(3):577‐82. [PUBMED: 25305703] NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , TsukudaS , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. International Journal of Cardiology2017;228:173‐9. [DOI: 10.1016/j.ijcard.2016.11.105] NosakaK , MiyoshiT , OkawaK , TsukudaS , SogoM , NishibeT , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. Journal of the American College of Cardiology2016;67:573. ">Doi 2014</a>; <a href="./references#CD003177-bbs2-0022" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BerstadP , SeljeflotI , VeierodMB , HjerkinnEM , ArnesenH , PedersenJI . Supplementation with fish oil affects the association between very long‐chain n‐3 polyunsaturated fatty acids in serum non‐esterified fatty acids and soluble vascular cell adhesion molecule‐1. Clinical Science2003;105(1):13‐20. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition &amp; Metabolism2006;3:4. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism2006;3:1‐10. EinvikG , EkebergO , KlemsdalTO , SandvikL , HjerkinnEM . Physical distress is associated with cardiovascular events in a high risk population of elderly men. BMC Cardiovascular Disorders2009;9:14. [PUBMED: 19331677] EinvikG , EkebergO , LavikJG , EllingsenI , KlemsdalTO , HjerkinnEM . The influence of long‐term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. Journal of Psychosomatic Research2010;68(6):567‐72. EinvikG , KlemsdalTO , SandvikL , HjerkinnEM . A randomized clinical trial on n‐3 polyunsaturated fatty acids supplementation and all‐cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention &amp; Rehabilitation2010;17(5):588‐92. EllingsenI , HjerkinnEM , ArnesenH , SeljeflotI , HjermannI , TonstadS . Follow‐up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. European Journal of Clinical Nutrition2006;60(3):378‐85. FurenesEB , SeljeflotI , SolheimS , HjerkinnEM , ArnesenH , FurenesEB . Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation2008;68(3):177‐84. HjerkinnEM , AbdelnoorM , BreivikL , BergengenL , EllingsenI , SeljeflotI , et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention &amp; Rehabilitation2006;13(3):325‐33. HjerkinnEM , SeljeflotI , EllingsenI , BerstadP , HjermannI , SandvikL , et al. Influence of long‐term intervention with dietary counselling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. American Journal of Clinical Nutrition2005;81(3):583‐9. LindmanAS , PedersenJI , HjerkinnEM , ArnesenH , VeierodMB , EllingsenI , et al. The effects of long‐term diet and omega‐3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis and Haemostasis2004;91(6):1097‐104. TroseidM , ArnesenH , HjerkinnEM , SeljeflotI . Serum levels of interleukin‐18 are reduced by diet and n‐3 fatty acid intervention in elderly high‐risk men. Metabolism: Clinical and Experimental2009;58(11):1543‐9. TroseidM , SeljeflotI , WeissTW , KlemsdalTO , HjerkinnEM , ArnesenH . Arterial stiffness is independently associated with interleukin‐18 and components of the metabolic syndrome. Atherosclerosis2010;209(2):337‐9. ">DO IT 2010</a>; <a href="./references#CD003177-bbs2-0023" title="AsbellPA , MaguireMG , PeskinE , BunyaVY , KuklinskiEJ . Dry Eye Assessment and Management (DREAM) Study: study design and baseline characteristics. Contemporary Clinical Trials2018;71:70‐9. [DOI: https://doi.org/10.1016/j.cct.2018.06.002] NCT02128763 . Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014). The Dry Eye Assessment and Management Study Research Group. n−3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine2018;378(18):1681‐90. [DOI: 10.1056/NEJMoa1709691] ">DREAM Asbell 2018</a>; <a href="./references#CD003177-bbs2-0024" title="CauleyJA , ManiniTM , LovatoL , TaltonJ , AntonSD , DomanchukK , et al. ENRGISE Investigators. The enabling reduction of low‐grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(8):1296‐302. [DOI: 10.1093/gerona/gly204] ManiniTM , AntonSD , BeaversDP , CauleyJA , EspelandMA , FieldingRA , et al. ENRGISE pilot study investigators. Eabling reduction of low‐grade inflammation in seniors pilot study: concept, rationale, and design. Journal of the American Geriatrics Society2017;65:1961‐68. [DOI: 10.1111/jgs.14965] NCT02676466 . The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low‐grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016). PahorM , AntonSD , BeaversDP , CauleyJA , FieldingRA , KritchevskySB , et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL‐6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(10):1612–19. [DOI: 10.1093/gerona/gly277] ">ENRGISE 2018</a>; <a href="./references#CD003177-bbs2-0025" title="SanyalAJ , AbdelmalekMF , SuzukiA , CummingsOW , ChojkierM . No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology2014;147(2):377‐84.e1. [PUBMED: 24818764] ">EPE‐A 2014</a> (as two different doses); <a href="./references#CD003177-bbs2-0026" title="FeaganBG , SandbornWJ , MittmannU , Bar‐MeirS , D'HaensG , BradetteM , et al. Omega‐3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA2008;299(14):1690‐7. ">EPIC‐1 2008</a>; <a href="./references#CD003177-bbs2-0027" title="FeaganBG , SandbornWJ , MittmannU , Bar‐MeirS , D'HaensG , BradetteM , et al. Omega‐3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA2008;229(14):1690‐7. ">EPIC‐2 2008</a>; <a href="./references#CD003177-bbs2-0028" title="DanthiirV , BurnsNR , NettelbeckT , WilsonC , WittertG . The older people, omega‐3, and cognitive health (EPOCH) trial design and methodology: a randomised, double‐blind, controlled trial investigating the effect of long‐chain omega‐3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Nutrition Journal2011;10:117. [PUBMED: 22011460] DanthiirV , HoskingD , BurnsNR , WilsonC , NettelbeckT , CalvaresiE , et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n‐3 fatty acids. Journal of Nutrition2014;144(3):311‐20. [PUBMED: 24353345] ">EPOCH 2014</a>; <a href="./references#CD003177-bbs2-0029" title="ErdoganA , BayerM , KollathD , GreissH , VossR , NeumannT , et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. Heart Rhythm2007;4(5):S185‐6. HeidtMC , VicianM , StrackeSK , StadlbauerT , GrebeMT , BoeningA , et al. Beneficial effects of intravenously administered n‐3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thoracic and Cardiovascular Surgeon2009;57:276‐80. [DOI: 10.1055/s‐0029‐1185301] MarianiJ , DovalHC , NulD , VariniS , GrancelliH , FerranteD , et al. N‐3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta‐analysis of randomized controlled trials. Journal of the American Heart Association2013;2(1):e005033. ">Erdogan 2007</a>; <a href="./references#CD003177-bbs2-0030" title="LeafA , AlbertCM , JosephsonM , SteinhausD , KlugerJ , KangJX , et al. Prevention of fatal arrhythmias in high‐risk subjects by fish oil n‐3 fatty acid intake. Circulation2005;112(18):2762‐8. ">FAAT 2005</a>; <a href="./references#CD003177-bbs2-0032" title="MacchiaA , GrancelliH , VariniS , NulD , FerranteD , MarianiJ , et al. Late‐breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. Circulation2012;126:2780‐1. MacchiaA , GrancelliH , VariniS , NulD , LaffayeN , MarianiJ , et al. Omega‐3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. Journal of the American College of Cardiology2013;61(4):463‐8. [PUBMED: 23265344] MacchiaA , VariniS , GrancelliH , NulD , LaffayeN , FerranteD , et al. The rationale and design of the FORomegaARD trial: a randomized, double‐blind, placebo‐controlled, independent study to test the efficacy of n‐3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal2009;157(3):423‐7. [PUBMED: 19249410] ">FORWARD 2013</a>; <a href="./references#CD003177-bbs2-0034" title="FranzenD . A prospective, randomized, and double‐blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Catheterization and Cardiovascular Diagnosis1993;28(4):301‐10. FranzenD , GeiselJ , HoppHW , OetteK , HilgerHH . Long‐term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem fischol auf serumlipide und lipoproteine]. Medizinische Klinik1993;88(3):134‐8. ">Franzen 1993</a>; <a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0038" title='PasternakRC , BrownLE , StonePH , SilvermanDI , GibsonCM , SacksFM . Effect of combination therapy with lipid‐reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo‐controlled trial. Annals of Internal Medicine1996;125(7):529‐40. [PUBMED: 8815751] SacksFM , PasternakRC , GibsonCM , RosnerB , StonePH . Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet1994;344(8931):1182‐6. [PUBMED: 7934538] SacksFM , StonePH , GibsonCM , SilvermanDI , RosnerB , PasternakRC . Controlled trial of fish oil for regression of human coronary atherosclerosis. Journal of the American College of Cardiology1995;25(7):1492‐8. '>HARP 1995</a>; <a href="./references#CD003177-bbs2-0039" title="AlfaddaghA , ElajamiTK , AshfaqueH , SalehM , BistrianBR , WeltyFK . Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. Journal of the American Heart Association2017;6(12):e006981. [DOI: 10.1161/JAHA.117.006981] AlfaddaghA , ElajamiTK , WeltyFK . Abstract 16294: Omega‐3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. Circulation2016;134:A16294. AlfaddaghA , MohebaliD , ElajamiTK , SalehM , WeltyFK . Abstract 17391: Omega‐3 fatty acid index &gt;= 4% prevents progression of coronary artery plaque in non‐diabetic subjects on statin therapy. Circulation2017;136 (Suppl 1):A17391. AlfaddaghA , WeltyFK . Abstract 17689: Omega‐3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short. ElajamiTK , AlfaddaghA , LakshminarayanD , SolimanM , ChandnaniM , WeltyFK . Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American Heart Association2017;6(7):e004740. [DOI: 10.1161/JAHA.116.004740] ElajamiTK , AlfaddaghA , WeltyFK . Abstract 16353: Triglyceride reduction with omega‐3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. Circulation2016;134:A16353. LakshminarayanDK , ElajamiTK , SolimanM , AlfaddaghA , WeltyFK . Omega‐3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. Circulation2015;132:A15530. ">HEARTS 2017</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0042" title="KumarS , SutherlandF , MortonJB , LeeG , MorganJ , WongJ , et al. Long‐term omega‐3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm2012;9(4):483‐91. [DOI: 10.1016/j.hrthm.2011.11.034] ">Kumar 2012</a>; <a href="./references#CD003177-bbs2-0043" title="KumarS , SutherlandF , StevensonI , LeeJM , GargML , SparksPB . Effects of long‐term omega‐3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. International Journal of Cardiology2013;168(4):3812‐7. [PUBMED: 23890856] ">Kumar 2013</a>; <a href="./references#CD003177-bbs2-0044" title="Lorenz‐MeyerH , BauerP , NicolayC , SchulzB , PurrmannJ , FleigWE , et al. Omega‐3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scandinavian Journal of Gastroenterology1996;31(8):778‐85. ">Lorenz‐Meyer 1996</a>; <a href="./references#CD003177-bbs2-0045" title="AndrieuS , GuyonnetS , ColeyN , CantetC , BonnefoyM , BordesS , et al. Effect of long‐term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo‐controlled trial. Lancet Neurology2017;16:377‐89. [DOI: 10.1016/S1474‐4422(17)30040‐6] BarretoPdS , RollandY , CesariM , DupuyC , AndrieuS , VellasB , for the MAPT Study Group. Effects of multidomain lifestyle intervention, omega‐3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. Age and Ageing2017;47(2):281‐8. [DOI: 10.1093/ageing/afx164] CarrieI , VanKanGA , Gillette‐GuyonnetS , AndrieuS , DartiguesJF , TouchonJ , et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). Journal of Nutrition, Health &amp; Aging2012;16(4):355‐9. DelrieuJ , AndrieuS , PahorM , CantetC , CesariM , OussetPJ , et al. Neuropsychological profile of &quot;cognitive frailty&quot; subjects in MAPT study. Journal of Prevention of Alzheimer's Disease2016;3(3):151‐9. [DOI: 10.14283/jpad.2016.94] DelrieuJ , PayouxP , HitzelA , PeifferS , Abellan Van KanG , GilletteS , et al. Multidomain Alzheimer's disease preventive trial: florbetapir ancillary study. Alzheimer's and Dementia2011;1:S419. FougereB , BarretoPD , GoisserS , SorianoG , GuyonnetS , AndrieuS , et al. Red blood cell membrane omega‐3 fatty acid levels and physical performance: cross‐sectional data from the MAPT study. Clinical Nutrition 2017 Apr 12 [Epub ahead of print]:1‐4. [DOI: 10.1016/j.clnu.2017.04.005] GilletteS . The Multidomain Alzheimer Preventive Trial (MAPT): a new approach for the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;S4‐02‐05:145. Gillette‐GuyonnetS , AndrieuS , DantoineT , DartiguesJF , TouchonJ , VellasB , et al. Commentary on &quot;A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.&quot; The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;5(2):114‐21. Gillette‐GuyonnetS , VellasB , AndrieuS , DupuyC , CarriéI . MAPT study: a 3‐year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects‐rationale, design and baseline data. Alzheimer's &amp; Dementia2011;1:S97‐8. VellasB , CarrieI , Gillette‐GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. Journal of Prevention of Alzheimers Disease2014;1(1):13‐22. VellasB , CarrieI , GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT (Multi‐domain Alzheimer's Prevention Trial): results at 36 months. Alzheimer's &amp; Dementia2015;1:331. VellasB , TouchonJ , WeinerM . MAPT (Multidomain Alzheimer Preventive Trial) imaging (MRI, FDG‐PET, amyloid‐PET) data. Journal of Nutrition, Health and Aging2012;16(9):812‐5. ">MAPT 2017</a>; <a href="./references#CD003177-bbs2-0047" title="Al‐HilalM , AlsalehA , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Genetic variation at the FADS1‐FADS2 gene locus influences delta‐5 desaturase activity and LC‐PUFA proportions after fish oil supplement. Journal of Lipid Research2013;54(2):542‐51. [PUBMED: 23160180] AlSalehA , ManiouZ , LewisFJ , HallWL , SandersTA , O'DellSD . Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. Journal of Nutrition2014;144(3):267‐72. [PUBMED: 24401815] AlsalehA , CrepostnaiaD , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. Journal of Nutrition2013;143(7):1021‐7. [PUBMED: 23658423] HallWL , HayG , ManiouZ , SeedPT , ChowienczykPJ , SandersTA . Effect of low doses of long chain n‐3 polyunsaturated fatty acids on sleep‐time heart rate variability: a randomized, controlled trial. International Journal of Cardiology2013;168:4439‐42. PintoAM , HallWL , SandersTAB . Effect of low doses of long chain n‐3 PUFA intake on daytime heart rate variability: results from the MARINA study. European Journal of Preventive Cardiology2015;1:S146. SandersTA , ChowienczykPJ , HallW , LewisF , SeedP , ManiouZ , et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report2011. SandersTA , HallWL , ManiouZ , LewisF , SeedPT , ChowienczykPJ . Effect of low doses of long‐chain n‐3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. American Journal of Clinical Nutrition2011;94(4):973‐80. [PUBMED: 21865334] ">MARINA 2011</a>; <a href="./references#CD003177-bbs2-0049" title="MitaT , WatadaH , OgiharaT , NomiyamaT , OgawaO , KinoshitaJ , et al. Eicosapentaenoic acid reduces the progression of carotid intima‐media thickness in patients with type 2 diabetes. Atherosclerosis2007;191(1):162‐7. ">Mita 2007</a>; <a href="./references#CD003177-bbs2-0050" title="MerleBM , BenlianP , PucheN , BassolsA , DelcourtC , SouiedEH . Circulating omega‐3 fatty acids and neovascular age‐related macular degeneration. Investigative Ophthalmology &amp; Visual Science2014;55(3):2010‐9. [PUBMED: 24557349] MerleBM , RichardF , BenlianP , PucheN , DelcourtC , SouiedEH . CFH Y402H and ARMS2 A69S polymorphisms and oral supplementation with docosahexaenoic acid in neovascular age‐related macular degeneration patients: the NAT2 study. PloS One2015;10(7):e0130816. [PUBMED: 26132079] QuerquesG , MerleBM , PumariegaNM , BenlianP , DelcourtC , ZourdaniA , et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment‐2 (NAT‐2) randomized trial. PLOS ONE2016;11(2):e0149219. [PUBMED: 26901353] SouiedEH , DelcourtC , QuerquesG , BassolsA , MerleB , ZourdaniA , et al. Oral docosahexaenoic acid in the prevention of exudative age‐related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology2013;120(8):1619‐31. [PUBMED: 23395546] ">NAT2 2013</a>; <a href="./references#CD003177-bbs2-0051" title="NodariS , TriggianiM , CampiaU , ManerbaA , MilesiG , CesanaBM , et al. N‐3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation2011;124(10):1100‐6. [PUBMED: 21844082] ">Nodari 2011 AF</a>; <a href="./references#CD003177-bbs2-0052" title="NCT01223703 . PUFAs and left ventricular function in heart failure (CS‐PUFA‐02) [Effects of n‐3 polyunsaturated fatty acids (PUFAs) on left ventricular function and functional capacity in patients with dilated cardiomyopathy]. clinicaltrials.gov/ct2/show/NCT01223703 (first received 19 October 2010). NodariS , TriggianiM , BerlinghieriN , MilesiG , ForestiA , GheorghiadeM , et al. Effects of n‐3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients. European Heart Journal2010;31:850. NodariS , TriggianiM , CampiaU , ManerbaA , MilesiG , CesanaBM , et al. Effects of n‐3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Journal of the American College of Cardiology2011;57(7):870‐9. NodariS , TriggianiM , CampiaU , ZhaoL , ManerbaA , MilesiG , et al. Plasma levels of n‐3 polyunsaturated fatty acids and risk of hospitalization in patients with non‐ischemic cardiomyopathy. Circulation2012;126(21 Suppl 1):A17431. ">Nodari 2011 HF</a>; <a href="./references#CD003177-bbs2-0053" title="Norouzi JavidanA , SabourH , LatifiS , AbrishamkarM , SoltaniZ , ShidfarF , et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord‐injured individuals? A double‐blinded clinical trial. Spinal Cord2014;52(5):378‐82. [PUBMED: 24637568] SabourH , Norouzi JavidanA , LatifiS , ShidfarF , HeshmatR , Emami RazaviSH , et al. Omega‐3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: a double‐blinded randomized clinical trial. Journal of Spinal Cord Medicine2015;38(5):599‐606. [PUBMED: 25096818] ">Norouzi 2014</a>; <a href="./references#CD003177-bbs2-0055" title="GarbagnatiF , CairellaG , DeMartinoA , MultariM , ScognamiglioU , VenturieroV , et al. Is antioxidant and n‐3 supplementation able to improve functional status in post‐stroke patients? Results from the Nutristroke Trial. Cerebrovascular Diseases2009;27(4):375‐83. [DOI: 10.1159/000207441] ">Nutristroke 2009</a>; <a href="./references#CD003177-bbs2-0056" title="IlseyCD , NyeER , SutherlandW , RamJ , AblettMB . Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty. Australian &amp; New Zealand Journal of Medicine1987;17:559. NyeER , AblettMB , RobertsonMC , IlsleyCD , SutherlandWH . Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Australian and New Zealand Journal of Medicine1990;20(4):549‐52. ">Nye 1990</a>; <a href="./references#CD003177-bbs2-0057" title="AarsetoyH , Brugger‐AndersenT , HetlandO , GrundtH , NilsenDW . Long term influence of regular intake of high dose n‐3 fatty acids on CD40‐ligand, pregnancy‐associated plasma protein A and matrix metalloproteinase‐9 following acute myocardial infarction. Thrombosis and Haemostasis2006;95(2):329‐36. GrundtH , HetlandO , NilsenDW . Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n‐3 polyunsaturated fatty acids. Thrombosis and Haemostasis2003;89(4):752‐9. GrundtH , NilsenDW , HetlandO , MansoorMA . Clinical outcome and atherothrombogenic risk profile after prolonged wash‐out following long‐term treatment with high doses of n‐3 PUFAs in patients with an acute myocardial infarction. Clinical Nutrition2004;23(4):491‐500. GrundtH , NilsenDW , MansoorMA , HetlandO , NordoyA . Reduction in homocysteine by n‐3 polyunsaturated fatty acids after 1 year in a randomised double‐blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiology of Haemostasis and Thrombosis2003;33(2):88‐95. GrundtH , NilsenDW , MansoorMA , NordoyA . Increased lipid peroxidation during long‐term intervention with high doses of n‐3 fatty acids (PUFAs) following an acute myocardial infarction. European Journal of Clinical Nutrition2003;57(6):793‐800. NaesgaardPA , GrundtH , BredeC , NilsenDW . The effect on vitamin D levels of long‐term high‐dose treatment with a concentrated omega‐3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction. Circulation2014;130(Suppl 2):A17245. NilsenDW , AlbrektsenG , LandmarkK , MoenS , AarslandT , WoieL . Effects of a high‐dose concentrate of n‐3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. American Journal of Clinical Nutrition2001;74(1):50‐6. PoenitzV , GrundtH , BottazziB , CuccovilloI , MantovaniA , NilsenDW . Pentraxin 3 is uninfluenced by high doses of concentrated omega‐3 fatty acids administered for 12 months following an acute myocardial infarction. Circulation2012;126(21 Suppl 1):A13464. ">OFAMI 2001</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0059" title="DangourAD , AllenE , ElbourneD , FaseyN , FletcherAE , HardyP , et al. Effect of 2‐y n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double‐blind, controlled trial. American Journal of Clinical Nutrition2010;91(6):1725‐32. DangourAD , AllenE , ElbourneD , FletcherA , RichardsM , UauyR . Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. Journal of Nutrition, Health &amp; Aging2009;13(3):198‐202. DangourAD , AllenE , ElbourneD , FletcherAE , NeveuMM , UauyR , et al. N‐3 fatty acids and retinal function. Ophthalmology2013;120(3):643. [DOI: dx.doi.org/10.1016/j.ophtha.2012.09.043] DangourAD , ClemensF , ElbourneD , FaseyN , FletcherAE , HardyP , et al. A randomised controlled trial investigating the effect of n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n‐3 Long‐chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutrition Journal2006;5:20. ISRCTN72331636 . The OPAL Study: older people and n‐3 long‐chain polyunsaturated fatty acids. www.isrctn.com/ISRCTN72331636 (first received 27 April 2004). [ISRCTN72331636] ">OPAL 2010</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0061" title="TatsunoI , SaitoY , KudouK , OotakeJ . Long‐term safety and efficacy of TAK‐085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega‐3 fatty acids randomized long‐term (ORL) study. Journal of Clinical Lipidology2013;7(6):615‐25. [PUBMED: 24314359] TatsunoIT , SaitoYS , KudouKK , OtakeJO , MinamideYM . Effects of long‐term treatment with omega‐3 polyunsaturated fatty acids (Lotriga) on atherogenic lipoproteins in hypertriglyceridemia: results from a phase 3 randomized, open‐label, 1‐year study. European Heart Journal2013;34:768. ">ORL 2013</a>; <a href="./references#CD003177-bbs2-0062" title="ÖzaydinM , ErdoğanD , TayyarS , UysalBA , DoğanA , IçliA , et al. N‐3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyoloji Dergisi2011;11(4):305‐9. [DOI: 10.5152/akd.2011.080] ">Özaydin 2011</a>; <a href="./references#CD003177-bbs2-0063" title="ProudmanS , SpargoL , HallC , McWilliamsL , LeeA , MaureenR , et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. Internal Medicine Journal2012;42(Suppl 1):2‐3. ProudmanSM , ClelandLG , MetcalfRG , SullivanTR , SpargoLD , JamesMJ . Plasma n‐3 fatty acids and clinical outcomes in recent‐onset rheumatoid arthritis. British Journal of Nutrition2015;114(6):885‐90. [PUBMED: 26283657] ProudmanSM , JamesMJ , SpargoLD , MetcalfRG , SullivanTR , RischmuellerM , et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double‐blind controlled trial within algorithm‐based drug use. Annals of the Rheumatic Diseases2015;74(1):89‐95. [PUBMED: 24081439] ">Proudman 2015</a>; <a href="./references#CD003177-bbs2-0064" title="PuriBK , LeavittBR , HaydenMR , RossCA , RosenblattA , GreenamyreJT , et al. Ethyl‐EPA in Huntington disease: a double‐blind, randomized, placebo‐controlled trial. Neurology2005;65(2):286‐92. ">Puri 2005</a>; <a href="./references#CD003177-bbs2-0065" title="RaittMH , ConnorWE , MorrisC , KronJ , HalperinB , ChughSS , et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA2005;293(23):2884‐91. ">Raitt 2005</a>; <a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0068" title="OlendzkiBC , LeungK , VanBuskirkS , ReedG , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evidence‐based Complementary and Alternative Medicine : ECAM2011;2011:827286. ReedGW , LeungK , RossettiRG , VanbuskirkS , SharpJT , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: an 18‐month, randomized, and double‐blind trial. Evidence‐based Complementary and Alternative Medicine : ECAM2014;2014:857456. ">Reed 2014</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0070" title="MyrupB , RossingP , JensenT , ParvingH‐H , HolmerG , GramJ , et al. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin‐dependent diabetic patients with diabetic nephropathy. Scandinavian Journal of Clinical &amp; Laboratory Investigation2001;61(5):349‐56. RossingP , HansenBV , NielsenFS , MyrupB , HolmerG , ParvingHH . Fish oil in diabetic nephropathy. Diabetes Care1996;19(11):1214‐9. ">Rossing 1996</a>; <a href="./references#CD003177-bbs2-0071" title="SandhuN , SchetterSE , LiaoJ , HartmanTJ , RichieJP , McGinleyJ , et al. Influence of obesity on breast density reduction by omega‐3 fatty acids: evidence from a randomized clinical trial. Cancer Prevention Research2016;9(4):275‐82. [PUBMED: 26714774] SignoriC , DuBrockC , RichieJP , ProkopczykB , DemersLM , HamiltonC , et al. Administration of omega‐3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. European Journal of Clinical Nutrition2012;66(8):878‐84. [PUBMED: 22669332] ">Sandhu 2016</a>; <a href="./references#CD003177-bbs2-0072" title="AngererP , KothnyW , StorkS , vonSchackyC . Effect of dietary supplementation with omega‐3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovascular Research2002;54(1):183‐90. vonSchackyC , AngererP , KothnyW , TheisenK , MudraH . The effect of dietary omega‐3 fatty acids on coronary atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine1999;130(7):554‐62. vonSchackyC , BaumannK , AngererP . The effect of n‐3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids2001;36(Suppl):S99‐102. ">SCIMO 1999</a>; <a href="./references#CD003177-bbs2-0073" title="HullMA , SandellAC , MontgomeryAA , LoganRF , CliffordGM , ReesCJ , et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:237. HullMA , SprangeK , HepburnT , TanW , ShafayatA , ReesCJ , et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double‐blind, placebo‐controlled, 2x2 factorial trial. Lancet2018;392(10164):2583‐94. [DOI: 10.1016/S0140‐6736(18)31775‐6] ">seAFOod Hull 2018</a>; <a href="./references#CD003177-bbs2-0074" title="NCT00090402 . Fish oil and alpha lipoic acid in treating Alzheimer's Disease [Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease]. clinicaltrials.gov/ct2/show/NCT00090402 (first received 24 August 2004). [CENTRAL: NCT00090402] ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardW , Baldauf‐WagnerS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimer's Disease2014;38(1):111‐20. [PUBMED: 24077434] ">Shinto 2014</a>; <a href="./references#CD003177-bbs2-0075" title="EritslandJ , ArnesenH , BergK , SeljeflotI , AbdelnoorM . Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long‐term n‐3 fatty acid supplementation. Scandinavian Journal of Clinical and Laboratory Investigation1995;55(4):295‐300. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of dietary supplementation with n‐3 fatty acids on coronary artery bypass graft patency. American Journal of Cardiology1996;77(1):31‐6. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of supplementation with n‐3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study. European Heart Journal1994;15:29. EritslandJ , ArnesenH , SeljeflotI , HostmarkAT . Long‐term metabolic effects of n‐3 polyunsaturated fatty acids in patients with coronary artery disease. American Journal of Clinical Nutrition1995;61(4):831‐6. EritslandJ , ArnesenH , SeljeflotI , KierulfP . Long‐term effects of n‐3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagulation &amp; Fibrinolysis1995;6(1):17‐22. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Fibrinolysis1994;8(2):120‐5. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH , TorjesenPA . Long‐term effects of n‐3 fatty acids on serum lipids and glycaemic control. Scandinavian Journal of Clinical and Laboratory Investigation1994;54(4):273‐80. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term effects of fish oil supplementation in patients with coronary artery disease: influence on lipoproteins, coagulation and fibrinolysis. Thrombosis Research1992;65:75. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Thrombosis and Haemostasis1993;69:1065. EritslandJ , SeljeflotI , ArnesenH , WestvikAB , KierulfP . Effect of long‐term, moderate‐dose supplementation with omega‐3 fatty acids on monocyte procoagulant activity and release of interleukin‐6 in patients with coronary artery disease. Thrombosis Research1995;77(4):337‐46. ">SHOT 1996</a>; <a href="./references#CD003177-bbs2-0076" title="SianniA , MatsoukisI , GanotopoulouA , ParaskevasP , AsimisA , TsivilisN , et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. Clinical Nutrition2013;32:S70‐1. ">Sianni 2013</a>; <a href="./references#CD003177-bbs2-0078" title="BrouwerIA , KatanMB , SchoutenEG , CammAJ , HauerRN , WeverEF , et al. Rationale and design of a clinical trial on n‐3 fatty acids and cardiac arrhythmia (SOFA). Annals of Nutrition &amp; Metabolism2001;45(Suppl 1):79. BrouwerIA , RaittMH , DullemeijerC , KraemerDF , ZockPL , MorrisC , et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. European Heart Journal2009;30(7):820‐6. BrouwerIA , ZockPL , CammAJ , BöckerD , HauerRN , WeverEF , et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega‐3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA2006;295(22):2613‐9. BrouwerIA , ZockPL , WeverEF , HauerRN , CammAJ , BockerD , et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n‐3 fatty acids and incidence of cardiac arrhythmia: SOFA. European Journal of Clinical Nutrition2003;57:1323‐30. ">SOFA 2006</a>; <a href="./references#CD003177-bbs2-0079" title="SofiF , GiangrandiI , CesariF , CorsaniI , AbbateR , GensiniGF , et al. Effects of a 1‐year dietary intervention with n‐3 polyunsaturated fatty acid‐enriched olive oil on non‐alcoholic fatty liver disease patients: a preliminary study. International Journal of Food Sciences and Nutrition2010;61(8):792‐802. [PUBMED: 20465434] ">Sofi 2010</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>; <a href="./references#CD003177-bbs2-0081" title="TandeKS , VoTD , LynchBS . Clinical safety evaluation of marine oil derived from Calanus finmarchicus. Regulatory Toxicology and Pharmacology: RTP2016;80:25‐31. [PUBMED: 27233921] ">Tande 2016</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>; <a href="./references#CD003177-bbs2-0086" title="BhatiaL , ScorlettiE , CurzenN , CloughGF , CalderPC , ByrneCD . Improvement in non‐alcoholic fatty liver disease severity is associated with a reduction in carotid intima‐media thickness progression. Atherosclerosis2016;246:13‐20. [PUBMED: 26748347] ByrneCD , TargherG . Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology2014;34(6):1155‐61. [PUBMED: 24743428] ByrneCD , TargherG . Time to replace assessment of liver histology with MR‐based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology2016; Vol. 150, issue 1:7‐10. [PUBMED: 26602219] CloughGF , McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , et al. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex evaluation of fatty liver and cardiovascular markers in NAFLD with Omacor therapy trial (WELCOME) trial. Diabetologia2016;59(7):1422‐9. [PUBMED: 27106721] HodsonL , BhatiaL , ScorlettiE , SmithDE , JacksonNC , Shojaee‐MoradieF , et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. European Journal of Clinical Nutrition2017;71(8):973‐9. [PUBMED: 28294174] McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Impact of high dose n‐3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non‐alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia2015;58(8):1916‐25. [PUBMED: 26021488] McCormickKG , ScorlettiES , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n‐3 fatty acids. Diabetic Medicine2015;32(S1):99. ScorlettiE , BhatiaB , McCormickKG , CloughGF , NashK , HodsonL , et al. Potential benefits of purified long chain omega‐3 fatty acid treatment in non‐alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study. Diabetic Medicine2014;31:1. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty acid treatment in non‐alcoholic fatty liver disease [corrected]. Contemporary Clinical Trials2014;37(2):301‐11. [PUBMED: 24556343] ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty treatment in non‐alcoholic fatty liver disease. Contemporary Clinical Trials2014;38(1):156. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , HodsonL , et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology (Baltimore, MD)2014;60(4):1211‐21. [PUBMED: 25043514] ScorlettiE , WestAL , BhatiaL , HoileSP , McCormickKG , BurdgeGC , et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. Journal of Hepatology2015;63(6):1476‐83. [PUBMED: 26272871] TargherG , ByrneCD . Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism2013;98(2):483‐95. [PUBMED: 23293330] ">WELCOME 2015</a>; <a href="./references#CD003177-bbs2-0087" title="ZhangY‐P , RujuanM , QingL , WuT , MaF . Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12‐month randomized, double‐blind, placebo‐controlled trial. Journal of Alzheimer's Disease2016;55(2):497‐507. ">Zhang 2017</a>). </p> </li> <li> <p>Two trials used supplemented or supplemental foods, either enriched margarine (<a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>) or orange juice (<a href="./references#CD003177-bbs2-0033" title="ChenJS , HillCL , LesterS , RuedigerCD , BattersbyR , JonesG , et al. Supplementation with omega‐3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2‐year randomized controlled trial. Osteoporosis International2016;27(5):1897‐905. [PUBMED: 26694596] HillC , LesterSE , JonesG . Response to 'Low‐dose versus high‐dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis' by Chen et al. Annals of the Rheumatic Diseases2016; Vol. 75, issue 1:e8. [PUBMED: 26662278] HillCL , MarchLM , AitkenD , LesterSE , BattersbyR , HynesK , et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Annals of the Rheumatic Diseases2016;75(1):23‐9. [PUBMED: 26353789] ">FOSTAR 2016</a>) to increase LCn3. </p> </li> <li> <p>Four increased LCn3 fats using dietary advice (<a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>; <a href="./references#CD003177-bbs2-0019" title="HarrisonRA . Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005. HarrisonRA , EltonP . From pies to pilchards: dietary assistants increase consumption of oil rich fish. Journal of Epidemiology and Community Health2000;Suppl:6. HarrisonRA , EltonPJ . Can an oil‐rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. International Society for the Study of Fatty Acids and Lipids (ISSFAL); 2002 May; Montreal, Canada. 2002. HarrisonRA , EltonPJ . Is there a role for long‐chain omega3 or oil‐rich fish in the treatment of atrial fibrillation?. Medical Hypotheses2005;64(1):59‐63. [PUBMED: 15533612] HarrisonRA , PurnellP , EltonPJ . Using community‐based dietary assistants to increase the intake of oil‐rich fish among older people. European Journal of Public Health2003;13(Suppl 1):105. HarrisonRA , SureshV , PurnellB , RobertsC , HoughtonP , MillerJ , et al. Can oil‐rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010. ">DISAF 2003</a>; <a href="./references#CD003177-bbs2-0082" title="PackardDP , MiltonJE , ShulerLA , ShortRA , TuttleKR . Implications of chronic kidney disease for dietary treatment of cardiovascular disease. Journal of Renal Nutrition2006;16(3):259‐68. TuttleKR , ShulerLA , PackardDP , MiltonJE , DarathaKB , BibusDM , et al. Comparison of low‐fat versus Mediterranean‐style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). American Journal of Cardiology2008;101(11):1523‐30. [PUBMED: 18489927] ">THIS DIET 2008</a>). </p> </li> <li> <p>Three provided some combination of these interventions to increase LCn3 (<a href="./references#CD003177-bbs2-0018" title="TokudomeS , KurikiK , YokoyamaY , SasakiM , JohT , KamiyaT , et al. Dietary n‐3/long‐chain n‐3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukotrienes and Essential Fatty Acids2015;94:1‐11. [PUBMED: 25451556] TokudomeS , YokoyamaY , KamiyaT , SenoK , OkuyamaH , KurikiK , et al. Rationale and study design of dietary intervention in patients polypectomized for tumors of the colorectum. Japanese Journal of Clinical Oncology2002;32(12):550‐3. [PUBMED: 12578906] ">DIPP 2015</a>; <a href="./references#CD003177-bbs2-0077" title="AnilS , CharltonKE , TapsellLC , ProbstY , NdanukoR , BatterhamMJ . Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. Journal of Human Hypertension2016;30(11):672‐8. [DOI: 10.1038/jhh.2016.10] TapsellLC , BatterhamMJ , CharltonKE . Effect of dietary restriction and n‐3 PUFA supplementation on insulin resistance in obese adults. FASEB Journal2010;24:733.9. TapsellLC , BatterhamMJ , CharltonKE , NealeEP , ProbstYC , O'SheaJE , et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. BMC Public Health2013;13:1231. [PUBMED: 24369765] ZhangQ , O'SheaJE , ThorneRL , TapsellLC , BatterhamM , CharltonKE . Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors. Nutrition and Dietetics2010;67(Suppl 1):67‐8. ">SMART 2013</a>; <a href="./references#CD003177-bbs2-0085" title="Weinstock‐GuttmanB , BaierM , ParkY , FeichterJ , Lee‐KwenP , GallagherE , et al. Low fat dietary intervention with n‐3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids2005;73:397‐404. [DOI: 10.1016/j.plefa.2005.05.024] ">Weinstock‐Guttman 2005</a>). </p> </li> </ul> </p> <p>Doses of LCn3 ranged from 0.5 g/d of EPA and DHA to more than 5 g/d (19 RCTs had a dose of LCn3 &lt; 1 g/d, 27 a dose of 1 to &lt; 2 g/d, 12 of 2 to &lt; 3 g/d, 19 RCTs had a dose of 3 or more g/d LCn3, 1 did not clearly state their dose). </p> <p>Fewer trials assessed the effects of ALA on health outcomes.</p> <p> <ul id="CD003177-list-0042"> <li> <p>One trial used supplementary capsules or medicinal oils to increase ALA (<a href="./references#CD003177-bbs2-0054" title="NatvigH . The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. Tidsskrift for Den Norske Laegeforening1967;87(11):1033‐41. NatvigH , BorchgrevinkCF , DedichenJ , OwrenPA , SchiotzEH , WestlundK . A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965‐66. Scandinavian Journal of Clinical and Laboratory Investigation1968;105(Suppl):1‐20. ">Norwegian 1968</a>). </p> </li> <li> <p>Seven increased ALA using supplemented or supplemental foods, such as enriched margarine, bread, walnuts or other enriched food products (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0020" title="DodinS , CunnaneSC , MasseB , LemayA , JacquesH , AsselinG , et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double‐blind, placebo‐controlled trial. Nutrition (Burbank, Los Angeles County, Calif.)2008;24(1):23‐30. [PUBMED: 17981439] DodinS , LemayA , JacquesH , LegareF , ForestJC , MasseB . The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double‐blind, wheat germ placebo‐controlled clinical trial. Journal of Clinical Endocrinology and Metabolism2005;90(3):1390‐7. [PUBMED: 15613422] ">Dodin 2005</a>; <a href="./references#CD003177-bbs2-0031" title="CaligiuriSP , AukemaHM , RavandiA , GuzmanR , DibrovE , PierceGN . Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha‐linolenic acid‐induced inhibition of soluble epoxide hydrolase. Hypertension2014;64(1):53‐9. [PUBMED: 24777981] CaligiuriSP , Rodriguez‐LeyvaD , AukemaHM , RavandiA , WeighellW , GuzmanR , et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension2016;68(4):1031‐8. [PUBMED: 27528063] EdelA , Rodriguez‐LeyvaD , WeighellW , LaValleeR , AlianiM , GuzmanR , et al. Flaxseed lignan metabolites elicit antihypertensive effects in PAD patients in the FLAX‐PAD trial. Annals of Nutrition and Metabolism2013;63:1339. EdelAL , Rodriguez‐LeyvaD , MaddafordTG , CaligiuriSP , AustriaJA , WeighellW , et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol‐lowering medications alone in patients with peripheral artery disease. Journal of Nutrition2015;145(4):749‐57. [PUBMED: 25694068] LeyvaDR , ZahradkaP , RamjiawanB , GuzmanR , AlianiM , PierceGN . The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX‐PAD randomized controlled trial. Contemporary Clinical Trials2011;32(5):724‐30. [PUBMED: 21616170] PierceGN , EdelAL , LaValleeR , CaligiuriS , AukemaH , RavandiA , et al. The use of dietary flaxseed to promote cardiovascular health. Acta Physiologica2014;211:15. PierceGN , Rodriguez‐LeyvaD , EdelA , GuzmanR , AlianiM . The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. Cardiology (Switzerland)2013;126:201. Rodriguez‐LeyvaD , WeighellW , EdelAL , LaValleeR , DibrovE , PinnekerR , et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension2013;62(6):1081‐9. [PUBMED: 24126178] ">FLAX‐PAD 2013</a>; <a href="./references#CD003177-bbs2-0040" title="TanSY . Dietary Manipulation and Weight Management [PhD thesis]. Wollongong, Australia: University of Wollonong, 2010. TapsellLC , BatterhamMJ , TeussG , TanSY , DaltonS , QuickCJ , et al. Long‐term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. European Journal of Clinical Nutrition2009;63(8):1008‐15. [PUBMED: 19352378] ">HERO 2009</a>; <a href="./references#CD003177-bbs2-0046" title="BemelmansWJ , BroerJ , DeVriesJH , HulshofKF , MayJF , Meyboom‐De JongB . Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. Public Health Nutrition2000;3(3):273‐83. BemelmansWJ , BroerJ , FeskensEJ , SmitAJ , MuskietAJ , LefrandtJD , et al. Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. American Journal of Clinical Nutrition2002;75:221‐7. BemelmansWJ , LefrandtJD , FeskensEJ , BroerJ , TervaertJW , MayJF , et al. Change in saturated fat intake is associated with progression of carotid and femoral intima‐media thickness, and with levels of soluble intercellular adhesion molecule‐1. Atherosclerosis2002;163(1):113‐20. BemelmansWJ , LefrandtJD , FeskensEJ , VanHaelstPL , BroerJ , Meyboom‐de JongB , et al. Increased alpha‐linolenic acid intake lowers C‐reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition2004;58(7):1083‐9. BemelmansWJ , MuskietFA , FeskensEJ , DeVriesJH , BroerJ , MayJF , et al. Associations of alpha‐linolenic acid and linoleic acid with risk factors for coronary heart disease. European Journal of Clinical Nutrition2000;54(12):865‐71. SieroFW , BroerJ , BemelmansWJ , Meyboom‐de JongBM . Impact of group nutrition education and surplus value of Prochaska based stage‐matched information on health‐related cognitions and on Mediterranean nutrition behaviour. Health Education Research2000;15(5):635‐47. ">MARGARIN 2002</a>; <a href="./references#CD003177-bbs2-0084" title="BitokE , Jaceldo‐SieglK , RajaramS , Serra‐MirM , RothI , Feitas‐SimoesT , et al. Favourable nutrient intake and displacement with long‐term walnut supplementation among elderly: results of a randomised trial. British Journal of Nutrition2017;118(3):201‐9. [DOI: 10.1017/S0007114517001957] BitokE , RajaramS , RosE . Does a daily walnut supplement given for a year result in body weight gain?. FASEB Journal2016; Vol. 30:1157.5. HueyL , BitokE , KazziN . Dietary compliance of walnut or no walnut intake in a 1‐year randomized intervention trial among free‐living elderly in the Walnuts and Healthy Aging Study (WAHA). FASEB Journal2016; Vol. 30:1157.10. RajaramS , Valls‐PedretC , CofanM , SabateJ , Serra‐MirM , Perez‐HerasAM , et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. Frontiers in Aging Neuroscience2017;8:333. [PUBMED: 28119602] RosE , RajaramS , Sala‐VilaA , Serra‐MirM , Vals‐PedretC , CofanM , et al. Effect of a 1‐year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. FASEB Journal2016; Vol. 30, issue 1 Suppl:293.4. ">WAHA 2016</a>). </p> </li> <li> <p>One used a combination of these to increase ALA (<a href="./references#CD003177-bbs2-0048" title="LeT , FlattSW , NatarajanL , PakizB , QuintanaEL , HeathDD , et al. Effects of diet composition and insulin resistance status on plasma lipid levels in a weight loss intervention in women. Journal of the American Heart Association2016;5(1):e002771. [DOI: 10.1161/JAHA.115.002771] RockCL , FlattSW , PakizB , QuintanaEL , HeathDD , RanaBK , et al. Effects of diet composition on weight loss, metabolic factors and biomarkers in a 1‐year weight loss intervention in obese women examined by baseline insulin resistance status. Metabolism2016;65(11):1605‐13. [DOI: 10.1016/j.metabol.2016.07.008] ">MENU 2016</a>). </p> </li> </ul> </p> <p>One trial provided an intervention combining LCn3 and ALA as capsules (<a href="./references#CD003177-bbs2-0018" title="TokudomeS , KurikiK , YokoyamaY , SasakiM , JohT , KamiyaT , et al. Dietary n‐3/long‐chain n‐3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukotrienes and Essential Fatty Acids2015;94:1‐11. [PUBMED: 25451556] TokudomeS , YokoyamaY , KamiyaT , SenoK , OkuyamaH , KurikiK , et al. Rationale and study design of dietary intervention in patients polypectomized for tumors of the colorectum. Japanese Journal of Clinical Oncology2002;32(12):550‐3. [PUBMED: 12578906] ">DIPP 2015</a>). However, trial authors did not state the ALA dose, so we treated the trial as an LCn3 intervention. </p> <p>Control groups received olive, corn, sunflower oils, other types of fats (including medium‐chain triglycerides and fat replicating the composition of an average European diet), other 'inert' or ill‐defined substances (liquid paraffin, aluminium hydroxide, 'placebo' not described), different dietary advice or foods without the omega‐3 enrichment, or no treatment/no placebo. These control groups or replacements are shown for each key outcome when subgrouping by replacement (for example <a href="./references#CD003177-fig-0012" title="">Analysis 1.6</a> shows effects of increasing LCn3 on all‐cause mortality, grouped by replacement). </p> <p>The main trial outcome was cardiovascular in 51 trials. Twenty‐one trials (22 comparisons) aimed to measure death or cardiovascular events (<a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>; <a href="./references#CD003177-bbs2-0021" title="DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome. European Heart Journal2014;35(Abstract Suppl):1156. DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. International Journal of Cardiology2014;176(3):577‐82. [PUBMED: 25305703] NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , TsukudaS , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. International Journal of Cardiology2017;228:173‐9. [DOI: 10.1016/j.ijcard.2016.11.105] NosakaK , MiyoshiT , OkawaK , TsukudaS , SogoM , NishibeT , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. Journal of the American College of Cardiology2016;67:573. ">Doi 2014</a>; <a href="./references#CD003177-bbs2-0030" title="LeafA , AlbertCM , JosephsonM , SteinhausD , KlugerJ , KangJX , et al. Prevention of fatal arrhythmias in high‐risk subjects by fish oil n‐3 fatty acid intake. Circulation2005;112(18):2762‐8. ">FAAT 2005</a>; <a href="./references#CD003177-bbs2-0031" title="CaligiuriSP , AukemaHM , RavandiA , GuzmanR , DibrovE , PierceGN . Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha‐linolenic acid‐induced inhibition of soluble epoxide hydrolase. Hypertension2014;64(1):53‐9. [PUBMED: 24777981] CaligiuriSP , Rodriguez‐LeyvaD , AukemaHM , RavandiA , WeighellW , GuzmanR , et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension2016;68(4):1031‐8. [PUBMED: 27528063] EdelA , Rodriguez‐LeyvaD , WeighellW , LaValleeR , AlianiM , GuzmanR , et al. Flaxseed lignan metabolites elicit antihypertensive effects in PAD patients in the FLAX‐PAD trial. Annals of Nutrition and Metabolism2013;63:1339. EdelAL , Rodriguez‐LeyvaD , MaddafordTG , CaligiuriSP , AustriaJA , WeighellW , et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol‐lowering medications alone in patients with peripheral artery disease. Journal of Nutrition2015;145(4):749‐57. [PUBMED: 25694068] LeyvaDR , ZahradkaP , RamjiawanB , GuzmanR , AlianiM , PierceGN . The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX‐PAD randomized controlled trial. Contemporary Clinical Trials2011;32(5):724‐30. [PUBMED: 21616170] PierceGN , EdelAL , LaValleeR , CaligiuriS , AukemaH , RavandiA , et al. The use of dietary flaxseed to promote cardiovascular health. Acta Physiologica2014;211:15. PierceGN , Rodriguez‐LeyvaD , EdelA , GuzmanR , AlianiM . The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. Cardiology (Switzerland)2013;126:201. Rodriguez‐LeyvaD , WeighellW , EdelAL , LaValleeR , DibrovE , PinnekerR , et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension2013;62(6):1081‐9. [PUBMED: 24126178] ">FLAX‐PAD 2013</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0054" title="NatvigH . The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. Tidsskrift for Den Norske Laegeforening1967;87(11):1033‐41. NatvigH , BorchgrevinkCF , DedichenJ , OwrenPA , SchiotzEH , WestlundK . A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965‐66. Scandinavian Journal of Clinical and Laboratory Investigation1968;105(Suppl):1‐20. ">Norwegian 1968</a>; <a href="./references#CD003177-bbs2-0056" title="IlseyCD , NyeER , SutherlandW , RamJ , AblettMB . Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty. Australian &amp; New Zealand Journal of Medicine1987;17:559. NyeER , AblettMB , RobertsonMC , IlsleyCD , SutherlandWH . Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Australian and New Zealand Journal of Medicine1990;20(4):549‐52. ">Nye 1990</a>; <a href="./references#CD003177-bbs2-0057" title="AarsetoyH , Brugger‐AndersenT , HetlandO , GrundtH , NilsenDW . Long term influence of regular intake of high dose n‐3 fatty acids on CD40‐ligand, pregnancy‐associated plasma protein A and matrix metalloproteinase‐9 following acute myocardial infarction. Thrombosis and Haemostasis2006;95(2):329‐36. GrundtH , HetlandO , NilsenDW . Changes in tissue factor and activated factor XII following an acute myocardial infarction were uninfluenced by high doses of n‐3 polyunsaturated fatty acids. Thrombosis and Haemostasis2003;89(4):752‐9. GrundtH , NilsenDW , HetlandO , MansoorMA . Clinical outcome and atherothrombogenic risk profile after prolonged wash‐out following long‐term treatment with high doses of n‐3 PUFAs in patients with an acute myocardial infarction. Clinical Nutrition2004;23(4):491‐500. GrundtH , NilsenDW , MansoorMA , HetlandO , NordoyA . Reduction in homocysteine by n‐3 polyunsaturated fatty acids after 1 year in a randomised double‐blind study following an acute myocardial infarction: no effect on endothelial adhesion properties. Pathophysiology of Haemostasis and Thrombosis2003;33(2):88‐95. GrundtH , NilsenDW , MansoorMA , NordoyA . Increased lipid peroxidation during long‐term intervention with high doses of n‐3 fatty acids (PUFAs) following an acute myocardial infarction. European Journal of Clinical Nutrition2003;57(6):793‐800. NaesgaardPA , GrundtH , BredeC , NilsenDW . The effect on vitamin D levels of long‐term high‐dose treatment with a concentrated omega‐3 compound (Omacor/Lovaza) in patients hospitalized with a myocardial infarction. Circulation2014;130(Suppl 2):A17245. NilsenDW , AlbrektsenG , LandmarkK , MoenS , AarslandT , WoieL . Effects of a high‐dose concentrate of n‐3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. American Journal of Clinical Nutrition2001;74(1):50‐6. PoenitzV , GrundtH , BottazziB , CuccovilloI , MantovaniA , NilsenDW . Pentraxin 3 is uninfluenced by high doses of concentrated omega‐3 fatty acids administered for 12 months following an acute myocardial infarction. Circulation2012;126(21 Suppl 1):A13464. ">OFAMI 2001</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0078" title="BrouwerIA , KatanMB , SchoutenEG , CammAJ , HauerRN , WeverEF , et al. Rationale and design of a clinical trial on n‐3 fatty acids and cardiac arrhythmia (SOFA). Annals of Nutrition &amp; Metabolism2001;45(Suppl 1):79. BrouwerIA , RaittMH , DullemeijerC , KraemerDF , ZockPL , MorrisC , et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. European Heart Journal2009;30(7):820‐6. BrouwerIA , ZockPL , CammAJ , BöckerD , HauerRN , WeverEF , et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega‐3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA2006;295(22):2613‐9. BrouwerIA , ZockPL , WeverEF , HauerRN , CammAJ , BockerD , et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n‐3 fatty acids and incidence of cardiac arrhythmia: SOFA. European Journal of Clinical Nutrition2003;57:1323‐30. ">SOFA 2006</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>; <a href="./references#CD003177-bbs2-0082" title="PackardDP , MiltonJE , ShulerLA , ShortRA , TuttleKR . Implications of chronic kidney disease for dietary treatment of cardiovascular disease. Journal of Renal Nutrition2006;16(3):259‐68. TuttleKR , ShulerLA , PackardDP , MiltonJE , DarathaKB , BibusDM , et al. Comparison of low‐fat versus Mediterranean‐style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). American Journal of Cardiology2008;101(11):1523‐30. [PUBMED: 18489927] ">THIS DIET 2008</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>). </p> <p>Thirty‐two trials aimed to measure various cardiovascular risk factors or progression of cardiovascular health. </p> <p> <ul id="CD003177-list-0043"> <li> <p>Atrial fibrillation recurrence or sinus rhythm (<a href="./references#CD003177-bbs2-0002" title="NigamA , TalajicM , RoyD , NattelS , LambertJ , NozzaA , et al. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. Journal of the American College of Cardiology2014;64(14):1441‐8. NigamA , TalajicM , RoyD , NattelS , LambertJ , NozzaA , et al. Multicentre trial of fish oil for the reduction of atrial fibrillation recurrence, inflammation and oxidative stress: the atrial fibrillation fish oil research study. Canadian Journal of Cardiology2013;1:S383. ">AFFORD 2013</a>; <a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0019" title="HarrisonRA . Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005. HarrisonRA , EltonP . From pies to pilchards: dietary assistants increase consumption of oil rich fish. Journal of Epidemiology and Community Health2000;Suppl:6. HarrisonRA , EltonPJ . Can an oil‐rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. International Society for the Study of Fatty Acids and Lipids (ISSFAL); 2002 May; Montreal, Canada. 2002. HarrisonRA , EltonPJ . Is there a role for long‐chain omega3 or oil‐rich fish in the treatment of atrial fibrillation?. Medical Hypotheses2005;64(1):59‐63. [PUBMED: 15533612] HarrisonRA , PurnellP , EltonPJ . Using community‐based dietary assistants to increase the intake of oil‐rich fish among older people. European Journal of Public Health2003;13(Suppl 1):105. HarrisonRA , SureshV , PurnellB , RobertsC , HoughtonP , MillerJ , et al. Can oil‐rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010. ">DISAF 2003</a>; <a href="./references#CD003177-bbs2-0029" title="ErdoganA , BayerM , KollathD , GreissH , VossR , NeumannT , et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. Heart Rhythm2007;4(5):S185‐6. HeidtMC , VicianM , StrackeSK , StadlbauerT , GrebeMT , BoeningA , et al. Beneficial effects of intravenously administered n‐3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thoracic and Cardiovascular Surgeon2009;57:276‐80. [DOI: 10.1055/s‐0029‐1185301] MarianiJ , DovalHC , NulD , VariniS , GrancelliH , FerranteD , et al. N‐3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta‐analysis of randomized controlled trials. Journal of the American Heart Association2013;2(1):e005033. ">Erdogan 2007</a>; <a href="./references#CD003177-bbs2-0030" title="LeafA , AlbertCM , JosephsonM , SteinhausD , KlugerJ , KangJX , et al. Prevention of fatal arrhythmias in high‐risk subjects by fish oil n‐3 fatty acid intake. Circulation2005;112(18):2762‐8. ">FAAT 2005</a>; <a href="./references#CD003177-bbs2-0032" title="MacchiaA , GrancelliH , VariniS , NulD , FerranteD , MarianiJ , et al. Late‐breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. Circulation2012;126:2780‐1. MacchiaA , GrancelliH , VariniS , NulD , LaffayeN , MarianiJ , et al. Omega‐3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. Journal of the American College of Cardiology2013;61(4):463‐8. [PUBMED: 23265344] MacchiaA , VariniS , GrancelliH , NulD , LaffayeN , FerranteD , et al. The rationale and design of the FORomegaARD trial: a randomized, double‐blind, placebo‐controlled, independent study to test the efficacy of n‐3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal2009;157(3):423‐7. [PUBMED: 19249410] ">FORWARD 2013</a>; <a href="./references#CD003177-bbs2-0042" title="KumarS , SutherlandF , MortonJB , LeeG , MorganJ , WongJ , et al. Long‐term omega‐3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm2012;9(4):483‐91. [DOI: 10.1016/j.hrthm.2011.11.034] ">Kumar 2012</a>; <a href="./references#CD003177-bbs2-0043" title="KumarS , SutherlandF , StevensonI , LeeJM , GargML , SparksPB . Effects of long‐term omega‐3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. International Journal of Cardiology2013;168(4):3812‐7. [PUBMED: 23890856] ">Kumar 2013</a>; <a href="./references#CD003177-bbs2-0051" title="NodariS , TriggianiM , CampiaU , ManerbaA , MilesiG , CesanaBM , et al. N‐3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation2011;124(10):1100‐6. [PUBMED: 21844082] ">Nodari 2011 AF</a>; <a href="./references#CD003177-bbs2-0062" title="ÖzaydinM , ErdoğanD , TayyarS , UysalBA , DoğanA , IçliA , et al. N‐3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyoloji Dergisi2011;11(4):305‐9. [DOI: 10.5152/akd.2011.080] ">Özaydin 2011</a>; <a href="./references#CD003177-bbs2-0065" title="RaittMH , ConnorWE , MorrisC , KronJ , HalperinB , ChughSS , et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA2005;293(23):2884‐91. ">Raitt 2005</a>; <a href="./references#CD003177-bbs2-0076" title="SianniA , MatsoukisI , GanotopoulouA , ParaskevasP , AsimisA , TsivilisN , et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. Clinical Nutrition2013;32:S70‐1. ">Sianni 2013</a>) </p> </li> <li> <p>Atherosclerosis progression/regression (<a href="./references#CD003177-bbs2-0003" title="AhnJ , ParkSK , ParkTS , KimJH , YunE , KimSP , et al. Effect of n‐3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. Korean Circulation Journal2016;46(4):481‐9. [PUBMED: 27482256] ">Ahn 2016</a>; <a href="./references#CD003177-bbs2-0022" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BerstadP , SeljeflotI , VeierodMB , HjerkinnEM , ArnesenH , PedersenJI . Supplementation with fish oil affects the association between very long‐chain n‐3 polyunsaturated fatty acids in serum non‐esterified fatty acids and soluble vascular cell adhesion molecule‐1. Clinical Science2003;105(1):13‐20. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition &amp; Metabolism2006;3:4. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism2006;3:1‐10. EinvikG , EkebergO , KlemsdalTO , SandvikL , HjerkinnEM . Physical distress is associated with cardiovascular events in a high risk population of elderly men. BMC Cardiovascular Disorders2009;9:14. [PUBMED: 19331677] EinvikG , EkebergO , LavikJG , EllingsenI , KlemsdalTO , HjerkinnEM . The influence of long‐term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. Journal of Psychosomatic Research2010;68(6):567‐72. EinvikG , KlemsdalTO , SandvikL , HjerkinnEM . A randomized clinical trial on n‐3 polyunsaturated fatty acids supplementation and all‐cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention &amp; Rehabilitation2010;17(5):588‐92. EllingsenI , HjerkinnEM , ArnesenH , SeljeflotI , HjermannI , TonstadS . Follow‐up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. European Journal of Clinical Nutrition2006;60(3):378‐85. FurenesEB , SeljeflotI , SolheimS , HjerkinnEM , ArnesenH , FurenesEB . Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation2008;68(3):177‐84. HjerkinnEM , AbdelnoorM , BreivikL , BergengenL , EllingsenI , SeljeflotI , et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention &amp; Rehabilitation2006;13(3):325‐33. HjerkinnEM , SeljeflotI , EllingsenI , BerstadP , HjermannI , SandvikL , et al. Influence of long‐term intervention with dietary counselling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. American Journal of Clinical Nutrition2005;81(3):583‐9. LindmanAS , PedersenJI , HjerkinnEM , ArnesenH , VeierodMB , EllingsenI , et al. The effects of long‐term diet and omega‐3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis and Haemostasis2004;91(6):1097‐104. TroseidM , ArnesenH , HjerkinnEM , SeljeflotI . Serum levels of interleukin‐18 are reduced by diet and n‐3 fatty acid intervention in elderly high‐risk men. Metabolism: Clinical and Experimental2009;58(11):1543‐9. TroseidM , SeljeflotI , WeissTW , KlemsdalTO , HjerkinnEM , ArnesenH . Arterial stiffness is independently associated with interleukin‐18 and components of the metabolic syndrome. Atherosclerosis2010;209(2):337‐9. ">DO IT 2010</a>; <a href="./references#CD003177-bbs2-0038" title='PasternakRC , BrownLE , StonePH , SilvermanDI , GibsonCM , SacksFM . Effect of combination therapy with lipid‐reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo‐controlled trial. Annals of Internal Medicine1996;125(7):529‐40. [PUBMED: 8815751] SacksFM , PasternakRC , GibsonCM , RosnerB , StonePH . Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet1994;344(8931):1182‐6. [PUBMED: 7934538] SacksFM , StonePH , GibsonCM , SilvermanDI , RosnerB , PasternakRC . Controlled trial of fish oil for regression of human coronary atherosclerosis. Journal of the American College of Cardiology1995;25(7):1492‐8. '>HARP 1995</a>; <a href="./references#CD003177-bbs2-0039" title="AlfaddaghA , ElajamiTK , AshfaqueH , SalehM , BistrianBR , WeltyFK . Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. Journal of the American Heart Association2017;6(12):e006981. [DOI: 10.1161/JAHA.117.006981] AlfaddaghA , ElajamiTK , WeltyFK . Abstract 16294: Omega‐3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. Circulation2016;134:A16294. AlfaddaghA , MohebaliD , ElajamiTK , SalehM , WeltyFK . Abstract 17391: Omega‐3 fatty acid index &gt;= 4% prevents progression of coronary artery plaque in non‐diabetic subjects on statin therapy. Circulation2017;136 (Suppl 1):A17391. AlfaddaghA , WeltyFK . Abstract 17689: Omega‐3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short. ElajamiTK , AlfaddaghA , LakshminarayanD , SolimanM , ChandnaniM , WeltyFK . Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American Heart Association2017;6(7):e004740. [DOI: 10.1161/JAHA.116.004740] ElajamiTK , AlfaddaghA , WeltyFK . Abstract 16353: Triglyceride reduction with omega‐3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. Circulation2016;134:A16353. LakshminarayanDK , ElajamiTK , SolimanM , AlfaddaghA , WeltyFK . Omega‐3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. Circulation2015;132:A15530. ">HEARTS 2017</a>; <a href="./references#CD003177-bbs2-0072" title="AngererP , KothnyW , StorkS , vonSchackyC . Effect of dietary supplementation with omega‐3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovascular Research2002;54(1):183‐90. vonSchackyC , AngererP , KothnyW , TheisenK , MudraH . The effect of dietary omega‐3 fatty acids on coronary atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine1999;130(7):554‐62. vonSchackyC , BaumannK , AngererP . The effect of n‐3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids2001;36(Suppl):S99‐102. ">SCIMO 1999</a>) </p> </li> <li> <p>Left ventricular function (<a href="./references#CD003177-bbs2-0052" title="NCT01223703 . PUFAs and left ventricular function in heart failure (CS‐PUFA‐02) [Effects of n‐3 polyunsaturated fatty acids (PUFAs) on left ventricular function and functional capacity in patients with dilated cardiomyopathy]. clinicaltrials.gov/ct2/show/NCT01223703 (first received 19 October 2010). NodariS , TriggianiM , BerlinghieriN , MilesiG , ForestiA , GheorghiadeM , et al. Effects of n‐3 polyunsaturated fatty acids on left ventricular function and functional capacity in heart failure patients. European Heart Journal2010;31:850. NodariS , TriggianiM , CampiaU , ManerbaA , MilesiG , CesanaBM , et al. Effects of n‐3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. Journal of the American College of Cardiology2011;57(7):870‐9. NodariS , TriggianiM , CampiaU , ZhaoL , ManerbaA , MilesiG , et al. Plasma levels of n‐3 polyunsaturated fatty acids and risk of hospitalization in patients with non‐ischemic cardiomyopathy. Circulation2012;126(21 Suppl 1):A17431. ">Nodari 2011 HF</a>) </p> </li> <li> <p>Coronary artery bypass graft patency (<a href="./references#CD003177-bbs2-0075" title="EritslandJ , ArnesenH , BergK , SeljeflotI , AbdelnoorM . Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long‐term n‐3 fatty acid supplementation. Scandinavian Journal of Clinical and Laboratory Investigation1995;55(4):295‐300. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of dietary supplementation with n‐3 fatty acids on coronary artery bypass graft patency. American Journal of Cardiology1996;77(1):31‐6. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of supplementation with n‐3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study. European Heart Journal1994;15:29. EritslandJ , ArnesenH , SeljeflotI , HostmarkAT . Long‐term metabolic effects of n‐3 polyunsaturated fatty acids in patients with coronary artery disease. American Journal of Clinical Nutrition1995;61(4):831‐6. EritslandJ , ArnesenH , SeljeflotI , KierulfP . Long‐term effects of n‐3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagulation &amp; Fibrinolysis1995;6(1):17‐22. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Fibrinolysis1994;8(2):120‐5. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH , TorjesenPA . Long‐term effects of n‐3 fatty acids on serum lipids and glycaemic control. Scandinavian Journal of Clinical and Laboratory Investigation1994;54(4):273‐80. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term effects of fish oil supplementation in patients with coronary artery disease: influence on lipoproteins, coagulation and fibrinolysis. Thrombosis Research1992;65:75. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Thrombosis and Haemostasis1993;69:1065. EritslandJ , SeljeflotI , ArnesenH , WestvikAB , KierulfP . Effect of long‐term, moderate‐dose supplementation with omega‐3 fatty acids on monocyte procoagulant activity and release of interleukin‐6 in patients with coronary artery disease. Thrombosis Research1995;77(4):337‐46. ">SHOT 1996</a>) </p> </li> <li> <p>Lipids and other cardiovascular disease risk factors (<a href="./references#CD003177-bbs2-0012" title="BroxJ , OlaussenK , OsterudB , ElvevollEO , BjornstadE , BrattebogG , et al. A long‐term seal‐ and cod‐liver‐oil supplementation in hypercholesterolemic subjects. Lipids2001;36(1):7‐13. ">Brox 2001</a>; <a href="./references#CD003177-bbs2-0017" title="BlokWL , DeslypereJP , DemackerPN , Van derVen‐JongekrijgJ , HectorsMP , Van derMeerJW , et al. Pro‐ and anti‐inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. European Journal of Clinical Investigation1997;27(12):1003‐8. [PUBMED: 9466128] DeslypereJP . Influence of supplementation with n‐3 fatty acids on different coronary risk factors in men: a placebo controlled study. Verhandelingen ‐ Koninklijke Academie voor Geneeskunde van Belgie1992;54(3):189‐216. [PUBMED: 1413984] KatanMB , DeslypereJP , VanBirgelenAP , PendersM , ZegwaardM . Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18‐month controlled study. Journal of Lipid Research1997;38(10):2012‐22. [PUBMED: 9374124] ">Deslypere 1992</a>; <a href="./references#CD003177-bbs2-0034" title="FranzenD . A prospective, randomized, and double‐blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Catheterization and Cardiovascular Diagnosis1993;28(4):301‐10. FranzenD , GeiselJ , HoppHW , OetteK , HilgerHH . Long‐term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem fischol auf serumlipide und lipoproteine]. Medizinische Klinik1993;88(3):134‐8. ">Franzen 1993</a>; <a href="./references#CD003177-bbs2-0046" title="BemelmansWJ , BroerJ , DeVriesJH , HulshofKF , MayJF , Meyboom‐De JongB . Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. Public Health Nutrition2000;3(3):273‐83. BemelmansWJ , BroerJ , FeskensEJ , SmitAJ , MuskietAJ , LefrandtJD , et al. Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. American Journal of Clinical Nutrition2002;75:221‐7. BemelmansWJ , LefrandtJD , FeskensEJ , BroerJ , TervaertJW , MayJF , et al. Change in saturated fat intake is associated with progression of carotid and femoral intima‐media thickness, and with levels of soluble intercellular adhesion molecule‐1. Atherosclerosis2002;163(1):113‐20. BemelmansWJ , LefrandtJD , FeskensEJ , VanHaelstPL , BroerJ , Meyboom‐de JongB , et al. Increased alpha‐linolenic acid intake lowers C‐reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition2004;58(7):1083‐9. BemelmansWJ , MuskietFA , FeskensEJ , DeVriesJH , BroerJ , MayJF , et al. Associations of alpha‐linolenic acid and linoleic acid with risk factors for coronary heart disease. European Journal of Clinical Nutrition2000;54(12):865‐71. SieroFW , BroerJ , BemelmansWJ , Meyboom‐de JongBM . Impact of group nutrition education and surplus value of Prochaska based stage‐matched information on health‐related cognitions and on Mediterranean nutrition behaviour. Health Education Research2000;15(5):635‐47. ">MARGARIN 2002</a>) </p> </li> <li> <p>Diabetes, insulin or glucose‐based outcomes (<a href="./references#CD003177-bbs2-0016" title="DerosaG , CiceroAF , D'AngeloA , BorghiC , MaffioliP . Effects of n‐3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors (Oxford, England)2016;42(3):316‐22. [PUBMED: 27040503] ">Derosa 2016</a>; <a href="./references#CD003177-bbs2-0070" title="MyrupB , RossingP , JensenT , ParvingH‐H , HolmerG , GramJ , et al. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin‐dependent diabetic patients with diabetic nephropathy. Scandinavian Journal of Clinical &amp; Laboratory Investigation2001;61(5):349‐56. RossingP , HansenBV , NielsenFS , MyrupB , HolmerG , ParvingHH . Fish oil in diabetic nephropathy. Diabetes Care1996;19(11):1214‐9. ">Rossing 1996</a>) </p> </li> <li> <p>Endothelial function or carotid intima‐media thickness (<a href="./references#CD003177-bbs2-0008" title="BaldassarreD , AmatoM , EliginiS , BarbieriSS , MussoniL , FrigerioB , et al. Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double‐blind pilot study in primary prevention. Annals of Medicine2006;38(5):367‐75. [DOI: 10.1080/07853890600852880] ">Baldassarre 2006</a>; <a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012</a>; <a href="./references#CD003177-bbs2-0047" title="Al‐HilalM , AlsalehA , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Genetic variation at the FADS1‐FADS2 gene locus influences delta‐5 desaturase activity and LC‐PUFA proportions after fish oil supplement. Journal of Lipid Research2013;54(2):542‐51. [PUBMED: 23160180] AlSalehA , ManiouZ , LewisFJ , HallWL , SandersTA , O'DellSD . Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. Journal of Nutrition2014;144(3):267‐72. [PUBMED: 24401815] AlsalehA , CrepostnaiaD , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. Journal of Nutrition2013;143(7):1021‐7. [PUBMED: 23658423] HallWL , HayG , ManiouZ , SeedPT , ChowienczykPJ , SandersTA . Effect of low doses of long chain n‐3 polyunsaturated fatty acids on sleep‐time heart rate variability: a randomized, controlled trial. International Journal of Cardiology2013;168:4439‐42. PintoAM , HallWL , SandersTAB . Effect of low doses of long chain n‐3 PUFA intake on daytime heart rate variability: results from the MARINA study. European Journal of Preventive Cardiology2015;1:S146. SandersTA , ChowienczykPJ , HallW , LewisF , SeedP , ManiouZ , et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report2011. SandersTA , HallWL , ManiouZ , LewisF , SeedPT , ChowienczykPJ . Effect of low doses of long‐chain n‐3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. American Journal of Clinical Nutrition2011;94(4):973‐80. [PUBMED: 21865334] ">MARINA 2011</a>; <a href="./references#CD003177-bbs2-0049" title="MitaT , WatadaH , OgiharaT , NomiyamaT , OgawaO , KinoshitaJ , et al. Eicosapentaenoic acid reduces the progression of carotid intima‐media thickness in patients with type 2 diabetes. Atherosclerosis2007;191(1):162‐7. ">Mita 2007</a>) </p> </li> <li> <p>Body weight and adiposity (<a href="./references#CD003177-bbs2-0040" title="TanSY . Dietary Manipulation and Weight Management [PhD thesis]. Wollongong, Australia: University of Wollonong, 2010. TapsellLC , BatterhamMJ , TeussG , TanSY , DaltonS , QuickCJ , et al. Long‐term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. European Journal of Clinical Nutrition2009;63(8):1008‐15. [PUBMED: 19352378] ">HERO 2009</a>; <a href="./references#CD003177-bbs2-0048" title="LeT , FlattSW , NatarajanL , PakizB , QuintanaEL , HeathDD , et al. Effects of diet composition and insulin resistance status on plasma lipid levels in a weight loss intervention in women. Journal of the American Heart Association2016;5(1):e002771. [DOI: 10.1161/JAHA.115.002771] RockCL , FlattSW , PakizB , QuintanaEL , HeathDD , RanaBK , et al. Effects of diet composition on weight loss, metabolic factors and biomarkers in a 1‐year weight loss intervention in obese women examined by baseline insulin resistance status. Metabolism2016;65(11):1605‐13. [DOI: 10.1016/j.metabol.2016.07.008] ">MENU 2016</a>; <a href="./references#CD003177-bbs2-0077" title="AnilS , CharltonKE , TapsellLC , ProbstY , NdanukoR , BatterhamMJ . Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. Journal of Human Hypertension2016;30(11):672‐8. [DOI: 10.1038/jhh.2016.10] TapsellLC , BatterhamMJ , CharltonKE . Effect of dietary restriction and n‐3 PUFA supplementation on insulin resistance in obese adults. FASEB Journal2010;24:733.9. TapsellLC , BatterhamMJ , CharltonKE , NealeEP , ProbstYC , O'SheaJE , et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. BMC Public Health2013;13:1231. [PUBMED: 24369765] ZhangQ , O'SheaJE , ThorneRL , TapsellLC , BatterhamM , CharltonKE . Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors. Nutrition and Dietetics2010;67(Suppl 1):67‐8. ">SMART 2013</a>) </p> </li> </ul> </p> <p>Thirty‐five RCTs assessed effects on other health states.</p> <p> <ul id="CD003177-list-0044"> <li> <p>Cognitive measures (<a href="./references#CD003177-bbs2-0001" title="QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. ">ADCS 2010</a>; <a href="./references#CD003177-bbs2-0028" title="DanthiirV , BurnsNR , NettelbeckT , WilsonC , WittertG . The older people, omega‐3, and cognitive health (EPOCH) trial design and methodology: a randomised, double‐blind, controlled trial investigating the effect of long‐chain omega‐3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Nutrition Journal2011;10:117. [PUBMED: 22011460] DanthiirV , HoskingD , BurnsNR , WilsonC , NettelbeckT , CalvaresiE , et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n‐3 fatty acids. Journal of Nutrition2014;144(3):311‐20. [PUBMED: 24353345] ">EPOCH 2014</a>; <a href="./references#CD003177-bbs2-0045" title="AndrieuS , GuyonnetS , ColeyN , CantetC , BonnefoyM , BordesS , et al. Effect of long‐term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo‐controlled trial. Lancet Neurology2017;16:377‐89. [DOI: 10.1016/S1474‐4422(17)30040‐6] BarretoPdS , RollandY , CesariM , DupuyC , AndrieuS , VellasB , for the MAPT Study Group. Effects of multidomain lifestyle intervention, omega‐3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. Age and Ageing2017;47(2):281‐8. [DOI: 10.1093/ageing/afx164] CarrieI , VanKanGA , Gillette‐GuyonnetS , AndrieuS , DartiguesJF , TouchonJ , et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). Journal of Nutrition, Health &amp; Aging2012;16(4):355‐9. DelrieuJ , AndrieuS , PahorM , CantetC , CesariM , OussetPJ , et al. Neuropsychological profile of &quot;cognitive frailty&quot; subjects in MAPT study. Journal of Prevention of Alzheimer's Disease2016;3(3):151‐9. [DOI: 10.14283/jpad.2016.94] DelrieuJ , PayouxP , HitzelA , PeifferS , Abellan Van KanG , GilletteS , et al. Multidomain Alzheimer's disease preventive trial: florbetapir ancillary study. Alzheimer's and Dementia2011;1:S419. FougereB , BarretoPD , GoisserS , SorianoG , GuyonnetS , AndrieuS , et al. Red blood cell membrane omega‐3 fatty acid levels and physical performance: cross‐sectional data from the MAPT study. Clinical Nutrition 2017 Apr 12 [Epub ahead of print]:1‐4. [DOI: 10.1016/j.clnu.2017.04.005] GilletteS . The Multidomain Alzheimer Preventive Trial (MAPT): a new approach for the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;S4‐02‐05:145. Gillette‐GuyonnetS , AndrieuS , DantoineT , DartiguesJF , TouchonJ , VellasB , et al. Commentary on &quot;A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.&quot; The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;5(2):114‐21. Gillette‐GuyonnetS , VellasB , AndrieuS , DupuyC , CarriéI . MAPT study: a 3‐year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects‐rationale, design and baseline data. Alzheimer's &amp; Dementia2011;1:S97‐8. VellasB , CarrieI , Gillette‐GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. Journal of Prevention of Alzheimers Disease2014;1(1):13‐22. VellasB , CarrieI , GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT (Multi‐domain Alzheimer's Prevention Trial): results at 36 months. Alzheimer's &amp; Dementia2015;1:331. VellasB , TouchonJ , WeinerM . MAPT (Multidomain Alzheimer Preventive Trial) imaging (MRI, FDG‐PET, amyloid‐PET) data. Journal of Nutrition, Health and Aging2012;16(9):812‐5. ">MAPT 2017</a>; <a href="./references#CD003177-bbs2-0059" title="DangourAD , AllenE , ElbourneD , FaseyN , FletcherAE , HardyP , et al. Effect of 2‐y n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double‐blind, controlled trial. American Journal of Clinical Nutrition2010;91(6):1725‐32. DangourAD , AllenE , ElbourneD , FletcherA , RichardsM , UauyR . Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. Journal of Nutrition, Health &amp; Aging2009;13(3):198‐202. DangourAD , AllenE , ElbourneD , FletcherAE , NeveuMM , UauyR , et al. N‐3 fatty acids and retinal function. Ophthalmology2013;120(3):643. [DOI: dx.doi.org/10.1016/j.ophtha.2012.09.043] DangourAD , ClemensF , ElbourneD , FaseyN , FletcherAE , HardyP , et al. A randomised controlled trial investigating the effect of n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n‐3 Long‐chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutrition Journal2006;5:20. ISRCTN72331636 . The OPAL Study: older people and n‐3 long‐chain polyunsaturated fatty acids. www.isrctn.com/ISRCTN72331636 (first received 27 April 2004). [ISRCTN72331636] ">OPAL 2010</a>; <a href="./references#CD003177-bbs2-0074" title="NCT00090402 . Fish oil and alpha lipoic acid in treating Alzheimer's Disease [Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease]. clinicaltrials.gov/ct2/show/NCT00090402 (first received 24 August 2004). [CENTRAL: NCT00090402] ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardW , Baldauf‐WagnerS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimer's Disease2014;38(1):111‐20. [PUBMED: 24077434] ">Shinto 2014</a>; <a href="./references#CD003177-bbs2-0084" title="BitokE , Jaceldo‐SieglK , RajaramS , Serra‐MirM , RothI , Feitas‐SimoesT , et al. Favourable nutrient intake and displacement with long‐term walnut supplementation among elderly: results of a randomised trial. British Journal of Nutrition2017;118(3):201‐9. [DOI: 10.1017/S0007114517001957] BitokE , RajaramS , RosE . Does a daily walnut supplement given for a year result in body weight gain?. FASEB Journal2016; Vol. 30:1157.5. HueyL , BitokE , KazziN . Dietary compliance of walnut or no walnut intake in a 1‐year randomized intervention trial among free‐living elderly in the Walnuts and Healthy Aging Study (WAHA). FASEB Journal2016; Vol. 30:1157.10. RajaramS , Valls‐PedretC , CofanM , SabateJ , Serra‐MirM , Perez‐HerasAM , et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. Frontiers in Aging Neuroscience2017;8:333. [PUBMED: 28119602] RosE , RajaramS , Sala‐VilaA , Serra‐MirM , Vals‐PedretC , CofanM , et al. Effect of a 1‐year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. FASEB Journal2016; Vol. 30, issue 1 Suppl:293.4. ">WAHA 2016</a>; <a href="./references#CD003177-bbs2-0087" title="ZhangY‐P , RujuanM , QingL , WuT , MaF . Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12‐month randomized, double‐blind, placebo‐controlled trial. Journal of Alzheimer's Disease2016;55(2):497‐507. ">Zhang 2017</a>) </p> </li> <li> <p>Eye health (<a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0010" title="BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Archives of Ophthalmology2004;122(9):1297‐305. BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Archives of Ophthalmology2004;122(9):1306‐14. ">Berson 2004</a>; <a href="./references#CD003177-bbs2-0023" title="AsbellPA , MaguireMG , PeskinE , BunyaVY , KuklinskiEJ . Dry Eye Assessment and Management (DREAM) Study: study design and baseline characteristics. Contemporary Clinical Trials2018;71:70‐9. [DOI: https://doi.org/10.1016/j.cct.2018.06.002] NCT02128763 . Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014). The Dry Eye Assessment and Management Study Research Group. n−3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine2018;378(18):1681‐90. [DOI: 10.1056/NEJMoa1709691] ">DREAM Asbell 2018</a>; <a href="./references#CD003177-bbs2-0050" title="MerleBM , BenlianP , PucheN , BassolsA , DelcourtC , SouiedEH . Circulating omega‐3 fatty acids and neovascular age‐related macular degeneration. Investigative Ophthalmology &amp; Visual Science2014;55(3):2010‐9. [PUBMED: 24557349] MerleBM , RichardF , BenlianP , PucheN , DelcourtC , SouiedEH . CFH Y402H and ARMS2 A69S polymorphisms and oral supplementation with docosahexaenoic acid in neovascular age‐related macular degeneration patients: the NAT2 study. PloS One2015;10(7):e0130816. [PUBMED: 26132079] QuerquesG , MerleBM , PumariegaNM , BenlianP , DelcourtC , ZourdaniA , et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment‐2 (NAT‐2) randomized trial. PLOS ONE2016;11(2):e0149219. [PUBMED: 26901353] SouiedEH , DelcourtC , QuerquesG , BassolsA , MerleB , ZourdaniA , et al. Oral docosahexaenoic acid in the prevention of exudative age‐related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology2013;120(8):1619‐31. [PUBMED: 23395546] ">NAT2 2013</a>) </p> </li> <li> <p>Multiple sclerosis outcomes (<a href="./references#CD003177-bbs2-0009" title="BatesD , CartlidgeNE , FrenchJM , JacksonMJ , NightingaleS , ShawDA , et al. A double‐blind controlled trial of long chain n‐3 polyunsaturated fatty acids in the treatment of multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry1989;52(1):18‐22. ">Bates 1989</a>; <a href="./references#CD003177-bbs2-0085" title="Weinstock‐GuttmanB , BaierM , ParkY , FeichterJ , Lee‐KwenP , GallagherE , et al. Low fat dietary intervention with n‐3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins, Leukotrienes and Essential Fatty Acids2005;73:397‐404. [DOI: 10.1016/j.plefa.2005.05.024] ">Weinstock‐Guttman 2005</a>) </p> </li> <li> <p>Cancer or pre‐cancer outcomes (<a href="./references#CD003177-bbs2-0018" title="TokudomeS , KurikiK , YokoyamaY , SasakiM , JohT , KamiyaT , et al. Dietary n‐3/long‐chain n‐3 polyunsaturated fatty acids for prevention of sporadic colorectal tumors: a randomized controlled trial in polypectomized participants. Prostaglandins Leukotrienes and Essential Fatty Acids2015;94:1‐11. [PUBMED: 25451556] TokudomeS , YokoyamaY , KamiyaT , SenoK , OkuyamaH , KurikiK , et al. Rationale and study design of dietary intervention in patients polypectomized for tumors of the colorectum. Japanese Journal of Clinical Oncology2002;32(12):550‐3. [PUBMED: 12578906] ">DIPP 2015</a>; <a href="./references#CD003177-bbs2-0073" title="HullMA , SandellAC , MontgomeryAA , LoganRF , CliffordGM , ReesCJ , et al. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial. Trials [Electronic Resource]2013;14:237. HullMA , SprangeK , HepburnT , TanW , ShafayatA , ReesCJ , et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double‐blind, placebo‐controlled, 2x2 factorial trial. Lancet2018;392(10164):2583‐94. [DOI: 10.1016/S0140‐6736(18)31775‐6] ">seAFOod Hull 2018</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>) </p> </li> <li> <p>Bone health (<a href="./references#CD003177-bbs2-0020" title="DodinS , CunnaneSC , MasseB , LemayA , JacquesH , AsselinG , et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double‐blind, placebo‐controlled trial. Nutrition (Burbank, Los Angeles County, Calif.)2008;24(1):23‐30. [PUBMED: 17981439] DodinS , LemayA , JacquesH , LegareF , ForestJC , MasseB . The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double‐blind, wheat germ placebo‐controlled clinical trial. Journal of Clinical Endocrinology and Metabolism2005;90(3):1390‐7. [PUBMED: 15613422] ">Dodin 2005</a>) </p> </li> <li> <p>Liver health (<a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0025" title="SanyalAJ , AbdelmalekMF , SuzukiA , CummingsOW , ChojkierM . No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology2014;147(2):377‐84.e1. [PUBMED: 24818764] ">EPE‐A 2014</a>; <a href="./references#CD003177-bbs2-0079" title="SofiF , GiangrandiI , CesariF , CorsaniI , AbbateR , GensiniGF , et al. Effects of a 1‐year dietary intervention with n‐3 polyunsaturated fatty acid‐enriched olive oil on non‐alcoholic fatty liver disease patients: a preliminary study. International Journal of Food Sciences and Nutrition2010;61(8):792‐802. [PUBMED: 20465434] ">Sofi 2010</a>; <a href="./references#CD003177-bbs2-0086" title="BhatiaL , ScorlettiE , CurzenN , CloughGF , CalderPC , ByrneCD . Improvement in non‐alcoholic fatty liver disease severity is associated with a reduction in carotid intima‐media thickness progression. Atherosclerosis2016;246:13‐20. [PUBMED: 26748347] ByrneCD , TargherG . Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology2014;34(6):1155‐61. [PUBMED: 24743428] ByrneCD , TargherG . Time to replace assessment of liver histology with MR‐based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology2016; Vol. 150, issue 1:7‐10. [PUBMED: 26602219] CloughGF , McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , et al. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex evaluation of fatty liver and cardiovascular markers in NAFLD with Omacor therapy trial (WELCOME) trial. Diabetologia2016;59(7):1422‐9. [PUBMED: 27106721] HodsonL , BhatiaL , ScorlettiE , SmithDE , JacksonNC , Shojaee‐MoradieF , et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. European Journal of Clinical Nutrition2017;71(8):973‐9. [PUBMED: 28294174] McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Impact of high dose n‐3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non‐alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia2015;58(8):1916‐25. [PUBMED: 26021488] McCormickKG , ScorlettiES , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n‐3 fatty acids. Diabetic Medicine2015;32(S1):99. ScorlettiE , BhatiaB , McCormickKG , CloughGF , NashK , HodsonL , et al. Potential benefits of purified long chain omega‐3 fatty acid treatment in non‐alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study. Diabetic Medicine2014;31:1. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty acid treatment in non‐alcoholic fatty liver disease [corrected]. Contemporary Clinical Trials2014;37(2):301‐11. [PUBMED: 24556343] ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty treatment in non‐alcoholic fatty liver disease. Contemporary Clinical Trials2014;38(1):156. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , HodsonL , et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology (Baltimore, MD)2014;60(4):1211‐21. [PUBMED: 25043514] ScorlettiE , WestAL , BhatiaL , HoileSP , McCormickKG , BurdgeGC , et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. Journal of Hepatology2015;63(6):1476‐83. [PUBMED: 26272871] TargherG , ByrneCD . Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism2013;98(2):483‐95. [PUBMED: 23293330] ">WELCOME 2015</a>) </p> </li> <li> <p>Gastrointestinal health (Crohn's; <a href="./references#CD003177-bbs2-0026" title="FeaganBG , SandbornWJ , MittmannU , Bar‐MeirS , D'HaensG , BradetteM , et al. Omega‐3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA2008;299(14):1690‐7. ">EPIC‐1 2008</a>; <a href="./references#CD003177-bbs2-0027" title="FeaganBG , SandbornWJ , MittmannU , Bar‐MeirS , D'HaensG , BradetteM , et al. Omega‐3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC randomized controlled trials. JAMA2008;229(14):1690‐7. ">EPIC‐2 2008</a>; <a href="./references#CD003177-bbs2-0044" title="Lorenz‐MeyerH , BauerP , NicolayC , SchulzB , PurrmannJ , FleigWE , et al. Omega‐3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scandinavian Journal of Gastroenterology1996;31(8):778‐85. ">Lorenz‐Meyer 1996</a>) </p> </li> <li> <p>Arthritis outcomes (<a href="./references#CD003177-bbs2-0033" title="ChenJS , HillCL , LesterS , RuedigerCD , BattersbyR , JonesG , et al. Supplementation with omega‐3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2‐year randomized controlled trial. Osteoporosis International2016;27(5):1897‐905. [PUBMED: 26694596] HillC , LesterSE , JonesG . Response to 'Low‐dose versus high‐dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis' by Chen et al. Annals of the Rheumatic Diseases2016; Vol. 75, issue 1:e8. [PUBMED: 26662278] HillCL , MarchLM , AitkenD , LesterSE , BattersbyR , HynesK , et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Annals of the Rheumatic Diseases2016;75(1):23‐9. [PUBMED: 26353789] ">FOSTAR 2016</a>; <a href="./references#CD003177-bbs2-0063" title="ProudmanS , SpargoL , HallC , McWilliamsL , LeeA , MaureenR , et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. Internal Medicine Journal2012;42(Suppl 1):2‐3. ProudmanSM , ClelandLG , MetcalfRG , SullivanTR , SpargoLD , JamesMJ . Plasma n‐3 fatty acids and clinical outcomes in recent‐onset rheumatoid arthritis. British Journal of Nutrition2015;114(6):885‐90. [PUBMED: 26283657] ProudmanSM , JamesMJ , SpargoLD , MetcalfRG , SullivanTR , RischmuellerM , et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double‐blind controlled trial within algorithm‐based drug use. Annals of the Rheumatic Diseases2015;74(1):89‐95. [PUBMED: 24081439] ">Proudman 2015</a>; <a href="./references#CD003177-bbs2-0068" title="OlendzkiBC , LeungK , VanBuskirkS , ReedG , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evidence‐based Complementary and Alternative Medicine : ECAM2011;2011:827286. ReedGW , LeungK , RossettiRG , VanbuskirkS , SharpJT , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: an 18‐month, randomized, and double‐blind trial. Evidence‐based Complementary and Alternative Medicine : ECAM2014;2014:857456. ">Reed 2014</a>) </p> </li> <li> <p>Functional status (<a href="./references#CD003177-bbs2-0024" title="CauleyJA , ManiniTM , LovatoL , TaltonJ , AntonSD , DomanchukK , et al. ENRGISE Investigators. The enabling reduction of low‐grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(8):1296‐302. [DOI: 10.1093/gerona/gly204] ManiniTM , AntonSD , BeaversDP , CauleyJA , EspelandMA , FieldingRA , et al. ENRGISE pilot study investigators. Eabling reduction of low‐grade inflammation in seniors pilot study: concept, rationale, and design. Journal of the American Geriatrics Society2017;65:1961‐68. [DOI: 10.1111/jgs.14965] NCT02676466 . The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low‐grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016). PahorM , AntonSD , BeaversDP , CauleyJA , FieldingRA , KritchevskySB , et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL‐6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(10):1612–19. [DOI: 10.1093/gerona/gly277] ">ENRGISE 2018</a>; <a href="./references#CD003177-bbs2-0055" title="GarbagnatiF , CairellaG , DeMartinoA , MultariM , ScognamiglioU , VenturieroV , et al. Is antioxidant and n‐3 supplementation able to improve functional status in post‐stroke patients? Results from the Nutristroke Trial. Cerebrovascular Diseases2009;27(4):375‐83. [DOI: 10.1159/000207441] ">Nutristroke 2009</a>) </p> </li> <li> <p>Neurological function after spinal injury or in Huntington's disease (<a href="./references#CD003177-bbs2-0053" title="Norouzi JavidanA , SabourH , LatifiS , AbrishamkarM , SoltaniZ , ShidfarF , et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord‐injured individuals? A double‐blinded clinical trial. Spinal Cord2014;52(5):378‐82. [PUBMED: 24637568] SabourH , Norouzi JavidanA , LatifiS , ShidfarF , HeshmatR , Emami RazaviSH , et al. Omega‐3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: a double‐blinded randomized clinical trial. Journal of Spinal Cord Medicine2015;38(5):599‐606. [PUBMED: 25096818] ">Norouzi 2014</a>; <a href="./references#CD003177-bbs2-0064" title="PuriBK , LeavittBR , HaydenMR , RossCA , RosenblattA , GreenamyreJT , et al. Ethyl‐EPA in Huntington disease: a double‐blind, randomized, placebo‐controlled trial. Neurology2005;65(2):286‐92. ">Puri 2005</a>) </p> </li> <li> <p>Safety outcomes and adverse events (<a href="./references#CD003177-bbs2-0061" title="TatsunoI , SaitoY , KudouK , OotakeJ . Long‐term safety and efficacy of TAK‐085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega‐3 fatty acids randomized long‐term (ORL) study. Journal of Clinical Lipidology2013;7(6):615‐25. [PUBMED: 24314359] TatsunoIT , SaitoYS , KudouKK , OtakeJO , MinamideYM . Effects of long‐term treatment with omega‐3 polyunsaturated fatty acids (Lotriga) on atherogenic lipoproteins in hypertriglyceridemia: results from a phase 3 randomized, open‐label, 1‐year study. European Heart Journal2013;34:768. ">ORL 2013</a>; <a href="./references#CD003177-bbs2-0081" title="TandeKS , VoTD , LynchBS . Clinical safety evaluation of marine oil derived from Calanus finmarchicus. Regulatory Toxicology and Pharmacology: RTP2016;80:25‐31. [PUBMED: 27233921] ">Tande 2016</a>) </p> </li> <li> <p>Breast health (<a href="./references#CD003177-bbs2-0071" title="SandhuN , SchetterSE , LiaoJ , HartmanTJ , RichieJP , McGinleyJ , et al. Influence of obesity on breast density reduction by omega‐3 fatty acids: evidence from a randomized clinical trial. Cancer Prevention Research2016;9(4):275‐82. [PUBMED: 26714774] SignoriC , DuBrockC , RichieJP , ProkopczykB , DemersLM , HamiltonC , et al. Administration of omega‐3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. European Journal of Clinical Nutrition2012;66(8):878‐84. [PUBMED: 22669332] ">Sandhu 2016</a>) </p> </li> <li> <p>Inflammatory markers (<a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a> plus <a href="./references#CD003177-bbs2-0024" title="CauleyJA , ManiniTM , LovatoL , TaltonJ , AntonSD , DomanchukK , et al. ENRGISE Investigators. The enabling reduction of low‐grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(8):1296‐302. [DOI: 10.1093/gerona/gly204] ManiniTM , AntonSD , BeaversDP , CauleyJA , EspelandMA , FieldingRA , et al. ENRGISE pilot study investigators. Eabling reduction of low‐grade inflammation in seniors pilot study: concept, rationale, and design. Journal of the American Geriatrics Society2017;65:1961‐68. [DOI: 10.1111/jgs.14965] NCT02676466 . The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low‐grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016). PahorM , AntonSD , BeaversDP , CauleyJA , FieldingRA , KritchevskySB , et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL‐6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(10):1612–19. [DOI: 10.1093/gerona/gly277] ">ENRGISE 2018</a>) </p> </li> </ul> </p> <p>Most trials took place in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were in upper‐middle‐income countries: Argentina (<a href="./references#CD003177-bbs2-0032" title="MacchiaA , GrancelliH , VariniS , NulD , FerranteD , MarianiJ , et al. Late‐breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. Circulation2012;126:2780‐1. MacchiaA , GrancelliH , VariniS , NulD , LaffayeN , MarianiJ , et al. Omega‐3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. Journal of the American College of Cardiology2013;61(4):463‐8. [PUBMED: 23265344] MacchiaA , VariniS , GrancelliH , NulD , LaffayeN , FerranteD , et al. The rationale and design of the FORomegaARD trial: a randomized, double‐blind, placebo‐controlled, independent study to test the efficacy of n‐3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal2009;157(3):423‐7. [PUBMED: 19249410] ">FORWARD 2013</a>), Iran (<a href="./references#CD003177-bbs2-0053" title="Norouzi JavidanA , SabourH , LatifiS , AbrishamkarM , SoltaniZ , ShidfarF , et al. Does consumption of polyunsaturated fatty acids influence on neurorehabilitation in traumatic spinal cord‐injured individuals? A double‐blinded clinical trial. Spinal Cord2014;52(5):378‐82. [PUBMED: 24637568] SabourH , Norouzi JavidanA , LatifiS , ShidfarF , HeshmatR , Emami RazaviSH , et al. Omega‐3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: a double‐blinded randomized clinical trial. Journal of Spinal Cord Medicine2015;38(5):599‐606. [PUBMED: 25096818] ">Norouzi 2014</a>), Turkey (<a href="./references#CD003177-bbs2-0062" title="ÖzaydinM , ErdoğanD , TayyarS , UysalBA , DoğanA , IçliA , et al. N‐3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyoloji Dergisi2011;11(4):305‐9. [DOI: 10.5152/akd.2011.080] ">Özaydin 2011</a>), and China (<a href="./references#CD003177-bbs2-0087" title="ZhangY‐P , RujuanM , QingL , WuT , MaF . Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12‐month randomized, double‐blind, placebo‐controlled trial. Journal of Alzheimer's Disease2016;55(2):497‐507. ">Zhang 2017</a>). No trials took place exclusively in low‐ or low‐ to middle‐income countries. <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> was a multi‐centre trial that randomised participants in the USA, Netherlands, Ukraine, Russia, South Africa, Poland, India, Romania, Australia and New Zealand. </p> <p>We identified a further 25 ongoing trials, which we describe in the table of <a href="./references#CD003177-sec-0202" title="">Characteristics of ongoing studies</a>. At the time of writing this review, all of these trials appear unpublished, and some were recruiting or delivering interventions or had recently been completed, and trial authors were presumably analysing data and writing up results. Others appear overdue for publication, and their status is unclear – they may constitute missing data. </p> </section> <section id="CD003177-sec-0089"> <h4 class="title">Excluded studies</h4> <p>We read the full texts of over 1000 papers, so the full list of excluded trials is too extensive to add to this review. The main reason for exclusion of full‐text papers was duration of less than 12 months (this was often unclear in abstracts, so we collected full‐text papers to check). </p> <p>We initially included several trials into our wider data set that we later excluded (<a href="./references#CD003177-bbs2-0177" title="SinghRB , FedackoJ , VargovaV , PellaD , NiazMA , GhoshS . Effect of low W‐6/W‐3 fatty acid ratio Paleolithic style diet in patients with acute coronary syndromes: a randomized, single blind, controlled trial. World Heart Journal2012;4(1):71‐84. SinghRB , RastogiSS , VermaR , LaxmiB , SinghR , GhoshS , et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ1992;304:1015‐9. ">Singh 1992</a>; <a href="./references#CD003177-bbs2-0178" title="SinghRB , NiazMA , SharmaJP , KumarR , RastogiV , MoshiriM . Randomized, double‐blind, placebo‐controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4. Cardiovascular Drugs and Therapy1997;11(3):485‐91. ">Singh 1997</a>; <a href="./references#CD003177-bbs2-0178" title="SinghRB , NiazMA , SharmaJP , KumarR , RastogiV , MoshiriM . Randomized, double‐blind, placebo‐controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival 4. Cardiovascular Drugs and Therapy1997;11(3):485‐91. ">Singh 1997</a>; <a href="./references#CD003177-bbs2-0179" title="PellaD , DubnovG , SinghRB , SharmaR , BerryEM , ManorO . Effects of an Indo‐Mediterranean diet on the omega‐6/omega‐3 ratio in patients at high risk of coronary artery disease: the Indian paradox. World Review of Nutrition and Dietetics2003;92:74‐80. SinghRB , DubnovG , NiazMA , GhoshS , SinghR , RastogiSS , et al. Effect of an Indo‐Mediterranean diet on progression of coronary artery disease in high risk patients (Indo‐Mediterranean Diet Heart Study): a randomised single‐blind trial. Lancet2002;360(9344):1455‐61. ">Singh 2002</a>). Their exclusion was due to expressions of concern published by the <i>BMJ</i> and <i>The Lancet</i> (<a href="./references#CD003177-bbs2-0224" title="BMJeditors . Expression of concern. BMJ2005;331:266. [DOI: 10.1136/bmj.331.7511.266] ">BMJ 2005</a>; <a href="./references#CD003177-bbs2-0252" title="HortonR . Expression of concern: Indo‐Mediterranean Diet Heart Study. Lancet2005;366(9483):354‐6. [DOI: 10.1016/S0140‐6736(05)67006‐7] ">Horton 2005</a>; <a href="./references#CD003177-bbs2-0288" title="WhiteC . Suspected research fraud: difficulties of getting at the truth. BMJ2005;331(7511):281‐8. [DOI: 10.1136/bmj.331.7511.281] ">White 2005</a>). These expressions of concern followed extensive examination of the conduct, results and publication of these trials and questioned the veracity of data behind several trials published by RB Singh. Another trial that would otherwise have been included was retracted and so not included (<a href="./references#CD003177-bbs2-0156" title="MatsuyamaW , MitsuyamaH , WatanabeM , OonakaharaK , HigashimotoI , OsameM , et al. Effects of omega‐3 polyunsaturated fatty acids on inflammatory markers in COPD. Chest2005;128(6):3817‐27. ">Matsuyama 2005</a>). </p> </section> </section> <section id="CD003177-sec-0090"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed summary risk of bias as low in 28 RCTs (29 comparisons: <a href="./references#CD003177-bbs2-0001" title="QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. ">ADCS 2010</a>; <a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a>; <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0010" title="BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Archives of Ophthalmology2004;122(9):1297‐305. BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Archives of Ophthalmology2004;122(9):1306‐14. ">Berson 2004</a>; <a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0016" title="DerosaG , CiceroAF , D'AngeloA , BorghiC , MaffioliP . Effects of n‐3 PUFAs on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. BioFactors (Oxford, England)2016;42(3):316‐22. [PUBMED: 27040503] ">Derosa 2016</a>; <a href="./references#CD003177-bbs2-0023" title="AsbellPA , MaguireMG , PeskinE , BunyaVY , KuklinskiEJ . Dry Eye Assessment and Management (DREAM) Study: study design and baseline characteristics. Contemporary Clinical Trials2018;71:70‐9. [DOI: https://doi.org/10.1016/j.cct.2018.06.002] NCT02128763 . Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014). The Dry Eye Assessment and Management Study Research Group. n−3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine2018;378(18):1681‐90. [DOI: 10.1056/NEJMoa1709691] ">DREAM Asbell 2018</a>; <a href="./references#CD003177-bbs2-0028" title="DanthiirV , BurnsNR , NettelbeckT , WilsonC , WittertG . The older people, omega‐3, and cognitive health (EPOCH) trial design and methodology: a randomised, double‐blind, controlled trial investigating the effect of long‐chain omega‐3 fatty acids on cognitive ageing and wellbeing in cognitively healthy older adults. Nutrition Journal2011;10:117. [PUBMED: 22011460] DanthiirV , HoskingD , BurnsNR , WilsonC , NettelbeckT , CalvaresiE , et al. Cognitive performance in older adults is inversely associated with fish consumption but not erythrocyte membrane n‐3 fatty acids. Journal of Nutrition2014;144(3):311‐20. [PUBMED: 24353345] ">EPOCH 2014</a>; <a href="./references#CD003177-bbs2-0031" title="CaligiuriSP , AukemaHM , RavandiA , GuzmanR , DibrovE , PierceGN . Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha‐linolenic acid‐induced inhibition of soluble epoxide hydrolase. Hypertension2014;64(1):53‐9. [PUBMED: 24777981] CaligiuriSP , Rodriguez‐LeyvaD , AukemaHM , RavandiA , WeighellW , GuzmanR , et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension2016;68(4):1031‐8. [PUBMED: 27528063] EdelA , Rodriguez‐LeyvaD , WeighellW , LaValleeR , AlianiM , GuzmanR , et al. Flaxseed lignan metabolites elicit antihypertensive effects in PAD patients in the FLAX‐PAD trial. Annals of Nutrition and Metabolism2013;63:1339. EdelAL , Rodriguez‐LeyvaD , MaddafordTG , CaligiuriSP , AustriaJA , WeighellW , et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol‐lowering medications alone in patients with peripheral artery disease. Journal of Nutrition2015;145(4):749‐57. [PUBMED: 25694068] LeyvaDR , ZahradkaP , RamjiawanB , GuzmanR , AlianiM , PierceGN . The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX‐PAD randomized controlled trial. Contemporary Clinical Trials2011;32(5):724‐30. [PUBMED: 21616170] PierceGN , EdelAL , LaValleeR , CaligiuriS , AukemaH , RavandiA , et al. The use of dietary flaxseed to promote cardiovascular health. Acta Physiologica2014;211:15. PierceGN , Rodriguez‐LeyvaD , EdelA , GuzmanR , AlianiM . The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. Cardiology (Switzerland)2013;126:201. Rodriguez‐LeyvaD , WeighellW , EdelAL , LaValleeR , DibrovE , PinnekerR , et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension2013;62(6):1081‐9. [PUBMED: 24126178] ">FLAX‐PAD 2013</a>; <a href="./references#CD003177-bbs2-0032" title="MacchiaA , GrancelliH , VariniS , NulD , FerranteD , MarianiJ , et al. Late‐breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. Circulation2012;126:2780‐1. MacchiaA , GrancelliH , VariniS , NulD , LaffayeN , MarianiJ , et al. Omega‐3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. Journal of the American College of Cardiology2013;61(4):463‐8. [PUBMED: 23265344] MacchiaA , VariniS , GrancelliH , NulD , LaffayeN , FerranteD , et al. The rationale and design of the FORomegaARD trial: a randomized, double‐blind, placebo‐controlled, independent study to test the efficacy of n‐3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal2009;157(3):423‐7. [PUBMED: 19249410] ">FORWARD 2013</a>; <a href="./references#CD003177-bbs2-0033" title="ChenJS , HillCL , LesterS , RuedigerCD , BattersbyR , JonesG , et al. Supplementation with omega‐3 fish oil has no effect on bone mineral density in adults with knee osteoarthritis: a 2‐year randomized controlled trial. Osteoporosis International2016;27(5):1897‐905. [PUBMED: 26694596] HillC , LesterSE , JonesG . Response to 'Low‐dose versus high‐dose fish oil for pain reduction and function improvement in patients with knee osteoarthritis' by Chen et al. Annals of the Rheumatic Diseases2016; Vol. 75, issue 1:e8. [PUBMED: 26662278] HillCL , MarchLM , AitkenD , LesterSE , BattersbyR , HynesK , et al. Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose. Annals of the Rheumatic Diseases2016;75(1):23‐9. [PUBMED: 26353789] ">FOSTAR 2016</a>; <a href="./references#CD003177-bbs2-0044" title="Lorenz‐MeyerH , BauerP , NicolayC , SchulzB , PurrmannJ , FleigWE , et al. Omega‐3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Scandinavian Journal of Gastroenterology1996;31(8):778‐85. ">Lorenz‐Meyer 1996</a>; <a href="./references#CD003177-bbs2-0045" title="AndrieuS , GuyonnetS , ColeyN , CantetC , BonnefoyM , BordesS , et al. Effect of long‐term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo‐controlled trial. Lancet Neurology2017;16:377‐89. [DOI: 10.1016/S1474‐4422(17)30040‐6] BarretoPdS , RollandY , CesariM , DupuyC , AndrieuS , VellasB , for the MAPT Study Group. Effects of multidomain lifestyle intervention, omega‐3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. Age and Ageing2017;47(2):281‐8. [DOI: 10.1093/ageing/afx164] CarrieI , VanKanGA , Gillette‐GuyonnetS , AndrieuS , DartiguesJF , TouchonJ , et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). Journal of Nutrition, Health &amp; Aging2012;16(4):355‐9. DelrieuJ , AndrieuS , PahorM , CantetC , CesariM , OussetPJ , et al. Neuropsychological profile of &quot;cognitive frailty&quot; subjects in MAPT study. Journal of Prevention of Alzheimer's Disease2016;3(3):151‐9. [DOI: 10.14283/jpad.2016.94] DelrieuJ , PayouxP , HitzelA , PeifferS , Abellan Van KanG , GilletteS , et al. Multidomain Alzheimer's disease preventive trial: florbetapir ancillary study. Alzheimer's and Dementia2011;1:S419. FougereB , BarretoPD , GoisserS , SorianoG , GuyonnetS , AndrieuS , et al. Red blood cell membrane omega‐3 fatty acid levels and physical performance: cross‐sectional data from the MAPT study. Clinical Nutrition 2017 Apr 12 [Epub ahead of print]:1‐4. [DOI: 10.1016/j.clnu.2017.04.005] GilletteS . The Multidomain Alzheimer Preventive Trial (MAPT): a new approach for the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;S4‐02‐05:145. Gillette‐GuyonnetS , AndrieuS , DantoineT , DartiguesJF , TouchonJ , VellasB , et al. Commentary on &quot;A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.&quot; The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;5(2):114‐21. Gillette‐GuyonnetS , VellasB , AndrieuS , DupuyC , CarriéI . MAPT study: a 3‐year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects‐rationale, design and baseline data. Alzheimer's &amp; Dementia2011;1:S97‐8. VellasB , CarrieI , Gillette‐GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. Journal of Prevention of Alzheimers Disease2014;1(1):13‐22. VellasB , CarrieI , GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT (Multi‐domain Alzheimer's Prevention Trial): results at 36 months. Alzheimer's &amp; Dementia2015;1:331. VellasB , TouchonJ , WeinerM . MAPT (Multidomain Alzheimer Preventive Trial) imaging (MRI, FDG‐PET, amyloid‐PET) data. Journal of Nutrition, Health and Aging2012;16(9):812‐5. ">MAPT 2017</a>; <a href="./references#CD003177-bbs2-0046" title="BemelmansWJ , BroerJ , DeVriesJH , HulshofKF , MayJF , Meyboom‐De JongB . Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. Public Health Nutrition2000;3(3):273‐83. BemelmansWJ , BroerJ , FeskensEJ , SmitAJ , MuskietAJ , LefrandtJD , et al. Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. American Journal of Clinical Nutrition2002;75:221‐7. BemelmansWJ , LefrandtJD , FeskensEJ , BroerJ , TervaertJW , MayJF , et al. Change in saturated fat intake is associated with progression of carotid and femoral intima‐media thickness, and with levels of soluble intercellular adhesion molecule‐1. Atherosclerosis2002;163(1):113‐20. BemelmansWJ , LefrandtJD , FeskensEJ , VanHaelstPL , BroerJ , Meyboom‐de JongB , et al. Increased alpha‐linolenic acid intake lowers C‐reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition2004;58(7):1083‐9. BemelmansWJ , MuskietFA , FeskensEJ , DeVriesJH , BroerJ , MayJF , et al. Associations of alpha‐linolenic acid and linoleic acid with risk factors for coronary heart disease. European Journal of Clinical Nutrition2000;54(12):865‐71. SieroFW , BroerJ , BemelmansWJ , Meyboom‐de JongBM . Impact of group nutrition education and surplus value of Prochaska based stage‐matched information on health‐related cognitions and on Mediterranean nutrition behaviour. Health Education Research2000;15(5):635‐47. ">MARGARIN 2002</a>; <a href="./references#CD003177-bbs2-0047" title="Al‐HilalM , AlsalehA , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Genetic variation at the FADS1‐FADS2 gene locus influences delta‐5 desaturase activity and LC‐PUFA proportions after fish oil supplement. Journal of Lipid Research2013;54(2):542‐51. [PUBMED: 23160180] AlSalehA , ManiouZ , LewisFJ , HallWL , SandersTA , O'DellSD . Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. Journal of Nutrition2014;144(3):267‐72. [PUBMED: 24401815] AlsalehA , CrepostnaiaD , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. Journal of Nutrition2013;143(7):1021‐7. [PUBMED: 23658423] HallWL , HayG , ManiouZ , SeedPT , ChowienczykPJ , SandersTA . Effect of low doses of long chain n‐3 polyunsaturated fatty acids on sleep‐time heart rate variability: a randomized, controlled trial. International Journal of Cardiology2013;168:4439‐42. PintoAM , HallWL , SandersTAB . Effect of low doses of long chain n‐3 PUFA intake on daytime heart rate variability: results from the MARINA study. European Journal of Preventive Cardiology2015;1:S146. SandersTA , ChowienczykPJ , HallW , LewisF , SeedP , ManiouZ , et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report2011. SandersTA , HallWL , ManiouZ , LewisF , SeedPT , ChowienczykPJ . Effect of low doses of long‐chain n‐3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. American Journal of Clinical Nutrition2011;94(4):973‐80. [PUBMED: 21865334] ">MARINA 2011</a>; <a href="./references#CD003177-bbs2-0050" title="MerleBM , BenlianP , PucheN , BassolsA , DelcourtC , SouiedEH . Circulating omega‐3 fatty acids and neovascular age‐related macular degeneration. Investigative Ophthalmology &amp; Visual Science2014;55(3):2010‐9. [PUBMED: 24557349] MerleBM , RichardF , BenlianP , PucheN , DelcourtC , SouiedEH . CFH Y402H and ARMS2 A69S polymorphisms and oral supplementation with docosahexaenoic acid in neovascular age‐related macular degeneration patients: the NAT2 study. PloS One2015;10(7):e0130816. [PUBMED: 26132079] QuerquesG , MerleBM , PumariegaNM , BenlianP , DelcourtC , ZourdaniA , et al. Dynamic drusen remodelling in participants of the nutritional AMD treatment‐2 (NAT‐2) randomized trial. PLOS ONE2016;11(2):e0149219. [PUBMED: 26901353] SouiedEH , DelcourtC , QuerquesG , BassolsA , MerleB , ZourdaniA , et al. Oral docosahexaenoic acid in the prevention of exudative age‐related macular degeneration: the nutritional AMD treatment 2 study. Ophthalmology2013;120(8):1619‐31. [PUBMED: 23395546] ">NAT2 2013</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0059" title="DangourAD , AllenE , ElbourneD , FaseyN , FletcherAE , HardyP , et al. Effect of 2‐y n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double‐blind, controlled trial. American Journal of Clinical Nutrition2010;91(6):1725‐32. DangourAD , AllenE , ElbourneD , FletcherA , RichardsM , UauyR . Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. Journal of Nutrition, Health &amp; Aging2009;13(3):198‐202. DangourAD , AllenE , ElbourneD , FletcherAE , NeveuMM , UauyR , et al. N‐3 fatty acids and retinal function. Ophthalmology2013;120(3):643. [DOI: dx.doi.org/10.1016/j.ophtha.2012.09.043] DangourAD , ClemensF , ElbourneD , FaseyN , FletcherAE , HardyP , et al. A randomised controlled trial investigating the effect of n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n‐3 Long‐chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutrition Journal2006;5:20. ISRCTN72331636 . The OPAL Study: older people and n‐3 long‐chain polyunsaturated fatty acids. www.isrctn.com/ISRCTN72331636 (first received 27 April 2004). [ISRCTN72331636] ">OPAL 2010</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0063" title="ProudmanS , SpargoL , HallC , McWilliamsL , LeeA , MaureenR , et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. Internal Medicine Journal2012;42(Suppl 1):2‐3. ProudmanSM , ClelandLG , MetcalfRG , SullivanTR , SpargoLD , JamesMJ . Plasma n‐3 fatty acids and clinical outcomes in recent‐onset rheumatoid arthritis. British Journal of Nutrition2015;114(6):885‐90. [PUBMED: 26283657] ProudmanSM , JamesMJ , SpargoLD , MetcalfRG , SullivanTR , RischmuellerM , et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double‐blind controlled trial within algorithm‐based drug use. Annals of the Rheumatic Diseases2015;74(1):89‐95. [PUBMED: 24081439] ">Proudman 2015</a>; <a href="./references#CD003177-bbs2-0064" title="PuriBK , LeavittBR , HaydenMR , RossCA , RosenblattA , GreenamyreJT , et al. Ethyl‐EPA in Huntington disease: a double‐blind, randomized, placebo‐controlled trial. Neurology2005;65(2):286‐92. ">Puri 2005</a>; <a href="./references#CD003177-bbs2-0068" title="OlendzkiBC , LeungK , VanBuskirkS , ReedG , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evidence‐based Complementary and Alternative Medicine : ECAM2011;2011:827286. ReedGW , LeungK , RossettiRG , VanbuskirkS , SharpJT , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: an 18‐month, randomized, and double‐blind trial. Evidence‐based Complementary and Alternative Medicine : ECAM2014;2014:857456. ">Reed 2014</a>; <a href="./references#CD003177-bbs2-0072" title="AngererP , KothnyW , StorkS , vonSchackyC . Effect of dietary supplementation with omega‐3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovascular Research2002;54(1):183‐90. vonSchackyC , AngererP , KothnyW , TheisenK , MudraH . The effect of dietary omega‐3 fatty acids on coronary atherosclerosis. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine1999;130(7):554‐62. vonSchackyC , BaumannK , AngererP . The effect of n‐3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids2001;36(Suppl):S99‐102. ">SCIMO 1999</a>; <a href="./references#CD003177-bbs2-0078" title="BrouwerIA , KatanMB , SchoutenEG , CammAJ , HauerRN , WeverEF , et al. Rationale and design of a clinical trial on n‐3 fatty acids and cardiac arrhythmia (SOFA). Annals of Nutrition &amp; Metabolism2001;45(Suppl 1):79. BrouwerIA , RaittMH , DullemeijerC , KraemerDF , ZockPL , MorrisC , et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. European Heart Journal2009;30(7):820‐6. BrouwerIA , ZockPL , CammAJ , BöckerD , HauerRN , WeverEF , et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega‐3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA2006;295(22):2613‐9. BrouwerIA , ZockPL , WeverEF , HauerRN , CammAJ , BockerD , et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n‐3 fatty acids and incidence of cardiac arrhythmia: SOFA. European Journal of Clinical Nutrition2003;57:1323‐30. ">SOFA 2006</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>; <a href="./references#CD003177-bbs2-0086" title="BhatiaL , ScorlettiE , CurzenN , CloughGF , CalderPC , ByrneCD . Improvement in non‐alcoholic fatty liver disease severity is associated with a reduction in carotid intima‐media thickness progression. Atherosclerosis2016;246:13‐20. [PUBMED: 26748347] ByrneCD , TargherG . Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology2014;34(6):1155‐61. [PUBMED: 24743428] ByrneCD , TargherG . Time to replace assessment of liver histology with MR‐based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology2016; Vol. 150, issue 1:7‐10. [PUBMED: 26602219] CloughGF , McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , et al. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex evaluation of fatty liver and cardiovascular markers in NAFLD with Omacor therapy trial (WELCOME) trial. Diabetologia2016;59(7):1422‐9. [PUBMED: 27106721] HodsonL , BhatiaL , ScorlettiE , SmithDE , JacksonNC , Shojaee‐MoradieF , et al. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. European Journal of Clinical Nutrition2017;71(8):973‐9. [PUBMED: 28294174] McCormickKG , ScorlettiE , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Impact of high dose n‐3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non‐alcoholic fatty liver disease: results from the randomised WELCOME trial. Diabetologia2015;58(8):1916‐25. [PUBMED: 26021488] McCormickKG , ScorlettiES , BhatiaL , CalderPC , GriffinMJ , CloughGF , et al. Peripheral sensory nerve function is independently associated with microvascular function, but neither are improved by n‐3 fatty acids. Diabetic Medicine2015;32(S1):99. ScorlettiE , BhatiaB , McCormickKG , CloughGF , NashK , HodsonL , et al. Potential benefits of purified long chain omega‐3 fatty acid treatment in non‐alcoholic fatty liver disease (NAFLD): a potential treatment for early NAFLD in metabolic syndrome and type 2 diabetes? Results from the WELCOME study. Diabetic Medicine2014;31:1. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty acid treatment in non‐alcoholic fatty liver disease [corrected]. Contemporary Clinical Trials2014;37(2):301‐11. [PUBMED: 24556343] ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , CalderPC , et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chainomega‐3 fatty treatment in non‐alcoholic fatty liver disease. Contemporary Clinical Trials2014;38(1):156. ScorlettiE , BhatiaL , McCormickKG , CloughGF , NashK , HodsonL , et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology (Baltimore, MD)2014;60(4):1211‐21. [PUBMED: 25043514] ScorlettiE , WestAL , BhatiaL , HoileSP , McCormickKG , BurdgeGC , et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial. Journal of Hepatology2015;63(6):1476‐83. [PUBMED: 26272871] TargherG , ByrneCD . Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. Journal of Clinical Endocrinology and Metabolism2013;98(2):483‐95. [PUBMED: 23293330] ">WELCOME 2015</a>), and we deemed it to be moderate to high in the remainder. Our definition of low summary risk of bias is in the section <a href="#CD003177-sec-0073">Assessment of risk of bias in included studies</a>. <a href="#CD003177-fig-0002">Figure 2</a> itemises risk of bias by domain and trial. </p> <div class="figure" id="CD003177-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD003177-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <section id="CD003177-sec-0091"> <h4 class="title">Allocation</h4> <p>Of the 86 RCTs (87 RCT arms as <a href="./references#CD003177-bbs2-0004" title="BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of n‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ ALA 2010</a> and <a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a> which include the same participants are represented twice) described in the 'Risk of bias' summary (<a href="#CD003177-fig-0002">Figure 2</a>), 69 trials (70 arms) described randomisation well enough to merit an assessment of low risk (the remainder were unclear), and 49 trials (50 arms) described adequate allocation concealment (the remaining 37 were unclear). </p> </section> <section id="CD003177-sec-0092"> <h4 class="title">Blinding</h4> <p>We considered blinding of participants and personnel to be at low risk of bias in 42 of the 86 trials (43 arms). Lack of blinding of participants put 24 trials at high risk of bias, while the remaining 20 trials were at unclear risk. Blinding of outcome assessors put 57 trials (58 arms) at low risk of detection bias and at seven at high risk; this aspect was unclear in the remainder. We found that 37 trials (38 arms) were at low risk of both performance and detection bias. </p> </section> <section id="CD003177-sec-0093"> <h4 class="title">Incomplete outcome data</h4> <p>We found that 57 trials (58 arms) were at low risk of attrition bias, 17 at high risk, and the remaining 12 at unclear risk. </p> </section> <section id="CD003177-sec-0094"> <h4 class="title">Selective reporting</h4> <p>We determined that 22 trials had a pre‐published trials registry entry or protocol and reported all planned outcomes appropriately so we considered them at low risk of selective reporting. Twenty‐five trials (26 arms) were at high risk of selective reporting, omitting reports on either pre‐stated outcomes or time points. We judged the remaining 39 trials to be at unclear risk of reporting bias as we could not find any protocol or prospective trial registry entry (often trials were published prior to trial registration availability). </p> </section> <section id="CD003177-sec-0095"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed risk of bias due to lack of compliance and attention bias and also noted other sources of bias. We found four trials to be at high risk of compliance bias (<a href="./references#CD003177-bbs2-0030" title="LeafA , AlbertCM , JosephsonM , SteinhausD , KlugerJ , KangJX , et al. Prevention of fatal arrhythmias in high‐risk subjects by fish oil n‐3 fatty acid intake. Circulation2005;112(18):2762‐8. ">FAAT 2005</a>; <a href="./references#CD003177-bbs2-0040" title="TanSY . Dietary Manipulation and Weight Management [PhD thesis]. Wollongong, Australia: University of Wollonong, 2010. TapsellLC , BatterhamMJ , TeussG , TanSY , DaltonS , QuickCJ , et al. Long‐term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. European Journal of Clinical Nutrition2009;63(8):1008‐15. [PUBMED: 19352378] ">HERO 2009</a>; <a href="./references#CD003177-bbs2-0063" title="ProudmanS , SpargoL , HallC , McWilliamsL , LeeA , MaureenR , et al. Fish oil in rheumatoid arthritis: a randomised, double blind trial comparing high dose with low dose. Internal Medicine Journal2012;42(Suppl 1):2‐3. ProudmanSM , ClelandLG , MetcalfRG , SullivanTR , SpargoLD , JamesMJ . Plasma n‐3 fatty acids and clinical outcomes in recent‐onset rheumatoid arthritis. British Journal of Nutrition2015;114(6):885‐90. [PUBMED: 26283657] ProudmanSM , JamesMJ , SpargoLD , MetcalfRG , SullivanTR , RischmuellerM , et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double‐blind controlled trial within algorithm‐based drug use. Annals of the Rheumatic Diseases2015;74(1):89‐95. [PUBMED: 24081439] ">Proudman 2015</a>; <a href="./references#CD003177-bbs2-0077" title="AnilS , CharltonKE , TapsellLC , ProbstY , NdanukoR , BatterhamMJ . Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. Journal of Human Hypertension2016;30(11):672‐8. [DOI: 10.1038/jhh.2016.10] TapsellLC , BatterhamMJ , CharltonKE . Effect of dietary restriction and n‐3 PUFA supplementation on insulin resistance in obese adults. FASEB Journal2010;24:733.9. TapsellLC , BatterhamMJ , CharltonKE , NealeEP , ProbstYC , O'SheaJE , et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. BMC Public Health2013;13:1231. [PUBMED: 24369765] ZhangQ , O'SheaJE , ThorneRL , TapsellLC , BatterhamM , CharltonKE . Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors. Nutrition and Dietetics2010;67(Suppl 1):67‐8. ">SMART 2013</a>), while 37 trials (38 arms) provided evidence of good compliance, and the remaining 45 trials were unclear. We noted a high risk of attention bias in three trials where intervention participants potentially had more dedicated time for dietary advice or follow‐up (<a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>; <a href="./references#CD003177-bbs2-0046" title="BemelmansWJ , BroerJ , DeVriesJH , HulshofKF , MayJF , Meyboom‐De JongB . Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. Public Health Nutrition2000;3(3):273‐83. BemelmansWJ , BroerJ , FeskensEJ , SmitAJ , MuskietAJ , LefrandtJD , et al. Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. American Journal of Clinical Nutrition2002;75:221‐7. BemelmansWJ , LefrandtJD , FeskensEJ , BroerJ , TervaertJW , MayJF , et al. Change in saturated fat intake is associated with progression of carotid and femoral intima‐media thickness, and with levels of soluble intercellular adhesion molecule‐1. Atherosclerosis2002;163(1):113‐20. BemelmansWJ , LefrandtJD , FeskensEJ , VanHaelstPL , BroerJ , Meyboom‐de JongB , et al. Increased alpha‐linolenic acid intake lowers C‐reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition2004;58(7):1083‐9. BemelmansWJ , MuskietFA , FeskensEJ , DeVriesJH , BroerJ , MayJF , et al. Associations of alpha‐linolenic acid and linoleic acid with risk factors for coronary heart disease. European Journal of Clinical Nutrition2000;54(12):865‐71. SieroFW , BroerJ , BemelmansWJ , Meyboom‐de JongBM . Impact of group nutrition education and surplus value of Prochaska based stage‐matched information on health‐related cognitions and on Mediterranean nutrition behaviour. Health Education Research2000;15(5):635‐47. ">MARGARIN 2002</a>). Eleven trials did not provide enough details to assess so we considered them to be at unclear risk of attention bias (<a href="./references#CD003177-bbs2-0003" title="AhnJ , ParkSK , ParkTS , KimJH , YunE , KimSP , et al. Effect of n‐3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. Korean Circulation Journal2016;46(4):481‐9. [PUBMED: 27482256] ">Ahn 2016</a>; <a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0029" title="ErdoganA , BayerM , KollathD , GreissH , VossR , NeumannT , et al. Omega AF study: polyunsaturated fatty acids (PUFA) for prevention of atrial fibrillation relapse after successful external cardioversion. Heart Rhythm2007;4(5):S185‐6. HeidtMC , VicianM , StrackeSK , StadlbauerT , GrebeMT , BoeningA , et al. Beneficial effects of intravenously administered n‐3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thoracic and Cardiovascular Surgeon2009;57:276‐80. [DOI: 10.1055/s‐0029‐1185301] MarianiJ , DovalHC , NulD , VariniS , GrancelliH , FerranteD , et al. N‐3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta‐analysis of randomized controlled trials. Journal of the American Heart Association2013;2(1):e005033. ">Erdogan 2007</a>; <a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012</a>; <a href="./references#CD003177-bbs2-0039" title="AlfaddaghA , ElajamiTK , AshfaqueH , SalehM , BistrianBR , WeltyFK . Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. Journal of the American Heart Association2017;6(12):e006981. [DOI: 10.1161/JAHA.117.006981] AlfaddaghA , ElajamiTK , WeltyFK . Abstract 16294: Omega‐3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. Circulation2016;134:A16294. AlfaddaghA , MohebaliD , ElajamiTK , SalehM , WeltyFK . Abstract 17391: Omega‐3 fatty acid index &gt;= 4% prevents progression of coronary artery plaque in non‐diabetic subjects on statin therapy. Circulation2017;136 (Suppl 1):A17391. AlfaddaghA , WeltyFK . Abstract 17689: Omega‐3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short. ElajamiTK , AlfaddaghA , LakshminarayanD , SolimanM , ChandnaniM , WeltyFK . Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American Heart Association2017;6(7):e004740. [DOI: 10.1161/JAHA.116.004740] ElajamiTK , AlfaddaghA , WeltyFK . Abstract 16353: Triglyceride reduction with omega‐3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. Circulation2016;134:A16353. LakshminarayanDK , ElajamiTK , SolimanM , AlfaddaghA , WeltyFK . Omega‐3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. Circulation2015;132:A15530. ">HEARTS 2017</a>; <a href="./references#CD003177-bbs2-0042" title="KumarS , SutherlandF , MortonJB , LeeG , MorganJ , WongJ , et al. Long‐term omega‐3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm2012;9(4):483‐91. [DOI: 10.1016/j.hrthm.2011.11.034] ">Kumar 2012</a>; <a href="./references#CD003177-bbs2-0043" title="KumarS , SutherlandF , StevensonI , LeeJM , GargML , SparksPB . Effects of long‐term omega‐3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. International Journal of Cardiology2013;168(4):3812‐7. [PUBMED: 23890856] ">Kumar 2013</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0076" title="SianniA , MatsoukisI , GanotopoulouA , ParaskevasP , AsimisA , TsivilisN , et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. Clinical Nutrition2013;32:S70‐1. ">Sianni 2013</a>; <a href="./references#CD003177-bbs2-0077" title="AnilS , CharltonKE , TapsellLC , ProbstY , NdanukoR , BatterhamMJ . Identification of dietary patterns associated with blood pressure in a sample of overweight Australians. Journal of Human Hypertension2016;30(11):672‐8. [DOI: 10.1038/jhh.2016.10] TapsellLC , BatterhamMJ , CharltonKE . Effect of dietary restriction and n‐3 PUFA supplementation on insulin resistance in obese adults. FASEB Journal2010;24:733.9. TapsellLC , BatterhamMJ , CharltonKE , NealeEP , ProbstYC , O'SheaJE , et al. Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial. BMC Public Health2013;13:1231. [PUBMED: 24369765] ZhangQ , O'SheaJE , ThorneRL , TapsellLC , BatterhamM , CharltonKE . Baseline characteristics of volunteers in the smart clinical trial: associations between habitual physical activity and lifestyle disease risk factors. Nutrition and Dietetics2010;67(Suppl 1):67‐8. ">SMART 2013</a>; <a href="./references#CD003177-bbs2-0084" title="BitokE , Jaceldo‐SieglK , RajaramS , Serra‐MirM , RothI , Feitas‐SimoesT , et al. Favourable nutrient intake and displacement with long‐term walnut supplementation among elderly: results of a randomised trial. British Journal of Nutrition2017;118(3):201‐9. [DOI: 10.1017/S0007114517001957] BitokE , RajaramS , RosE . Does a daily walnut supplement given for a year result in body weight gain?. FASEB Journal2016; Vol. 30:1157.5. HueyL , BitokE , KazziN . Dietary compliance of walnut or no walnut intake in a 1‐year randomized intervention trial among free‐living elderly in the Walnuts and Healthy Aging Study (WAHA). FASEB Journal2016; Vol. 30:1157.10. RajaramS , Valls‐PedretC , CofanM , SabateJ , Serra‐MirM , Perez‐HerasAM , et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. Frontiers in Aging Neuroscience2017;8:333. [PUBMED: 28119602] RosE , RajaramS , Sala‐VilaA , Serra‐MirM , Vals‐PedretC , CofanM , et al. Effect of a 1‐year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. FASEB Journal2016; Vol. 30, issue 1 Suppl:293.4. ">WAHA 2016</a>), while we thought the remaining 72 trials (73 arms) were at low risk of attention bias. We judged four trials to be at high risk of other potential biases: <a href="./references#CD003177-bbs2-0003" title="AhnJ , ParkSK , ParkTS , KimJH , YunE , KimSP , et al. Effect of n‐3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. Korean Circulation Journal2016;46(4):481‐9. [PUBMED: 27482256] ">Ahn 2016</a> because it is unclear whether it was placebo‐controlled, and there was concern over reported standard deviations; <a href="./references#CD003177-bbs2-0019" title="HarrisonRA . Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005. HarrisonRA , EltonP . From pies to pilchards: dietary assistants increase consumption of oil rich fish. Journal of Epidemiology and Community Health2000;Suppl:6. HarrisonRA , EltonPJ . Can an oil‐rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. International Society for the Study of Fatty Acids and Lipids (ISSFAL); 2002 May; Montreal, Canada. 2002. HarrisonRA , EltonPJ . Is there a role for long‐chain omega3 or oil‐rich fish in the treatment of atrial fibrillation?. Medical Hypotheses2005;64(1):59‐63. [PUBMED: 15533612] HarrisonRA , PurnellP , EltonPJ . Using community‐based dietary assistants to increase the intake of oil‐rich fish among older people. European Journal of Public Health2003;13(Suppl 1):105. HarrisonRA , SureshV , PurnellB , RobertsC , HoughtonP , MillerJ , et al. Can oil‐rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010. ">DISAF 2003</a> because the trial stopped early; <a href="./references#CD003177-bbs2-0043" title="KumarS , SutherlandF , StevensonI , LeeJM , GargML , SparksPB . Effects of long‐term omega‐3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study. International Journal of Cardiology2013;168(4):3812‐7. [PUBMED: 23890856] ">Kumar 2013</a> due to concerns over design; and <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> because some data were presented for opposite arms in different publications. Four trials were at unclear risk due to insufficient methodological detail being provided (<a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012</a>; <a href="./references#CD003177-bbs2-0076" title="SianniA , MatsoukisI , GanotopoulouA , ParaskevasP , AsimisA , TsivilisN , et al. Effect of omega 3 fatty acids in patients with hypertension and atrial fibrillation. Clinical Nutrition2013;32:S70‐1. ">Sianni 2013</a>; <a href="./references#CD003177-bbs2-0087" title="ZhangY‐P , RujuanM , QingL , WuT , MaF . Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12‐month randomized, double‐blind, placebo‐controlled trial. Journal of Alzheimer's Disease2016;55(2):497‐507. ">Zhang 2017</a>). </p> </section> </section> <section id="CD003177-sec-0096"> <h3 class="title" id="CD003177-sec-0096">Effects of interventions</h3> <p>See: <a href="./full#CD003177-tbl-0001"><b>Summary of findings for the main comparison</b> High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</a>; <a href="./full#CD003177-tbl-0002"><b>Summary of findings 2</b> High versus low alpha‐linolenic acid omega‐3 fats for preventing cardiovascular disease (primary outcomes)</a>; <a href="./full#CD003177-tbl-0003"><b>Summary of findings 3</b> High versus low omega‐3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes</a> </p> <section id="CD003177-sec-0097"> <h4 class="title">Primary outcomes</h4> <p>See <a href="./full#CD003177-tbl-0001">summary of findings Table for the main comparison</a> for a GRADE summary of our evidence on effects of long‐chain omega‐3 (LCn3) fats (including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA)) on our primary outcomes. </p> <section id="CD003177-sec-0098"> <h5 class="title">Effects of long‐chain omega‐3 fats on primary health outcomes</h5> <section id="CD003177-sec-0099"> <h6 class="title">All‐cause mortality (LCn3)</h6> <p>High‐certainty evidence showed little or no effect of LCn3 on all‐cause mortality.</p> <p>There was little or no effect of increasing LCn3 fats on all‐cause mortality, despite 11,297 deaths in more than 143,000 participants (RR 0.97, 95% CI 0.93 to 1.01; I<sup>2</sup> = 5%; <a href="./references#CD003177-fig-0007" title="">Analysis 1.1</a>). The funnel plot suggested that some small trials with higher numbers of deaths in the intervention group might be missing (<a href="#CD003177-fig-0003">Figure 3</a>), indicating small study bias, though there was almost no difference between random‐effects and fixed‐effect analysis. If any such missing trials were added back in the RR would rise slightly (towards the null value of 1.0). </p> <div class="figure" id="CD003177-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. High versus low long‐chain omega‐3 fats (primary outcomes), outcome 1.3, all‐cause mortality, sensitivity analysis by summary risk of bias" data-id="CD003177-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. High versus low long‐chain omega‐3 fats (primary outcomes), outcome 1.3, all‐cause mortality, sensitivity analysis by summary risk of bias </p> </div> </div> </div> <p>Sensitivity analyses using fixed‐effect meta‐analysis did not alter the lack of effect on all‐cause mortality (RR 0.97, 95% CI 0.93 to 1.00; <a href="./references#CD003177-fig-0008" title="">Analysis 1.2</a>). Removing RCTs not at low summary risk of bias left us with 19 RCTs involving over 75,000 participants, 5579 of whom died, suggesting no effect of LCn3 on mortality (RR 0.99, 95% CI 0.95 to 1.04; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0009" title="">Analysis 1.3</a>). This lack of effect was also evident in sensitivity analyses limited to trials at low risk of compliance bias and to larger trials (<a href="./references#CD003177-fig-0010" title="">Analysis 1.4</a>). </p> <p>The lack of effect for LCn3 on mortality did not differ by replacement with MUFA, omega‐6 fats or other types of placebo compounds (<a href="./references#CD003177-fig-0012" title="">Analysis 1.6</a>). There was no suggestion of any dose effect for LCn3 fats on mortality (<a href="./references#CD003177-fig-0011" title="">Analysis 1.5</a>), and subgroups with RRs further away from 1.00 had wide 95% confidence intervals. The lack of effect did not differ by primary versus secondary prevention (<a href="./references#CD003177-fig-0015" title="">Analysis 1.9</a>), statin use (<a href="./references#CD003177-fig-0016" title="">Analysis 1.10</a>), mode of intervention (dietary advice, supplemental foods, or capsules, <a href="./references#CD003177-fig-0013" title="">Analysis 1.7</a>), baseline triglycerides (<a href="./references#CD003177-fig-0017" title="">Analysis 1.11</a>) or baseline diabetic status (<a href="./references#CD003177-fig-0018" title="">Analysis 1.12</a>). While there was some suggestion of a small risk reduction in total mortality with LCn3 in trials with medium to long duration (2 to &lt; 4 years, RR 0.91, 95% CI 0.86 to 0.96) and this subgroup was clearly different from other durations (test for subgroup differences P = 0.03), the effect was not evident in shorter (1 to &lt; 2 years) or longer trials (≥ 4 years, RR 1.00, 95% CI 0.96 to 1.05). Because of the lack of effect in longer trials, we did not assume any duration effects (<a href="./references#CD003177-fig-0014" title="">Analysis 1.8</a>). </p> <p>As there was no suggestion of any effect of LCn3 fats on all‐cause mortality, we did not carry out meta‐regression. </p> <p>GRADE assessment suggested that the finding of little or no effect of LCn3 on all‐cause mortality was supported by high‐certainty evidence (not downgraded, <a href="./full#CD003177-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD003177-sec-0100"> <h6 class="title">Cardiovascular disease mortality (LCn3)</h6> <p>Moderate‐certainty evidence suggests that LCn3 fat intake probably makes little or no difference to cardiovascular deaths. </p> <p>Twenty‐nine trials in 117,837 participants, 5658 of whom died of cardiovascular disease, reported on cardiovascular mortality (RR 0.92, 95% CI 0.86 to 0.99; I<sup>2</sup> = 22%; <a href="./references#CD003177-fig-0019" title="">Analysis 1.13</a>). The funnel plot suggested that some smaller trials with more cardiovascular deaths in the intervention group were missing (some small study bias, <a href="#CD003177-fig-0004">Figure 4</a>). If this were the case then adding the missing trials would increase the RR slightly towards the null (no effect). This was supported by the fixed‐effect meta‐analysis effect being closer to the null than the random‐effects model. </p> <div class="figure" id="CD003177-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.15, cardiovascular disease mortality, sensitivity analysis by summary risk of bias" data-id="CD003177-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.15, cardiovascular disease mortality, sensitivity analysis by summary risk of bias </p> </div> </div> </div> <p>Fixed‐effect meta‐analysis suggested little or no effect on cardiovascular disease mortality risk (RR 0.93, 95% CI 0.88 to 0.97; <a href="./references#CD003177-fig-0020" title="">Analysis 1.14</a>). Sensitivity analyses removing RCTs not at low summary risk of bias left 12 RCTs in 71,019 participants, 2266 of whom died, also suggesting little or no effect of LCn3 on cardiovascular disease mortality (RR 0.95, 95% CI 0.88 to 1.03; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0021" title="">Analysis 1.15</a>). Removing trials not at low risk of compliance bias and retaining only larger trials produced similar effects to the main analysis (<a href="./references#CD003177-fig-0022" title="">Analysis 1.16</a>). </p> <p>There were no statistically significant differences between subgroups and no differential effects by replacement (<a href="./references#CD003177-fig-0024" title="">Analysis 1.18</a>), mode of intervention (<a href="./references#CD003177-fig-0025" title="">Analysis 1.19</a>), duration (<a href="./references#CD003177-fig-0026" title="">Analysis 1.20</a>), primary or secondary prevention (<a href="./references#CD003177-fig-0027" title="">Analysis 1.21</a>), statin use (<a href="./references#CD003177-fig-0028" title="">Analysis 1.22</a>), omega‐3 dose (<a href="./references#CD003177-fig-0023" title="">Analysis 1.17</a>), baseline triglyceride level (<a href="./references#CD003177-fig-0029" title="">Analysis 1.23</a>) or diabetes status (<a href="./references#CD003177-fig-0030" title="">Analysis 1.24</a>). There was no suggestion of a dose‐response effect. </p> <p>Meta‐regression to assess effects of LCn3 dose, ALA, omega‐6 and total PUFA dose, trial duration, intervention type, primary or secondary prevention and risk of bias (as well as a single multiple regression of the three factors with the smallest P values) showed no association between these factors and risk of cardiovascular mortality (all P values were &gt; 0.2, <a href="#CD003177-tbl-0005">Table 2</a>). We saw no suggestion of dose‐response or duration effects. </p> <div class="table" id="CD003177-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Meta‐regression results for cardiovascular mortalitya </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> <p>+ LCn3 dose</p> <p>+ n6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> <p>0.37</p> <p>0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>The suggestion of a marginally protective effect disappeared in trials at low summary risk of bias, the funnel plot suggests that the true risk ratio is slightly higher than the main estimate, and there was no suggestion of dose or duration effects; thus we summarised the evidence as showing little or no effect of LCn3 on cardiovascular disease mortality. GRADE assessment suggested moderate‐certainty evidence that LCn3 fat intake probably makes little or no difference to cardiovascular deaths (downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0101"> <h6 class="title">Combined cardiovascular events (LCn3)</h6> <p>High‐certainty evidence suggests that LCn3 intake makes little or no difference to risk of cardiovascular events. </p> <p>There was little or no effect of increasing LCn3 fats on cardiovascular events (RR 0.96, 95% CI 0.92 to 1.01; I<sup>2</sup> = 44%; <a href="./references#CD003177-fig-0031" title="">Analysis 1.25</a>). Analyses included 17,619 participants with cardiovascular events in 140,482 participants in 43 trials. The funnel plot suggested that some smaller trials with more participants experiencing cardiovascular events in the intervention group were missing (some small study bias, not shown). If this were the case then adding the missing trials would increase the RR. However effect sizes were the same in fixed‐effect and random‐effects analyses suggesting any bias is limited. </p> <p>Sensitivity analyses removing trials at moderate to high risk of bias left 16 trials, including 73,000 participants, 7951 of whom had cardiovascular disease events, with no suggestion of any effect of LCn3 fats (RR 0.98, 95% CI 0.95 to 1.02; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0033" title="">Analysis 1.27</a>). Sensitivity analyses including trials at low risk of compliance bias, at low risk of small study bias and using fixed‐effect meta‐analysis did not suggest any effect of LCn3 on cardiovascular disease events (<a href="./references#CD003177-fig-0032" title="">Analysis 1.26</a>; <a href="./references#CD003177-fig-0034" title="">Analysis 1.28</a>). </p> <p>In subgroup analysis there was no suggestion of a dose‐response effect (<a href="./references#CD003177-fig-0035" title="">Analysis 1.29</a>). Effects did not differ by replacement (<a href="./references#CD003177-fig-0036" title="">Analysis 1.30</a>), baseline cardiovascular disease risk (<a href="./references#CD003177-fig-0039" title="">Analysis 1.33</a>), type of intervention (<a href="./references#CD003177-fig-0037" title="">Analysis 1.31</a>), statin use (<a href="./references#CD003177-fig-0040" title="">Analysis 1.34</a>), LCn3 dose (<a href="./references#CD003177-fig-0035" title="">Analysis 1.29</a>), trial duration (<a href="./references#CD003177-fig-0038" title="">Analysis 1.32</a>), baseline triglycerides (<a href="./references#CD003177-fig-0041" title="">Analysis 1.35</a>) or baseline diabetic status (<a href="./references#CD003177-fig-0042" title="">Analysis 1.36</a>), and there were no important differences between subgroups. </p> <p>Meta‐regression suggested a negative relationship between LCn3 dose and risk of cardiovascular disease events (P = 0.02), suggesting reduction in cardiovascular disease risk at higher LCn3 doses, as would be expected from a dose response. However, when the single outlying trial <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> (with a large effect size and high dose) was omitted, the P value was 0.997 suggesting no relationship between LCn3 dose and risk of cardiovascular disease events. The effect was also moderated in the multiple regression (P = 0.07). Meta‐regression did not suggest associations between ALA, omega‐6 or total PUFA dose, trial duration, intervention type, primary or secondary prevention, risk of bias or the single multiple regression of the three factors with the smallest P values (<a href="#CD003177-tbl-0006">Table 3</a>). </p> <div class="table" id="CD003177-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Meta‐regression results for cardiovascular eventsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (lower CVD event risk with higher LCn3 dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> <p>+ LCn3 dose</p> <p>+ duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> <p>0.07</p> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (lower CVD event risk with higher LCn3 dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LCn3 dose ‐ analysis omitting <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>GRADE assessment suggested high‐certainty evidence that LCn3 intake makes little or no difference to risk of cardiovascular events (not downgraded). </p> </section> <section id="CD003177-sec-0102"> <h6 class="title">Coronary heart disease mortality (LCn3)</h6> <p>Low‐certainty evidence suggests that increasing LCn3 fat intake may slightly reduce coronary heart mortality (NNTB 334). </p> <p>Increasing LCn3 fats reduced the risk of coronary heart mortality by 10% (RR 0.90, 95% CI 0.81 to 1.00; I<sup>2</sup> = 35%) in 24 trials reporting 3598 events in more than 127,000 participants (<a href="./references#CD003177-fig-0043" title="">Analysis 1.37</a>). Sensitivity analyses using a fixed‐effect model suggested little or no effect on coronary heart disease mortality (RR 0.92, 95% CI 0.86 to 0.98; <a href="./references#CD003177-fig-0044" title="">Analysis 1.38</a>). </p> <p>Retaining only RCTs at low summary risk of bias, meta‐analysis of 10 trials with more than 70,000 participants and 1180 coronary heart disease deaths suggested that increasing LCn3 fats reduced coronary heart disease deaths (RR 0.89, 95% CI 0.76 to 1.04; I<sup>2</sup> = 22%; <a href="./references#CD003177-fig-0045" title="">Analysis 1.39</a>). Sensitivity analyses retaining only trials with low risk of compliance bias suggested a 17% reduction in risk with LCn3, retaining only larger trials suggested a 13% reduction (<a href="./references#CD003177-fig-0046" title="">Analysis 1.40</a>). The funnel plot suggested that some smaller trials with higher RRs were missing, and if added back these would increase the RR. The presence of such small study bias is supported by the reduction in effect size in fixed‐effect compared to random‐effects meta‐analysis (random‐effects meta‐analysis weighs information from small trials more heavily). </p> <p>When we added this outcome we prespecified that we would use the first of the following list reported in any trial: coronary death, ischaemic heart disease death, fatal myocardial infarction and cardiac death. We used cardiac death only when no other outcomes in this category were available, and we ran a sensitivity analysis omitting cardiac death as it potentially includes other causes of death in addition to coronary heart disease, such as cardiomyopathies and congenital and valvular heart diseases (though numbers are likely to be small). Omitting cardiac death resulted in a 19% reduction in coronary heart disease deaths with LCn3 (RR 0.81, 95% CI 0.73 to 0.90, I<sup>2</sup> = 0%, 18 trials including 106,676 participants, <a href="./references#CD003177-fig-0047" title="">Analysis 1.41</a>). </p> <p>There were no statistically significant differences between subgroups for LCn3 dose (<a href="./references#CD003177-fig-0048" title="">Analysis 1.42</a>), type of intervention (<a href="./references#CD003177-fig-0050" title="">Analysis 1.44</a>), duration (<a href="./references#CD003177-fig-0051" title="">Analysis 1.45</a>), primary or secondary prevention (<a href="./references#CD003177-fig-0052" title="">Analysis 1.46</a>), statin use (<a href="./references#CD003177-fig-0053" title="">Analysis 1.47</a>), baseline coronary artery disease status (<a href="./references#CD003177-fig-0054" title="">Analysis 1.48</a>), replacement (<a href="./references#CD003177-fig-0049" title="">Analysis 1.43</a>), baseline triglycerides (<a href="./references#CD003177-fig-0055" title="">Analysis 1.49</a>) or diabetes status (<a href="./references#CD003177-fig-0056" title="">Analysis 1.50</a>). </p> <p>Meta‐regression to assess associations between LCn3 dose and risk of coronary heart disease mortality found no relationship (P = 0.89, <a href="#CD003177-tbl-0007">Table 4</a>). Similarly we saw no relationships between ALA dose, omega‐6 dose, total PUFA dose, duration, intervention type, primary or secondary prevention, or risk of bias and coronary heart disease deaths (all P values were &gt; 0.40, <a href="#CD003177-tbl-0007">Table 4</a>). Multiple regression of the three factors with the smallest P value found no factors associated with risk of coronary heart disease deaths. We saw no suggestion of dose or duration effects. </p> <div class="table" id="CD003177-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐regression results for coronary heart disease deathsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> <p>+ Food or capsule</p> <p>+ PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> <p>0.81</p> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on coronary heart disease mortality. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>The NNTB is 334 (95% CI 200 to infinity), so 334 people would need to increase their LCn3 intake to prevent one death from coronary heart disease. If we assess NNTB by primary or secondary prevention of cardiovascular disease, people without previous cardiovascular disease (needing primary prevention) have an NNTB of 1000 (95% CI NNTB 334 to NNTH 1000), while those with existing cardiovascular disease have an NNTB of 200 (95% CI NNTB 112 to NNTH 500). </p> <p>The suggestion of a small protective effect was seen across sensitivity analyses, excepting fixed‐effect analysis. We summarised the evidence as indicating that increasing LCn3 reduces coronary heart disease mortality. GRADE assessment suggested low‐certainty evidence that LCn3 fat intake may slightly reduce coronary heart mortality (downgraded once for imprecision and once for publication bias). </p> </section> <section id="CD003177-sec-0103"> <h6 class="title">Coronary heart disease events (LCn3)</h6> <p>Low‐certainty evidence suggests that LCn3 fat intake may slightly reduce the risk of coronary heart events (NNTB 167). </p> <p>The main meta‐analysis suggested a 9% reduction in people experiencing coronary heart disease events with higher intake of LCn3 fats (RR 0.91, 95% CI 0.85 to 0.97; I<sup>2</sup> = 37%; 32 trials, 8777 events, 134,116 participants; <a href="./references#CD003177-fig-0057" title="">Analysis 1.51</a>). The funnel plot did not suggest serious small study bias (<a href="#CD003177-fig-0005">Figure 5</a>), but effect sizes in fixed‐effect meta‐analysis were slightly smaller. </p> <div class="figure" id="CD003177-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.51, coronary heart disease events (overall)" data-id="CD003177-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.51, coronary heart disease events (overall) </p> </div> </div> </div> <p>The size of any effect was reduced in sensitivity analyses using a fixed‐effect model (RR 0.93, 95% CI 0.89 to 0.96; <a href="./references#CD003177-fig-0058" title="">Analysis 1.52</a>) and when we limited trials to those at low summary risk of bias (RR 0.93, 95% CI 0.82 to 1.05, I<sup>2</sup> = 38%, <a href="./references#CD003177-fig-0059" title="">Analysis 1.53</a>), but increased when analyses were limited to trials with good compliance and to larger trials (<a href="./references#CD003177-fig-0060" title="">Analysis 1.54</a>). </p> <p>There were no statistically significant differences between subgroups (<a href="./references#CD003177-fig-0061" title="">Analysis 1.55</a>; <a href="./references#CD003177-fig-0062" title="">Analysis 1.56</a>; <a href="./references#CD003177-fig-0063" title="">Analysis 1.57</a>; <a href="./references#CD003177-fig-0064" title="">Analysis 1.58</a>; <a href="./references#CD003177-fig-0065" title="">Analysis 1.59</a>; <a href="./references#CD003177-fig-0066" title="">Analysis 1.60</a>; <a href="./references#CD003177-fig-0067" title="">Analysis 1.61</a>; <a href="./references#CD003177-fig-0069" title="">Analysis 1.63</a>), except for subgrouping by baseline triglyceride, where the subgroup of trials with raised triglyceride suggested a greater reduction in coronary heart disease events (<a href="./references#CD003177-fig-0068" title="">Analysis 1.62</a>). </p> <p>Meta‐regression suggested a negative relationship between LCn3 dose and risk of coronary heart disease events (P = 0.02), suggesting reduction in coronary heart disease risk at higher LCn3 doses, as would be expected from a dose response. This was weakened in the single multiple regression of the three factors with the smallest P value (P = 0.06). When we omitted the single outlying trial <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>, meta‐regression no longer suggested any relationship between LCn3 dose and risk of coronary heart disease events (P = 0.81). Meta‐regression did not suggest associations between ALA, omega‐6 or total PUFA dose, trial duration, intervention type, primary or secondary prevention, or risk of bias and risk of coronary heart disease events (<a href="#CD003177-tbl-0008">Table 5</a>). </p> <div class="table" id="CD003177-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metaregression results for coronary heart disease eventsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (risk of CHD events falls as LCn3 dose increases)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> <p>+ duration</p> <p>+ LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> <p>0.35</p> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (risk of CHD events falls as LCn3 dose increases)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LCn3 dose ‐ analysis omitting REDUCE‐IT data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CHD:</b> coronary heart disease; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>167 people would need to increase their LCn3 intake for one person to avoid a coronary heart disease event (NNTB 167, 95% CI 100 to 500). If we separate this out for people without existing cardiovascular disease the NNTB is 200 for primary prevention (95% CI NNTB 112 to NNTB infinity), and the NNTB is 143 for people with existing cardiovascular disease, secondary prevention, (95% CI NNTB 91 to NNTH 500). </p> <p>While there was a small protective effect in the main analysis and some sensitivity analyses, but not in sensitivity analyses limiting to RCTs at low summary risk of bias or using fixed‐effect analysis, there was also a suggestion of a dose response. We summarised this as suggesting a true effect of around 8%. GRADE assessment suggested low‐certainty evidence that increasing LCn3 fat intake may slightly reduce risk of coronary heart events (downgraded twice for risk of bias). </p> </section> <section id="CD003177-sec-0104"> <h6 class="title">Stroke (LCn3)</h6> <p>Moderate‐certainty evidence suggests that LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke. </p> <p>Increasing intake of LCn3 appears to have little effect on risk of stroke (RR 1.02, 95% CI 0.94 to 1.12; I<sup>2</sup> = 11%; 31 trials reported 2850 strokes; <a href="./references#CD003177-fig-0070" title="">Analysis 1.64</a>), and the funnel plot did not suggest small study bias (not shown). </p> <p>Sensitivity analyses removing trials not at low summary risk of bias left 14 trials with 1684 participants experiencing strokes, suggesting little or no effect of LCn3 fats on stroke (RR 0.99, 95% CI 0.90 to 1.09; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0072" title="">Analysis 1.66</a>). Using fixed‐effect meta‐analysis and sensitivity analysis removing trials with risk from poor compliance and smaller trials all suggested no effect of increased LCn3 (<a href="./references#CD003177-fig-0072" title="">Analysis 1.66</a>; <a href="./references#CD003177-fig-0074" title="">Analysis 1.68</a>). </p> <p>When trials reported stroke type separately, the risk of haemorrhagic stroke was increased (RR 1.23, 95% CI 0.93 to 1.64; I<sup>2</sup> = 0%; 197 participants with events), while ischaemic stroke was unaltered (RR 0.98, 95% CI 0.79 to 1.20; I<sup>2</sup> = 47%; 985 people with events in 10 trials; <a href="./references#CD003177-fig-0074" title="">Analysis 1.68</a>). Six trials reported only 152 participants experiencing transient ischaemic attack, suggesting a 10% increase in risk but with very wide confidence intervals (transient ischaemic attacks were not included in any other stroke categories; <a href="./references#CD003177-fig-0074" title="">Analysis 1.68</a>). Subgrouping did not suggest important differences by intervention type, replacement, statin use, trial duration, baseline triglycerides or diabetic status (<a href="./references#CD003177-fig-0076" title="">Analysis 1.70</a>; <a href="./references#CD003177-fig-0077" title="">Analysis 1.71</a>; <a href="./references#CD003177-fig-0078" title="">Analysis 1.72</a>; <a href="./references#CD003177-fig-0080" title="">Analysis 1.74</a>; <a href="./references#CD003177-fig-0081" title="">Analysis 1.75</a>; <a href="./references#CD003177-fig-0082" title="">Analysis 1.76</a>). Subgrouping by dose suggested important differences in effect at different doses, but there was no pattern to these effects so they were assumed to be spurious (<a href="./references#CD003177-fig-0075" title="">Analysis 1.69</a>). There was a suggestion of increased stroke risk in people with cardiovascular disease at baseline (RR 1.21, 95% CI 1.05 to 1.40; I<sup>2</sup> = 0%; with differences in effect size between subgroups by primary or secondary prevention, P = 0.002; <a href="./references#CD003177-fig-0079" title="">Analysis 1.73</a>). </p> <p>Meta‐regression to assess effects of LCn3 dose did not find any clear dose response on risk of stroke (P = 0.12, <a href="#CD003177-tbl-0009">Table 6</a>). Univariate meta‐regression suggested that trials of longer duration showed smaller risk ratios (or lower risk, P = 0.03), and this effect was retained in the multivariate regression (P = 0.03). There were no clear relationships between dose of any PUFA type, risk of bias, or use of food or capsules, and only trial duration remained statistically significant in multivariate meta‐regression. </p> <div class="table" id="CD003177-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metaregression results for strokea </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (lower risk with higher dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (smaller risk with longer duration)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration</p> <p>+ LCn3 dose</p> <p>+ total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> <p>0.06</p> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>Analyses consistently suggested little or no effect of LCn3 on stroke risk, and there were no dose‐response relationships, though there is a possible increase in risk of haemorrhagic stroke with increased LCn3. GRADE assessment suggests moderate‐certainty evidence that LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke (downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0105"> <h6 class="title">Arrhythmia (LCn3)</h6> <p>Low‐certainty evidence suggests that LCn3 fat intake may slightly increase the risk of arrhythmia (NNTH 1000). </p> <p>There was little or no effect of LCn3 fats on incidence of new or recurrent (fatal and non‐fatal) arrhythmias (RR 0.99, 95% CI 0.92 to 1.06; I<sup>2</sup> = 44%; 4586 events in more than 77,000 participants; <a href="./references#CD003177-fig-0083" title="">Analysis 1.77</a>). The funnel plot was not interpretable as trials were clustered (not shown), but the effect size moved above 1 in fixed‐effect meta‐analysis, suggesting that some trials suggesting harm from increased LCn3 may be missing. </p> <p>Sensitivity analyses removing trials not at low summary risk of bias left 12 trials with 1602 events (&gt; 41,000 participants), suggesting a 9% increase in risk of arrhythmia with increased LCn3 (RR 1.09, 95% CI 0.99 to 1.20, I<sup>2</sup> = 0%, <a href="./references#CD003177-fig-0085" title="">Analysis 1.79</a>). Restricting the analysis to trials at low summary risk of bias removed heterogeneity, and there was a statistically significant difference in effect size between subgroups at low versus moderate to high risk of bias (P = 0.04, <a href="./references#CD003177-fig-0085" title="">Analysis 1.79</a>). Using fixed‐effect methodology did not alter the apparent lack of effect of LCn3 on arrhythmia (<a href="./references#CD003177-fig-0084" title="">Analysis 1.78</a>), and sensitivity analysis by compliance and trial size also suggested little or no effect of LCn3 on arrhythmia (<a href="./references#CD003177-fig-0086" title="">Analysis 1.80</a>). </p> <p>Subgrouping by new or recurrent arrhythmias suggested differences between subgroups, with LCn3 increasing the risk of new arrhythmias and having little or no effect on the risk of recurrent arrhythmia (<a href="./references#CD003177-fig-0087" title="">Analysis 1.81</a>). There were also statistically significant differences between subgroups by fatality, suggesting that LCn3 increases the risk of fatal arrhythmia, but protects against non‐fatal arrhythmia (<a href="./references#CD003177-fig-0088" title="">Analysis 1.82</a>), primary or secondary prevention, suggesting harm in primary prevention, little or no effect in secondary prevention (<a href="./references#CD003177-fig-0093" title="">Analysis 1.87</a>) and duration, suggesting little or no effect in trials of up to four years' duration and harm in longer trials (<a href="./references#CD003177-fig-0092" title="">Analysis 1.86</a>). Subgroup analyses by type of intervention, replacement, statin use, dose and baseline triglyceride did not suggest statistically significant differences between subgroups (<a href="./references#CD003177-fig-0089" title="">Analysis 1.83</a>; <a href="./references#CD003177-fig-0090" title="">Analysis 1.84</a>; <a href="./references#CD003177-fig-0091" title="">Analysis 1.85</a>; <a href="./references#CD003177-fig-0094" title="">Analysis 1.88</a>; <a href="./references#CD003177-fig-0095" title="">Analysis 1.89</a>). Subgrouping by diabetes status suggested significant differences between subgroups, with little or no effect of increasing LCn3 on arrhythmia for those recruited without specific diabetes risk factors, but increased risk of arrhythmia in those with diabetes risk factors and in those with diabetes at baseline (<a href="./references#CD003177-fig-0096" title="">Analysis 1.90</a>). </p> <p>Meta‐regression suggested a positive relationship between trial duration and risk ratio, such that longer trials appeared to increase arrhythmia risk (P = 0.03; <a href="#CD003177-tbl-0010">Table 7</a>). This relationship was lost when we controlled for primary or secondary prevention and ALA dose (P = 0.42). There was also a relationship between arrhythmia with primary versus secondary prevention, suggesting greater risk ratio (harm) in primary prevention (P = 0.03; <a href="#CD003177-tbl-0010">Table 7</a>). There were no other suggested relationships, and neither of these relationships were maintained in multivariate analysis. </p> <div class="table" id="CD003177-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Meta‐regression results for arrhythmiaa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive (higher risk with longer duration)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (greater effect with primary prevention)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> <p>+ Primary secondary prevention</p> <p>+ duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> <p>0.42</p> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </div> <p>Overall, the trials at lower risk of bias, and the longer trials, suggested slight harm from increasing LCn3. This suggests that there may be some harm associated with increasing LCn3 on arrhythmia risk, and fatal arrhythmia, particularly in the longer term and in primary prevention. One thousand people would need to increase their LCn3 intake for one additional person to experience arrhythmia (NNTH 1000, 95% CI 200 to −334). GRADE assessment suggested low‐certainty evidence that LCn3 fat intake may slightly increase the risk of arrhythmia (downgraded once for risk of bias and once for imprecision). </p> </section> </section> <section id="CD003177-sec-0106"> <h5 class="title">Effects of alpha‐linolenic acid (ALA) on primary health outcomes</h5> <p>See <a href="./full#CD003177-tbl-0002">summary of findings Table 2</a> for a summary of our evidence on effects of ALA on our primary outcomes. </p> <p>As there were fewer than 10 trials for all ALA analyses we did not create or assess funnel plots, though we did run sensitivity analyses and subgroups. We assessed ALA dose‐response and duration effects in meta‐regression of all included LCn3, ALA, omega‐6 and total PUFA trials (but not of ALA trials alone as there were too few trials to carry out meta‐regression with any reliability). None of the trials that increased ALA intakes were in participants with raised baseline triglycerides, increased risk of diabetes or diabetes at baseline, so we did not subgroup by baseline triglycerides or diabetic status. </p> <section id="CD003177-sec-0107"> <h6 class="title">All‐cause mortality (ALA)</h6> <p>Moderate‐certainty evidence suggests that ALA intake probably makes little or no difference to all‐cause mortality. </p> <p>There was little or no effect of increasing ALA omega‐3 fats on all‐cause mortality, with 459 deaths in more than 19,000 participants involved in five trials (RR 1.01, 95% CI 0.84 to 1.20; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0177" title="">Analysis 4.1</a>). </p> <p>Sensitivity analyses removing trials not at low summary risk of bias left three trials with 375 deaths, again suggesting little or no effect (RR 1.02, 95% CI 0.72 to 1.45; I<sup>2</sup> = 3%; <a href="./references#CD003177-fig-0179" title="">Analysis 4.3</a>). Other sensitivity analyses all suggested little or no effect (<a href="./references#CD003177-fig-0178" title="">Analysis 4.2</a>; <a href="./references#CD003177-fig-0180" title="">Analysis 4.4</a>). </p> <p>Subgrouping by ALA dose, trial duration, statin use, replacement, primary or secondary prevention, or intervention type did not result in any significant differences between subgroups (<a href="./references#CD003177-fig-0181" title="">Analysis 4.5</a>; <a href="./references#CD003177-fig-0182" title="">Analysis 4.6</a>; <a href="./references#CD003177-fig-0183" title="">Analysis 4.7</a>; <a href="./references#CD003177-fig-0184" title="">Analysis 4.8</a>; <a href="./references#CD003177-fig-0185" title="">Analysis 4.9</a>; <a href="./references#CD003177-fig-0186" title="">Analysis 4.10</a>). As there was no suggestion of effect in any subgroup, we did not carry out meta‐regression. </p> <p>GRADE assessment suggested that ALA intake probably makes little or no difference to all‐cause mortality (moderate‐certainty evidence, downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0108"> <h6 class="title">Cardiovascular mortality (ALA)</h6> <p>Moderate‐certainty evidence suggests that increasing ALA intake probably has little or no effect on cardiovascular mortality. </p> <p>Four trials contributed data to this outcome. There was little or no effect of increasing ALA omega‐3 fats on cardiovascular mortality (RR 0.96, 95% CI 0.74 to 1.25; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0187" title="">Analysis 4.11</a>), but confidence intervals were very wide. Analyses included 219 cardiovascular disease deaths in more than 18,000 participants. All sensitivity analyses suggested little or no effect of increasing ALA (<a href="./references#CD003177-fig-0188" title="">Analysis 4.12</a>; <a href="./references#CD003177-fig-0189" title="">Analysis 4.13</a>; <a href="./references#CD003177-fig-0190" title="">Analysis 4.14</a>). </p> <p>Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not suggest important differences between subgroups (<a href="./references#CD003177-fig-0191" title="">Analysis 4.15</a>; <a href="./references#CD003177-fig-0192" title="">Analysis 4.16</a>; <a href="./references#CD003177-fig-0193" title="">Analysis 4.17</a>; <a href="./references#CD003177-fig-0194" title="">Analysis 4.18</a>; <a href="./references#CD003177-fig-0195" title="">Analysis 4.19</a>; <a href="./references#CD003177-fig-0196" title="">Analysis 4.20</a>). Meta‐regression to assess for effects of ALA dose on cardiovascular mortality did not suggest dose effects (P = 0.88; <a href="#CD003177-tbl-0005">Table 2</a>). </p> <p>GRADE assessment suggested that increasing ALA intake probably has little or no effect on cardiovascular mortality (moderate‐certainty evidence, downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0109"> <h6 class="title">Cardiovascular events (ALA)</h6> <p>GRADE assessment suggested low‐certainty evidence that increasing ALA intake may slightly reduce the risk of cardiovascular events (NNTB 500). </p> <p>There was little or no effect on risk of cardiovascular events in five trials with increased ALA intake (RR 0.95, 95% CI 0.83 to 1.07; I<sup>2</sup> = 0%; 884 out of &gt; 19,000 participants experienced at least one cardiovascular event; <a href="./references#CD003177-fig-0197" title="">Analysis 4.21</a>). Sensitivity analyses removing trials at moderate to high risk of bias left three trials in which 691 of more than 5000 enrolled participants experienced at least one cardiovascular event, suggesting a 9% reduction in risk of cardiovascular disease events with higher ALA (RR 0.91, 95% CI 0.79 to 1.04; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0199" title="">Analysis 4.23</a>). Fixed‐effect analysis, and limiting to larger trials, suggested little or no effect on cardiovascular disease event risk (<a href="./references#CD003177-fig-0198" title="">Analysis 4.22</a>; <a href="./references#CD003177-fig-0200" title="">Analysis 4.24</a>), while trials at low risk of compliance bias suggested a 10% reduction in risk (<a href="./references#CD003177-fig-0200" title="">Analysis 4.24</a>). </p> <p>Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not suggest significant differences between subgroups (<a href="./references#CD003177-fig-0201" title="">Analysis 4.25</a>; <a href="./references#CD003177-fig-0202" title="">Analysis 4.26</a>; <a href="./references#CD003177-fig-0203" title="">Analysis 4.27</a>; <a href="./references#CD003177-fig-0204" title="">Analysis 4.28</a>; <a href="./references#CD003177-fig-0205" title="">Analysis 4.29</a>; <a href="./references#CD003177-fig-0206" title="">Analysis 4.30</a>). Meta‐regression to assess for effects of ALA dose on cardiovascular events did not suggest dose effects (P = 0.67; <a href="#CD003177-tbl-0006">Table 3</a>). </p> <p>The NNTB was 500 (95% CI 125 to −334), so 500 people would need to increase their ALA intake to prevent one person experiencing a cardiovascular event. The NNTB for primary prevention was 500 (95% CI 125 to −112), the NNTB for secondary prevention was 84 (95% CI 35 to 143). GRADE assessment suggested that increasing ALA intake may reduce the risk of cardiovascular events by a small amount (low‐certainty evidence, downgraded once for risk of bias and once for imprecision). </p> </section> <section id="CD003177-sec-0110"> <h6 class="title">Coronary heart disease mortality (ALA)</h6> <p>GRADE assessment suggested that increasing ALA intake probably has little or no effect on coronary heart disease mortality. </p> <p>Three trials reported 193 coronary heart disease deaths in more than 18,000 participants, suggesting little or no effect on coronary heart disease mortality with increased ALA (RR 0.95, 95% CI 0.72 to 1.26; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0207" title="">Analysis 4.31</a>). No sensitivity analyses suggested benefits or harms (<a href="./references#CD003177-fig-0208" title="">Analysis 4.32</a>; <a href="./references#CD003177-fig-0209" title="">Analysis 4.33</a>; <a href="./references#CD003177-fig-0210" title="">Analysis 4.34</a>). </p> <p>Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, primary or secondary prevention, or previous history of coronary artery disease did not suggest important differences between subgroups (<a href="./references#CD003177-fig-0211" title="">Analysis 4.35</a>; <a href="./references#CD003177-fig-0212" title="">Analysis 4.36</a>; <a href="./references#CD003177-fig-0213" title="">Analysis 4.37</a>; <a href="./references#CD003177-fig-0214" title="">Analysis 4.38</a>; <a href="./references#CD003177-fig-0215" title="">Analysis 4.39</a>; <a href="./references#CD003177-fig-0216" title="">Analysis 4.40</a>; <a href="./references#CD003177-fig-0217" title="">Analysis 4.41</a>), and meta‐regression did not suggest dose effects (P = 0.94; <a href="#CD003177-tbl-0007">Table 4</a>). </p> <p>GRADE assessment suggested that increasing ALA intake probably has little or no effect on coronary heart disease mortality (moderate‐certainty evidence, downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0111"> <h6 class="title">Coronary heart disease events (ALA)</h6> <p>Low‐certainty evidence suggests that ALA intake may make little or no difference to coronary heart disease events. </p> <p>Four trials contributed data to this outcome, with 397 of more than 19,000 participants experiencing at least one coronary heart disease event. There was little or no effect on coronary heart disease risk with increased ALA (RR 1.00, 95% CI 0.82 to 1.22 I<sup>2</sup> = 2%; <a href="./references#CD003177-fig-0218" title="">Analysis 4.42</a>). Sensitivity analyses using fixed‐effect meta‐analysis did not alter the lack of effect (RR 1.00, 95% CI 0.82 to 1.21; <a href="./references#CD003177-fig-0219" title="">Analysis 4.43</a>). Removing trials not at low summary risk of bias left two trials with almost 5000 participants, suggesting a 9% reduction in risk of a coronary heart disease event (RR 0.91, 95% CI 0.71 to 1.15; <a href="./references#CD003177-fig-0220" title="">Analysis 4.44</a>), though little or no effect was seen when restricting analysis to larger trials or those with better compliance (<a href="./references#CD003177-fig-0221" title="">Analysis 4.45</a>). </p> <p>Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, primary or secondary prevention, or previous history of coronary artery disease did not suggest important differences between subgroups (<a href="./references#CD003177-fig-0222" title="">Analysis 4.46</a>; <a href="./references#CD003177-fig-0223" title="">Analysis 4.47</a>; <a href="./references#CD003177-fig-0224" title="">Analysis 4.48</a>; <a href="./references#CD003177-fig-0225" title="">Analysis 4.49</a>; <a href="./references#CD003177-fig-0226" title="">Analysis 4.50</a>; <a href="./references#CD003177-fig-0227" title="">Analysis 4.51</a>; <a href="./references#CD003177-fig-0228" title="">Analysis 4.52</a>). Meta‐regression did not suggest a correlation between ALA dose and coronary heart disease events (P = 0.18; <a href="#CD003177-tbl-0008">Table 5</a>). </p> <p>Given the differences in sensitivity analyses, GRADE assessment suggested that ALA intake may make little or no difference to coronary heart disease events (low‐certainty evidence, downgraded once for risk of bias and once for imprecision). </p> </section> <section id="CD003177-sec-0112"> <h6 class="title">Stroke (ALA)</h6> <p>The effect of ALA intake on stroke is unclear, as the evidence is of very low certainty.</p> <p>Five RCTs included more than 19,000 participants, of whom 51 experienced a stroke, suggesting a 15% increase in stroke risk with increased ALA (RR 1.15, 95% CI 0.66 to 2.01; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0229" title="">Analysis 4.53</a>). Sensitivity analyses removing trials not at low summary risk of bias left three trials with 27 stroke events and no suggestion of effect (<a href="./references#CD003177-fig-0231" title="">Analysis 4.55</a>). Using a fixed‐effect model suggested a 23% increased risk of stroke (<a href="./references#CD003177-fig-0230" title="">Analysis 4.54</a>), while removing trials at high risk of bias due to compliance suggested a 15% reduction in stroke risk, larger trials suggested a 15% greater stroke risk (<a href="./references#CD003177-fig-0232" title="">Analysis 4.56</a>). </p> <p>Subgrouping by ALA dose, trial duration, replacement, intervention type, statin use, or primary or secondary prevention did not result in significant differences between subgroups (<a href="./references#CD003177-fig-0233" title="">Analysis 4.57</a>; <a href="./references#CD003177-fig-0234" title="">Analysis 4.58</a>; <a href="./references#CD003177-fig-0235" title="">Analysis 4.59</a>; <a href="./references#CD003177-fig-0236" title="">Analysis 4.60</a>; <a href="./references#CD003177-fig-0237" title="">Analysis 4.61</a>; <a href="./references#CD003177-fig-0238" title="">Analysis 4.62</a>). When examining data reported by type of stroke, only three trials reported on 28 ischaemic strokes, with no clear effects, and no trials reported haemorrhagic stroke (<a href="./references#CD003177-fig-0239" title="">Analysis 4.63</a>). Meta‐regression did not suggest any relationship between ALA dose and risk of stroke (P = 0.73; <a href="#CD003177-tbl-0009">Table 6</a>). </p> <p>The effect of ALA on stroke is unclear as the evidence is of very low certainty (downgraded twice for risk of bias and once for imprecision). </p> </section> <section id="CD003177-sec-0113"> <h6 class="title">Arrhythmia (ALA)</h6> <p>Moderate‐certainty evidence suggested that ALA intake probably slightly reduces the risk of arrhythmias (NNTB 91). </p> <p>Two trials reported effects of ALA on arrhythmia, with 173 arrhythmias in 4912 participants, suggesting a 27% reduction in arrhythmia but with wide confidence intervals (RR 0.73, 95% CI 0.55 to 0.97, I<sup>2</sup> = 0%, <a href="./references#CD003177-fig-0240" title="">Analysis 4.64</a>). All sensitivity analyses suggested that ALA reduced arrhythmia (<a href="./references#CD003177-fig-0241" title="">Analysis 4.65</a>; <a href="./references#CD003177-fig-0242" title="">Analysis 4.66</a>; <a href="./references#CD003177-fig-0243" title="">Analysis 4.67</a>). There was no suggestion of a dose‐response relationship between ALA and arrhythmia risk in meta‐regression (P = 0.45; <a href="#CD003177-tbl-0010">Table 7</a>). </p> <p>The NNTB was 91 (95% CI 56 to 1000) so 91 people would need to increase their ALA intake for one person to avoid experiencing arrhythmia. With only two trials it was not possible to estimate NNTB by primary or secondary prevention. GRADE assessment suggested that ALA intake probably slightly reduces the risk of arrhythmias (moderate‐certainty evidence, downgraded once for imprecision). </p> </section> </section> </section> <section id="CD003177-sec-0114"> <h4 class="title">Secondary outcomes</h4> <p>See <a href="./full#CD003177-tbl-0003">summary of findings Table 3</a> for a summary of our evidence on effects of LCn3 fats and ALA on serum lipids and measures of adiposity. </p> <section id="CD003177-sec-0115"> <h5 class="title">Effects of long‐chain omega‐3 fats (EPA, DHA and DPA) on secondary health outcomes</h5> <p>We did not carry out sensitivity analyses or subgrouping on secondary outcomes, except for adiposity and lipids, which were key outcomes. We did carry out some post hoc sensitivity analyses to further assess effects of LCn3 on myocardial infarction, to ascertain whether the suggested protection was stable to sensitivity analyses. </p> <section id="CD003177-sec-0116"> <h6 class="title">Major adverse cerebrovascular or cardiovascular events (LCn3)</h6> <p>Five trials reported on major adverse cerebrovascular or cardiovascular events (MACCEs) in more than 34,000 participants, 4232 of whom suffered from a MACCE, suggesting little or no effect of LCn3 fats (RR 1.03, 95% CI 0.97 to 1.09; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0097" title="">Analysis 2.1</a>). </p> </section> <section id="CD003177-sec-0117"> <h6 class="title">Myocardial infarction (LCn3)</h6> <p>Twenty‐seven trials (&gt; 133,000 participants) reported on total (fatal and non‐fatal) myocardial infarction. Meta‐analyses suggested that increasing LCn3 fats resulted in a reduction in total myocardial infarction (RR 0.88, 95% CI 0.81 to 0.96; I<sup>2</sup> = 25%; 3992 people experiencing at least one myocardial infarction; <a href="./references#CD003177-fig-0098" title="">Analysis 2.2</a>). This was confirmed in fixed‐effect analysis (<a href="./references#CD003177-fig-0099" title="">Analysis 2.3</a>), sensitivity analyses limited to trials without compliance problems and to those that randomised at least 100 participants (<a href="./references#CD003177-fig-0101" title="">Analysis 2.5</a>), but analyses limited to trials at low summary risk of bias suggested little or no effect of LCn3 on myocardial infarction (RR 0.93, 95% CI 0.83 to 1.05; I<sup>2</sup> = 20%; &gt; 71,000 participants in 13 trials reporting on 1885 people experiencing at least one myocardial infarction; <a href="./references#CD003177-fig-0100" title="">Analysis 2.4</a>). This undermines a true protective effect of LCn3 on myocardial infarction. </p> <p>We ran subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, finding no significant difference between fatal and non‐fatal myocardial infarction subgroups (P = 0.20; <a href="./references#CD003177-fig-0102" title="">Analysis 2.6</a>). </p> </section> <section id="CD003177-sec-0118"> <h6 class="title">Sudden cardiac death (LCn3)</h6> <p>There was little or no effect of LCn3 fats on sudden cardiac death (RR 0.93, 95% CI 0.77 to 1.11; I<sup>2</sup> = 41%; 1422 deaths, 14 trials in &gt; 73,000 people; <a href="./references#CD003177-fig-0103" title="">Analysis 2.7</a>). </p> </section> <section id="CD003177-sec-0119"> <h6 class="title">Angina (LCn3)</h6> <p>Meta‐analysis of 13 trials involving more than 48,000 participants, 2829 of whom reported new or worsening angina, suggested little or no effect of increasing LCn3 fats (RR 0.99, 95% CI 0.92 to 1.06; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0104" title="">Analysis 2.8</a>). </p> </section> <section id="CD003177-sec-0120"> <h6 class="title">Heart failure (LCn3)</h6> <p>Meta‐analysis suggested little or no effect of LCn3 fatty acids on heart failure diagnosis in 17 trials with 4651 people experiencing events (RR 0.94, 95% CI 0.87 to 1.02; I<sup>2</sup> = 23%; <a href="./references#CD003177-fig-0105" title="">Analysis 2.9</a>). Sensitivity analysis limiting to the seven trials at low summary risk of bias also suggested little or no effect (RR 0.97, 95% CI 0.89 to 1.05; I<sup>2</sup> = 0%; 2017 participants experiencing heart failure). We concluded that there was little or no effect of LCn3 on risk of heart failure. </p> </section> <section id="CD003177-sec-0121"> <h6 class="title">Revascularisation (LCn3)</h6> <p>Meta‐analysis suggested little or no effect of LCn3 fats on revascularisation, all types combined (RR 0.93, 95% CI 0.86 to 1.00; I<sup>2</sup> = 56%; 10,793 participants experiencing revascularisation; <a href="./references#CD003177-fig-0106" title="">Analysis 2.10</a>). </p> </section> <section id="CD003177-sec-0122"> <h6 class="title">Peripheral arterial disease (LCn3)</h6> <p>Meta‐analysis suggested that LCn3 had little or no effect on risk of peripheral arterial disease (RR 0.95, 95% CI 0.76 to 1.18; I<sup>2</sup> = 0%; 6 trials, 325 events in &gt; 57,000 participants; <a href="./references#CD003177-fig-0107" title="">Analysis 2.11</a>). Sensitivity analysis, limiting to trials at low summary risk of bias, suggested that increasing LCn3 increased the risk of peripheral arterial disease by 10% (<a href="./references#CD003177-fig-0109" title="">Analysis 2.13</a>), other sensitivity analyses all suggested little or no effect (<a href="./references#CD003177-fig-0108" title="">Analysis 2.12</a>; <a href="./references#CD003177-fig-0110" title="">Analysis 2.14</a>). The data suggest that there is little or no effect of LCn3 on risk of peripheral arterial disease. </p> </section> <section id="CD003177-sec-0123"> <h6 class="title">Acute coronary syndrome (LCn3)</h6> <p>There were limited data on effects of increasing LCn3 fats on acute coronary syndrome (RR 1.19, 95% CI 0.71 to 2.00; I<sup>2</sup> = 0%; 2 trials, 55 events in &gt; 2000 participants; <a href="./references#CD003177-fig-0111" title="">Analysis 2.15</a>). </p> </section> <section id="CD003177-sec-0124"> <h6 class="title">Body weight, body mass index (BMI) and other measures of adiposity (LCn3)</h6> <section id="CD003177-sec-0125"> <p><b>Body weight</b></p> <p>High‐certainty evidence shows that increasing LCn3 intake makes little or no difference to body weight. </p> <p>Fourteen trials reported on the effect of increasing LCn3 on body weight and were included in meta‐analysis, suggesting little or no effect in 17,000 participants (mean difference (MD) 0.00 kg, 95% CI −0.69 to 0.70; I<sup>2</sup> = 42%; <a href="./references#CD003177-fig-0112" title="">Analysis 2.16</a>). Sensitivity analysis limited to trials at low summary risk of bias, low risk from compliance, larger trials or fixed‐effect analysis (not shown) did not alter this lack of effect (<a href="./references#CD003177-fig-0113" title="">Analysis 2.17</a>; <a href="./references#CD003177-fig-0114" title="">Analysis 2.18</a>; <a href="./references#CD003177-fig-0115" title="">Analysis 2.19</a>). </p> <p>Subgroup analysis by intervention type, primary or secondary prevention, statin use and trial duration did not suggest important differences between subgroups (<a href="./references#CD003177-fig-0118" title="">Analysis 2.22</a>; <a href="./references#CD003177-fig-0119" title="">Analysis 2.23</a>; <a href="./references#CD003177-fig-0120" title="">Analysis 2.24</a>; <a href="./references#CD003177-fig-0121" title="">Analysis 2.25</a>). There was a marginally significant difference between dose subgroups (P = 0.05; <a href="./references#CD003177-fig-0116" title="">Analysis 2.20</a>) and increased body weight when participants received very high LCn3 doses (&gt; 4.4 g/d LCn3, MD 1.51 kg, 95% CI 0.28 to 2.75; I<sup>2</sup> = 0%; 2 trials, 261 participants; <a href="./references#CD003177-fig-0116" title="">Analysis 2.20</a>). Subgrouping by replacement suggested differences between subgroups (P = 0.001; <a href="./references#CD003177-fig-0117" title="">Analysis 2.21</a>), with reduced body weight when LCn3 replaced saturated fatty acids or carbohydrates but increased weight when LCn3 replaced nil or low LCn3 (<a href="./references#CD003177-fig-0117" title="">Analysis 2.21</a>). </p> <p>Several trials clearly measured body weight but did not report it in a useable way (<a href="./references#CD003177-bbs2-0008" title="BaldassarreD , AmatoM , EliginiS , BarbieriSS , MussoniL , FrigerioB , et al. Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double‐blind pilot study in primary prevention. Annals of Medicine2006;38(5):367‐75. [DOI: 10.1080/07853890600852880] ">Baldassarre 2006</a>; <a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0017" title="BlokWL , DeslypereJP , DemackerPN , Van derVen‐JongekrijgJ , HectorsMP , Van derMeerJW , et al. Pro‐ and anti‐inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. European Journal of Clinical Investigation1997;27(12):1003‐8. [PUBMED: 9466128] DeslypereJP . Influence of supplementation with n‐3 fatty acids on different coronary risk factors in men: a placebo controlled study. Verhandelingen ‐ Koninklijke Academie voor Geneeskunde van Belgie1992;54(3):189‐216. [PUBMED: 1413984] KatanMB , DeslypereJP , VanBirgelenAP , PendersM , ZegwaardM . Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18‐month controlled study. Journal of Lipid Research1997;38(10):2012‐22. [PUBMED: 9374124] ">Deslypere 1992</a>; <a href="./references#CD003177-bbs2-0025" title="SanyalAJ , AbdelmalekMF , SuzukiA , CummingsOW , ChojkierM . No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology2014;147(2):377‐84.e1. [PUBMED: 24818764] ">EPE‐A 2014</a>; <a href="./references#CD003177-bbs2-0047" title="Al‐HilalM , AlsalehA , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Genetic variation at the FADS1‐FADS2 gene locus influences delta‐5 desaturase activity and LC‐PUFA proportions after fish oil supplement. Journal of Lipid Research2013;54(2):542‐51. [PUBMED: 23160180] AlSalehA , ManiouZ , LewisFJ , HallWL , SandersTA , O'DellSD . Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. Journal of Nutrition2014;144(3):267‐72. [PUBMED: 24401815] AlsalehA , CrepostnaiaD , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. Journal of Nutrition2013;143(7):1021‐7. [PUBMED: 23658423] HallWL , HayG , ManiouZ , SeedPT , ChowienczykPJ , SandersTA . Effect of low doses of long chain n‐3 polyunsaturated fatty acids on sleep‐time heart rate variability: a randomized, controlled trial. International Journal of Cardiology2013;168:4439‐42. PintoAM , HallWL , SandersTAB . Effect of low doses of long chain n‐3 PUFA intake on daytime heart rate variability: results from the MARINA study. European Journal of Preventive Cardiology2015;1:S146. SandersTA , ChowienczykPJ , HallW , LewisF , SeedP , ManiouZ , et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report2011. SandersTA , HallWL , ManiouZ , LewisF , SeedPT , ChowienczykPJ . Effect of low doses of long‐chain n‐3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. American Journal of Clinical Nutrition2011;94(4):973‐80. [PUBMED: 21865334] ">MARINA 2011</a>; <a href="./references#CD003177-bbs2-0055" title="GarbagnatiF , CairellaG , DeMartinoA , MultariM , ScognamiglioU , VenturieroV , et al. Is antioxidant and n‐3 supplementation able to improve functional status in post‐stroke patients? Results from the Nutristroke Trial. Cerebrovascular Diseases2009;27(4):375‐83. [DOI: 10.1159/000207441] ">Nutristroke 2009</a>). Body weight is commonly measured in healthcare settings, so there may be considerably more missing data than this. The funnel plot was not easily interpretable but small differences in effect size between fixed‐effect and random‐effects meta‐analysis supports the possibility of a small amount of small study bias. </p> <p>GRADE offers high‐certainty evidence that LCn3 intake makes little or no difference to body weight (not downgraded). </p> </section> <section id="CD003177-sec-0126"> <p><b>Body mass index (BMI)</b></p> <p>High‐certainty evidence shows that LCn3 intake makes little or no difference to BMI.</p> <p>Fifteen trials, 13 of which we included in meta‐analysis, reported on BMI, suggesting little or no effect of LCn3 on BMI (MD 0.06 kg/m<sup>2</sup>, 95% CI −0.14 to 0.25; I<sup>2</sup> = 39%; &gt; 15,000 participants; <a href="./references#CD003177-fig-0122" title="">Analysis 2.26</a>). This lack of effect was also apparent in sensitivity analyses limited to trials at low summary risk of bias (<a href="./references#CD003177-fig-0124" title="">Analysis 2.28</a>), with good compliance or with large trial size (<a href="./references#CD003177-fig-0125" title="">Analysis 2.29</a>), as well as fixed‐effect analysis (<a href="./references#CD003177-fig-0123" title="">Analysis 2.27</a>). Subgroup analyses by primary or secondary prevention, intervention type, statin use and trial duration did not suggest important differences between subgroups (<a href="./references#CD003177-fig-0128" title="">Analysis 2.32</a>; <a href="./references#CD003177-fig-0129" title="">Analysis 2.33</a>; <a href="./references#CD003177-fig-0130" title="">Analysis 2.34</a>; <a href="./references#CD003177-fig-0131" title="">Analysis 2.35</a>). There were significant differences between subgroups when subgrouped by replacement, suggesting lower BMI when LCn3 replaced saturated fatty acids or carbohydrate, and increased BMI when LCn3 replaced nil or low LCn3 (P = 0.02; <a href="./references#CD003177-fig-0127" title="">Analysis 2.31</a>). There was also a suggestion that increasing LCn3 increased BMI when the dose was above 2.4 g/d (<a href="./references#CD003177-fig-0126" title="">Analysis 2.30</a>). </p> <p>Several trials clearly measured BMI but did not report it in a useable way (<a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0025" title="SanyalAJ , AbdelmalekMF , SuzukiA , CummingsOW , ChojkierM . No significant effects of ethyl‐eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology2014;147(2):377‐84.e1. [PUBMED: 24818764] ">EPE‐A 2014</a>; <a href="./references#CD003177-bbs2-0055" title="GarbagnatiF , CairellaG , DeMartinoA , MultariM , ScognamiglioU , VenturieroV , et al. Is antioxidant and n‐3 supplementation able to improve functional status in post‐stroke patients? Results from the Nutristroke Trial. Cerebrovascular Diseases2009;27(4):375‐83. [DOI: 10.1159/000207441] ">Nutristroke 2009</a>; <a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a>; <a href="./references#CD003177-bbs2-0079" title="SofiF , GiangrandiI , CesariF , CorsaniI , AbbateR , GensiniGF , et al. Effects of a 1‐year dietary intervention with n‐3 polyunsaturated fatty acid‐enriched olive oil on non‐alcoholic fatty liver disease patients: a preliminary study. International Journal of Food Sciences and Nutrition2010;61(8):792‐802. [PUBMED: 20465434] ">Sofi 2010</a>), suggesting that missing data may be an issue with this outcome. The funnel plot was not interpretable, but effect sizes from random‐effects and fixed‐effect meta‐analysis were similar suggesting minimal small study bias. </p> <p>GRADE offers high‐certainty evidence that LCn3 intake makes little or no difference to BMI (not downgraded). </p> </section> <section id="CD003177-sec-0127"> <p><b>Other measures of adiposity</b></p> <p>Few trials reported on other measures of adiposity (percentage body fat, percentage visceral fat, waist circumference, waist/hip ratio, abdominal circumference and hip circumference) with some suggesting higher adiposity and some lower adiposity in groups with more LCn3 (<a href="./references#CD003177-fig-0132" title="">Analysis 2.36</a>). </p> </section> </section> <section id="CD003177-sec-0128"> <h6 class="title">Serum lipids (LCn3)</h6> <p>Several trials clearly measured lipids but did not report them in a way that we could include in our meta‐analyses. These included <a href="./references#CD003177-bbs2-0008" title="BaldassarreD , AmatoM , EliginiS , BarbieriSS , MussoniL , FrigerioB , et al. Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double‐blind pilot study in primary prevention. Annals of Medicine2006;38(5):367‐75. [DOI: 10.1080/07853890600852880] ">Baldassarre 2006</a>, <a href="./references#CD003177-bbs2-0035" title="GillEA , ChenMA , ParamsothyP , FishB , IsquithD , ThirumalaiA , et al. Omega‐3 fatty acids effects on carotid IMT in metabolic syndrome. Circulation2014;130:A1269. Abstract no. 12697. GillEA , ChenMA , ThirumalaiA , FishB , ParamsothyP . Omega‐3 fatty acids improve dyslipidemia but not inflammatory markers in metabolic syndrome. Journal of Clinical Lipidology2012;6:278‐9. ">Gill 2012,</a><a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a> and <a href="./references#CD003177-bbs2-0068" title="OlendzkiBC , LeungK , VanBuskirkS , ReedG , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. Evidence‐based Complementary and Alternative Medicine : ECAM2011;2011:827286. ReedGW , LeungK , RossettiRG , VanbuskirkS , SharpJT , ZurierRB . Treatment of rheumatoid arthritis with marine and botanical oils: an 18‐month, randomized, and double‐blind trial. Evidence‐based Complementary and Alternative Medicine : ECAM2014;2014:857456. ">Reed 2014</a>. Further trials assessed but did not report triglycerides (<a href="./references#CD003177-bbs2-0003" title="AhnJ , ParkSK , ParkTS , KimJH , YunE , KimSP , et al. Effect of n‐3 polyunsaturated fatty acids on regression of coronary atherosclerosis in statin treated patients undergoing percutaneous coronary intervention. Korean Circulation Journal2016;46(4):481‐9. [PUBMED: 27482256] ">Ahn 2016</a>; <a href="./references#CD003177-bbs2-0013" title="ArgoCK , PatrieJT , LacknerC , HenryTD , deLangeEE , WeltmanAL , et al. Effects of n‐3 fish oil on metabolic and histological parameters in NASH: a double‐blind, randomized, placebo‐controlled trial. Journal of Hepatology2015;62(1):190‐7. [PUBMED: 25195547] CaldwellSH , ArgoCK , HenryTD , LacknerC , PramoonjagoP , WeltmanAL , et al. Dissociated histological and metabolic effects of omega‐3 (3000 mg/d) versus placebo with both exercise and diet in a double‐blind randomized controlled trial of NASH. Journal of Hepatology2011; Vol. 54, issue Supplement 1:S8. ">Caldwell 2011</a>; <a href="./references#CD003177-bbs2-0034" title="FranzenD . A prospective, randomized, and double‐blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Catheterization and Cardiovascular Diagnosis1993;28(4):301‐10. FranzenD , GeiselJ , HoppHW , OetteK , HilgerHH . Long‐term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem fischol auf serumlipide und lipoproteine]. Medizinische Klinik1993;88(3):134‐8. ">Franzen 1993</a>; <a href="./references#CD003177-bbs2-0070" title="MyrupB , RossingP , JensenT , ParvingH‐H , HolmerG , GramJ , et al. Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin‐dependent diabetic patients with diabetic nephropathy. Scandinavian Journal of Clinical &amp; Laboratory Investigation2001;61(5):349‐56. RossingP , HansenBV , NielsenFS , MyrupB , HolmerG , ParvingHH . Fish oil in diabetic nephropathy. Diabetes Care1996;19(11):1214‐9. ">Rossing 1996</a>), or HDL and LDL cholesterol (<a href="./references#CD003177-bbs2-0034" title="FranzenD . A prospective, randomized, and double‐blind trial on the effect of fish oil on the incidence of restenosis following PTCA. Catheterization and Cardiovascular Diagnosis1993;28(4):301‐10. FranzenD , GeiselJ , HoppHW , OetteK , HilgerHH . Long‐term effects of low dosage fish oil on serum lipids and lipoproteins [Langzeiteffekte von niedrigdosiertem fischol auf serumlipide und lipoproteine]. Medizinische Klinik1993;88(3):134‐8. ">Franzen 1993</a>). Because of the volume of potentially missing data, small study bias may potentially bias these outcomes. </p> </section> <section id="CD003177-sec-0129"> <h6 class="title">Serum total cholesterol</h6> <p>High‐certainty evidence shows that LCn3 intake makes little or no difference to serum total cholesterol. </p> <p>Thirty trials provided data on long‐term effects of LCn3 fats on serum total cholesterol, suggesting little or no effect in more than 38,000 participants (MD −0.01 mmol/L, 95% CI −0.05 to 0.03, I<sup>2</sup> = 14%, <a href="./references#CD003177-fig-0133" title="">Analysis 2.37</a>). Sensitivity analyses using a fixed‐effect model, or limited to trials at low summary risk of bias, low risk of compliance issues, and larger trials also suggested little or no effect of LCn3 on serum total cholesterol (<a href="./references#CD003177-fig-0134" title="">Analysis 2.38</a>; <a href="./references#CD003177-fig-0135" title="">Analysis 2.39</a>; <a href="./references#CD003177-fig-0136" title="">Analysis 2.40</a>). Subgrouping by duration, primary or secondary prevention and statin use did not suggest any differential effects of LCn3 (<a href="./references#CD003177-fig-0140" title="">Analysis 2.44</a>; <a href="./references#CD003177-fig-0141" title="">Analysis 2.45</a>; <a href="./references#CD003177-fig-0142" title="">Analysis 2.46</a>). There were almost significant differences between subgroups by dose but no logical sequence suggesting no true dose‐response effect (P = 0.05; <a href="./references#CD003177-fig-0137" title="">Analysis 2.41</a>). There were also subgroup differences for replacement and intervention type but there were no subgroups with changes of at least 5% of baseline (<a href="./references#CD003177-fig-0138" title="">Analysis 2.42</a>; <a href="./references#CD003177-fig-0139" title="">Analysis 2.43</a>). </p> <p>GRADE assessment suggests high‐certainty evidence that LCn3 intake makes little or no difference to serum total cholesterol (not downgraded). </p> </section> <section id="CD003177-sec-0130"> <h6 class="title">Serum triglycerides</h6> <p>High‐certainty evidence suggests that increasing LCn3 intake reduces serum triglycerides, in a dose‐dependent manner, by around 15%. </p> <p>LCn3 fats significantly reduced serum triglycerides in more than 43,000 participants in 23 trials (MD −0.24 mmol/L, 95% CI −0.31 to −0.16; I<sup>2</sup> = 48%; <a href="./references#CD003177-fig-0143" title="">Analysis 2.47</a>). This effect was not lost in sensitivity analysis excluding trials at moderate to high risk of bias, those without clear compliance or small trials, or using fixed‐effect analysis (<a href="./references#CD003177-fig-0144" title="">Analysis 2.48</a>; <a href="./references#CD003177-fig-0145" title="">Analysis 2.49</a>; <a href="./references#CD003177-fig-0146" title="">Analysis 2.50</a>). Subgrouping suggested that the reduction of serum triglycerides did not differ between subgroups by primary or secondary prevention, statin use, replacement, intervention type or trial duration (<a href="./references#CD003177-fig-0148" title="">Analysis 2.52</a>; <a href="./references#CD003177-fig-0149" title="">Analysis 2.53</a>; <a href="./references#CD003177-fig-0150" title="">Analysis 2.54</a>; <a href="./references#CD003177-fig-0151" title="">Analysis 2.55</a>; <a href="./references#CD003177-fig-0152" title="">Analysis 2.56</a>). There was a suggestion of a dose‐response relationship with greater reductions in triglycerides at higher LCn3 doses, with significant differences between subgroups (P = 0.04; <a href="./references#CD003177-fig-0147" title="">Analysis 2.51</a>). </p> <p>GRADE assessment suggests high‐certainty evidence that increasing LCn3 intake reduces serum triglycerides in a dose‐dependent manner (not downgraded). </p> </section> <section id="CD003177-sec-0131"> <h6 class="title">HDL cholesterol</h6> <p>High‐certainty evidence suggests that LCn3 intake has little or no effect on HDL cholesterol.</p> <p>Thirty trials including more than 46,000 participants suggested little or no effect (an increase of &lt; 5%) in serum HDL cholesterol with increased LCn3 (MD 0.03 mmol/L, 95% CI 0.01 to 0.05; P = 0.005, I<sup>2</sup> = 50%; <a href="./references#CD003177-fig-0153" title="">Analysis 2.57</a>). The finding of little or no effect was retained in all sensitivity analyses (<a href="./references#CD003177-fig-0154" title="">Analysis 2.58</a>; <a href="./references#CD003177-fig-0155" title="">Analysis 2.59</a>; <a href="./references#CD003177-fig-0156" title="">Analysis 2.60</a>). There were no significant differences between subgroups in any analysis and no suggestion of a dose‐response relationship (<a href="./references#CD003177-fig-0157" title="">Analysis 2.61</a>; <a href="./references#CD003177-fig-0158" title="">Analysis 2.62</a>; <a href="./references#CD003177-fig-0159" title="">Analysis 2.63</a>; <a href="./references#CD003177-fig-0160" title="">Analysis 2.64</a>; <a href="./references#CD003177-fig-0161" title="">Analysis 2.65</a>; <a href="./references#CD003177-fig-0162" title="">Analysis 2.66</a>). </p> <p>GRADE assessment suggests high‐certainty evidence that LCn3 intake has little or no effect on HDL cholesterol (not downgraded). </p> </section> <section id="CD003177-sec-0132"> <h6 class="title">LDL cholesterol</h6> <p>GRADE assessment suggests high‐certainty evidence that LCn3 intake makes little or no difference to LDL cholesterol. </p> <p>There was little or no effect of increasing LCn3 on serum LDL cholesterol in over 43,000 participants from 25 trials (MD 0.01 mmol/L, 95% CI −0.01 to 0.03; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0163" title="">Analysis 2.67</a>). This lack of effect did not alter in any sensitivity analysis (<a href="./references#CD003177-fig-0164" title="">Analysis 2.68</a>; <a href="./references#CD003177-fig-0165" title="">Analysis 2.69</a>; <a href="./references#CD003177-fig-0166" title="">Analysis 2.70</a>). We saw no statistically significant differences between subgroups except for with regard to statin use, where there was a less than 5% increase in LDL cholesterol in nine trials where statin use was low (<a href="./references#CD003177-fig-0167" title="">Analysis 2.71</a>; <a href="./references#CD003177-fig-0168" title="">Analysis 2.72</a>; <a href="./references#CD003177-fig-0169" title="">Analysis 2.73</a>; <a href="./references#CD003177-fig-0170" title="">Analysis 2.74</a>; <a href="./references#CD003177-fig-0171" title="">Analysis 2.75</a>; <a href="./references#CD003177-fig-0172" title="">Analysis 2.76</a>). </p> <p>GRADE assessment provides high‐certainty evidence that LCn3 intake makes little or no difference to LDL cholesterol (not downgraded). </p> </section> </section> <section id="CD003177-sec-0133"> <h5 class="title">Effects of ALA on secondary health outcomes</h5> <p>We did not plan any sensitivity or subgroup analyses on secondary outcomes, except for the key outcomes of adiposity and lipids. As fewer than 10 ALA trials were available for these outcomes, we carried out only sensitivity analyses. </p> <section id="CD003177-sec-0134"> <h6 class="title">Major adverse cerebrovascular or cardiovascular events (ALA)</h6> <p>One trial reported on MACCEs in 110 participants, nine of whom experienced an event. There were insufficient data to suggest any effect of ALA on MACCEs (RR 1.12, 95% CI 0.32 to 3.95; <a href="./references#CD003177-fig-0244" title="">Analysis 5.1</a>). </p> </section> <section id="CD003177-sec-0135"> <h6 class="title">Myocardial infarction (ALA)</h6> <p>Three trials reported that 333 out of more than 18,000 participants experienced a fatal or non‐fatal myocardial infarction, suggesting little or no effect of ALA on myocardial infarction (RR 1.00, 95% CI 0.76 to 1.32; I<sup>2</sup> = 26%; <a href="./references#CD003177-fig-0245" title="">Analysis 5.2</a>). We carried out subgroup analyses by fatality at the request of the WHO NUGAG Subgroup on Diet and Health, and these suggested no significant differences between fatal and non‐fatal myocardial infarction subgroups (P = 0.36; <a href="./references#CD003177-fig-0246" title="">Analysis 5.3</a>). </p> </section> <section id="CD003177-sec-0136"> <h6 class="title">Sudden cardiac death (ALA)</h6> <p>No trials assessed effects of ALA on sudden cardiac death.</p> </section> <section id="CD003177-sec-0137"> <h6 class="title">Angina (ALA)</h6> <p>Two trials assessed the effects of increasing ALA on diagnosis of new or worsening angina (39 of &gt; 13,000 participants experienced this). There were insufficient data to suggest any effect of ALA on angina (RR 1.41, 95% CI 0.75 to 2.64; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0247" title="">Analysis 5.4</a>). </p> </section> <section id="CD003177-sec-0138"> <h6 class="title">Heart failure (ALA)</h6> <p>No trials assessed effects of ALA on heart failure.</p> </section> <section id="CD003177-sec-0139"> <h6 class="title">Revascularisation (ALA)</h6> <p>Only one trial (3 events in 266 participants) reported on the effects of increased ALA on revascularisation (RR 0.72, 95% CI 0.07 to 7.84; 3 events; <a href="./references#CD003177-fig-0248" title="">Analysis 5.5</a>) or CABG specifically (RR 0.29, 95% CI 0.01 to 5.93; 2 events; <a href="./references#CD003177-fig-0248" title="">Analysis 5.5</a>). There were insufficient data to suggest any effect of ALA on revascularisation. </p> </section> <section id="CD003177-sec-0140"> <h6 class="title">Peripheral arterial disease (ALA)</h6> <p>Meta‐analysis suggested no clear effect of ALA on peripheral arterial disease in a single trial (RR 0.25, 95% CI 0.05 to 1.17; 10 of the &gt; 13,000 participants experienced peripheral arterial disease; <a href="./references#CD003177-fig-0249" title="">Analysis 5.6</a>). There were insufficient data to suggest any effect of ALA on the outcome. </p> </section> <section id="CD003177-sec-0141"> <h6 class="title">Acute coronary syndrome (ALA)</h6> <p>No trials assessed effects of ALA on acute coronary syndrome.</p> </section> <section id="CD003177-sec-0142"> <h6 class="title">Body weight, body mass index (BMI) and other measures of adiposity (ALA)</h6> <p>The effect of LCn3 intake on body weight and BMI is unclear as the evidence is of very low certainty. </p> <p>Four trials reported on the effect of ALA on body weight in 664 participants, suggesting some weight reduction in those taking more ALA but with extremely high heterogeneity (MD −1.49 kg, 95% CI −4.17 to 1.18; I<sup>2</sup> = 73%; <a href="./references#CD003177-fig-0250" title="">Analysis 5.7</a>). Sensitivity analysis using fixed‐effect meta‐analysis suggested little or no effect of ALA on body weight (<a href="./references#CD003177-fig-0251" title="">Analysis 5.8</a>), while no trials were at low summary risk of bias (<a href="./references#CD003177-fig-0252" title="">Analysis 5.9</a>). Retaining only trials at low risk for compliance bias or only larger trials suggested weight reduction with ALA (<a href="./references#CD003177-fig-0253" title="">Analysis 5.10</a>). There were no significant differences between subgroups by intervention type, dose, duration, replacement, statin use, or primary or secondary prevention of cardiovascular disease (<a href="./references#CD003177-fig-0254" title="">Analysis 5.11</a>; <a href="./references#CD003177-fig-0255" title="">Analysis 5.12</a>; <a href="./references#CD003177-fig-0256" title="">Analysis 5.13</a>; <a href="./references#CD003177-fig-0257" title="">Analysis 5.14</a>; <a href="./references#CD003177-fig-0258" title="">Analysis 5.15</a>; <a href="./references#CD003177-fig-0259" title="">Analysis 5.16</a>). GRADE assessment suggests that the effect of ALA intake on body weight is unclear, as the evidence is of very low certainty (downgraded once each for risk of bias, inconsistency, publication bias and imprecision). </p> <p>Three trials reported on BMI, suggesting a reduction in BMI with increased ALA (MD −0.42 kg/m<sup>2</sup>, 95% CI −1.53 to 0.69; I<sup>2</sup> = 65%; 1581 participants; <a href="./references#CD003177-fig-0260" title="">Analysis 5.17</a>), again with high heterogeneity. Sensitivity analyses using fixed‐effect analysis or only retaining trials at low summary risk of bias suggested a small increase in BMI with ALA (<a href="./references#CD003177-fig-0261" title="">Analysis 5.18</a>; <a href="./references#CD003177-fig-0262" title="">Analysis 5.19</a>), while limiting to trials at low risk of compliance bias or eliminating smaller trials suggested a small reduction in BMI with increased ALA (<a href="./references#CD003177-fig-0263" title="">Analysis 5.20</a>). There were no statistically significant differences between subgroups differentiated by replacement or statin use (<a href="./references#CD003177-fig-0266" title="">Analysis 5.23</a>; <a href="./references#CD003177-fig-0268" title="">Analysis 5.25</a>), but there were differences by dose; subgrouping by dose suggested greater reduction of BMI in trials giving more ALA (P = 0.03; <a href="./references#CD003177-fig-0264" title="">Analysis 5.21</a>). All included trials gave supplemental foods (<a href="./references#CD003177-fig-0265" title="">Analysis 5.22</a>). There were greater reductions in BMI in shorter trials (P = 0.02; <a href="./references#CD003177-fig-0267" title="">Analysis 5.24</a>) and in primary prevention trials (P = 0.03; <a href="./references#CD003177-fig-0269" title="">Analysis 5.26</a>), but the inclusion of <a href="./references#CD003177-bbs2-0020" title="DodinS , CunnaneSC , MasseB , LemayA , JacquesH , AsselinG , et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double‐blind, placebo‐controlled trial. Nutrition (Burbank, Los Angeles County, Calif.)2008;24(1):23‐30. [PUBMED: 17981439] DodinS , LemayA , JacquesH , LegareF , ForestJC , MasseB . The effects of flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms in menopausal women: a randomized, double‐blind, wheat germ placebo‐controlled clinical trial. Journal of Clinical Endocrinology and Metabolism2005;90(3):1390‐7. [PUBMED: 15613422] ">Dodin 2005</a> in any subgroup tended to differentiate that group from the others. GRADE assessment suggests that the effect of ALA intake on BMI is unclear, as the evidence is of very low certainty (downgraded once each for risk of bias, inconsistency, publication bias and imprecision). </p> <p>One trial reported on visceral adipose tissue, suggesting no clear effect. Three trials reported on waist circumference. Meta‐analysis of two of these suggested that increasing ALA resulted in reduced weight circumference (MD −1.59 cm, 95% CI −3.10 to −0.07; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0270" title="">Analysis 5.27</a>). However, the single trial that we could not include in the meta‐analysis due to lack of information on variance suggested effects in the opposite direction. Sensitivity analyses (only retaining trials at low summary risk of bias, not shown) removed all trials. </p> </section> <section id="CD003177-sec-0143"> <h6 class="title">Serum lipids (ALA)</h6> <section id="CD003177-sec-0144"> <p><b>Serum total cholesterol</b></p> <p>Low‐certainty evidence suggests that ALA intake may make little or no difference to serum total cholesterol. </p> <p>Six trials provided data on the long‐term effects of ALA on serum total cholesterol, suggesting that increased ALA intake has little or no effect on total cholesterol, with high heterogeneity (MD −0.09 mmol/L, 95% CI −0.23 to 0.05; I<sup>2</sup> = 63%; in &gt; 2000 participants; <a href="./references#CD003177-fig-0271" title="">Analysis 5.28</a>). The suggestion of little or no effect did not alter in any sensitivity analyses (<a href="./references#CD003177-fig-0272" title="">Analysis 5.29</a>; <a href="./references#CD003177-fig-0273" title="">Analysis 5.30</a>; <a href="./references#CD003177-fig-0274" title="">Analysis 5.31</a>). All trials provided food supplements (<a href="./references#CD003177-fig-0276" title="">Analysis 5.33</a>), but subgroup analyses suggested greater (though still small) reductions in total cholesterol in trials of shorter duration (P = 0.02; <a href="./references#CD003177-fig-0278" title="">Analysis 5.35</a>). Other differences between subgroups resulted from effect groups where ALA replacement or statin use was 'unclear' (<a href="./references#CD003177-fig-0277" title="">Analysis 5.34</a>; <a href="./references#CD003177-fig-0279" title="">Analysis 5.36</a>), or there were no differences (<a href="./references#CD003177-fig-0275" title="">Analysis 5.32</a>; <a href="./references#CD003177-fig-0280" title="">Analysis 5.37</a>). GRADE assessment suggests low‐certainty evidence that ALA intake may make little or no difference to serum total cholesterol (downgraded once each for imprecision and inconsistency). </p> </section> <section id="CD003177-sec-0145"> <p><b>Serum triglycerides</b></p> <p>Moderate‐certainty evidence suggests that increasing ALA intake probably makes little or no difference to serum triglycerides. </p> <p>There was little or no effect of ALA on serum triglycerides in 1776 participants in six trials (MD −0.03 mmol/L, 95% CI −0.11 to 0.05; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0281" title="">Analysis 5.38</a>). There was little or no effect of ALA in sensitivity analysis removing trials of moderate to high risk of bias (<a href="./references#CD003177-fig-0283" title="">Analysis 5.40</a>), in fixed‐effect meta‐analysis (<a href="./references#CD003177-fig-0282" title="">Analysis 5.39</a>), or limiting by compliance bias or trial size (<a href="./references#CD003177-fig-0284" title="">Analysis 5.41</a>). Subgrouping suggested no important differential effects by dose, duration, replacement, intervention type, statin use, or primary or secondary prevention (<a href="./references#CD003177-fig-0285" title="">Analysis 5.42</a>; <a href="./references#CD003177-fig-0286" title="">Analysis 5.43</a>; <a href="./references#CD003177-fig-0287" title="">Analysis 5.44</a>; <a href="./references#CD003177-fig-0288" title="">Analysis 5.45</a>; <a href="./references#CD003177-fig-0289" title="">Analysis 5.46</a>; <a href="./references#CD003177-fig-0290" title="">Analysis 5.47</a>). GRADE assessment suggests moderate‐certainty evidence that ALA intake probably makes little or no difference to serum triglycerides (downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0146"> <p><b>HDL cholesterol</b></p> <p>Moderate‐certainty evidence suggests that ALA probably has little or no effect on HDL cholesterol. </p> <p>There was little or no effect of ALA on HDL cholesterol in 1776 participants of six trials (MD −0.02 mmol/L, 95% CI −0.08 to 0.03; I<sup>2</sup> = 53%; <a href="./references#CD003177-fig-0291" title="">Analysis 5.48</a>), or in any sensitivity analyses (<a href="./references#CD003177-fig-0292" title="">Analysis 5.49</a>; <a href="./references#CD003177-fig-0293" title="">Analysis 5.50</a>; <a href="./references#CD003177-fig-0294" title="">Analysis 5.51</a>). A further trial, <a href="./references#CD003177-bbs2-0084" title="BitokE , Jaceldo‐SieglK , RajaramS , Serra‐MirM , RothI , Feitas‐SimoesT , et al. Favourable nutrient intake and displacement with long‐term walnut supplementation among elderly: results of a randomised trial. British Journal of Nutrition2017;118(3):201‐9. [DOI: 10.1017/S0007114517001957] BitokE , RajaramS , RosE . Does a daily walnut supplement given for a year result in body weight gain?. FASEB Journal2016; Vol. 30:1157.5. HueyL , BitokE , KazziN . Dietary compliance of walnut or no walnut intake in a 1‐year randomized intervention trial among free‐living elderly in the Walnuts and Healthy Aging Study (WAHA). FASEB Journal2016; Vol. 30:1157.10. RajaramS , Valls‐PedretC , CofanM , SabateJ , Serra‐MirM , Perez‐HerasAM , et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. Frontiers in Aging Neuroscience2017;8:333. [PUBMED: 28119602] RosE , RajaramS , Sala‐VilaA , Serra‐MirM , Vals‐PedretC , CofanM , et al. Effect of a 1‐year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. FASEB Journal2016; Vol. 30, issue 1 Suppl:293.4. ">WAHA 2016</a>, also measured HDL but did not provide data in a useable format for meta‐analysis. There were no statistically significant differences between subgroups (<a href="./references#CD003177-fig-0295" title="">Analysis 5.52</a>; <a href="./references#CD003177-fig-0296" title="">Analysis 5.53</a>; <a href="./references#CD003177-fig-0297" title="">Analysis 5.54</a>; <a href="./references#CD003177-fig-0298" title="">Analysis 5.55</a>; <a href="./references#CD003177-fig-0299" title="">Analysis 5.56</a>; <a href="./references#CD003177-fig-0300" title="">Analysis 5.57</a>). GRADE assessment suggests moderate‐certainty evidence that ALA probably has little or no effect on HDL cholesterol (downgraded once for imprecision). </p> </section> <section id="CD003177-sec-0147"> <p><b>LDL cholesterol</b></p> <p>Moderate‐certainty evidence suggests that ALA intake probably makes little or no difference to LDL cholesterol. </p> <p>There was little or no effect of increasing ALA on LDL cholesterol in 2201 participants of seven trials (MD −0.05 mmol/L, 95% CI −0.15 to 0.04; I<sup>2</sup> = 46%; <a href="./references#CD003177-fig-0301" title="">Analysis 5.58</a>), with similar effects in all sensitivity analyses (<a href="./references#CD003177-fig-0302" title="">Analysis 5.59</a>; <a href="./references#CD003177-fig-0303" title="">Analysis 5.60</a>; <a href="./references#CD003177-fig-0304" title="">Analysis 5.61</a>). Subgrouping suggested no differences in effect by ALA dose or primary or secondary prevention (<a href="./references#CD003177-fig-0305" title="">Analysis 5.62</a>; <a href="./references#CD003177-fig-0306" title="">Analysis 5.63</a>; <a href="./references#CD003177-fig-0307" title="">Analysis 5.64</a>; <a href="./references#CD003177-fig-0309" title="">Analysis 5.66</a>; <a href="./references#CD003177-fig-0310" title="">Analysis 5.67</a>), but there was a statistically significant difference between trials of longer and shorter duration, though little or no effect in both groups (<a href="./references#CD003177-fig-0308" title="">Analysis 5.65</a>). GRADE assessment suggests moderate‐certainty evidence that ALA intake may make little or no difference to LDL cholesterol (downgraded once for imprecision). </p> </section> </section> </section> </section> <section id="CD003177-sec-0148"> <h4 class="title">Tertiary outcomes</h4> <section id="CD003177-sec-0149"> <h5 class="title">Effects of long‐chain omega‐3 fats (EPA, DHA and DPA) on tertiary health outcomes</h5> <p>We extracted these outcomes from trials that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes. We are aware of missing data for some of these outcomes, including blood pressure in <a href="./references#CD003177-bbs2-0066" title="Ramirez‐RamirezV , Macias‐IslasMA , OrtizGG , Pacheco‐MoisesF , Torres‐SanchezED , Sorto‐GomezTE , et al. Efficacy of fish oil on serum of TNF α , IL‐1 β , and IL‐6 oxidative stress markers in multiple sclerosis treated with interferon beta‐1b. Oxidative Medicine and Cellular Longevity2013;2013:709493. [DOI: 10.1155/2013/709493] Sorto‐GomezTE , OrtizGG , Pacheco‐MoisesFP , Torres‐SanchezED , Ramirez‐RamirezV , Macias‐IslasMA , et al. Effect of fish oil on glutathione redox system in multiple sclerosis. American Journal of Neurodegenerative Disease2016;5(2):145‐51. ">Ramirez‐Ramirez 2013</a>. </p> <section id="CD003177-sec-0150"> <h6 class="title">Blood pressure (LCn3)</h6> <p>Seventeen included trials (&gt; 35,000 participants) contributed data on effects of LCn3 fats on blood pressure. Meta‐analysis suggested little or no effect of LCn3 on systolic (MD 0.01 mmHg, 95% CI −0.31 to 0.34; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0173" title="">Analysis 3.1</a>) or diastolic (MD −0.02 mmHg, 95% CI −0.22 to 0.17; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0173" title="">Analysis 3.1</a>) blood pressure in trials of at least one year. </p> </section> <section id="CD003177-sec-0151"> <h6 class="title">Serious adverse effects (LCn3)</h6> <p>As part of the larger set of reviews, we formally systematically reviewed effects of omega‐3 fats on type 2 diabetes diagnoses, measures of glucose metabolism (<a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>), cancers including breast cancer (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>), neurocognitive outcomes such as dementia (<a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>), irritable bowel disease (IBD) and inflammatory factors (<a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>), depression and anxiety (<a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>), and functional outcomes (<a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>), so we do not present these outcomes here. </p> <p>We collected data on the following potentially important health outcomes (<a href="./references#CD003177-fig-0174" title="">Analysis 3.2</a>). </p> <p> <ul id="CD003177-list-0045"> <li> <p>Any serious adverse event (RR 1.00, 95% CI 0.94 to 1.06; I<sup>2</sup> = 0%; 3 trials, &gt; 9000 participants, 2668 events). </p> </li> <li> <p>Bleeding (RR 1.12, 95% CI 0.91 to 1.37; I<sup>2</sup> = 44%; 11 trials, &gt; 80,000 participants, 1324 events). Assessed as being very low‐certainty evidence, so the effect of LCn3 on bleeding is unclear (<a href="./full#CD003177-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>Serious gastrointestinal events (RR 1.34, 95% CI 0.64 to 2.80; I<sup>2</sup> 22%; 3 trials, 774 participants, 49 events). </p> </li> <li> <p>Pulmonary embolus or DVT (RR 1.15, 95% CI 0.44 to 2.98; I<sup>2</sup> = 0%; 5 trials, &gt; 3000 participants, 20 events). Assessed as being very low‐certainty evidence, so the effect of LCn3 on pulmonary embolus or DVT is unclear (<a href="./full#CD003177-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>Progression to advanced age‐related macular degeneration (RR 0.96, 95% CI 0.90 to 1.02; 1 trial, &gt; 4000 participants, 2049 events). </p> </li> <li> <p>Thrombophlebitis: no data identified</p> </li> <li> <p>Urolithiasis: no data identified</p> </li> </ul> </p> </section> <section id="CD003177-sec-0152"> <h6 class="title">Side effects (non‐serious, LCn3)</h6> <p>To assess side effects we collected data on the following potential side effects (<a href="./references#CD003177-fig-0175" title="">Analysis 3.3</a>). </p> <p> <ul id="CD003177-list-0046"> <li> <p>Withdrawal due to side effects: the data suggest more participants taking LCn3 fats dropped out because of side effects (RR 1.16, 95% CI 0.99 to 1.36; I<sup>2</sup> = 1%; 23 trials, &gt; 16,000 participants, 620 dropouts). </p> </li> <li> <p>Increased abdominal pain or discomfort: data suggest an association with higher LCn3 (RR 1.05, 95% CI 0.91 to 1.20; I<sup>2</sup> = 16%; 9 trials, &gt; 41,000 participants, 10,040 events). </p> </li> <li> <p>Diarrhoea: the data suggested an increased risk with increased LCn3 (RR 1.02, 95% CI 0.87 to 1.19; I<sup>2</sup> = 49%; 13 trials, &gt; 37,000 participants, 12,303 events). </p> </li> <li> <p>Nausea: risk increased with LCn3 (RR 1.20, 95% CI 0.96 to 1.49; I<sup>2</sup> = 54%; 8 trials, &gt; 35,000 participants, 7639 events). </p> </li> <li> <p>Any gastrointestinal side effect: risk also appeared to increase with LCn3, albeit with very high heterogeneity (RR 1.10, 95% CI 0.97 to 1.26; I<sup>2</sup> = 74%; 33 trials, &gt; 895,000 participants, 6651 events). </p> </li> <li> <p>Skin problems, including itching or rashes: these were not affected by LCn3 in a meta‐analysis with high heterogeneity (RR 1.11, 95% CI 0.52 to 2.37; I<sup>2</sup> = 68%; 9 trials, &gt; 36,000 participants, 293 events). </p> </li> <li> <p>Headache or worsening migraine: there were limited data on this outcome (RR 0.85, 95% CI 0.51 to 1.40; I<sup>2</sup> = 0%; 4 trials, 1526 participants, 60 events). </p> </li> <li> <p>Reflux: there were limited data (RR 1.23, 95% CI 0.79 to 1.91; I<sup>2</sup> = 32%; 3 trials, &gt; 8000 participants, 282 events). </p> </li> <li> <p>Joint, lumbar and muscle pain: meta‐analysis of data from three trials suggested that LCn3 had little or no effect on such pain (RR 0.95, 95% CI 0.74 to 1.23; &gt; 27,000 participants, 989 people experienced pain). </p> </li> <li> <p>All side effects: there was no suggestion that LCn3 increased or decreased all side effects combined in a meta‐analysis with very high heterogeneity (RR 1.01, 95% CI 0.95 to 1.08; I<sup>2</sup> = 79%; 14 trials, &gt; 39,000 participants, 9863 people with at least one side effect). </p> </li> </ul> </p> </section> <section id="CD003177-sec-0153"> <h6 class="title">Dropouts (LCn3)</h6> <p>Included trials reported 6643 dropouts in over 56,000 participants in 35 trials, suggesting no difference in dropout rates between intervention and control arms (RR 0.97, 95% CI 0.90 to 1.04; I<sup>2</sup> = 28%; <a href="./references#CD003177-fig-0176" title="">Analysis 3.4</a>). </p> </section> <section id="CD003177-sec-0154"> <h6 class="title">Quality of life, economic costs (LCn3)</h6> <p>We found no data on quality‐of‐life outcomes or economic costs.</p> </section> </section> <section id="CD003177-sec-0155"> <h5 class="title">Effects of ALA on tertiary health outcomes</h5> <p>We extracted these outcomes from trials that we included for other outcomes, so we did not assess them completely or systematically. We did not carry out sensitivity analyses or subgrouping for these outcomes. </p> <section id="CD003177-sec-0156"> <h6 class="title">Blood pressure (ALA)</h6> <p>Four included trials (1671 participants) contributed data on effects of ALA on blood pressure. Meta‐analysis suggested little or no effect of ALA on systolic (MD −0.87 mmHg, 95% CI −4.48 to 2.75; I<sup>2</sup> = 58%; <a href="./references#CD003177-fig-0311" title="">Analysis 6.1</a>) or diastolic (MD −1.42 mmHg, 95% CI −4.40 to 1.57; I<sup>2</sup> = 74%; <a href="./references#CD003177-fig-0311" title="">Analysis 6.1</a>) blood pressure in trials of at least one year. The heterogeneity in these results reflect a single trial, <a href="./references#CD003177-bbs2-0031" title="CaligiuriSP , AukemaHM , RavandiA , GuzmanR , DibrovE , PierceGN . Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an alpha‐linolenic acid‐induced inhibition of soluble epoxide hydrolase. Hypertension2014;64(1):53‐9. [PUBMED: 24777981] CaligiuriSP , Rodriguez‐LeyvaD , AukemaHM , RavandiA , WeighellW , GuzmanR , et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension2016;68(4):1031‐8. [PUBMED: 27528063] EdelA , Rodriguez‐LeyvaD , WeighellW , LaValleeR , AlianiM , GuzmanR , et al. Flaxseed lignan metabolites elicit antihypertensive effects in PAD patients in the FLAX‐PAD trial. Annals of Nutrition and Metabolism2013;63:1339. EdelAL , Rodriguez‐LeyvaD , MaddafordTG , CaligiuriSP , AustriaJA , WeighellW , et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond the effects of cholesterol‐lowering medications alone in patients with peripheral artery disease. Journal of Nutrition2015;145(4):749‐57. [PUBMED: 25694068] LeyvaDR , ZahradkaP , RamjiawanB , GuzmanR , AlianiM , PierceGN . The effect of dietary flaxseed on improving symptoms of cardiovascular disease in patients with peripheral artery disease: rationale and design of the FLAX‐PAD randomized controlled trial. Contemporary Clinical Trials2011;32(5):724‐30. [PUBMED: 21616170] PierceGN , EdelAL , LaValleeR , CaligiuriS , AukemaH , RavandiA , et al. The use of dietary flaxseed to promote cardiovascular health. Acta Physiologica2014;211:15. PierceGN , Rodriguez‐LeyvaD , EdelA , GuzmanR , AlianiM . The clinical use of flaxseed as a powerful nutritional intervention to treat cardiovascular disease. Cardiology (Switzerland)2013;126:201. Rodriguez‐LeyvaD , WeighellW , EdelAL , LaValleeR , DibrovE , PinnekerR , et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension2013;62(6):1081‐9. [PUBMED: 24126178] ">FLAX‐PAD 2013</a>, that showed large diastolic and systolic blood pressure effects. The other (larger) trials did not suggest such effects. </p> </section> <section id="CD003177-sec-0157"> <h6 class="title">Serious adverse effects (ALA)</h6> <p>As part of the larger set of reviews we formally systematically reviewed effects of omega‐3 fats on type 2 diabetes diagnoses and measures of glucose metabolism (<a href="./references#CD003177-bbs2-0228" title="BrownTJ , BrainardJ , SongF , WangX , AbdelhamidA , the PUFAH Group. Omega‐3, omega‐6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta‐analysis of randomised controlled trials. BMJ2019;366:l4697. [DOI: http://dx.doi.org/10.1136/bmj.l4697] ">Brown 2019</a>), cancers including breast cancer (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>), neurocognitive outcomes such as dementia (<a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>), irritable bowel disease (IBD) and inflammatory factors (<a href="./references#CD003177-bbs2-0283" title="ThorpeG , AjabnoorS , AhmedZ , AbdelhamidA , HooperL . Dietary polyunsaturated fat for prevention and treatment of inflammatory bowel disease. PROSPERO2017;www.crd.york.ac.uk/prospero/display_record.php?RecordID=68704:CRD42017068704. ">Thorpe 2017</a>), depression and anxiety (<a href="./references#CD003177-bbs2-0236" title="DeaneKH , JimohOF , BiswasP , O'BrienAT , HansonS , AbdelhamidAS , et al. Omega‐3 and polyunsaturated fat for prevention of depression and anxiety symptoms: a systematic review and meta‐analysis of randomised trials. British Journal of Psychiatry2019;online:1‐8. [DOI: 10.1192/bjp.2019.234] ">Deane 2019</a>), and functional outcomes (<a href="./references#CD003177-bbs2-0215" title="AbdelhamidA , HooperL , SivakaranR , HayhoeRP , WelchA . The relationship between omega 3, omega 6 and total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta analysis of RCTs. Calcified Tissue International2019;105:353‐72. [DOI: https://doi.org/10.1007/s00223‐019‐00584‐3] ">Abdelhamid 2019</a>), so we do not present these outcomes here. </p> <p>We collected data on the following potentially important health outcomes (<a href="./references#CD003177-fig-0312" title="">Analysis 6.2</a>). </p> <p> <ul id="CD003177-list-0047"> <li> <p>Any serious adverse event: no data identified</p> </li> <li> <p>Bleeding: no data identified</p> </li> <li> <p>Serious gastrointestinal effects: no data identified</p> </li> <li> <p>Pulmonary embolus or DVT: only one event was identified in a single trial, so there were insufficient data to assess effects. GRADE assessment suggested very low‐certainty evidence (downgraded once for risk of bias and twice for imprecision (<a href="./full#CD003177-tbl-0002">summary of findings Table 2</a>). </p> </li> <li> <p>Progression to advanced age‐related macular degeneration: no data identified</p> </li> <li> <p>Thrombophlebitis: there were insufficient data to assess effects (RR 1.59, 95% CI 0.72 to 3.51; 1 trial, &gt; 13,000 participants, 26 events). </p> </li> <li> <p>Urolithiasis: there were insufficient data to assess effects (RR 0.80, 95% CI 0.47 to 1.36; 1 trial, &gt; 13,000 participants, 54 events). </p> </li> </ul> </p> </section> <section id="CD003177-sec-0158"> <h6 class="title">Side effects (non‐serious, ALA)</h6> <p>To assess potential side effects, we collected data on the following (<a href="./references#CD003177-fig-0313" title="">Analysis 6.3</a>). </p> <p> <ul id="CD003177-list-0048"> <li> <p>Dropouts due to side effects: data suggested that ALA increased the risk of withdrawal, although there was high heterogeneity (RR 2.10, 95% CI 0.66 to 6.71; I<sup>2</sup> = 62%; 5 trials, &gt; 3000 participants, 68 events). </p> </li> <li> <p>Abdominal pain or discomfort: no data identified</p> </li> <li> <p>Diarrhoea: a single trial identified 10 participants with diarrhoea, suggesting a higher risk of diarrhoea with greater ALA intake (RR 3.82, 95% CI 0.82 to 17.88). </p> </li> <li> <p>Nausea: there were insufficient data to assess effects of ALA (RR 6.29, 95% CI 0.33 to 118.93; 1 trial, 110 participants, 3 events). </p> </li> <li> <p>Any gastrointestinal side effect: there were insufficient data to assess effects of ALA (RR 2.06, 95% CI 0.62 to 6.80; I<sup>2</sup> = 58%; 4 trials, &gt; 3000 participants, 49 events). The high heterogeneity suggests that gastrointestinal side effects may be collected in different ways in different trials. </p> </li> <li> <p>Skin problems, including itching or rashes: no data identified</p> </li> <li> <p>Headache or worsening migraine: no data identified</p> </li> <li> <p>Reflux: no data identified</p> </li> <li> <p>All side effects combined: no data identified</p> </li> </ul> </p> </section> <section id="CD003177-sec-0159"> <h6 class="title">Dropouts (ALA)</h6> <p>Included trials reported 558 dropouts in over 3000 participants in six trials, suggesting slightly similar dropout rates in participants taking higher and lower ALA (RR 1.08, 95% CI 0.92 to 1.25; I<sup>2</sup> = 0%; <a href="./references#CD003177-fig-0314" title="">Analysis 6.4</a>). </p> </section> <section id="CD003177-sec-0160"> <h6 class="title">Quality of life, economic costs (ALA)</h6> <p>We found no data on quality of life outcomes or economic costs.</p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003177-sec-0161" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003177-sec-0161"></div> <section id="CD003177-sec-0162"> <h3 class="title" id="CD003177-sec-0162">Summary of main results</h3> <p>We included 86 randomised controlled trials (162,796 participants), of which 28 were at low summary risk of bias (randomisation, allocation concealment, selection and detection bias all at low risk for supplementation trials; randomisation, allocation concealment and detection bias all at low risk for dietary advice trials). This compares to 79 RCTs including 112,059 participants, of which 25 were at low summary risk of bias in the previous review (<a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>). Trials of 12 to 88 months' duration included adults at varying levels of cardiovascular risk, mainly in high‐income countries. Most trials assessed LCn3 supplementation with capsules, but some used LCn3‐ or ALA‐rich or enriched foods or dietary advice compared to placebo or usual diet. </p> <p>Pooled trial results suggested there is probably little or no effect of increasing LCn3 fats on risk of all‐cause mortality, cardiovascular deaths, cardiovascular events, stroke or arrhythmias (moderate‐ and high‐certainty evidence). But in this update we found low‐certainty evidence suggesting that increasing LCn3 intake may reduce coronary heart disease mortality (NNTB 334) and coronary heart disease events (NNTB 167). These are small effects and have not been apparent in the more limited data sets of the past. </p> <p>Limiting LCn3 analyses to trials at low summary risk of bias moved the effect size towards 1.0 (the null value) for most primary outcomes except coronary heart disease mortality and arrhythmia. We found no suggestion of dose responses in subgrouping but there were suggestions of dose response by LCn3 dose in meta‐regression for cardiovascular disease events and coronary heart disease events. These results apply to supplemental LCn3 intake. We did not see important differences in LCn3 trials between those providing oily fish (dietary source) or EPA/DHA capsules (supplemental source), but as few trials provided whole fish health effects may differ. </p> <p>Increasing ALA intake suggested moderate‐ and low‐certainty evidence of little or no effect on all‐cause mortality, cardiovascular mortality, coronary heart disease mortality or events, but low‐certainty evidence suggested a small protection from cardiovascular events (NNTB 500) and moderate‐certainty evidence, protection from arrhythmia (NNTB 91). Effects on stroke were unclear. Data were more limited than for LCn3, and there were too few trials for informative funnel plots or subgroup analyses. These suggested that benefits of ALA need to be considered with caution, as effects were small, and few trials addressed the outcomes. </p> <p>Meta‐analyses suggested little or no effect of increasing LCn3 fats intake on secondary outcomes: major adverse cerebrovascular or cardiovascular events, fatal or non‐fatal myocardial infarction, or both, sudden cardiac death, new or worsening angina, heart failure, revascularisation, peripheral arterial disease or acute coronary syndrome. There were very limited data on effects of ALA on these outcomes. </p> <p>High‐certainty evidence suggested that increasing LCn3 has little or no effect on measures of adiposity (body weight or BMI), but effects of ALA on measures of adiposity were unclear as the evidence was of very low‐certainty. High‐certainty evidence shows that increasing LCn3 reduces serum triglycerides by ˜15% in a dose‐dependent manner, but moderate‐certainty evidence suggests little or no effect of ALA on triglycerides. High‐certainty evidence showed no effect of increasing LCn3 on total, HDL or LDL cholesterol in these long‐term trials, while moderate‐ and low‐certainty evidence suggested little or no effect of increasing ALA on these lipids. Within the included trials we assessed effects on blood pressure, serious adverse effects, side effects and dropouts. There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. Thus, proposed mechanisms for omega‐3 activity, including lowering of blood pressure, reduced thrombotic tendency and anti‐arrhythmic effects are not apparent in long‐term trials of adult humans, but LCn3 does lower serum triglyceride levels. </p> <p>The review has provided some answers for its secondary questions.</p> <p> <ul id="CD003177-list-0049"> <li> <p>If omega‐3 fatty acids confer protection:</p> <ul id="CD003177-list-0050"> <li> <p>does protection occur equally in those at low and at high risk of cardiovascular disease? There is no evidence of differential effects on mortality or cardiovascular health by primary or secondary cardiovascular disease prevention, except in the case of LCn3 and arrhythmia, where there is a suggestion of harm in primary prevention, little or no effect in secondary prevention. However, because the underlying risk of an event is different in primary and secondary prevention the NNTB differs in these two groups. For example, in assessing the effects of LCn3 on coronary heart disease mortality the NNTB is 334 (95% CI 200 to infinity), so 334 people would need to increase their LCn3 intake to prevent one death from coronary heart disease. If we assess NNTB by primary or secondary prevention of cardiovascular disease, people without previous cardiovascular disease (needing primary prevention) have an NNTB of 1000 (95% CI NNTB 334 to NNTH 1000), while those with existing cardiovascular disease have an NNTB of 200 (NNTB 91 to NNTH 500). When assessing effects of LCn3 on coronary heart disease events, the NNTB overall is 167 (95% CI 100 to 500), while the NNTB is 200 for primary prevention (95% CI NNTB 112 to NNTB infinity) and 143 for people with existing cardiovascular disease, secondary prevention (NNTB 143, 95% CI NNTB 91 to NNTH 500). </p> </li> <li> <p>does protection depend on the dose of omega‐3 fats taken per day? We ran subgroup analyses for primary and key outcomes and meta‐regression for primary outcomes but found no evidence of differential effects by LCn3 or ALA dose on any outcomes except LCn3 on serum triglycerides, cardiovascular disease events and coronary heart disease events, where there were statistically significantly greater reductions with higher LCn3 dose. </p> </li> <li> <p>do effects differ between dietary and supplemental omega‐3 sources? We assessed this question by looking for statistically significant differences between subgroups but found no evidence of differential effects by dietary or supplemental LCn3 or ALA sources. However, few of the LCn3 trials advised or gave fish, most gave supplemental fish oils, so our ability to assess effects of eating more oily whole fish are limited. </p> </li> <li> <p>does protection depend on trial summary risk of bias? Some analyses suggested a protective effect of LCn3 fats, but these effects disappeared when analyses were limited to trials at low summary risk of bias. The stronger trials with higher internal validity suggested few or no effects of LCn3 on mortality or most cardiovascular disease outcomes, but effects of LCn3 were greater for coronary heart disease mortality and arrhythmia when limited to the trials at low summary risk of bias. On the other hand, for all‐cause mortality, cardiovascular disease mortality and events and coronary heart disease mortality and events, ALA trials at low summary risk of bias suggested greater protection with higher ALA than in the main analysis (including trials of all levels of summary risk of bias). </p> </li> </ul> </li> <li> <p>Is protection or harm stronger with longer trial duration? In subgroup analyses for primary and key outcomes and in meta‐regression for primary outcomes, there was no evidence that longer trials increased the effect of LCn3 or ALA. The exceptions were effects of LCn3 on stroke (where trials of longer duration showed smaller risk ratios, or lower risk) and arrhythmia (where the risk of arrhythmia was higher in longer trials). </p> </li> <li> <p>Are effects of omega‐3 fatty acids dependent on baseline triglyceride levels or diabetic status? In subgroup analyses for primary outcomes we found no evidence that increasing LCn3 had different effects in trials with higher baseline triglycerides or with diabetes or diabetes risk factors, however few trials had raised triglycerides or diabetes at baseline so the assessment was not well powered. The exception was when assessing coronary heart disease events, where the subgroup of three trials with raised triglyceride suggested a greater reduction in coronary heart disease events (<a href="./references#CD003177-fig-0068" title="">Analysis 1.62</a>), this effect relied on <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>. No trials of increased ALA had raised baseline triglycerides or diabetes, so effects could not be assessed for ALA. </p> </li> </ul> </p> </section> <section id="CD003177-sec-0163"> <h3 class="title" id="CD003177-sec-0163">Overall completeness and applicability of evidence</h3> <p>We searched very carefully to find all trials relevant to this review and located 86 trials randomising 162,796 participants to higher and lower omega‐3 fats (LCn3 or ALA) for at least 12 months. </p> <p>To reduce selection bias, we contacted authors of trials that appeared to have randomised appropriate participants to appropriate intervention and comparator but may not have published relevant outcomes (to April 2017). If trial authors had assessed any of our outcomes, we requested data and included the trial. This enabled us to include several additional trials. We also contacted authors of all included trials that randomised at least 100 participants (and most smaller trials to April 2017) to request data on any further outcomes (as well as on methodological issues) that may have been recorded but not reported. We tried to contact 72 of the 86 included trials (all except <a href="./references#CD003177-bbs2-0008" title="BaldassarreD , AmatoM , EliginiS , BarbieriSS , MussoniL , FrigerioB , et al. Effect of n‐3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: a double‐blind pilot study in primary prevention. Annals of Medicine2006;38(5):367‐75. [DOI: 10.1080/07853890600852880] ">Baldassarre 2006</a>; <a href="./references#CD003177-bbs2-0040" title="TanSY . Dietary Manipulation and Weight Management [PhD thesis]. Wollongong, Australia: University of Wollonong, 2010. TapsellLC , BatterhamMJ , TeussG , TanSY , DaltonS , QuickCJ , et al. Long‐term effects of increased dietary polyunsaturated fat from walnuts on metabolic parameters in type II diabetes. European Journal of Clinical Nutrition2009;63(8):1008‐15. [PUBMED: 19352378] ">HERO 2009</a>; <a href="./references#CD003177-bbs2-0049" title="MitaT , WatadaH , OgiharaT , NomiyamaT , OgawaO , KinoshitaJ , et al. Eicosapentaenoic acid reduces the progression of carotid intima‐media thickness in patients with type 2 diabetes. Atherosclerosis2007;191(1):162‐7. ">Mita 2007</a>; <a href="./references#CD003177-bbs2-0055" title="GarbagnatiF , CairellaG , DeMartinoA , MultariM , ScognamiglioU , VenturieroV , et al. Is antioxidant and n‐3 supplementation able to improve functional status in post‐stroke patients? Results from the Nutristroke Trial. Cerebrovascular Diseases2009;27(4):375‐83. [DOI: 10.1159/000207441] ">Nutristroke 2009</a>; <a href="./references#CD003177-bbs2-0062" title="ÖzaydinM , ErdoğanD , TayyarS , UysalBA , DoğanA , IçliA , et al. N‐3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyoloji Dergisi2011;11(4):305‐9. [DOI: 10.5152/akd.2011.080] ">Özaydin 2011</a>; <a href="./references#CD003177-bbs2-0074" title="NCT00090402 . Fish oil and alpha lipoic acid in treating Alzheimer's Disease [Fish Oil and Alpha Lipoic Acid in Mild Alzheimer's Disease]. clinicaltrials.gov/ct2/show/NCT00090402 (first received 24 August 2004). [CENTRAL: NCT00090402] ShintoL , QuinnJ , MontineT , DodgeHH , WoodwardW , Baldauf‐WagnerS , et al. A randomized placebo‐controlled pilot trial of omega‐3 fatty acids and alpha lipoic acid in Alzheimer's disease. Journal of Alzheimer's Disease2014;38(1):111‐20. [PUBMED: 24077434] ">Shinto 2014</a>; <a href="./references#CD003177-bbs2-0079" title="SofiF , GiangrandiI , CesariF , CorsaniI , AbbateR , GensiniGF , et al. Effects of a 1‐year dietary intervention with n‐3 polyunsaturated fatty acid‐enriched olive oil on non‐alcoholic fatty liver disease patients: a preliminary study. International Journal of Food Sciences and Nutrition2010;61(8):792‐802. [PUBMED: 20465434] ">Sofi 2010</a>; and the newly added trials <a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0011" title="Lanzmann‐PetithoryD , BroustetJ‐P , FlammangD , SorainF , CombeN , LaBelleRS , et al. Prevention of atrial fibrillation recurrence with an α‐linolenic acid enriched diet: a randomized study. Journal of Clinical Lipidology2007;1(5):524, abstract 439. NCT00410020 . Arrhythmia prevention with an alpha‐linolenic enriched diet [Secondary prevention of atrial fibrillation with an alpha‐linolenic enriched diet: a randomized study]. clinicaltrials.gov/ct2/show/NCT00410020 (first received 12 December 2006). ">Broutset 2007</a>; <a href="./references#CD003177-bbs2-0023" title="AsbellPA , MaguireMG , PeskinE , BunyaVY , KuklinskiEJ . Dry Eye Assessment and Management (DREAM) Study: study design and baseline characteristics. Contemporary Clinical Trials2018;71:70‐9. [DOI: https://doi.org/10.1016/j.cct.2018.06.002] NCT02128763 . Dry eye assessment and management study (DREAM). clinicaltrials.gov/ct2/show/NCT02128763 (first received 1 May 2014). The Dry Eye Assessment and Management Study Research Group. n−3 fatty acid supplementation for the treatment of dry eye disease. New England Journal of Medicine2018;378(18):1681‐90. [DOI: 10.1056/NEJMoa1709691] ">DREAM Asbell 2018</a>; <a href="./references#CD003177-bbs2-0024" title="CauleyJA , ManiniTM , LovatoL , TaltonJ , AntonSD , DomanchukK , et al. ENRGISE Investigators. The enabling reduction of low‐grade inflammation in seniors (ENRGISE) pilot study: screening methods and recruitment results. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(8):1296‐302. [DOI: 10.1093/gerona/gly204] ManiniTM , AntonSD , BeaversDP , CauleyJA , EspelandMA , FieldingRA , et al. ENRGISE pilot study investigators. Eabling reduction of low‐grade inflammation in seniors pilot study: concept, rationale, and design. Journal of the American Geriatrics Society2017;65:1961‐68. [DOI: 10.1111/jgs.14965] NCT02676466 . The ENRGISE pilot study (ENRGISE) [The ENRGISE (enabling reduction of low‐grade inflammation in seniors) pilot study]. clinicaltrials.gov/ct2/show/NCT02676466 (first received 8 February 2016). PahorM , AntonSD , BeaversDP , CauleyJA , FieldingRA , KritchevskySB , et al. for the ENRGISE study investigators. Effect of losartan and fish oil on plasma IL‐6 and mobility in older persons. the ENRGISE pilot randomized clinical trial. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences2018;74(10):1612–19. [DOI: 10.1093/gerona/gly277] ">ENRGISE 2018</a>; <a href="./references#CD003177-bbs2-0039" title="AlfaddaghA , ElajamiTK , AshfaqueH , SalehM , BistrianBR , WeltyFK . Effect of eicosapentaenoic and docosahexaenoic acids added to statin therapy on coronary artery plaque in patients with coronary artery disease: a randomized clinical trial. Journal of the American Heart Association2017;6(12):e006981. [DOI: 10.1161/JAHA.117.006981] AlfaddaghA , ElajamiTK , WeltyFK . Abstract 16294: Omega‐3 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease. Circulation2016;134:A16294. AlfaddaghA , MohebaliD , ElajamiTK , SalehM , WeltyFK . Abstract 17391: Omega‐3 fatty acid index &gt;= 4% prevents progression of coronary artery plaque in non‐diabetic subjects on statin therapy. Circulation2017;136 (Suppl 1):A17391. AlfaddaghA , WeltyFK . Abstract 17689: Omega‐3 fatty acid supplementation reduces inflammation and improves physical function in patient with coronary artery disease. American Heart Association Conference. 2015:circ.ahajournals.org/content/132/Suppl_3/A17689.short. ElajamiTK , AlfaddaghA , LakshminarayanD , SolimanM , ChandnaniM , WeltyFK . Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease. Journal of the American Heart Association2017;6(7):e004740. [DOI: 10.1161/JAHA.116.004740] ElajamiTK , AlfaddaghA , WeltyFK . Abstract 16353: Triglyceride reduction with omega‐3 fatty acids is associated with regression of coronary plaque volume in subjects with coronary artery disease on maximal statin therapy. Circulation2016;134:A16353. LakshminarayanDK , ElajamiTK , SolimanM , AlfaddaghA , WeltyFK . Omega‐3 fatty acids supplementation attenuates the progression of microalbuminuria in diabetics with coronary artery disease. Circulation2015;132:A15530. ">HEARTS 2017</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>). This allowed us to collect useful additional data on outcomes such as deaths and cardiovascular events that we would not have had access to otherwise. For all trials we carefully searched out and data extracted trials registry entries, protocols, supplementary materials, letters, conference abstracts and additional publications to help us locate additional data. </p> <p>Most of our newly included trials were previously ongoing. We have detailed 25 remaining ongoing trials, of which seven are newly ongoing, that appear to be unpublished at the time of writing (<a href="./references#CD003177-sec-0202" title="">Characteristics of ongoing studies</a>). We have labelled these trials as ongoing, although some appear overdue for publication, and their status is unclear – they may constitute missing data. We tried to contact authors of all 'overdue' ongoing trials, and some stated that publications are forthcoming; others did not reply. We suspect that if trial authors have not published outcomes, it is likely that any protective health effects did not reach statistical significance. Given that existing trials suggest no effects of omega‐3 fats on cardiovascular health outcomes, any missing data may not affect outcomes greatly; however, for completeness we would prefer to include all available data. </p> <p>Post hoc, we followed advice to assess differences in effects between EPA and DHA within the review. However, most LCn3 trials provided or advised changes resulting in increased intakes of both EPA and DHA (as in natural fish oil), though in different ratios. Only three trials provided data on DHA only (<a href="./references#CD003177-bbs2-0001" title="QuinnJF , RamanR , ThomasRG , Yurko‐MauroK , NelsonEB , VanDyckC , et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA2010;304(17):1903‐11. ">ADCS 2010</a>; <a href="./references#CD003177-bbs2-0010" title="BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Archives of Ophthalmology2004;122(9):1297‐305. BersonEL , RosnerB , SandbergMA , Weigel‐DiFrancoC , MoserA , BrockhurstRJ , et al. Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Archives of Ophthalmology2004;122(9):1306‐14. ">Berson 2004</a>; <a href="./references#CD003177-bbs2-0087" title="ZhangY‐P , RujuanM , QingL , WuT , MaF . Effects of DHA supplementation on hippocampal volume and cognitive function in older adults with mild cognitive impairment: a 12‐month randomized, double‐blind, placebo‐controlled trial. Journal of Alzheimer's Disease2016;55(2):497‐507. ">Zhang 2017</a>), and six provided data on EPA only (<a href="./references#CD003177-bbs2-0021" title="DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Clinical outcomes of early initiation of pure eicosapentaenoic acid supplement after percutaneous coronary intervention in patients with acute coronary syndrome. European Heart Journal2014;35(Abstract Suppl):1156. DoiM , NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , et al. Early eicosapentaenoic acid treatment after percutaneous coronary intervention reduces acute inflammatory responses and ventricular arrhythmias in patients with acute myocardial infarction: a randomized, controlled study. International Journal of Cardiology2014;176(3):577‐82. [PUBMED: 25305703] NosakaK , MiyoshiT , IwamotoM , KajiyaM , OkawaK , TsukudaS , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. International Journal of Cardiology2017;228:173‐9. [DOI: 10.1016/j.ijcard.2016.11.105] NosakaK , MiyoshiT , OkawaK , TsukudaS , SogoM , NishibeT , et al. Early initiation of eicosapentaenoic acid and statin treatment is associated with better clinical outcomes than statin alone in patients with acute coronary syndromes: 1‐year outcomes of a randomized controlled study. Journal of the American College of Cardiology2016;67:573. ">Doi 2014</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0049" title="MitaT , WatadaH , OgiharaT , NomiyamaT , OgawaO , KinoshitaJ , et al. Eicosapentaenoic acid reduces the progression of carotid intima‐media thickness in patients with type 2 diabetes. Atherosclerosis2007;191(1):162‐7. ">Mita 2007</a>; <a href="./references#CD003177-bbs2-0056" title="IlseyCD , NyeER , SutherlandW , RamJ , AblettMB . Randomised placebo controlled trial of MAXEPA and aspirin/persantin after successful coronary angioplasty. Australian &amp; New Zealand Journal of Medicine1987;17:559. NyeER , AblettMB , RobertsonMC , IlsleyCD , SutherlandWH . Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty. Australian and New Zealand Journal of Medicine1990;20(4):549‐52. ">Nye 1990</a>; <a href="./references#CD003177-bbs2-0064" title="PuriBK , LeavittBR , HaydenMR , RossCA , RosenblattA , GreenamyreJT , et al. Ethyl‐EPA in Huntington disease: a double‐blind, randomized, placebo‐controlled trial. Neurology2005;65(2):286‐92. ">Puri 2005</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>). Unfortunately, for any single outcome, only two or three of these trials were represented, so our ability to assess differential effects of the DHA‐only and EPA‐only interventions was very limited, and we have not presented these analyses or attempted to draw any information from them. </p> </section> <section id="CD003177-sec-0164"> <h3 class="title" id="CD003177-sec-0164">Quality of the evidence</h3> <p><a href="#CD003177-fig-0002">Figure 2</a> displays risk of bias of included trials. Of the 86 RCTs, 28 were at low summary risk of bias (at low risk of selection bias, performance bias and detection bias, plus low risk of performance bias in supplemental trials). We assessed the validity of evidence in meta‐analyses by running sensitivity analyses that removed trials not at low summary risk of bias. Funnel plots for LCn3 trials suggested that there may be missing trials for all primary outcomes except stroke and arrhythmia, and in all cases adding such trials back in would move effect sizes closer to no effect (RR 1.0). This lack of effect in the trials at lowest risk of bias (with suggestions of effect in trials at moderate to high risk of bias) supported our interpretation of lack of effect of LCn3 fats on many of our primary outcomes. </p> <p>However, the increased numbers of trials, of longer trials and of greater numbers of people randomised within included trials (up by 31% in this review from the previous iteration, <a href="./references#CD003177-bbs2-0294" title="AbdelhamidAS , BrownTJ , BrainardJS , BiswasP , ThorpeGC , MooreHJ , et al. Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.CD003177.pub4] ">Abdelhamid 2018a</a>), has increased our power to see small effects of increasing LCn3. We pre‐stated that effect sizes needed to be greater than 8% (RR &lt; 0.92 or &gt; 1.08) to suggest an important effect. Effect sizes of 9% or 10% are still small, and for the outcomes that have reached this level of effectiveness in this review NNTBs are still very large. The effects of LCn3 and ALA we are seeing on cardiovascular diseases and triglycerides are small. </p> </section> <section id="CD003177-sec-0165"> <h3 class="title" id="CD003177-sec-0165">Potential biases in the review process</h3> <p>Potential adverse effects include cancers and neurological problems associated with polychlorinated biphenyls (PCBs) or mercury in fish oils, and bleeds associated with reductions in clotting (see <a href="#CD003177-sec-0054">How the intervention might work</a>). We have collated any data on bleeds, including haemorrhagic stroke, in this review, though we did not ask trial authors specifically for additional data on these outcomes. Unfortunately there were insufficient data on serious harms (bleeding and pulmonary embolism or deep vein thrombosis) to assess these potential harms. We have not collated data on cancers (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>), and neurological problems (<a href="./references#CD003177-bbs2-0227" title="BrainardJ , JimohOF , DeaneK , BiswasP , DonaldsonD , MaasK , et al. Omega‐3, omega‐6 and total polyunsaturated fat for cognition and dementia: systematic review and meta‐analysis of RCTs. submitted2019. ">Brainard 2019</a>), within this review but have formally systematically reviewed them elsewhere. This approach is preferable to including data on these outcomes from within included trials, which would be incomplete and potentially underpowered to show important effects. </p> <p>One problem with cardiovascular disease outcomes is that they are collected together in a variety of ways, depending on the trial. For example, in assessing coronary heart disease mortality, we prespecified that we would include the first of the following list reported in any trial: coronary death, ischaemic heart disease death, fatal myocardial infarction, cardiac death. Each included trial collates outcome data in its own way, so we had to adapt to this in our analysis. One way to get around this problem would be to ask trial authors to go back to their original datasets to assess outcomes in a single prespecified way. This was done by a recent meta‐analysis that included only 10 trials but was able to formulate their outcome data to match between trials (<a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>). In doing this they were able to include data on outcomes that we were not able to access. For example, numbers of coronary heart disease deaths for <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a> have risen considerably in this version of the review, as we were able to include data on coronary heart disease deaths from a greater range of sources than were previously published: sudden cardiac deaths, deaths due to ventricular arrhythmias, and heart failure in patients with coronary heart disease, myocardial infarction, or deaths occurring after coronary revascularisation or heart transplant. Their data are also richer with regard to summing people with events (rather than numbers of events). Numbers of events are relatively easy to extract from published papers, but are not additive across composite endpoints such as cardiovascular disease events or coronary heart disease events (as a single individual may have experienced a stroke and a heart attack as well as onset of angina, but should be counted once only within any one composite outcome ‐ counting events would lead to their inclusion twice in coronary heart disease events and three times for cardiovascular disease events). For that reason previous versions of this review have been conservative in the data we have used, but use of the <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> data has allowed more data inclusion. The next section discusses similarities and differences between this review and <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>, but their findings were highly similar. For example, effects of LCn3 on coronary heart disease mortality, our meta‐analytic estimate of effect of LCn3 was RR 0.90, (95% CI 0.81 to 1.00; I<sup>2</sup> = 35%) in 24 trials reporting 3598 coronary heart disease deaths (<a href="./references#CD003177-fig-0043" title="">Analysis 1.37</a>), while theirs was RR 0.93 (95% CI 0.83 to 1.03) in 10 trials reporting 2695 coronary heart disease deaths. </p> <p>While we tried hard to locate all available trials and collect additional outcome data where possible, there was evidence from funnel plots of some small study bias. Some smaller trials showing increased risk of cardiovascular disease outcomes with omega‐3 fats may be missing from some of the meta‐analyses. If these trials were replaced they would tend to increase risk ratios. This suggests that there is some underlying small study bias within the review. </p> <p>Underlying risks vary from trial to trial. For example, the risk of death in <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a> was 28% in people with heart failure at baseline, but less than 4% in the healthy population recruited to <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>. Despite this there was little suggestion of heterogeneity between trials (I<sup>2</sup> = 5%; <a href="./references#CD003177-fig-0007" title="">Analysis 1.1</a>). Where there have been suggestions of effects we have translated these into benefits or harms in both higher‐ and lower‐risk populations to clarify. </p> <p>Given that the many LCn3 trials at moderate to high risk of bias appear to be inflating any protective effects, and that small trial bias is also inflating any protective effects, it is justified to view with skepticism the occasional suggestion of a protective effect. We do see some protective effects, but they are small. Given the very large number of subgroup analyses we carried out, it is also important to treat the occasional subgroup analysis that throws up a statistically significant difference between subgroups very cautiously. </p> <p>A secondary question asked by this review was about differential effects of dietary and supplemental LCn3 fats. LCn3 interventions included dietary advice (advice to eat more oily fish), supplemental foods (LCn3 fats incorporated into other foods such as margarine) and supplements or capsules (by far the greatest proportion of trials). Dietary fish is likely to have different health effects, as it may take the place of less healthy foods in the diet (leading to reduced saturated fat intake, for example) and provides many nutrients in addition to omega‐3 fats (such as protein, selenium, iodine, calcium, magnesium, etc.). There were only four LCn3 dietary advice trials with event data (<a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>; <a href="./references#CD003177-bbs2-0019" title="HarrisonRA . Dietary Intervention for Maintaining Sinus Rhythm Following Cardioversion for Atrial Fibrillation: a Randomised Controlled Trial [PhD thesis]. Manchester (UK): Faculty of Medicine, Dentistry, Nursing and Pharmacy, 2005. HarrisonRA , EltonP . From pies to pilchards: dietary assistants increase consumption of oil rich fish. Journal of Epidemiology and Community Health2000;Suppl:6. HarrisonRA , EltonPJ . Can an oil‐rich fish diet improve treatment outcomes following cardioversion for atrial fibrillation? A randomised controlled trial. Study design and compliance. International Society for the Study of Fatty Acids and Lipids (ISSFAL); 2002 May; Montreal, Canada. 2002. HarrisonRA , EltonPJ . Is there a role for long‐chain omega3 or oil‐rich fish in the treatment of atrial fibrillation?. Medical Hypotheses2005;64(1):59‐63. [PUBMED: 15533612] HarrisonRA , PurnellP , EltonPJ . Using community‐based dietary assistants to increase the intake of oil‐rich fish among older people. European Journal of Public Health2003;13(Suppl 1):105. HarrisonRA , SureshV , PurnellB , RobertsC , HoughtonP , MillerJ , et al. Can oil‐rich fish sustain normal sinus rhythm after cardioversion for atrial fibrillation? An RCT (DISAF). Author supplied data 29 September 2010. ">DISAF 2003</a>; <a href="./references#CD003177-bbs2-0082" title="PackardDP , MiltonJE , ShulerLA , ShortRA , TuttleKR . Implications of chronic kidney disease for dietary treatment of cardiovascular disease. Journal of Renal Nutrition2006;16(3):259‐68. TuttleKR , ShulerLA , PackardDP , MiltonJE , DarathaKB , BibusDM , et al. Comparison of low‐fat versus Mediterranean‐style dietary intervention after first myocardial infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial). American Journal of Cardiology2008;101(11):1523‐30. [PUBMED: 18489927] ">THIS DIET 2008</a>), and two of these also provided fish oil capsules when participants did not want to eat more fish (<a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>; <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>). We found no statistically significant differences between dietary advice subgroups and supplemental foods or capsule subgroups for primary outcomes. This may mean that health effects between the two types of intervention are not different, but it is likely that our analysis was underpowered to see any such differences if they exist. </p> <p>Population LCn3 status varies widely across the world, from over 8% of fatty acids in Japan, Scandinavia and other areas with non‐Westernised dietary patterns to less than 4% in North, South and Central America; Europe; the Middle East; Southeast Asia; and Africa (<a href="./references#CD003177-bbs2-0282" title="StarkKD , VanElswykME , HigginsR , WeatherfordCA , SalemNJr . Global survey of the omega‐3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Progress in Lipid Research2016;63:132‐52. [DOI: 10.1016/j.plipres.2016.05.001] ">Stark 2016</a>). We hypothesised that additional LCn3 might have greater health effects in people whose usual LCn3 intake was relatively low, but unfortunately we were not able to ascertain baseline LCn3 intake or status for most of our included trials. However, most of the included trials were carried out in areas of the world with lower LCn3 status, so we would expect to see effects of increasing LCn3 in most included trials if such effects exist. </p> </section> <section id="CD003177-sec-0166"> <h3 class="title" id="CD003177-sec-0166">Agreements and disagreements with other studies or reviews</h3> <p>One potential difference between the findings of this review and some other trials and reviews is our running sensitivity analyses assessing effects exclusively in trials at low summary risk of bias. This clarified the lack of effect of LCn3 fats on stroke, which otherwise appeared slightly harmful. On the other hand, these sensitivity analyses suggested protective effects of LCn3 on coronary heart disease mortality and ALA on cardiovascular events. The effectiveness or lack of effectiveness of LCn3 on coronary heart disease events is harder to call. The main analysis suggests a 9% reduction in coronary heart disease events, but sensitivity analyses limiting trials to those at low summary risk of bias, or fixed‐effect analysis suggested 7% and 8% reductions, while limiting to trials with low risk of compliance problems or to larger trials suggested reductions of 16% and 11% respectively. We have suggested that this implies that LCn3 does slightly reduce risk of coronary heart disease events, but the interpretation that there was little or no effect is also logical. </p> <p>There was no suggestion that blood pressure or risk of adverse events such as bleeding differed by LCn3 or ALA intake. This suggests that possible mechanisms for omega‐3 activity, including lowering of blood pressure, reduced thrombotic tendency and anti‐arrhythmic effects are not important in most adults, though LCn3 does lower serum triglyceride levels. We did not systematically review blood pressure data so may have missed a few long‐term trials (though not many) – missing data from included trials is likely to be a bigger issue. Of the 15 included trials that reported blood pressure outcomes, nine reported numbers of hypertensive participants at baseline, ranging from 5% in <a href="./references#CD003177-bbs2-0047" title="Al‐HilalM , AlsalehA , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Genetic variation at the FADS1‐FADS2 gene locus influences delta‐5 desaturase activity and LC‐PUFA proportions after fish oil supplement. Journal of Lipid Research2013;54(2):542‐51. [PUBMED: 23160180] AlSalehA , ManiouZ , LewisFJ , HallWL , SandersTA , O'DellSD . Interaction between a CSK gene variant and fish oil intake influences blood pressure in healthy adults. Journal of Nutrition2014;144(3):267‐72. [PUBMED: 24401815] AlsalehA , CrepostnaiaD , ManiouZ , LewisFJ , HallWL , SandersTA , et al. Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals. Journal of Nutrition2013;143(7):1021‐7. [PUBMED: 23658423] HallWL , HayG , ManiouZ , SeedPT , ChowienczykPJ , SandersTA . Effect of low doses of long chain n‐3 polyunsaturated fatty acids on sleep‐time heart rate variability: a randomized, controlled trial. International Journal of Cardiology2013;168:4439‐42. PintoAM , HallWL , SandersTAB . Effect of low doses of long chain n‐3 PUFA intake on daytime heart rate variability: results from the MARINA study. European Journal of Preventive Cardiology2015;1:S146. SandersTA , ChowienczykPJ , HallW , LewisF , SeedP , ManiouZ , et al. The influences of increasing intakes of EPA and DHA on vascular function and risk factors for cardiovascular disease. Food Standards Agency Project N02041. Final Report2011. SandersTA , HallWL , ManiouZ , LewisF , SeedPT , ChowienczykPJ . Effect of low doses of long‐chain n‐3 PUFAs on endothelial function and arterial stiffness: a randomized controlled trial. American Journal of Clinical Nutrition2011;94(4):973‐80. [PUBMED: 21865334] ">MARINA 2011</a> to 79% of participants in <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>. Effects did not differ by proportions of hypertensive participants (I<sup>2</sup> was 0% for both systolic and diastolic blood pressure; <a href="./references#CD003177-fig-0173" title="">Analysis 3.1</a>). </p> <p>Nearly 20 years ago, the <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a> trial suggested that LCn3 had its primary effects in reducing sudden cardiac death. However, the forest plot clearly shows that subsequent trials have not seen this effect individually or in aggregate (<a href="./references#CD003177-fig-0103" title="">Analysis 2.7</a>). </p> <p>The scope of this review is similar to that of the extensive Agency for Healthcare Research and Quality review (<a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>), so we have compared our results with theirs. Given that our review included 86 RCTs randomising more than 162,000 participants, who experienced over 11,000 deaths and more than 5000 cardiovascular disease deaths, we were surprised to read that Balk and colleagues characterised the body of evidence as having "limited data ... from RCTs on the effect of n‐3 FA on clinical CVD [cardiovascular disease] outcomes" (<a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>). This appears to be because the Balk review excluded RCTs of people with non‐cardiovascular disease and non‐diabetes‐related diseases at baseline, while we included them. While <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a> excluded some trials that we included, it did not include any trials providing all‐cause mortality data that we excluded. This meant that in analysing effects on all‐cause mortality, <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a> included 18 RCTs randomising 81,027 participants experiencing 8480 deaths, while we included more than 143,000 participants randomised to high or low LCn3 or ALA experiencing 11,297 deaths. <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a> excluded trials that we included, such as <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>, a high‐quality trial with 368 deaths in more than 4000 participants with age‐related macular degeneration. This sort of population appeared ideal to us for assessment of omega‐3 fats on primary prevention of cardiovascular disease, as these people tend to be elderly but there is no clear reason why omega‐3 fats would affect cardiovascular disease differently in this population than in other older adults at usual cardiovascular disease risk. </p> <p>Despite these slight differences in approach, we obtained very similar effect estimates to <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>. We meta‐analysed effects of LCn3 and ALA trials, finding an RR for all‐cause mortality of 0.97 (95% CI 0.93 to 1.01; I<sup>2</sup> = 5%), compared to a pooled RR for all‐cause mortality of 0.97 (95% CI 0.92 to 1.03) in <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>. While that review seldom pooled their results, we can compare our results with theirs where they did. Despite our slightly different inclusion criteria, our results are very comparable (<a href="#CD003177-tbl-0011">Table 8</a>). </p> <div class="table" id="CD003177-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of the results of long‐chain omega‐3 interventions in this review with other major recent reviewsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>This review</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8480</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.92 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.93 to 1.01)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular deaths</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.82 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4630</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.88 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5658</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.86 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CVD events (MACCEs in Balk 2016)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8085</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.91 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.93 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.94 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,619</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.92 to 1.01)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHD deaths</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2695</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93, (0.83 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2934</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.86 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3598</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.81 to 1.00)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHD events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96, (0.90 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7536</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.91 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8791</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.85 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.88 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.93 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.98 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.94, 1.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.92 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>CHD:</b> coronary heart disease; <b>CI:</b> confidence interval; <b>CVD:</b> cardiovascular disease; <b>MACCE:</b> major adverse cerebrovascular or cardiovascular event; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Meta‐analysis of effects of long‐chain omega‐3 in three recent systematic reviews, <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>, <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> and <a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a>, comparing their findings with our findings for our primary outcomes. </p> </div> </div> <p>A recent individual meta‐analysis of 10 large trials in almost 78,000 people at high risk of cardiovascular disease found no associations of LCn3 with coronary heart disease mortality (RR 0.93, 99% CI 0.83 to 1.03), nonfatal myocardial infarction (RR 0.97, 99% CI 0.87 to 1.08), coronary heart disease events (RR 0.96, 95% CI 0.90 to 1.01) or major vascular events (RR 0.97, 95% CI 0.93 to 1.01; <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a>). <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> included individual patient data from the participants of large, long trials (randomising at least 500 participants and following them for at least one year) (<a href="./references#CD003177-bbs2-0005" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BrouwerIA , GeleijnseJM , KlaasenVM , SmitLA , GiltayEJ , DeGoedeJ , et al. Effect of alpha linolenic acid supplementation on serum prostate specific antigen (PSA): results from the Alpha Omega Trial. PLOS ONE2013;8(12):e81519. EussenSR , GeleijnseJM , GiltayEJ , RompelbergCJ , KlungelOH , KromhoutD . Effects of n‐3 fatty acids on major cardiovascular events in statin users and non‐users with a history of myocardial infarction. European Heart Journal2012;33(13):1582‐8. GeleijnseJ , GiltayE , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2011;1:S512. GeleijnseJM , GiltayEJ , KromhoutD . Effects of n‐3 fatty acids on cognitive decline: a randomized, double‐blind, placebo‐controlled trial in stable myocardial infarction patients. Alzheimer's &amp; Dementia2012;8(4):278‐87. GeleijnseJM , GiltayEJ , SchoutenEG , DeGoedeJ , Oude GriepLM , Teitsma‐JansenAM , et al. Effect of low doses of n‐3 fatty acids on cardiovascular diseases in 4,837 post‐myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. American Heart Journal2010;159(4):539‐46. [DOI: 10/1016/j.ahj.2009.12.033] GiltayEJ , GeleijnseJM , HeijboerAC , DeGoedeJ , Oude GriepLM , BlankensteinMA , et al. No effects of n‐3 fatty acid supplementation on serum total testosterone levels in older men: the Alpha Omega Trial. International Journal of Andrology2012;35(5):680‐7. GiltayEJ , GeleijnseJM , KromhoutD . Effects of n‐3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. American Journal of Clinical Nutrition2011;94(6):1442‐50. HoogeveenE , GemenE , GeleijnseM , KustersR , KromhoutD , GiltayE . Effects of N‐3 fatty acids on decline of kidney function after myocardial infarction: Alpha Omega Trial. Nephrology Dialysis Transplantation2012;27:ii64. HoogeveenEK , GeleijnseJM , KromhoutD , GiltayEJ . No effect of n‐3 fatty acids on high‐sensitivity C‐reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology2014;21(11):1429‐36. HoogeveenEK , GeleijnseJM , KromhoutD , StijnenT , GemenEF , KustersR , et al. Effect of omega‐3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial. Clinical Journal of The American Society of Nephrology: CJASN2014;9(10):1676‐83. KromhoutD , GeleijnseJM , DeGoedeJ , Oude GriepLM , MulderBJ , DeBoerMJ , et al. N‐3 fatty acids, ventricular arrhythmia‐related events, and fatal myocardial infarction in post myocardial infarction patients with diabetes. Diabetes Care2011;34(12):2515‐20. KromhoutD , GiltayEJ , GeleijnseJM , Alpha Omega Trial Group. N‐3 fatty acids and cardiovascular events after myocardial infarction. New England Journal of Medicine2010;363(18):2015‐26. ">AlphaOmega ‐ EPA+DHA 2010</a>; <a href="./references#CD003177-bbs2-0006" title="Age‐Related Eye Disease Study 2 (AREDS2) Research Group. Lutein + zeaxanthin and omega‐3 fatty acids for age‐related macular degeneration: the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA2013;309(19):2005‐15. [PUBMED: 23644932] Age‐Related Eye Disease Study, ChewEY , ClemonsTE , SanGiovanniJP , DanisRP , FerrisFL3rd , et al. Secondary analyses of the effects of lutein/zeaxanthin on age‐related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmology2014;132(2):142‐9. Age‐Related Eye Disease Study, ChewEY , SanGiovanniJP , FerrisFL , WongWT , AgronE , et al. Lutein/zeaxanthin for the treatment of age‐related cataract: AREDS2 randomized trial report no. 4. JAMA Ophthalmology2013;131(7):843‐50. Age‐Related Eye Disease Study, HuynhN , NicholsonBP , AgronE , ClemonsTE , BresslerSB , et al. Visual acuity after cataract surgery in patients with age‐related macular degeneration: age‐related eye disease study 2 report number 5. Ophthalmology2014;121(6):1229‐36. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BondsDE , HarringtonM , WorrallBB , BertoniAG , EatonCB , et al. Writing Group for the AREDS Research Group. Effect of long‐chain omega‐3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age‐Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA Internal Medicine2014;174(5):763‐71. ChewEY , ClemonsT , SanGiovanniJP , DanisR , DomalpallyA , Group AREDS Research. The Age‐Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1). Ophthalmology2012;119(11):2282‐9. ChewEY , ClemonsTE . In reply: making sense of the evidence from the age‐related eye disease study 2 randomized clinical trial. JAMA Ophthalmology2014;132(8):1031‐2. ChewEY , ClemonsTE , AgronE , LaunerLJ , GrodsteinF , BernsteinPS , et al. Effect of omega‐3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: the AREDS2 randomized clinical trial. JAMA2015;314(8):791‐801. ">AREDS2 2014</a>; <a href="./references#CD003177-bbs2-0022" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BerstadP , SeljeflotI , VeierodMB , HjerkinnEM , ArnesenH , PedersenJI . Supplementation with fish oil affects the association between very long‐chain n‐3 polyunsaturated fatty acids in serum non‐esterified fatty acids and soluble vascular cell adhesion molecule‐1. Clinical Science2003;105(1):13‐20. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition &amp; Metabolism2006;3:4. EidHM , ArnesenH , HjerkinnEM , LybergT , EllingsenI , SeljeflotI . Effect of diet and omega‐3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism2006;3:1‐10. EinvikG , EkebergO , KlemsdalTO , SandvikL , HjerkinnEM . Physical distress is associated with cardiovascular events in a high risk population of elderly men. BMC Cardiovascular Disorders2009;9:14. [PUBMED: 19331677] EinvikG , EkebergO , LavikJG , EllingsenI , KlemsdalTO , HjerkinnEM . The influence of long‐term awareness of hyperlipidemia and of 3 years of dietary counselling on depression, anxiety, and quality of life. Journal of Psychosomatic Research2010;68(6):567‐72. EinvikG , KlemsdalTO , SandvikL , HjerkinnEM . A randomized clinical trial on n‐3 polyunsaturated fatty acids supplementation and all‐cause mortality in elderly men at high cardiovascular risk. European Journal of Cardiovascular Prevention &amp; Rehabilitation2010;17(5):588‐92. EllingsenI , HjerkinnEM , ArnesenH , SeljeflotI , HjermannI , TonstadS . Follow‐up of diet and cardiovascular risk factors 20 years after cessation of intervention in the Oslo Diet and Antismoking study. European Journal of Clinical Nutrition2006;60(3):378‐85. FurenesEB , SeljeflotI , SolheimS , HjerkinnEM , ArnesenH , FurenesEB . Long‐term influence of diet and/or omega‐3 fatty acids on matrix metalloproteinase‐9 and pregnancy‐associated plasma protein‐A in men at high risk of coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation2008;68(3):177‐84. HjerkinnEM , AbdelnoorM , BreivikL , BergengenL , EllingsenI , SeljeflotI , et al. Effect of diet or very long chain omega‐3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima‐media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. European Journal of Cardiovascular Prevention &amp; Rehabilitation2006;13(3):325‐33. HjerkinnEM , SeljeflotI , EllingsenI , BerstadP , HjermannI , SandvikL , et al. Influence of long‐term intervention with dietary counselling, long‐chain n‐3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long‐standing hyperlipidemia. American Journal of Clinical Nutrition2005;81(3):583‐9. LindmanAS , PedersenJI , HjerkinnEM , ArnesenH , VeierodMB , EllingsenI , et al. The effects of long‐term diet and omega‐3 fatty acid supplementation on coagulation factor VII and serum phospholipids with special emphasis on the R353Q polymorphism of the FVII gene. Thrombosis and Haemostasis2004;91(6):1097‐104. TroseidM , ArnesenH , HjerkinnEM , SeljeflotI . Serum levels of interleukin‐18 are reduced by diet and n‐3 fatty acid intervention in elderly high‐risk men. Metabolism: Clinical and Experimental2009;58(11):1543‐9. TroseidM , SeljeflotI , WeissTW , KlemsdalTO , HjerkinnEM , ArnesenH . Arterial stiffness is independently associated with interleukin‐18 and components of the metabolic syndrome. Atherosclerosis2010;209(2):337‐9. ">DO IT 2010</a>; <a href="./references#CD003177-bbs2-0036" title="AleksovaA , MassonS , MaggioniAP , LucciD , FabbriG , BerettaL , et al. N‐3 polyunsaturated fatty acids and atrial fibrillation in patients with chronic heart failure: the GISSI‐HF trial. European Journal of Heart Failure2013;15(11):1289‐95. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] CanepaM , TemporelliPL , RossiA , GonziniL , NicolosiGL , StaszewskyL , et al. Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure. Data from the GISSI‐Heart Failure trial. European Journal of Heart Failure2016;18:442‐3. CowieMR , CureS , BianicF , McGuireA , GoodallG , TavazziL . Cost‐effectiveness of highly purified omega‐3 polyunsaturated fatty acid ethyl esters in the treatment of chronic heart failure: results of Markov modelling in a UK setting. European Journal of Heart Failure2011;13(6):681‐9. [DOI: 10.1093/eurjhf/hfr023] FinziA , BarleraS , SerraDM , RossiMG , RuggeriA , MezzaniA , et al. Antiarrhythmic effects of n‐3 PUFA in patients with heart failure and an implantable cardioverter defibrillator in the GISSI‐HF trial. European Heart Journal2009;30:279. FinziAA , LatiniR , BarleraS , RossiMG , RuggeriA , MezzaniA , et al. Effects of n‐3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter‐defibrillators: a substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) trial. American Heart Journal2011;161(2):338‐43. [DOI: 10.1016/j.ahj.2010.10.032] GhioS , ScelsiL , LatiniR , MassonS , EleuteriE , PalvariniM , et al. Effects of n‐3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI‐HF trial. European Journal of Heart Failure2010;12(12):1345‐53. Gissi‐HF Investigators, TavazziL , MaggioniAP , MarchioliR , BarleraS , FranzosiMG , et al. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial. Lancet2008;372(9645):1223‐30. [DOI: 10.1016/S01406736(08)61239‐8] LaRovereMT , BarleraS , StaszewskyL , MezzaniA , MidiP , MarchioliR , et al. Effect of n‐3PUFA on heart rate variability. Data from the GISSI‐HF Holter substudy. Circulation2011;124(21 Suppl 1):A14829. LaRovereMT , PinnaGD , MaestriR , BarleraS , BernardinangeliM , VenianiM , et al. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI‐HF trial. European Journal of Heart Failure2012;14(12):1410‐9. LaRovereMT , StaszewskyL , BarleraS , MaestriR , MezzaniA , MidiP , et al. n‐3PUFA and Holter‐derived autonomic variables in patients with heart failure: data from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI‐HF) Holter substudy. Heart Rhythm2013;10(2):226‐32. LatiniR , MassonS , TacconiM , BernasconiR , DraganiL , MilaniV , et al. Circulating levels of n‐3 polyunsaturated fatty acids in patients with chronic heart failure. Data from the GISSI‐HF trial. European Heart Journal2011;32:919. MaggioniAP , FabbriG , LucciD , MarchioliR , FranzosiMG , LatiniR , et al. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI‐HF trial. Eupropean Heart Journal2009;30(19):232736. MarchioliR , AldegheriMP , BorgheseL , FranzosiMG , LatiniR , MarfisiRM , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal arrhythmias in heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:165. MarchioliR , CucchiG , GualcoA , FranzosiMG , LevantesiG , MaggioniAP , et al. Time course analysis of the effect of n‐3 PUFA on fatal and non fatal heart failure: secondary results of the GISSI‐HF trial. European Heart Journal2009;30:432. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , MinneciC , et al. Prognostic ability of a Mediterranean dietary score in heart failure: preliminary analysis of the GISSI‐Heart failure Trial. European Heart Journal2009;30:1026. MarchioliR , FranzosiMG , LatiniR , MaggioniAP , MarfisiRM , NicolosiGL , et al. Effect of n‐3 PUFA in heart failure patients with different dietary habits: preliminary results of the GISSI‐heart failure trial. European Heart Journal2009;30:426. MarchioliR , FranzosiMG , LevantesiG , MarfisiRM , MaggioniAP , NicolosiGL , et al. Effect of n‐3 PUFA according to fish intake: preliminary results of GISSI‐Heart Failure. European Heart Journal2009;30:707. MarchioliR , LevantesiG , SillettaMG , BarleraS , BernardinangeliM , CarbonieriE , et al. Effect of n‐3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI‐HF trial. Expert Review of Cardiovascular Therapy2009;7(7):735‐48. MassonS , LatiniR , MilaniV , MorettiL , RossiMG , CarbonieriE , et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI‐Heart Failure trial. Circulation. Heart Failure2010;3(1):65‐72. MassonS , MarchioliR , MozaffarianD , BernasconiR , MilaniV , DraganiL , et al. Plasma n‐3 polyunsaturated fatty acids in chronic heart failure in the GISSI‐Heart Failure Trial: relation with fish intake, circulating biomarkers, and mortality. American Heart Journal2013;165(2):208‐15. RøyslandR , MassonS , OmlandT , MilaniV , BjerreM , FlyvbjergA , et al. Prognostic value of osteoprotegerin in chronic heart failure: the GISSI‐HF trial. American Heart Journal2010;160(2):286‐93. [DOI: 10.1016/j.ahj.2010.05.015] TavazziL , TognoniG , FranzosiMG , LatiniR , MaggioniAP , MarchioliR , et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n‐3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. European Journal of Heart Failure2004;6(5):635‐41. [DOI: 10.1016/j.ejheart.2004.03.001] ">GISSI‐HF 2008</a>; <a href="./references#CD003177-bbs2-0037" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] FranzosiMG , BrunettiM , MarchioliR , MarfisiRM , TognoniG , ValagussaF , GISSI‐PrevenzioneI . Cost‐effectiveness analysis of n‐3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)‐Prevenzione Trial. Pharmacoeconomics2001;19(4):411‐20. GISSI‐Prevenzione Investigators. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet1999;354:447‐55. MarchioliR . Treatment with n‐3 polyunsaturated fatty acids after myocardial infarction: results of GISSI‐Prevenzione Trial. European Heart Journal Supplements2001;3(Suppl D):D85‐D97. MarchioliR , BarziF , BombaE , ChieffoC , DiGregorioDD , FranzosiMG , et al. Early protection against sudden death by n‐3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)‐Prevenzione. Circulation2002;105:1897‐903. MarchioliR , DiPasqualeA . The biochemical, pharmacological and epidemiological reference picture of the GISSI‐Prevention. The Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico. Giornale Italiano di Cardiologia1993;23(9):933‐64. MarchioliR , ValagussaF . The results of the GISSI‐Prevenzione trial in the general framework of secondary prevention. European Heart Journal2000;21(12):949‐52. ">GISSI‐P 1999</a>; <a href="./references#CD003177-bbs2-0041" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ClelandJG , FreemantleN , ColettaAP , ClarkAL . Clinical trials update from the American Heart Association: REPAIR‐AMI, ASTAMI, JELIS, MEGA, REVIVE‐II, SURVIVE, and PROACTIVE. European Journal of Heart Failure2006;8(1):105‐10. [DOI: 10.1016/j.ejheart.2005.12.003] IshikawaY , YokoyamaM , SaitoY , MatsuzakiM , OrigasaH , OikawaS , et al. Preventive effects of eicosapentaenoic acid on coronary artery disease in patients with peripheral artery disease. Circulation Journal2010;74(7):1451‐7. [DOI: 10.1253/circj.CJ‐09‐0520] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. Relationships between plasma fatty acid composition and coronary artery disease. Journal of Atherosclerosis and Thrombosis2011;18(2):99‐107. [PUBMED: 21099130] ItakuraH , YokoyamaM , MatsuzakiM , SaitoY , OrigasaH , IshikawaY , et al. The change in low‐density lipoprotein cholesterol concentration is positively related to plasma docosahexaenoic acid but not eicosapentaenoic acid. Journal of Atherosclerosis and Thrombosis2012;19(7):673‐9. [PUBMED: 22653220] MatsuzakiM , YokoyamaM , SaitoY , OrigasaH , IshikawaY , OikawaS , et al. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin‐treated patients with coronary artery disease. Secondary prevention analysis from JELIS. Circulation Journal2009;73(7):1283‐90. OikawaS , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: sub‐analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2009;206(2):535‐9. [DOI: 10.1016/j.atherosclerosis.2009.03.029] OrigasaH , YokoyamaM , MatsuzakiM , SaitoY , MatsuzawaY , JELIS Investigators. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circulation Journal2010;74(3):510‐7. [DOI: 10.1253/circj.CJ‐09‐0746] SaitoY , YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , IshikawaY , et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub‐analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis2008;200(1):135‐40. [DOI: 10.1016/j.atherosclerosis.2008.06.003] TanakaK , IshikawaY , YokoyamaM , OrigasaH , MatsuzakiM , SaitoY , et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke2008;39(8):2052‐8. [DOI: 10.1161/STROKEAHA.107.509455] YamanouchiD , KomoriK . Eicosapentaenoic acid as the gold standard for patients with peripheral artery disease? Subanalysis of the JELIS trial. Circulation Journal2010;74(7):1298‐9. [DOI: 10.1253/circj.CJ‐10‐0449] YokoyamaM , OrigasaH , MatsuzakiM , MatsuzawaY , SaitoY , IshikawaY , et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis. Lancet2007;369(9567):1090‐8. YokoyamaM , OrigasaH , for the JELIS Investigators. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolaemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). American Heart Journal2003;146:613‐20. ">JELIS 2007</a>; <a href="./references#CD003177-bbs2-0058" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] RauchB , SchieleR , SchneiderS , DillerF , VictorN , GohlkeH , et al. OMEGA, a randomized, placebo‐controlled trial to test the effect of highly purified omega‐3 fatty acids on top of modern guideline‐adjusted therapy after myocardial infarction. Circulation2010;122(21):2152‐9. [DOI: 10.1161/CIRCULATIONAHA.110.948562] RauchB , SchieleR , SchneiderS , GohlkeH , DillerF , GottwikM , et al. Highly purified omega‐3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction‐aims and methods of the OMEGA‐study. Cardiovascular Drugs Therapy2006;20(5):365‐75. [DOI: 10.1007/s10557‐006‐0495‐6] ZimmerR , RiemerT , RauchB , SchneiderS , SchieleR , GohlkeH , et al. Effects of 1‐year treatment with highly purified omega‐3 fatty acids on depression after myocardial infarction: results from the OMEGA trial. Journal of Clinical Psychiatry2013;74(11):e1037‐45. [PUBMED: 24330904] ">OMEGA 2009</a>; <a href="./references#CD003177-bbs2-0060" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BordeleauL , YakubovichN , DagenaisG , RosenstockJ , RydenLE , SpinasG , et al. Cancer outcomes in patients with dysglycemia on basal insulin: results of the Origin trial. Diabetes2013;62:A72. BordeleauL , YakubovichN , DagenaisGR , RosenstockJ , ProbstfieldJ , Chang YuP , et al. The association of basal insulin glargine and/or n‐3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care2014;37(5):1360‐6. LonnEM , BoschJ , DiazR , Lopez‐JaramilloP , RamachandranA , HancuN , et al. Effect of insulin glargine and n‐3FA on carotid intima‐media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN‐GRACE). Diabetes Care2013;36(9):2466‐74. MaggioniAP , FabbriG , BoschJ , DyalL , RydenLE , GersteinHC , et al. Effects of n‐3 fatty acids on long‐term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction. European Heart Journal2013;34:352. Origin Trial Investigators, BoschJ , GersteinHC , DagenaisGR , DiazR , DyalL , et al. N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New England Journal of Medicine2012;367(4):309‐18. Origin Trial Investigators, GersteinH , YusufS , RiddleMC , RydenL , BoschJ . Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an initial glargine intervention). American Heart Journal2008;155(1):26‐32, 32. Origin Trial Investigators, GersteinHC , BoschJ , DagenaisGR , DiazR , JungH , et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. New England Journal of Medicine2012;367(4):319‐28. PunthakeeZ , GersteinHC , BoschJ , TyrwhittJ , JungH , LeeSF , et al. Cardiovascular and other outcomes postintervention with insulin glargine and omega‐3 fatty acids (ORIGINALE). Diabetes Care2016;39(5):709‐16. ">ORIGIN 2012</a>; <a href="./references#CD003177-bbs2-0069" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] Rischio and Prevenzione Investigators. Efficacy of n‐3 polyunsaturated fatty acids and feasibility of optimizing preventive strategies in patients at high cardiovascular risk: rationale, design and baseline characteristics of the Rischio and Prevenzione study, a large randomised trial in general practice. Trials2010;11(1):68. Risk and Prevention Study Collaborative Group, RoncaglioniMC , TombesiM , AvanziniF , BarleraS , CaimiV , et al. N‐3 fatty acids in patients with multiple cardiovascular risk factors. New England Journal of Medicine2013;368(19):1800‐8. VisentinG , Risk &amp; Prevention Study Group. Towards evidence‐based practice via practice‐based evidence: the Italian experience. Family Practice2008;25(Suppl 1):i71‐4. ">Risk &amp; Prevention 2013</a>; <a href="./references#CD003177-bbs2-0080" title="AhluwaliaN , BlacherJ , Szabo De EdelenyiF , FaureP , JuliaC , HercbergS , et al. Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease. Atherosclerosis2013;228(2):478‐84. AndreevaVA , GalanP , TorresM , JuliaC , HercbergS , Kesse‐GuyotE . Supplementation with B vitamins or n‐3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B‐6 and B‐12 and/or OMega‐3 fatty acids (SU.FOL.OM3) randomized trial. American Journal of Clinical Nutrition2012;96(1):208‐14. AndreevaVA , Kesse‐GuyotE , Barberger‐GateauP , FezeuL , HercbergS , GalanP . Cognitive function after supplementation with B vitamins and long‐chain omega‐3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. American Journal of Clinical Nutrition2011;94(1):278‐86. AndreevaVA , LatarcheC , HercbergS , BrianconS , GalanP , Kesse‐GuyotE . B vitamin and/or n‐3 fatty acid supplementation and health‐related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial. PloS One2014;9(1):e84844. AndreevaVA , TouvierM , Kesse‐GuyotE , JuliaC , GalanP , HercbergS . B vitamin and/or omega‐3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega‐3 fatty acids (SU.FOL.OM3) randomized trial. Archives of Internal Medicine2012;172(7):540‐7. AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] BlacherJ , CzernichowS , PaillardF , DucimetiereP , HercbergS , GalanP , et al. Cardiovascular effects of B‐vitamins and/or n‐3 fatty acids: the SU.FOL.OM3 trial. International Journal of Cardiology2013;167(2):508‐13. BlacherJ , SafarME , LyC , Szabo De EdelenyiF , HercbergS , GalanP . Blood pressure variability: cardiovascular risk integrator or independent risk factor. Journal of Human Hypertension2015;29(2):122‐6. FezeuLK , LaporteF , Kesse‐GuyotE , AndreevaVA , BlacherJ , HercbergS , et al. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited. PLOS ONE2014;9(4):e92548. GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The SU.FOL.OM3 study: a secondary prevention trial testing the impact of supplementation with folate and B‐vitamins and/or omega‐3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials2008;9:35. [DOI: 10.1186/1745‐6215‐9‐35] GalanP , BrianconS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , BriançonS , BlacherJ , CzernichowS , HercbergS . The scientific basis of the SU.FOL.OM3 study: a secondary intervention trial of folate, B6 and B12 vitamins and/or omega3 fatty acid supplements in the prevention of recurrent ischemic events [Bases scientifiques de l'étude SUFOLOM3: essai de prévention secondaire visant à tester l'impact d'une supplémentation en folates, vitamines B6 et B12 et/ ou acides gras oméga‐3 dans la prévention de la récidive de pathologies ischémiques]. Sang Thrombose Vaisseaux2009;21(4):207‐13. GalanP , Kesse‐GuyotE , CzernichowS , BrianconS , BlacherJ , HercbergS , SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ2010;341:c6273. [DOI: 10.1136/bmj.c6273] GalanP , deBreeA , MennenL , Potier de CourcyG , PrezioziP , BertraisS , et al. Background and rationale of the SU.FOL.OM3 study: double‐blind randomized placebo‐controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega‐3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries. Journal of Nutrition, Health and Aging2003;7(6):428‐35. Kesse‐GuyotE , PeneauS , HercbergS , GalanP , VogtL , EscandeM , et al. Thirteen‐year prospective study between fish consumption, long‐chain N‐3 fatty acids intakes and cognitive function. Journal of Nutrition, Health and Aging2011;15(2):115‐20. Szabo De EdelenyiF , VergnaudAC , AhluwaliaN , JuliaC , HercbergS , BlacherJ , et al. Effect of B‐vitamins and n‐3 PUFA supplementation for 5 years on blood pressure in patients with CVD. British Journal of Nutrition2012;107(6):921‐7. VesinC , GalanP , GautierB , CzernichowS , HercbergS , BlacherJ . Control of baseline cardiovascular risk factors in the SU‐FOL‐OM3 study cohort: does the localization of the arterial event matter?. European Journal of Cardiovascular Prevention and Rehabilitation2010;17(5):541‐8. deBreeA , MennenLI , HercbergS , GalanP . Evidence for a protective (synergistic?) effect of B‐vitamins and omega‐3 fatty acids on cardiovascular diseases. European Journal of Clinical Nutrition2004;58(5):732‐44. ">SU.FOL.OM3 2010</a>), and this review includes all these trials. Their review had the advantage of being able to ensure that they had complete and equivalent data for all of their key outcomes from all the trials, reducing the risk of publication bias (and this review has incorporated some of their data to improve and extend our data set), but the disadvantage of missing all the data from many large LCn3 trials such as <a href="./references#CD003177-bbs2-0014" title="BurrML , FehilyAM . Fatty fish and heart disease: a randomized controlled trial. World Review of Nutrition and Dietetics1991;66:306‐12. BurrML , FehilyAM . Fish and the heart. Lancet1989;ii:1451‐2. BurrML , FehilyAM , GilbertJF , RogersS , HollidayRM , SweetnamPM , et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet1989;2(8666):757‐61. BurrML , FehilyAM , RogersS , WelsbyE , KingS , SandhamS . Diet and reinfarction trial (DART): design, recruitment, and compliance. European Heart Journal1989;10(6):558‐67. BurrML , HollidayRM , FehilyAM , WhiteheadPJ . Haematological prognostic indices after myocardial infarction: evidence from the diet and reinfarction trial (DART). European Heart Journal1992;13(2):166‐70. BurrML , SweethamPM , FehilyAM . Diet and reinfarction. European Heart Journal1994;15(8):1152‐3. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. Factors influencing compliance with dietary advice: the Diet and Reinfarction Trial (DART). Journal of Human Nutrition and Dietetics1991;4:33‐42. FehilyAM , Vaughan‐WilliamsE , ShielsK , WilliamsAH , HornerM , BinghamG , et al. The effect of dietary advice on nutrient intakes: evidence from the diet and reinfarction trial (DART). Journal of Human Nutrition &amp; Dietetics1989;2:4235. NessAR , HughesJ , ElwoodPC , WhitleyE , SmithGD , BurrML . The long‐term effect of dietary advice in men with coronary disease: follow‐up of the Diet and Reinfarction Trial (DART). European Journal of Clinical Nutrition2002;56(6):512‐8. NessAR , WhitleyE , BurrML , ElwoodPC , SmithGD , EbrahimS . The long‐term effect of advice to eat more fish on blood pressure in men with coronary disease: results from the diet and reinfarction trial. Journal of Human Hypertension1999;13(11):729‐33. ">DART 1989</a>, <a href="./references#CD003177-bbs2-0015" title="BurrML . Secondary prevention of CHD in UK men: the diet and reinfarction trial and its sequel. Proceedings of the Nutrition Society2007;66(1):9‐15. [PUBMED: 17343767] BurrML , Ashfield‐WattPA , DunstanFD , FehilyAM , BreayP , AshtonT , et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. European Journal of Clinical Nutrition2003;57(2):193‐200. BurrML , DunstanFD , GeorgeCH . Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. Journal of Membrane Biology2005;206(2):155‐63. [PUBMED: 16456725] NessAR , Ashfield‐WattPA , WhitingJM , SmithGD , HughesJ , BurrML . The long‐term effect of dietary advice on the diet of men with angina: the diet and angina randomized trial. Journal of Human Nutrition and Dietetics2004;17:1‐3. NessAR , GallacherJE , BennettPD , GunnellDJ , RogersPJ , KesslerD , et al. Advice to eat fish and mood: a randomised controlled trial in men with angina. Nutritional Neuroscience2003;6(1):63‐5. ">DART2 2003</a>, <a href="./references#CD003177-bbs2-0032" title="MacchiaA , GrancelliH , VariniS , NulD , FerranteD , MarianiJ , et al. Late‐breaking clinical trials: treatments for prevention of cardiovascular events: a population perspective. Circulation2012;126:2780‐1. MacchiaA , GrancelliH , VariniS , NulD , LaffayeN , MarianiJ , et al. Omega‐3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (randomized trial to assess efficacy of PUFA for the maintenance of sinus rhythm in persistent atrial fibrillation) trial. Journal of the American College of Cardiology2013;61(4):463‐8. [PUBMED: 23265344] MacchiaA , VariniS , GrancelliH , NulD , LaffayeN , FerranteD , et al. The rationale and design of the FORomegaARD trial: a randomized, double‐blind, placebo‐controlled, independent study to test the efficacy of n‐3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. American Heart Journal2009;157(3):423‐7. [PUBMED: 19249410] ">FORWARD 2013</a>, <a href="./references#CD003177-bbs2-0045" title="AndrieuS , GuyonnetS , ColeyN , CantetC , BonnefoyM , BordesS , et al. Effect of long‐term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo‐controlled trial. Lancet Neurology2017;16:377‐89. [DOI: 10.1016/S1474‐4422(17)30040‐6] BarretoPdS , RollandY , CesariM , DupuyC , AndrieuS , VellasB , for the MAPT Study Group. Effects of multidomain lifestyle intervention, omega‐3 supplementation or their combination on physical activity levels in older adults: secondary analysis of the Multidomain Alzheimer Preventive Trial (MAPT) randomised controlled trial. Age and Ageing2017;47(2):281‐8. [DOI: 10.1093/ageing/afx164] CarrieI , VanKanGA , Gillette‐GuyonnetS , AndrieuS , DartiguesJF , TouchonJ , et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). Journal of Nutrition, Health &amp; Aging2012;16(4):355‐9. DelrieuJ , AndrieuS , PahorM , CantetC , CesariM , OussetPJ , et al. Neuropsychological profile of &quot;cognitive frailty&quot; subjects in MAPT study. Journal of Prevention of Alzheimer's Disease2016;3(3):151‐9. [DOI: 10.14283/jpad.2016.94] DelrieuJ , PayouxP , HitzelA , PeifferS , Abellan Van KanG , GilletteS , et al. Multidomain Alzheimer's disease preventive trial: florbetapir ancillary study. Alzheimer's and Dementia2011;1:S419. FougereB , BarretoPD , GoisserS , SorianoG , GuyonnetS , AndrieuS , et al. Red blood cell membrane omega‐3 fatty acid levels and physical performance: cross‐sectional data from the MAPT study. Clinical Nutrition 2017 Apr 12 [Epub ahead of print]:1‐4. [DOI: 10.1016/j.clnu.2017.04.005] GilletteS . The Multidomain Alzheimer Preventive Trial (MAPT): a new approach for the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;S4‐02‐05:145. Gillette‐GuyonnetS , AndrieuS , DantoineT , DartiguesJF , TouchonJ , VellasB , et al. Commentary on &quot;A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.&quot; The Multidomain Alzheimer Preventive Trial (MAPT): a new approach to the prevention of Alzheimer's disease. Alzheimer's &amp; Dementia2009;5(2):114‐21. Gillette‐GuyonnetS , VellasB , AndrieuS , DupuyC , CarriéI . MAPT study: a 3‐year randomized trial of omega 3 and/or multidomain intervention for the prevention of cognitive decline in frail elderly subjects‐rationale, design and baseline data. Alzheimer's &amp; Dementia2011;1:S97‐8. VellasB , CarrieI , Gillette‐GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT study: a multidomain approach for preventing Alzheimer's disease: design and baseline data. Journal of Prevention of Alzheimers Disease2014;1(1):13‐22. VellasB , CarrieI , GuyonnetS , TouchonJ , DantoineT , DartiguesJF , et al. MAPT (Multi‐domain Alzheimer's Prevention Trial): results at 36 months. Alzheimer's &amp; Dementia2015;1:331. VellasB , TouchonJ , WeinerM . MAPT (Multidomain Alzheimer Preventive Trial) imaging (MRI, FDG‐PET, amyloid‐PET) data. Journal of Nutrition, Health and Aging2012;16(9):812‐5. ">MAPT 2017</a>, <a href="./references#CD003177-bbs2-0075" title="EritslandJ , ArnesenH , BergK , SeljeflotI , AbdelnoorM . Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long‐term n‐3 fatty acid supplementation. Scandinavian Journal of Clinical and Laboratory Investigation1995;55(4):295‐300. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of dietary supplementation with n‐3 fatty acids on coronary artery bypass graft patency. American Journal of Cardiology1996;77(1):31‐6. EritslandJ , ArnesenH , GronsethK , FjeldNB , AbdelnoorM . Effect of supplementation with n‐3 fatty acids on graft patency in patients undergoing coronary artery bypass operation. Results from SHOT study. European Heart Journal1994;15:29. EritslandJ , ArnesenH , SeljeflotI , HostmarkAT . Long‐term metabolic effects of n‐3 polyunsaturated fatty acids in patients with coronary artery disease. American Journal of Clinical Nutrition1995;61(4):831‐6. EritslandJ , ArnesenH , SeljeflotI , KierulfP . Long‐term effects of n‐3 polyunsaturated fatty acids on haemostatic variables and bleeding episodes in patients with coronary artery disease. Blood Coagulation &amp; Fibrinolysis1995;6(1):17‐22. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Fibrinolysis1994;8(2):120‐5. EritslandJ , SeljeflotI , AbdelnoorM , ArnesenH , TorjesenPA . Long‐term effects of n‐3 fatty acids on serum lipids and glycaemic control. Scandinavian Journal of Clinical and Laboratory Investigation1994;54(4):273‐80. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term effects of fish oil supplementation in patients with coronary artery disease: influence on lipoproteins, coagulation and fibrinolysis. Thrombosis Research1992;65:75. EritslandJ , SeljeflotI , ArnesenH , AbdelnoorM . Long‐term influence of omega‐3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Thrombosis and Haemostasis1993;69:1065. EritslandJ , SeljeflotI , ArnesenH , WestvikAB , KierulfP . Effect of long‐term, moderate‐dose supplementation with omega‐3 fatty acids on monocyte procoagulant activity and release of interleukin‐6 in patients with coronary artery disease. Thrombosis Research1995;77(4):337‐46. ">SHOT 1996</a> and <a href="./references#CD003177-bbs2-0078" title="BrouwerIA , KatanMB , SchoutenEG , CammAJ , HauerRN , WeverEF , et al. Rationale and design of a clinical trial on n‐3 fatty acids and cardiac arrhythmia (SOFA). Annals of Nutrition &amp; Metabolism2001;45(Suppl 1):79. BrouwerIA , RaittMH , DullemeijerC , KraemerDF , ZockPL , MorrisC , et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. European Heart Journal2009;30(7):820‐6. BrouwerIA , ZockPL , CammAJ , BöckerD , HauerRN , WeverEF , et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the study on omega‐3 fatty acids and ventricular arrhythmia (SOFA) randomized trial. JAMA2006;295(22):2613‐9. BrouwerIA , ZockPL , WeverEF , HauerRN , CammAJ , BockerD , et al. Rationale and design of a randomised controlled clinical trial on supplemental intake of n‐3 fatty acids and incidence of cardiac arrhythmia: SOFA. European Journal of Clinical Nutrition2003;57:1323‐30. ">SOFA 2006</a>, all LCn3 trials randomising at least 500 participants. It also missed large trials of LCn3 in lower‐risk participants such as <a href="./references#CD003177-bbs2-0059" title="DangourAD , AllenE , ElbourneD , FaseyN , FletcherAE , HardyP , et al. Effect of 2‐y n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double‐blind, controlled trial. American Journal of Clinical Nutrition2010;91(6):1725‐32. DangourAD , AllenE , ElbourneD , FletcherA , RichardsM , UauyR . Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. Journal of Nutrition, Health &amp; Aging2009;13(3):198‐202. DangourAD , AllenE , ElbourneD , FletcherAE , NeveuMM , UauyR , et al. N‐3 fatty acids and retinal function. Ophthalmology2013;120(3):643. [DOI: dx.doi.org/10.1016/j.ophtha.2012.09.043] DangourAD , ClemensF , ElbourneD , FaseyN , FletcherAE , HardyP , et al. A randomised controlled trial investigating the effect of n‐3 long‐chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n‐3 Long‐chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutrition Journal2006;5:20. ISRCTN72331636 . The OPAL Study: older people and n‐3 long‐chain polyunsaturated fatty acids. www.isrctn.com/ISRCTN72331636 (first received 27 April 2004). [ISRCTN72331636] ">OPAL 2010</a>, and large trials of ALA such as <a href="./references#CD003177-bbs2-0046" title="BemelmansWJ , BroerJ , DeVriesJH , HulshofKF , MayJF , Meyboom‐De JongB . Impact of Mediterranean diet education versus posted leaflet on dietary habits and serum cholesterol in a high risk population for cardiovascular disease. Public Health Nutrition2000;3(3):273‐83. BemelmansWJ , BroerJ , FeskensEJ , SmitAJ , MuskietAJ , LefrandtJD , et al. Effect of an increased intake of alpha‐linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean alpha‐linolenic enriched Groningen dietary intervention (MARGARIN) study. American Journal of Clinical Nutrition2002;75:221‐7. BemelmansWJ , LefrandtJD , FeskensEJ , BroerJ , TervaertJW , MayJF , et al. Change in saturated fat intake is associated with progression of carotid and femoral intima‐media thickness, and with levels of soluble intercellular adhesion molecule‐1. Atherosclerosis2002;163(1):113‐20. BemelmansWJ , LefrandtJD , FeskensEJ , VanHaelstPL , BroerJ , Meyboom‐de JongB , et al. Increased alpha‐linolenic acid intake lowers C‐reactive protein, but has no effect on markers of atherosclerosis. European Journal of Clinical Nutrition2004;58(7):1083‐9. BemelmansWJ , MuskietFA , FeskensEJ , DeVriesJH , BroerJ , MayJF , et al. Associations of alpha‐linolenic acid and linoleic acid with risk factors for coronary heart disease. European Journal of Clinical Nutrition2000;54(12):865‐71. SieroFW , BroerJ , BemelmansWJ , Meyboom‐de JongBM . Impact of group nutrition education and surplus value of Prochaska based stage‐matched information on health‐related cognitions and on Mediterranean nutrition behaviour. Health Education Research2000;15(5):635‐47. ">MARGARIN 2002</a>, <a href="./references#CD003177-bbs2-0054" title="NatvigH . The effect of unsaturated fatty acids on the incidence of coronary infarction, etc [Effekten av umettede fettsyrer hyppigheten av hjerteinfarkt M.M.]. Tidsskrift for Den Norske Laegeforening1967;87(11):1033‐41. NatvigH , BorchgrevinkCF , DedichenJ , OwrenPA , SchiotzEH , WestlundK . A controlled trial of the effect of linolenic acid on incidence of coronary heart disease. The Norwegian vegetable oil experiment of 1965‐66. Scandinavian Journal of Clinical and Laboratory Investigation1968;105(Suppl):1‐20. ">Norwegian 1968</a> and <a href="./references#CD003177-bbs2-0084" title="BitokE , Jaceldo‐SieglK , RajaramS , Serra‐MirM , RothI , Feitas‐SimoesT , et al. Favourable nutrient intake and displacement with long‐term walnut supplementation among elderly: results of a randomised trial. British Journal of Nutrition2017;118(3):201‐9. [DOI: 10.1017/S0007114517001957] BitokE , RajaramS , RosE . Does a daily walnut supplement given for a year result in body weight gain?. FASEB Journal2016; Vol. 30:1157.5. HueyL , BitokE , KazziN . Dietary compliance of walnut or no walnut intake in a 1‐year randomized intervention trial among free‐living elderly in the Walnuts and Healthy Aging Study (WAHA). FASEB Journal2016; Vol. 30:1157.10. RajaramS , Valls‐PedretC , CofanM , SabateJ , Serra‐MirM , Perez‐HerasAM , et al. The Walnuts and Healthy Aging Study (WAHA): protocol for a nutritional intervention trial with walnuts on brain aging. Frontiers in Aging Neuroscience2017;8:333. [PUBMED: 28119602] RosE , RajaramS , Sala‐VilaA , Serra‐MirM , Vals‐PedretC , CofanM , et al. Effect of a 1‐year walnut supplementation on blood lipids among older individuals: findings from the Walnuts and Healthy Aging (WAHA) study. FASEB Journal2016; Vol. 30, issue 1 Suppl:293.4. ">WAHA 2016</a>, as well as all the smaller trials. However, though taking different approaches, the numerical results of this review and <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> are also very similar (<a href="#CD003177-tbl-0011">Table 8</a>). <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> has been updated with data from the three largest recent trials (<a href="./references#CD003177-bbs2-0007" title="ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. New England Journal of Medicine2018;379(16):1540‐50. [DOI: 10.1056/NEJMoa1804989] BowmanL , AungT , HaynesR , ArmitageJ . ASCEND: design and baseline characteristics of a large randomised trial in diabetes. Diabetes2012;61:A556‐7. NCT00135226 . ASCEND: a study of cardiovascular events in diabetes [A study of cardiovascular events in diabetes ‐ a randomized 2x2 factorial study of aspirin versus placebo, and of omega‐3 fatty acid supplementation versus placebo, for primary prevention of cardiovascular events in people with diabetes]. clinicaltrials.gov/ct2/show/NCT00135226 (first received 25 August 2005). ">ASCEND 2018</a>; <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a>; <a href="./references#CD003177-bbs2-0083" title="BassukSS , MansonJE , LeeIM , CookNR , ChristenWG , BubesVY , et al. Baseline characteristics of participants in the Vitamin D and omega‐3 triaL (VITAL). Contemporary Clinical Trials2016;47:235‐43. GoldDR , LitonjuaAA , CareyVJ , MansonJE , BuringJE , LeeIM , et al. Lung VITAL: rationale, design, and baseline characteristics of an ancillary study evaluating the effects of vitamin D and/or marine omega‐3 fatty acid supplements on acute exacerbations of chronic respiratory disease, asthma control, pneumonia and lung function in adults. Contemporary Clinical Trials2016;47:185‐95. GoldDR , Luttmann‐GibsonH , LitonjuaAA , FriedenbergG , GordonD , LeeIM , et al. Baseline chronic obstructive pulmonary disease in the lung vitamin D and omega‐3 trial. American Journal of Respiratory and Critical Care Medicine2014;189:D44 COPD. KangJH , GrodsteinF , MansonJAE . Cognitive substudy of the vitamin d and omega‐3 trial (VITAL‐COG): design of a large randomized trial of omega‐3 and vitamin D supplements in relation to cognitive change. Alzheimer's &amp; Dementia2015;1:608. LeBoffMS , YueAY , CopelandT , CookNR , BuringJE , MansonJE . VITAL‐Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega‐3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA‐3 TriaL (VITAL). Contemporary Clinical Trials2015;41:259‐68. MansonJA . Vitamin D and cancer and cardiovascular disease: ready for prime time?. Menopause2010;17(6):1215. MansonJE . Vitamin D and the heart: why we need large‐scale clinical trials. Cleveland Clinic Journal of Medicine2010;77(12):903‐10. MansonJE , BassukSS , LeeIM , CookNR , AlbertMA , GordonD , et al. The VITamin D and OmegA‐3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega‐3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials2012;33(1):159‐71. MansonJE , CookNR , LeeIM , ChristenW , BassukSS , MoraS , et al. Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine2019;380:23‐32. [DOI: 10.1056/NEJMoa1811403] NCT01169259 . Vitamin D and omega‐3 trial (VITAL). clinicaltrials.gov/ct2/show/record/NCT01169259 (first received 26 July 2010). PradhanAD , MansonJE . Update on the vitamin D and omega‐3 trial (VITAL). Journal of Steroid Biochemistry &amp; Molecular Biology2016;155(Pt B):252‐6. ">VITAL 2019</a>), published as <a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a>. This review, <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>, <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> and <a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a> addressed the analysis of the data in slightly different ways, creating sensitivity analyses for each other. The fact that they came to similar numerical conclusions reassures us that our conclusions are solidly based. However, the risk ratios for coronary heart disease mortality and events have fallen in this update of the review and crossed the line to suggest small beneficial effects of LCn3. </p> <p>Cardiovascular diseases and cancers are both major non‐communicable killers, so overall assessment of the utility of increasing omega‐3 fats will depend on effects on both sets of outcomes. <a href="#CD003177-fig-0006">Figure 6</a> summarises the information on absolute effects of LCn3 and ALA on cardiovascular and cancer outcomes (focusing on outcomes where risk ratios were &lt; 0.92 or &gt; 1.08). The cancer data come from a sister review (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>). Combining data from the two reviews suggests that for every 1000 men increasing their intake of LCn3, three will avoid dying from coronary heart disease, six will avoid a coronary heart disease event, one will avoid the diagnosis of arrhythmia and three additional men will be diagnosed with prostate cancer. Similarly, for every 1000 men increasing their intake of ALA two will avoid a cardiovascular disease event and 11 will avoid diagnosis of arrhythmia but three additional men will be diagnosed with prostate cancer (<a href="#CD003177-fig-0006">Figure 6</a>). These small negative effects on cancer outcomes for men attenuate the small beneficial effects of LCn3 and ALA on cardiovascular outcomes. </p> <div class="figure" id="CD003177-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Assessment of health effects across cancers and cardiovascular outcomes. Bars above zero suggest the number of people who would benefit out of 1000 people consuming more long‐chain omega‐3 (LCn3) or alpha‐linolenic acid (ALA), bars below zero suggest the number of people who would be harmed out of 1000 people consuming more LCn3 or ALA. Cardiovascular disease (CVD) data are from this review, cancer data from a sister review (Hanson 2019). CHD: coronary heart disease." data-id="CD003177-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Assessment of health effects across cancers and cardiovascular outcomes. Bars above zero suggest the number of people who would benefit out of 1000 people consuming more long‐chain omega‐3 (LCn3) or alpha‐linolenic acid (ALA), bars below zero suggest the number of people who would be harmed out of 1000 people consuming more LCn3 or ALA. Cardiovascular disease (CVD) data are from this review, cancer data from a sister review (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>). CHD: coronary heart disease. </p> </div> </div> </div> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003177-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD003177-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD003177-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. High versus low long‐chain omega‐3 fats (primary outcomes), outcome 1.3, all‐cause mortality, sensitivity analysis by summary risk of bias" data-id="CD003177-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. High versus low long‐chain omega‐3 fats (primary outcomes), outcome 1.3, all‐cause mortality, sensitivity analysis by summary risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.15, cardiovascular disease mortality, sensitivity analysis by summary risk of bias" data-id="CD003177-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.15, cardiovascular disease mortality, sensitivity analysis by summary risk of bias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.51, coronary heart disease events (overall)" data-id="CD003177-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison 1. High vs low long‐chain omega‐3 fats (primary outcomes), outcome 1.51, coronary heart disease events (overall) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Assessment of health effects across cancers and cardiovascular outcomes. Bars above zero suggest the number of people who would benefit out of 1000 people consuming more long‐chain omega‐3 (LCn3) or alpha‐linolenic acid (ALA), bars below zero suggest the number of people who would be harmed out of 1000 people consuming more LCn3 or ALA. Cardiovascular disease (CVD) data are from this review, cancer data from a sister review (Hanson 2019). CHD: coronary heart disease." data-id="CD003177-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Assessment of health effects across cancers and cardiovascular outcomes. Bars above zero suggest the number of people who would benefit out of 1000 people consuming more long‐chain omega‐3 (LCn3) or alpha‐linolenic acid (ALA), bars below zero suggest the number of people who would be harmed out of 1000 people consuming more LCn3 or ALA. Cardiovascular disease (CVD) data are from this review, cancer data from a sister review (<a href="./references#CD003177-bbs2-0244" title="HansonS , ThorpeG , WinstanleyL , AbdelhamidAS , HooperL . Omega‐3, omega‐6 and total dietary polyunsaturated fat on cancer incidence: systematic review and meta‐analysis of randomised trials. British Journal of Cancer2020. [DOI: 10.1038/s41416‐020‐0761‐6] ">Hanson 2019</a>). CHD: coronary heart disease. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 1 All‐cause mortality (overall) ‐ LCn3." data-id="CD003177-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 1 All‐cause mortality (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 2 All‐cause mortality ‐LCn3 ‐ sensitivity analysis (SA) fixed‐effect." data-id="CD003177-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 2 All‐cause mortality ‐LCn3 ‐ sensitivity analysis (SA) fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 3 All‐cause mortality ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 3 All‐cause mortality ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 4 All‐cause mortality ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 4 All‐cause mortality ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 5 All‐cause mortality ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 5 All‐cause mortality ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 6 All‐cause mortality ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 6 All‐cause mortality ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 7 All‐cause mortality ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 7 All‐cause mortality ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 8 All‐cause mortality ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 8 All‐cause mortality ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 9 All‐cause mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 9 All‐cause mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 10 All‐cause mortality ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 10 All‐cause mortality ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 11 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 11 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 12 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 12 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 13 Cardiovascular mortality (overall) ‐ LCn3." data-id="CD003177-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 13 Cardiovascular mortality (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 14 CVD mortality ‐ LCn3 ‐ SA fixed‐effect." data-id="CD003177-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 14 CVD mortality ‐ LCn3 ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-15.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 15 CVD mortality ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 15 CVD mortality ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 16 CVD mortality ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 16 CVD mortality ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 17 CVD mortality ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 17 CVD mortality ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 18 CVD mortality ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 18 CVD mortality ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 19 CVD mortality ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 19 CVD mortality ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 20 CVD mortality ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 20 CVD mortality ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 21 CVD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 21 CVD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 22 CVD mortality ‐ LCn3 ‐ subgroup by statin uses." data-id="CD003177-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 22 CVD mortality ‐ LCn3 ‐ subgroup by statin uses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 23 CVD mortality ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 23 CVD mortality ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 24 CVD mortality ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 24 CVD mortality ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 25 Cardiovascular events (overall) ‐ LCn3." data-id="CD003177-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 25 Cardiovascular events (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 26 CVD events ‐ LCn3 ‐ SA fixed effect." data-id="CD003177-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 26 CVD events ‐ LCn3 ‐ SA fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 27 CVD events ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 27 CVD events ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 28 CVD events ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 28 CVD events ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 29 CVD events ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 29 CVD events ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 30 CVD events ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 30 CVD events ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 31 CVD events ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 31 CVD events ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 32 CVD events ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 32 CVD events ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 33 CVD events ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 33 CVD events ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 34 CVD events ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 34 CVD events ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 35 CVD events ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 35 CVD events ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 36 CVD events ‐ LCn3 ‐ subgroup by baseline diabetes." data-id="CD003177-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 36 CVD events ‐ LCn3 ‐ subgroup by baseline diabetes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 37 Coronary heart disease mortality (overall) ‐ LCn3." data-id="CD003177-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 37 Coronary heart disease mortality (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 38 CHD mortality ‐ LCn3 ‐ SA fixed effect." data-id="CD003177-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 38 CHD mortality ‐ LCn3 ‐ SA fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 39 CHD mortality ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 39 CHD mortality ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 40 CHD mortality ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 40 CHD mortality ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 41 CHD mortality ‐ LCn3 ‐ SA omitting cardiac death." data-id="CD003177-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 41 CHD mortality ‐ LCn3 ‐ SA omitting cardiac death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 42 CHD mortality ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 42 CHD mortality ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 43 CHD mortality ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 43 CHD mortality ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 44 CHD mortality ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 44 CHD mortality ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 45 CHD mortality ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 45 CHD mortality ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 46 CHD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 46 CHD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 47 CHD mortality ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 47 CHD mortality ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 48 CHD mortality ‐ LCn3 ‐ subgroup by CAD history." data-id="CD003177-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 48 CHD mortality ‐ LCn3 ‐ subgroup by CAD history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 49 CHD mortality ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.49</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 49 CHD mortality ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 50 CHD mortality ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.50</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 50 CHD mortality ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-51.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 51 Coronary heart disease events (overall) ‐ LCn3." data-id="CD003177-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.51</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 51 Coronary heart disease events (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 52 CHD events ‐ LCn3 ‐ SA fixed effect." data-id="CD003177-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.52</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 52 CHD events ‐ LCn3 ‐ SA fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 53 CHD events ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.53</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 53 CHD events ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 54 CHD events ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.54</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 54 CHD events ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 55 CHD events ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.55</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 55 CHD events ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 56 CHD events ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.56</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 56 CHD events ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 57 CHD events ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.57</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 57 CHD events ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 58 CHD events ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.58</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 58 CHD events ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 59 CHD events ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.59</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 59 CHD events ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 60 CHD events ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.60</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 60 CHD events ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 61 CHD events ‐ LCn3 subgroup by CAD history." data-id="CD003177-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.61</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 61 CHD events ‐ LCn3 subgroup by CAD history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 62 CHD events ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.62</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 62 CHD events ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 63 CHD events ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0069" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.63</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 63 CHD events ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 64 Stroke (overall) ‐ LCn3." data-id="CD003177-fig-0070" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.64</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 64 Stroke (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 65 Stroke ‐ LCn3 ‐ SA fixed effect." data-id="CD003177-fig-0071" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.65</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 65 Stroke ‐ LCn3 ‐ SA fixed effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 66 Stroke ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0072" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.66</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 66 Stroke ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 67 Stroke ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0073" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.67</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 67 Stroke ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-68" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-68.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 68 Stroke ‐ LCn3 ‐ subgroup by stroke type." data-id="CD003177-fig-0074" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-68.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.68</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 68 Stroke ‐ LCn3 ‐ subgroup by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-68.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-69" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-69.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 69 Stroke ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0075" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-69.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.69</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 69 Stroke ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-69.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-70" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-70.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 70 Stroke ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0076" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-70.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.70</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 70 Stroke ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-70.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-71" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-71.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 71 Stroke ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0077" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-71.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.71</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 71 Stroke ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-71.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-72" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-72.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 72 Stroke ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0078" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-72.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.72</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 72 Stroke ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-72.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-73" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-73.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 73 Stroke ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0079" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-73.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.73</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 73 Stroke ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-73.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-74" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-74.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 74 Stroke ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0080" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-74.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.74</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 74 Stroke ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-74.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-75" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-75.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 75 Stroke ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0081" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-75.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.75</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 75 Stroke ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-75.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-76" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-76.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 76 Stroke ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0082" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-76.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.76</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 76 Stroke ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-76.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-77" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-77.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 77 Arrythmia (overall) ‐ LCn3." data-id="CD003177-fig-0083" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-77.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.77</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 77 Arrythmia (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-77.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-78" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-78.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 78 Arrythmia ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0084" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-78.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.78</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 78 Arrythmia ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-78.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-79" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-79.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 79 Arrhythmia‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0085" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-79.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.79</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 79 Arrhythmia‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-79.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-80" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-80.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 80 Arrhythmia‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0086" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-80.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.80</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 80 Arrhythmia‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-80.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-81" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-81.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 81 Arrhythmia ‐ LCn3 ‐ subgroup by new or recurrent." data-id="CD003177-fig-0087" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-81.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.81</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 81 Arrhythmia ‐ LCn3 ‐ subgroup by new or recurrent. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-81.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-82" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-82.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 82 Arrhythmia ‐ LCn3 ‐ subgroup by fatality." data-id="CD003177-fig-0088" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-82.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.82</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 82 Arrhythmia ‐ LCn3 ‐ subgroup by fatality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-82.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-83" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-83.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 83 Arrhythmia ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0089" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-83.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.83</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 83 Arrhythmia ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-83.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-84" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-84.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 84 Arrhythmia ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0090" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-84.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.84</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 84 Arrhythmia ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-84.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-85" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-85.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 85 Arrhythmia ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0091" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-85.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.85</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 85 Arrhythmia ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-85.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-86" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-86.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 86 Arrhythmia ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0092" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-86.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.86</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 86 Arrhythmia ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-86.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-87" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-87.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 87 Arrhythmia ‐ LCn3 ‐ subgroup by primary or secondary prevention3." data-id="CD003177-fig-0093" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-87.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.87</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 87 Arrhythmia ‐ LCn3 ‐ subgroup by primary or secondary prevention3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-87.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-88" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-88.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 88 Arrhythmia ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0094" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-88.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.88</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 88 Arrhythmia ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-88.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-89" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-89.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 89 Arrythmia ‐ LCn3 ‐ subgroup by baseline TG." data-id="CD003177-fig-0095" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-89.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.89</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 89 Arrythmia ‐ LCn3 ‐ subgroup by baseline TG. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-89.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-001-90" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-001-90.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 90 Arrythmia ‐ LCn3 ‐ subgroup by baseline DM." data-id="CD003177-fig-0096" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-90.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.90</div> <div class="figure-caption"> <p>Comparison 1 High vs low LCn3 omega‐3 fats (primary outcomes), Outcome 90 Arrythmia ‐ LCn3 ‐ subgroup by baseline DM. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-001-90.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 1 MACCEs ‐ LCn3." data-id="CD003177-fig-0097" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 1 MACCEs ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) ‐ LCn3." data-id="CD003177-fig-0098" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 2 Myocardial infarction (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 3 Total MI ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0099" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 3 Total MI ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 4 Total MI ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0100" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 4 Total MI ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 5 Total MI ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0101" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 5 Total MI ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 6 Total MI ‐ LCn3 ‐ subgroup by fatality." data-id="CD003177-fig-0102" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 6 Total MI ‐ LCn3 ‐ subgroup by fatality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 7 Sudden cardiac death (overall) ‐ LCn3." data-id="CD003177-fig-0103" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 7 Sudden cardiac death (overall) ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 8 Angina ‐ LCn3." data-id="CD003177-fig-0104" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 8 Angina ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 9 Heart failure ‐ LCn3." data-id="CD003177-fig-0105" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 9 Heart failure ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 10 Revascularisation ‐ LCn3." data-id="CD003177-fig-0106" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 10 Revascularisation ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 11 Peripheral arterial disease ‐ LCn3." data-id="CD003177-fig-0107" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 11 Peripheral arterial disease ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 12 PAD ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0108" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 12 PAD ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 13 PAD ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0109" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 13 PAD ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 14 PAD ‐ LCn3 ‐ SA compliance and study size." data-id="CD003177-fig-0110" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 14 PAD ‐ LCn3 ‐ SA compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 15 Acute coronary syndrome ‐ LCn3." data-id="CD003177-fig-0111" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 15 Acute coronary syndrome ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 16 Body weight, kg ‐ LCn3." data-id="CD003177-fig-0112" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 16 Body weight, kg ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 17 Weight, kg ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0113" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 17 Weight, kg ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 18 Weight, kg ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0114" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 18 Weight, kg ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 19 Weight, kg ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0115" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 19 Weight, kg ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 20 Weight, kg ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0116" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 20 Weight, kg ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 21 Weight, kg ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0117" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 21 Weight, kg ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 22 Weight, kg ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0118" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 22 Weight, kg ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 23 Weight, kg ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0119" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 23 Weight, kg ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 24 Weight, kg ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0120" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 24 Weight, kg ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 25 Weight, kg ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0121" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 25 Weight, kg ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 26 Body mass index, kg/m² ‐ LCn3." data-id="CD003177-fig-0122" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 26 Body mass index, kg/m² ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 27 BMI, kg/m² ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0123" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 27 BMI, kg/m² ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 28 BMI, kg/m²‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0124" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 28 BMI, kg/m²‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 29 BMI, kg/m²‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0125" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 29 BMI, kg/m²‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 30 BMI, kg/m² ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0126" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 30 BMI, kg/m² ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 31 BMI, kg/m² ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0127" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 31 BMI, kg/m² ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 32 BMI, kg/m² ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0128" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.32</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 32 BMI, kg/m² ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 33 BMI, kg/m² ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0129" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.33</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 33 BMI, kg/m² ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 34 BMI, kg/m² ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0130" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.34</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 34 BMI, kg/m² ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 35 BMI, kg/m² ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0131" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.35</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 35 BMI, kg/m² ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 36 Other measures of adiposity ‐ LCn3." data-id="CD003177-fig-0132" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.36</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 36 Other measures of adiposity ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 37 Total cholesterol, serum, mmoL/L ‐ LCn3." data-id="CD003177-fig-0133" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.37</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 37 Total cholesterol, serum, mmoL/L ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 38 TC, mmoL/L ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0134" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.38</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 38 TC, mmoL/L ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 39 TC, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0135" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.39</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 39 TC, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 40 TC, mmoL/L ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0136" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.40</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 40 TC, mmoL/L ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 41 TC, mmoL/L ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0137" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.41</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 41 TC, mmoL/L ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 42 TC, mmoL/L ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0138" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.42</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 42 TC, mmoL/L ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 43 TC, mmoL/L ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0139" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.43</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 43 TC, mmoL/L ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 44 TC, mmoL/L ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0140" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.44</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 44 TC, mmoL/L ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 45 TC, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0141" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.45</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 45 TC, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 46 TC, mmoL/L ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0142" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.46</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 46 TC, mmoL/L ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 47 Triglycerides, fasting, serum, mmoL/L ‐ LCn3." data-id="CD003177-fig-0143" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.47</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 47 Triglycerides, fasting, serum, mmoL/L ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 48 TG, fasting, mmoL/L ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0144" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.48</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 48 TG, fasting, mmoL/L ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 49 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0145" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.49</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 49 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 50 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0146" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.50</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 50 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 51 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0147" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.51</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 51 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 52 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0148" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.52</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 52 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 53 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0149" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.53</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 53 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 54 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0150" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.54</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 54 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 55 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0151" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.55</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 55 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 56 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0152" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.56</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 56 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 57 High‐density lipoprotein, serum, mmoL/L ‐ LCn3." data-id="CD003177-fig-0153" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.57</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 57 High‐density lipoprotein, serum, mmoL/L ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 58 HDL, mmoL/L ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0154" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.58</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 58 HDL, mmoL/L ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 59 HDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0155" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.59</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 59 HDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 60 HDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0156" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.60</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 60 HDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 61 HDL, mmoL/L ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0157" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.61</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 61 HDL, mmoL/L ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 62 HDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0158" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.62</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 62 HDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 63 HDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0159" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.63</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 63 HDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 64 HDL, mmoL/L ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0160" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.64</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 64 HDL, mmoL/L ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 65 HDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0161" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.65</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 65 HDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 66 HDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0162" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.66</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 66 HDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 67 Low‐density lipoprotein, serum, mmoL/L ‐ LCn3." data-id="CD003177-fig-0163" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.67</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 67 Low‐density lipoprotein, serum, mmoL/L ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-68" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-68.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 68 LDL, mmoL/L ‐ LCn3 ‐ SA fixed effects." data-id="CD003177-fig-0164" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-68.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.68</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 68 LDL, mmoL/L ‐ LCn3 ‐ SA fixed effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-68.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-69" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-69.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 69 LDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias." data-id="CD003177-fig-0165" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-69.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.69</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 69 LDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-69.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-70" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-70.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 70 LDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size." data-id="CD003177-fig-0166" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-70.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.70</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 70 LDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-70.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-71" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-71.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 71 LDL, mmoL/L ‐ LCn3 ‐ subgroup by dose." data-id="CD003177-fig-0167" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-71.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.71</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 71 LDL, mmoL/L ‐ LCn3 ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-71.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-72" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-72.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 72 LDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement." data-id="CD003177-fig-0168" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-72.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.72</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 72 LDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-72.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-73" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-73.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 73 LDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type." data-id="CD003177-fig-0169" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-73.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.73</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 73 LDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-73.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-74" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-74.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 74 LDL, mmoL/L ‐ LCn3 ‐ subgroup by duration." data-id="CD003177-fig-0170" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-74.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.74</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 74 LDL, mmoL/L ‐ LCn3 ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-74.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-75" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-75.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 75 LDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0171" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-75.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.75</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 75 LDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-75.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-002-76" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-002-76.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 76 LDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use." data-id="CD003177-fig-0172" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-76.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.76</div> <div class="figure-caption"> <p>Comparison 2 High vs low LCn3 omega‐3 fats (secondary outcomes), Outcome 76 LDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-002-76.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg ‐ LCn3." data-id="CD003177-fig-0173" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 2 Serious adverse events ‐ LCn3." data-id="CD003177-fig-0174" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 2 Serious adverse events ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 3 Side effects ‐ LCn3." data-id="CD003177-fig-0175" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 3 Side effects ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 4 Dropouts ‐ LCn3." data-id="CD003177-fig-0176" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 High vs low LCn3 omega‐3 fats (tertiary outcomes), Outcome 4 Dropouts ‐ LCn3. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 1 All‐cause mortality (overall) ‐ ALA." data-id="CD003177-fig-0177" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 1 All‐cause mortality (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 2 All‐cause mortality ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect." data-id="CD003177-fig-0178" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 2 All‐cause mortality ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 3 All‐cause mortality ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0179" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 3 All‐cause mortality ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 4 All‐cause mortality ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0180" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 4 All‐cause mortality ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 5 All‐cause mortality ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0181" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 5 All‐cause mortality ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 6 All‐cause mortality ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0182" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 6 All‐cause mortality ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 7 All cause mortality ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0183" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 7 All cause mortality ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0184"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 8 All‐cause mortality ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0184" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 8 All‐cause mortality ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0184">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0185"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 9 All‐cause mortality ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0185" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 9 All‐cause mortality ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0185">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0186"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 10 All‐cause mortality ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0186" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 10 All‐cause mortality ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0186">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0187"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) ‐ ALA." data-id="CD003177-fig-0187" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 11 Cardiovascular mortality (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0187">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0188"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 12 CVD mortality ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0188" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 12 CVD mortality ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0188">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0189"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 13 CVD mortality ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0189" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 13 CVD mortality ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0189">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0190"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 14 CVD mortality ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0190" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 14 CVD mortality ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0190">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0191"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 15 CVD mortality ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0191" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 15 CVD mortality ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0191">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0192"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 16 CVD mortality ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0192" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 16 CVD mortality ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0192">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0193"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 17 CVD mortality ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0193" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 17 CVD mortality ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0193">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0194"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 18 CVD mortality ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0194" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 18 CVD mortality ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0194">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0195"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 19 CVD mortality ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0195" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 19 CVD mortality ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0195">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0196"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 20 CVD mortality ‐ ALA ‐ subgroup by statin uses." data-id="CD003177-fig-0196" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 20 CVD mortality ‐ ALA ‐ subgroup by statin uses. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0196">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0197"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) ‐ ALA." data-id="CD003177-fig-0197" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 21 Cardiovascular events (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0197">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0198"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 22 CVD events ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0198" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 22 CVD events ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0198">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0199"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 23 CVD events ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0199" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 23 CVD events ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0199">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0200"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 24 CVD events ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0200" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 24 CVD events ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0200">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0201"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 25 CVD events ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0201" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 25 CVD events ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0201">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0202"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 26 CVD events ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0202" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.26</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 26 CVD events ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0202">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0203"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 27 CVD events ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0203" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.27</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 27 CVD events ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0203">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0204"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 28 CVD events ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0204" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.28</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 28 CVD events ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0204">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0205"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 29 CVD events ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0205" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.29</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 29 CVD events ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0205">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0206"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 30 CVD events ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0206" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.30</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 30 CVD events ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0206">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0207"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) ‐ ALA." data-id="CD003177-fig-0207" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.31</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 31 Coronary heart disease mortality (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0207">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0208"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 32 CHD mortality ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0208" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.32</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 32 CHD mortality ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0208">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0209"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 33 CHD mortality ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0209" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.33</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 33 CHD mortality ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0209">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0210"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 34 CHD mortality ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0210" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.34</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 34 CHD mortality ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0210">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0211"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 35 CHD mortality ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0211" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.35</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 35 CHD mortality ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0211">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0212"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 36 CHD mortality ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0212" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.36</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 36 CHD mortality ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0212">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0213"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 37 CHD mortality ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0213" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.37</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 37 CHD mortality ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0213">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0214"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 38 CHD mortality ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0214" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.38</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 38 CHD mortality ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0214">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0215"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 39 CHD mortality ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0215" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.39</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 39 CHD mortality ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0215">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0216"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 40 CHD mortality ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0216" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.40</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 40 CHD mortality ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0216">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0217"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 41 CHD mortality ‐ ALA ‐ subgroup by CAD history." data-id="CD003177-fig-0217" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.41</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 41 CHD mortality ‐ ALA ‐ subgroup by CAD history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0217">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0218"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) ‐ ALA." data-id="CD003177-fig-0218" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.42</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 42 Coronary heart disease events (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0218">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0219"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 43 CHD events ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0219" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.43</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 43 CHD events ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0219">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0220"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 44 CHD events ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0220" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.44</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 44 CHD events ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0220">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0221"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 45 CHD events ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0221" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.45</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 45 CHD events ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0221">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0222"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 46 CHD events ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0222" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.46</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 46 CHD events ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0222">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0223"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 47 CHD events ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0223" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.47</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 47 CHD events ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0223">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0224"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 48 CHD events ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0224" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.48</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 48 CHD events ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0224">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0225"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 49 CHD events ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0225" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.49</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 49 CHD events ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0225">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0226"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 50 CHD events ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0226" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.50</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 50 CHD events ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0226">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0227"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 51 CHD events ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0227" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.51</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 51 CHD events ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0227">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0228"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 52 CHD events ‐ ALA ‐ subgroup by CAD history." data-id="CD003177-fig-0228" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.52</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 52 CHD events ‐ ALA ‐ subgroup by CAD history. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0228">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0229"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 53 Stroke (overall) ‐ ALA." data-id="CD003177-fig-0229" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.53</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 53 Stroke (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0229">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0230"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 54 Stroke ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0230" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.54</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 54 Stroke ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0230">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0231"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 55 Stroke ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0231" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.55</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 55 Stroke ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0231">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0232"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 56 Stroke ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0232" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.56</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 56 Stroke ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0232">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0233"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 57 Stroke ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0233" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.57</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 57 Stroke ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0233">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0234"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 58 Stroke ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0234" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.58</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 58 Stroke ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0234">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0235"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 59 Stroke ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0235" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.59</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 59 Stroke ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0235">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0236"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 60 Stroke ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0236" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.60</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 60 Stroke ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0236">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0237"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 61 Stroke ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0237" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.61</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 61 Stroke ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0237">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0238"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 62 Stroke ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0238" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.62</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 62 Stroke ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0238">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0239"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 63 Stroke ‐ ALA ‐ subgroup by stroke type." data-id="CD003177-fig-0239" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.63</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 63 Stroke ‐ ALA ‐ subgroup by stroke type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0239">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0240"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 64 Arrythmia (overall) ‐ ALA." data-id="CD003177-fig-0240" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.64</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 64 Arrythmia (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0240">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0241"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 65 Arrythmia ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0241" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.65</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 65 Arrythmia ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0241">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0242"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 66 Arrhythmia ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0242" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.66</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 66 Arrhythmia ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0242">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0243"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-004-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-004-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 67 Arrythmia ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0243" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.67</div> <div class="figure-caption"> <p>Comparison 4 High vs low ALA omega‐3 fat (primary outcomes), Outcome 67 Arrythmia ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0243">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-004-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0244"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 1 MACCEs ‐ ALA." data-id="CD003177-fig-0244" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 1 MACCEs ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0244">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0245"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) ‐ ALA." data-id="CD003177-fig-0245" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 2 Myocardial infarction (overall) ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0245">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0246"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 3 Total MI ‐ ALA ‐ subgroup by fatality." data-id="CD003177-fig-0246" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 3 Total MI ‐ ALA ‐ subgroup by fatality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0246">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0247"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 4 Angina ‐ ALA." data-id="CD003177-fig-0247" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 4 Angina ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0247">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0248"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 5 Revascularisation ‐ ALA." data-id="CD003177-fig-0248" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 5 Revascularisation ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0248">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0249"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease ‐ ALA." data-id="CD003177-fig-0249" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 6 Peripheral arterial disease ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0249">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0250"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 7 Body weight, kg ‐ ALA." data-id="CD003177-fig-0250" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 7 Body weight, kg ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0250">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0251"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 8 Weight, kg ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect." data-id="CD003177-fig-0251" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 8 Weight, kg ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0251">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0252"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 9 Weight, kg ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0252" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 9 Weight, kg ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0252">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0253"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 10 Weight, kg ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0253" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 10 Weight, kg ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0253">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0254"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 11 Weight, kg ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0254" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 11 Weight, kg ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0254">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0255"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 12 Weight, kg ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0255" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 12 Weight, kg ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0255">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0256"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 13 Weight, kg ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0256" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 13 Weight, kg ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0256">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0257"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 14 Weight, kg ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0257" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 14 Weight, kg ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0257">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0258"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 15 Weight, kg ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0258" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 15 Weight, kg ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0258">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0259"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 16 Weight, kg ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0259" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 16 Weight, kg ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0259">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0260"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m² ‐ ALA." data-id="CD003177-fig-0260" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 17 Body mass index, kg/m² ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0260">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0261"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 18 BMI, kg/m² ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0261" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 18 BMI, kg/m² ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0261">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0262"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 19 BMI, kg/m² ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0262" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 19 BMI, kg/m² ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0262">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0263"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 20 BMI, kg/m² ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0263" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.20</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 20 BMI, kg/m² ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0263">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0264"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 21 BMI, kg/m² ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0264" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.21</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 21 BMI, kg/m² ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0264">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0265"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 22 BMI, kg/m² ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0265" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.22</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 22 BMI, kg/m² ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0265">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0266"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 23 BMI, kg/m² ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0266" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.23</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 23 BMI, kg/m² ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0266">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0267"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 24 BMI, kg/m² ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0267" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.24</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 24 BMI, kg/m² ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0267">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0268"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 25 BMI, kg/m² ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0268" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.25</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 25 BMI, kg/m² ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0268">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0269"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 26 BMI, kg/m² ‐ ALA ‐ subgroup by primary or secondary preventionA." data-id="CD003177-fig-0269" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.26</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 26 BMI, kg/m² ‐ ALA ‐ subgroup by primary or secondary preventionA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0269">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0270"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 27 Other measures of adiposity ‐ ALA." data-id="CD003177-fig-0270" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.27</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 27 Other measures of adiposity ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0270">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0271"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmoL/L ‐ ALA." data-id="CD003177-fig-0271" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.28</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 28 Total cholesterol, serum, mmoL/L ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0271">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0272"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 29 TC, mmoL/L ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0272" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.29</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 29 TC, mmoL/L ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0272">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0273"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 30 TC, mmoL/L ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0273" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.30</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 30 TC, mmoL/L ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0273">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0274"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 31 TC, mmoL/L ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0274" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.31</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 31 TC, mmoL/L ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0274">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0275"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 32 TC, mmoL/L ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0275" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.32</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 32 TC, mmoL/L ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0275">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0276"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 33 TC, mmoL/L ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0276" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.33</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 33 TC, mmoL/L ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0276">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0277"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 34 TC, mmoL/L ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0277" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.34</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 34 TC, mmoL/L ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0277">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0278"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 35 TC, mmoL/L ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0278" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.35</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 35 TC, mmoL/L ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0278">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0279"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 36 TC, mmoL/L ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0279" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.36</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 36 TC, mmoL/L ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0279">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0280"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 37 TC, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0280" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.37</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 37 TC, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0280">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0281"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmoL/L ‐ ALA." data-id="CD003177-fig-0281" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.38</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 38 Triglycerides, fasting, serum, mmoL/L ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0281">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0282"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 39 TG, fasting, mmoL/L ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0282" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.39</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 39 TG, fasting, mmoL/L ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0282">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0283"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 40 TG, fasting, mmoL/L‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0283" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.40</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 40 TG, fasting, mmoL/L‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0283">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0284"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 41 TG, fasting, mmoL/L‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0284" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.41</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 41 TG, fasting, mmoL/L‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0284">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0285"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 42 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0285" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.42</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 42 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0285">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0286"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 43 TG, fasting, mmoL/L‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0286" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.43</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 43 TG, fasting, mmoL/L‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0286">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0287"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 44 TG, fasting, mmoL/L‐AL ‐ subgroup by replacement." data-id="CD003177-fig-0287" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.44</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 44 TG, fasting, mmoL/L‐AL ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0287">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0288"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 45 TG, fasting, mmoL/L‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0288" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.45</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 45 TG, fasting, mmoL/L‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0288">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0289"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 46 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0289" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.46</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 46 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0289">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0290"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 47 TG, fasting, mmoL/L‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0290" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.47</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 47 TG, fasting, mmoL/L‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0290">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0291"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 48 High‐density lipoprotein, serum, mmoL/L ‐ ALA." data-id="CD003177-fig-0291" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.48</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 48 High‐density lipoprotein, serum, mmoL/L ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0291">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0292"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-49" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-49.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 49 HDL, mmoL/L ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0292" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-49.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.49</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 49 HDL, mmoL/L ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0292">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-49.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0293"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-50" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-50.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 50 HDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0293" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-50.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.50</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 50 HDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0293">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-50.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0294"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-51" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-51.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 51 HDL, mmoL/L ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0294" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-51.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.51</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 51 HDL, mmoL/L ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0294">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-51.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0295"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-52" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-52.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 52 HDL, mmoL/L ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0295" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-52.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.52</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 52 HDL, mmoL/L ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0295">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-52.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0296"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-53" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-53.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 53 HDL, mmoL/L ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0296" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-53.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.53</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 53 HDL, mmoL/L ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0296">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-53.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0297"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-54" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-54.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 54 HDL, mmoL/L ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0297" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-54.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.54</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 54 HDL, mmoL/L ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0297">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-54.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0298"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-55" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-55.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 55 HDL, mmoL/L ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0298" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-55.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.55</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 55 HDL, mmoL/L ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0298">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-55.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0299"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-56" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-56.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 56 HDL, mmoL/L ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0299" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-56.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.56</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 56 HDL, mmoL/L ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0299">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-56.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0300"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-57" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-57.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 57 HDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0300" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-57.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.57</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 57 HDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0300">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-57.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0301"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-58" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-58.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 58 Low‐density lipoprotein, serum, mmoL/L ‐ ALA." data-id="CD003177-fig-0301" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-58.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.58</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 58 Low‐density lipoprotein, serum, mmoL/L ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0301">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-58.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0302"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-59" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-59.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 59 LDL, mmoL/L ‐ ALA ‐ SA fixed‐effect." data-id="CD003177-fig-0302" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-59.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.59</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 59 LDL, mmoL/L ‐ ALA ‐ SA fixed‐effect. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0302">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-59.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0303"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-60" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-60.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 60 LDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias." data-id="CD003177-fig-0303" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-60.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.60</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 60 LDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0303">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-60.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0304"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-61" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-61.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 61 LDL, mmoL/L ‐ ALA ‐ SA by compliance and study size." data-id="CD003177-fig-0304" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-61.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.61</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 61 LDL, mmoL/L ‐ ALA ‐ SA by compliance and study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0304">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-61.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0305"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-62" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-62.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 62 LDL, mmoL/L ‐ ALA ‐ subgroup by dose." data-id="CD003177-fig-0305" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-62.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.62</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 62 LDL, mmoL/L ‐ ALA ‐ subgroup by dose. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0305">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-62.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0306"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-63" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-63.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 63 LDL, mmoL/L ‐ ALA ‐ subgroup by intervention type." data-id="CD003177-fig-0306" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-63.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.63</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 63 LDL, mmoL/L ‐ ALA ‐ subgroup by intervention type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0306">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-63.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0307"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-64" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-64.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 64 LDL, mmoL/L ‐ ALA ‐ subgroup by replacement." data-id="CD003177-fig-0307" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-64.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.64</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 64 LDL, mmoL/L ‐ ALA ‐ subgroup by replacement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0307">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-64.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0308"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-65" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-65.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 65 LDL, mmoL/L ‐ ALA ‐ subgroup by duration." data-id="CD003177-fig-0308" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-65.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.65</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 65 LDL, mmoL/L ‐ ALA ‐ subgroup by duration. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0308">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-65.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0309"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-66" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-66.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 66 LDL, mmoL/L ‐ ALA ‐ subgroup by statin use." data-id="CD003177-fig-0309" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-66.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.66</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 66 LDL, mmoL/L ‐ ALA ‐ subgroup by statin use. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0309">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-66.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0310"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-005-67" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-005-67.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 67 LDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention." data-id="CD003177-fig-0310" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-67.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.67</div> <div class="figure-caption"> <p>Comparison 5 High vs low ALA omega‐3 fat (secondary outcomes), Outcome 67 LDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0310">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-005-67.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0311"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg ‐ ALA." data-id="CD003177-fig-0311" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 1 Blood pressure, mmHg ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0311">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0312"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 2 Serious adverse events ‐ ALA." data-id="CD003177-fig-0312" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 2 Serious adverse events ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0312">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0313"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 3 Side effects ‐ ALA." data-id="CD003177-fig-0313" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 3 Side effects ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0313">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003177-fig-0314"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/urn:x-wiley:14651858:media:CD003177:CD003177-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_t/tCD003177-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 4 Dropouts ‐ ALA." data-id="CD003177-fig-0314" src="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 High vs low ALA omega‐3 fats (tertiary outcomes), Outcome 4 Dropouts ‐ ALA. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-fig-0314">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/media/CDSR/CD003177/image_n/nCD003177-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003177-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : adults with or without existing CVD<br/> <b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle‐income countries (Argentina, Iran, Turkey and China). No trials took place wholly in low‐ or low‐middle income countries.<br/> <b>Intervention</b> : higher intake of LCn3 fats<br/> <b>Comparison</b>: lower intake of LCn3 fats </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish or fish oils as a food, oil, made into a spreading fat, or supplementing another food (such as bread or eggs). Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or concentrated fish or algal oils, were also accepted. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lower LCn3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with higher LCn3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> – deaths<br/> Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>80 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>78 per 1000<br/> (74 to 81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.93 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143,693</p> <p>(45 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake makes little or no difference to risk of all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> – cardiovascular deaths<br/> Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>50 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000<br/> (43 to 49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.92<br/> (0.86 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117,837<br/> (29 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake probably makes little or no difference to risk of cardiovascular death</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular events</b> </p> <p>Assessed with number of participants experiencing any cardiovascular event</p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>128 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/> (118 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.92 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140,482<br/> (43 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake makes little or no difference to risk of cardiovascular events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality</b> – CHD deaths<br/> Assessed with coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000<br/> (24 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.90<br/> (0.81 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127,378<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may slightly reduce CHD mortality (<b>NNTB 334</b>, 95% CI 200 to infinity; NNTB 1000 for primary prevention; NNTB 200 for secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease events</b> – CHD events<br/> Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>62 per 1000<br/> (58 to 66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91<br/> (0.85 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134,116<br/> (32 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may slightly reduce the risk of CHD events (<b>NNTB 167</b>, 95% CI 100 to 500; NNTB 200 for primary prevention; NNTB 143 for secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> <p>Assessed with number of participants experiencing at least 1 fatal or non‐fatal, ischaemic or haemorrhagic stroke </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (19 to 23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.02<br/> (0.94 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138,888<br/> (31 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 fat intake probably makes little or no difference to risk of experiencing a stroke</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmias</b> </p> <p>Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation </p> <p>Duration: range 12‐88 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>56 per 1000<br/> (52 to 60) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.92 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77,990<br/> (30 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 fat intake may make little or no difference to risk of arrhythmia</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: bleeding</b> </p> <p>Assessed with number of participants experiencing bleeding events</p> <p>Duration: range 12‐72 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>18 per</b> 1000<br/> (14 to 22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b><br/> (0.91 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80,147<br/> (11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of LCn3 fat intake on bleeding is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: pulmonary embolus or DVT</b> </p> <p>Assessed with number of participants experiencing pulmonary embolus or DVT</p> <p>Duration: range 18‐36 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>6 per</b> 1000<br/> (2 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.15</b><br/> (0.44 to 2.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3546<br/> (5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of LCn3 fat intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CHD</b> : coronary heart disease; <b>CI</b> : confidence interval; <b>CVD:</b> cardiovascular disease; <b>DHA:</b> docosahexaenoic acid; <b>DVT</b> : deep vein thrombosis; <b>EPA:</b> eicosapentaenoic acid; <b>IHD</b> : ischaemic heart disease; <b>LCn3:</b> long‐chain omega‐3; <b>MI</b> : myocardial infarction; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><b>All‐cause mortality, long‐chain omega‐3 (LCn3)</b> </p> <p> <ul id="CD003177-list-0001"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (risk ratio (RR) 1.0) when analysis was limited to trials at low summary risk of bias and low risk of compliance bias (adding weight to the suggestion of little or no effect) but did not alter with fixed‐effect meta‐analysis or results in the analysis limited to larger trials. It was further noted by the World Health Organization Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health that although many of the trials had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: tight confidence intervals, very large numbers of participants took part in long‐term randomised controlled trials (RCTs) with consistent results. Given the lack of a statistically significant effect in this very large set of participants, any effect appears too small to be individually relevant. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Cardiovascular mortality, LCn3</b> </p> <p> <ul id="CD003177-list-0002"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias and with fixed‐effect analysis (adding weight to the suggestion of little or no effect) but did not alter when the analyses were limited to trials at low risk of compliance bias or larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude important benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Cardiovascular events, LCn3</b> </p> <p> <ul id="CD003177-list-0003"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias (adding weight to the suggestion of little or no effect) but did not alter with fixed‐effect meta‐analysis or results in the analysis limited to larger trials. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60% and I<sup>2</sup> reduced when analysis was limited to trials at low summary risk of bias. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: very large numbers of participants took part in long‐term RCTs with consistent results. Given the lack of an important effect in this very large set of participants, any effect appears too small to be individually relevant. The 95% confidence intervals excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in, the RR would rise. This adds weight to the suggestion of little or no effect. Not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Coronary heart disease mortality, LCn3</b> </p> <p> <ul id="CD003177-list-0004"> <li> <p><b>Risk of bias</b>: effect size more than 8% was retained when analysis was limited to trials at low summary risk of bias, low risk of compliance bias and larger trials. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. As 95% confidence intervals did not exclude lack of effect we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot suggested that some small trials with higher numbers of events in the intervention group might be missing. If such missing trials were added back in the RR would rise. This weakens the suggestion of an effect. Downgraded once. </p> </li> </ul> </p> <p><sup>e</sup><b>Coronary heart disease events, LCn3</b> </p> <p> <ul id="CD003177-list-0005"> <li> <p><b>Risk of bias</b>: effect size moved closer to no effect (RR 1.0) when analysis was limited to trials at low summary risk of bias, but increased when limiting trials to those at low risk of compliance problems and larger trials. There was a small protective effect in the main analysis and some sensitivity analyses, but not in sensitivity analyses limiting to RCTs at low summary risk of bias or using fixed‐effect analysis. The suggestion of a dose response in meta‐regression was lost when <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> data were omitted. We summarised this as suggesting a true effect of around 8%. This is on the borderline of little or no effect and a more than 8% effect. Downgraded twice. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence interval did not include the null. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: no suggestion from the funnel plot of publication bias. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Stroke, LCn3</b> </p> <p> <ul id="CD003177-list-0006"> <li> <p><b>Risk of bias</b>: effect size consistently suggested little or no effect for all sensitivity analyses. It was further noted by the WHO NUGAG Subgroup on Diet and Health that although many of the RCTs had issues with blinding, the tendency for lack of blinding is an overestimation of effect. This is less of a concern for this outcome, as the pooled effect was approaching null and not statistically significant. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: very large numbers of participants took part in long‐term RCTs with consistent results. Given the lack of a statistically significant effect in this very large set of participants any effect appears too small to be individually relevant. However, as 95% confidence intervals do not exclude important harms, we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: the funnel plot did not suggest any small trial bias. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Arrhythmias, LCn3</b> </p> <p> <ul id="CD003177-list-0007"> <li> <p><b>Risk of bias</b>: effect size remained similar in most sensitivity analyses, but suggested harm when limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries were represented but underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals of the sensitivity analysis excluding trials at higher risk of bias included both harm and no effect, and there was a statistically significant difference in effect size between trials at low summary risk of bias and other trials, we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot not interpretable as trials all of a similar size and weight. Not downgraded. </p> </li> </ul> </p> <p><sup>h</sup><b>Bleeding, LCn3</b> </p> <p> <ul id="CD003177-list-0008"> <li> <p><b>Risk of bias</b>: effect size changed direction (from harmful to protective) when analysis limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude large and important benefits or harms. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>i</sup><b>Pulmonary embolus or DVD, LCn3</b> </p> <p> <ul id="CD003177-list-0009"> <li> <p><b>Risk of bias</b>: effect size suggested greater harm when analysis limited to trials at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. Low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals do not exclude large benefits or large harms. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">High versus low long‐chain omega‐3 fats for preventing cardiovascular disease and mortality (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003177-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High versus low alpha‐linolenic acid omega‐3 fats for preventing cardiovascular disease (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>High versus low alpha‐linolenic omega‐3 fats for preventing cardiovascular disease (primary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adults with or without existing CVD </p> <p><b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle‐income countries (Argentina, Iran, Turkey and China). No trials took place in low‐ or low‐ to middle‐income countries.<br/> <b>Intervention</b> : higher intake of ALA<br/> <b>Comparison</b>: lower intake of ALA </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been refined ALA: linseed (flax); canola (rapeseed); perilla; purslane; mustard seed; candlenut; stillingia; or walnut, as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega‐3 fat content of at least 10% of the total fat content. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with lower ALA</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with higher ALA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> – deaths<br/> Assessed with number of participants dying of any cause, whether reported as an outcome or a reason for dropout </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000<br/> (20 to 28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/> (0.84 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to risk of all‐cause mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> – cardiovascular deaths<br/> Assessed with deaths from any cardiovascular cause. Where this was not available, we used cardiac death instead where known. </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000<br/> (9 to 15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.96<br/> (0.74 to 1.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,619<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to risk of cardiovascular mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular events</b> </p> <p>Assessed with number of participants experiencing any cardiovascular event</p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>47 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000<br/> (39 to 50) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.83 to 1.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing ALA intake may slightly reduce the risk of cardiovascular events. (<b>NNTB 500</b>, 95% CI 125 to −334; NNTB 500 in primary prevention; NNTB 84 in secondary prevention) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease mortality</b> – CHD deaths<br/> Assessed with: coronary deaths, or where these were not reported, IHD death, fatal MI or cardiac death (in that order) </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (8 to 14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.72 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18,353<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on risk of CHD mortality</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coronary heart disease events</b><br/> Assessed with number of participants experiencing the first outcome in this list reported for each trial: CHD or coronary events; total MI; acute coronary syndrome; or angina (stable and unstable) </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000<br/> (17 to 26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00<br/> (0.82 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,061<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake may make little or no difference to CHD events</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> <p>Assessed with: number of participants experiencing at least one fatal or non‐fatal, ischaemic or haemorrhagic stroke </p> <p>Duration: range 12 to 40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.15<br/> (0.66 to 2.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,327<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on stroke is unclear as the evidence is of very low certainty</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmias</b> </p> <p>Assessed with number of participants experiencing fatal or nonfatal, new or recurrent arrhythmia, including atrial fibrillation, ventricular tachycardia and ventricular fibrillation </p> <p>Duration: range 12‐40 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 1000<br/> (22 to 39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.55 to 0.97) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4912<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably slightlyreduces the risk of arrhythmias. (<b>NNTB 91</b>, 95% CI 56 to 1000; assessment by primary or secondary prevention not possible) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: bleeding</b> </p> <p>Assessed with number of participants experiencing bleeding events</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The effect of ALA intake on bleeding is unclear as no trials reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Harms: pulmonary embolus or DVT</b> </p> <p>Assessed with number of participants experiencing pulmonary embolus or DVT</p> <p>Duration: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1 per</b> 1000<br/> (0 to 23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.32</b><br/> (0.01 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>708<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on pulmonary embolus or DVT is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALA</b> : alpha‐linolenic acid; <b>CHD</b> : coronary heart disease; <b>CI</b> : confidence interval; <b>DVT</b> : deep vein thrombosis; <b>IHD</b> : ischaemic heart disease; <b>MI</b> : myocardial infarction; <b>RCT</b> : randomised controlled trial; <b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><b>All‐cause mortality, alpha‐linolenic acid (ALA)</b> </p> <p> <ul id="CD003177-list-0010"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main meta‐analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with cardiovascular disease (CVD) risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Cardiovascular mortality, ALA</b> </p> <p> <ul id="CD003177-list-0011"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis, or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in RCTs in long‐term trials with consistent results. However, as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Cardiovascular events, ALA</b> </p> <p> <ul id="CD003177-list-0012"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis, with larger trials and in fixed‐effect analysis, and a 9%‐10% reduction in risk when data were limited to RCTs at low summary risk of bias or at low risk from compliance problems. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals do not exclude important benefits we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Coronary heart disease mortality, ALA</b> </p> <p> <ul id="CD003177-list-0013"> <li> <p><b>Risk of bias</b>: all sensitivity analyses suggested little or no effect. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: As 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>e</sup><b>Coronary heart disease events, ALA</b> </p> <p> <ul id="CD003177-list-0014"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analyses, in fixed‐effect meta‐analysis, in larger trials or when limiting to trials at low risk of compliance bias, but some risk reduction (9%) when data were limited to RCTs at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: as 95% confidence intervals do not exclude important benefits or harms we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Stroke, ALA</b> </p> <p> <ul id="CD003177-list-0015"> <li> <p><b>Risk of bias</b>: the main analysis, fixed‐effect analysis, and larger trials suggest increased risk of stroke with more ALA, but there was little or no effect when data were limited to RCTs at low summary risk of bias, and a suggestion of benefit when limited to trials with low risk of compliance problems. Downgraded twice. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with CVD risk factors or previous CVD as well as non‐CVD health problems. All trials were conducted in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: only 49 participants experienced strokes in the included trials; 95% confidence intervals do not exclude important benefits or harms, downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Arrhythmias, ALA</b> </p> <p> <ul id="CD003177-list-0016"> <li> <p><b>Risk of bias</b>: increasing ALA reduced the risk of arrhythmia in the main analysis, and also in all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: two trials, which included adults with previous myocardial infarction or successful cardioversion in high‐income countries. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: as 95% confidence intervals do not exclude little or no effect we downgraded once. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> <p><sup>h</sup><b>Pulmonary embolus or DVD, ALA</b> </p> <p> <ul id="CD003177-list-0017"> <li> <p><b>Risk of bias</b>: the single trial was not at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: with one trial no inconsistency. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: healthy men and women, no participants with CVD risk factors or previous CVD; low‐ and middle‐income countries not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: only one event included in a single trial. Downgraded twice. </p> </li> <li> <p><b>Publication bias</b>: insufficient trials for funnel plot. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">High versus low alpha‐linolenic acid omega‐3 fats for preventing cardiovascular disease (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003177-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low omega‐3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>High versus low omega‐3 fats for modification of CVD risk factors (adiposity and lipids)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b>: adults with or without existing CVD </p> <p><b>Setting</b>: participants were living at home for most or all of the duration of their trials. Most trials were carried out in high‐income economies (<a href="./references#CD003177-bbs2-0291" title="WorldBank . World Bank Country and Lending Groups ‐ country classification. datahelpdesk.worldbank.org/knowledgebase/articles/906519‐world‐bank‐country‐and‐lending‐groups (accessed 3 April 2018). ">World Bank 2018</a>), but four were carried out in upper‐middle income countries. No trials took place in low‐ or low‐middle income countries. </p> <p><b>Intervention</b> : higher omega‐3 intake (LCn3 or ALA)<br/> <b>Comparison</b>: lower omega‐3 intake (LCn3 or ALA) </p> <p>The intervention was dietary supplementation, a provided diet or advice on diet. Supplementation may have been in oil or capsule form or as foodstuffs provided, to be consumed by mouth (excluding enteral and parenteral feeds and enemas). The foodstuffs or supplements must have been oily fish; fish oils; linseed (flax), canola (rapeseed), perilla, purslane, mustard seed, candlenut, stillingia or walnut as a food, oil, made into a spreading fat or supplementing another food (such as bread or eggs). For ALA sources the product consumed had to have an omega‐3 fat content of at least 10% of the total fat content. Refined eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or ALAs, or concentrated fish or algal oils, were also accepted. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> <p><b>All in trials of 12 to 72 months' duration</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with low omega‐3</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with high omega‐3</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, LCn3 ‐ weight, kg </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean body weight was 81.2 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.00 kg lower<br/> (0.69 lower to 0.70 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,000<br/> (14 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to body weight</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, LCn3 ‐ BMI, kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BMI was 27.3 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 higher<br/> (0.14 lower to 0.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,474<br/> (15 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to BMI</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum total cholesterol,</b> LCn3 – TC, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TC was 5.61 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 lower<br/> (0.05 lower to 0.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38,469<br/> (30 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to serum TC</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum triglyceride</b>,LCn3 ‐ fasting TG, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TG was 1.59 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.24 lower<br/> (0.31 lower to 0.16 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,998<br/> (27 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 intake reduces serum TG by about 0.24 mmol/L or 15%</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum high‐density lipoprotein</b>, LCn3 – HDL, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HDL was 1.32 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 higher<br/> (0.01 to 0.05 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46,604<br/> (30 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increasing LCn3 intake has little or no effect on serum HDL</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum low‐density lipoprotein</b>, LCn3 – LDL, mmol/L </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean LDL was 3.27 mmol/L</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.01 higher<br/> (0.01 lower to 0.03 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43,454<br/> (25 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 intake makes little or no difference to serum LDL.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, ALA – weight, kg </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean weight was 80.9 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.49 lower<br/> (4.17 lower to 1.18 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>664<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> Very low<sup>g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on body weight is unclear as the evidence is of very low certainty </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Measures of adiposity</b>, ALA – BMI, kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean BMI was 27.4 kg/m<sup>2</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.42 lower<br/> (1.53 lower to 0.69 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1581<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊝⊝⊝⊝<br/> Very low<sup>h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The effect of ALA intake on BMI is unclear as the evidence is of very low certainty</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum total cholesterol</b>, ALA – TC, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TC was 5.02 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.09 lower<br/> (0.23 lower to 0.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2164<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake may make little or no difference to serum TC</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum triglyceride</b>, ALA ‐ fasting TG, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean TG was 1.48 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.03 lower<br/> (0.11 lower to 0.05 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1776<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>j</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably makes little or no difference to serum TG</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum high‐density lipoprotein</b>, ALA – HDL, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean HDL was 1.49 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.02 lower<br/> (0.08 lower to 0.03 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1776<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>k</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on serum HDL</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum low‐density lipoprotein</b>, ALA – LDL, mmol/L </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean LDL was 2.88 mmol/L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.05 lower<br/> (0.15 lower to 0.04 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2201<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>l</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA intake probably has little or no effect on serum LDL</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ALA</b> : alpha‐linolenic acid; <b>BMI</b> : body mass index; <b>CI</b> : confidence interval; <b>DHA:</b> docosahexaenoic acid; <b>EPA:</b> eicosapentaenoic acid; <b>HDL</b> : high‐density lipoprotein; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>LDL</b> : low‐density lipoprotein; <b>MD</b> : mean difference; <b>RCT</b> : randomised controlled trial; <b>TC</b> : total cholesterol; <b>TG</b>: triglycerides </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup><b>Measures of adiposity, weight, long‐chain omega‐3 (LCn3)</b> </p> <p> <ul id="CD003177-list-0018"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term randomised controlled trials (RCTs) with consistent results; 95% confidence intervals exclude important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>b</sup><b>Measures of adiposity, body mass index (BMI), LCn3</b> </p> <p> <ul id="CD003177-list-0019"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were underrepresented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. 95% confidence intervals exclude important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>c</sup><b>Lipids, serum total cholesterol, LCn3</b> </p> <p> <ul id="CD003177-list-0020"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: the 95% CI excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot did not suggest clear small trial bias. However, we are aware of several trials whose data could not be included; not downgraded. </p> </li> </ul> </p> <p><sup>d</sup><b>Lipids, serum triglycerides, LCn3</b> </p> <p> <ul id="CD003177-list-0021"> <li> <p><b>Risk of bias</b>: there was a greater than 5% (and statistically significant) effect overall and in all sensitivity analyses, including when data were limited to RCTs at low summary risk of bias. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: large numbers of participants took part in long‐term RCTs with consistent results. 95% confidence intervals exclude harm and lack of effect. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but results of fixed‐effect and random‐effects analyses were similar, suggesting little small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>e</sup><b>Lipids, high‐density lipoprotein (HDL), LCn3</b> </p> <p> <ul id="CD003177-list-0022"> <li> <p><b>Risk of bias</b>: the suggested little or no effect (less than 5% increase) in HDL with increased LCn3 was apparent in all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals exclude harms or benefits. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot suggested no clear small trial bias. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>f</sup><b>Lipids, low‐density lipoprotein (LDL), LCn3</b> </p> <p> <ul id="CD003177-list-0023"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals excluded important benefits or harms. Not downgraded. </p> </li> <li> <p><b>Publication bias</b>: funnel plot did not suggest clear small trial bias, and results of fixed‐effect and random‐effects analyses were similar. However, we are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>g</sup><b>Measures of adiposity, weight, alpha‐linolenic acid (ALA)</b> </p> <p> <ul id="CD003177-list-0024"> <li> <p><b>Risk of bias</b>: no included trials were at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals included both benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but effects in fixed‐effect and random‐effects meta‐analysis were different suggesting that small trial bias may be present. We are aware of several trials whose data could not be included. Downgraded once. </p> </li> </ul> </p> <p><sup>h</sup><b>Measures of adiposity, BMI, ALA</b> </p> <p> <ul id="CD003177-list-0025"> <li> <p><b>Risk of bias</b>: the main analysis and some sensitivity analyses suggested that ALA reduced BMI, but this was not seen when trials were limited to those at low summary risk of bias. Downgraded once. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals include benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, but effects of fixed‐effect and random‐effects analyses were distinct, suggesting some small trial bias. We are aware of several trials whose data could not be included. Downgraded once. </p> </li> </ul> </p> <p><sup>i</sup><b>Lipids, serum total cholesterol, ALA</b> </p> <p> <ul id="CD003177-list-0026"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was greater than 60%. Downgraded once. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: the main analysis included both benefits and harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias, fixed‐effect and random‐effects meta‐analysis suggested similar effects. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>j</sup><b>Lipids, serum triglycerides, ALA</b> </p> <p> <ul id="CD003177-list-0027"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis or in any sensitivity analysis. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence intervals included benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, no clear small trial bias and fixed‐effect and random‐effects analysis results were similar. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>k</sup><b>Lipids, HDL, ALA</b> </p> <p> <ul id="CD003177-list-0028"> <li> <p><b>Risk of bias</b>: there was little or no effect in the main analysis and all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: 95% confidence interval includes harms. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, effects of fixed‐effect and random‐effects meta‐analysis was very similar suggesting lack of small trial bias. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> <p><sup>l</sup><b>Lipids, LDL, ALA</b> </p> <p> <ul id="CD003177-list-0029"> <li> <p><b>Risk of bias</b>: little or no effect in main analysis and all sensitivity analyses. Not downgraded. </p> </li> <li> <p><b>Inconsistency</b>: I<sup>2</sup> statistic was less than 60%. Not downgraded. </p> </li> <li> <p><b>Indirectness</b>: representative, generalisable adult population including men and women, including healthy participants and participants with previous CVD. However, low‐ and middle‐income countries were not represented. Not downgraded. </p> </li> <li> <p><b>Imprecision</b>: for main analysis 95% confidence interval included benefits. Downgraded once. </p> </li> <li> <p><b>Publication bias</b>: funnel plot was not interpretable, effects of fixed‐effect and random‐effects meta‐analysis were similar suggesting no small trial bias. We are aware of several trials whose data could not be included. Not downgraded. </p> </li> </ul> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">High versus low omega‐3 fats for modification of cardiovascular disease risk factors (adiposity and lipids): key outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment methods in greater detail</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk of bias element</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for low risk of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for unclear</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Criteria for high risk of bias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias: random sequence generation</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. For example "the randomisation sequence was computer generated". We allowed that a good method of randomisation was strongly implied if the authors discussed stratification and/or blocking. Therefore, if the authors were not explicit about their randomisation method but did describe stratification or blocking we assessed this as corresponding to low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors have not described their method in sufficient detail for the assessment of whether it would produce comparable groups. For example, the authors state "the trial was randomised" and provide no further information. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The randomisation method was assessed as not truly random, and may not produce comparable groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Selection bias: allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described the method used to conceal allocation sequence in sufficient detail to determine whether the allocations could have been foreseen in advance of, or during, enrolment. Good methods included putting allocation codes in opaque sealed envelopes (ideally prepared by someone outside the treatment or assessment teams and sequentially numbered), using a telephone allocation system after the participants had consented to participate or providing a random number that links to a specific set of capsules prepared and distributed centrally or by an arms‐length pharmacist. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors gave insufficient detail as to method.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The allocation was known in advance of participants consenting to take part in the trial. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Performance bias: blinding of participants and personnel</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have described all measures used, if any, to blind trial participants and personnel from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "both the intervention and placebo capsules looked and tasted the same." However, if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding, then we assumed that the blinding was effective and the risk of bias was low. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient methodological details were provided e.g. "the trial was blinded."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was unblinded or where blinding was broken, e.g. "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Detection bias: blinding of outcome assessment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Trial authors needed to have described measures used, if any, to blind outcome assessors from knowledge of which intervention a participant received. Ideally, they should also have provided information relating to whether the intended blinding was effective. For example, the authors could say "the outcome assessors had no knowledge of the group allocation, and both the intervention and placebo capsules looked and tasted the same so the self‐assessment scales were also blinded." However if the trial authors did not provide information on whether the blinding was effective, but sufficient detail was given on a good method of blinding of the assessors, then we assumed that the blinding was effective and the risk of bias is low. All biochemical assessment (lipids, glucose, CRP, insulin, PSA, etc.) were considered at low risk of detection bias if outcome assessor blinding or double‐blinding was stated. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient methodological details were provided e.g. "the trial was blinded."</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial was unblinded or blinding was broken, e.g. for a self‐assessment measure "the capsules were visually identical but the participants reported a strong fishy flavour in the intervention group only." </p> <p>Because the level of blinding could vary by outcome, assessment of risk of bias was based on blinding of the review's primary outcome(s). Where primary outcomes had different assessments we opted for the higher risk of bias but noted that risk of bias was lower for other outcomes. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Attrition bias: incomplete outcome data</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis. They needed to report the number of attrition/exclusions, the numbers in each group at each time point, reasons for attrition/exclusion and any re‐inclusions in analyses. Ideally, they would report how they imputed any missing data e.g. last observation carried forward. There needed to be a reasonable balance of attrition/exclusions between trial arms and ≤ 20% of the sample should be lost over a year. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors didn't state reasons for attrition/exclusion, or were unclear about the numbers lost to attrition/exclusion in each trial arm. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors demonstrated a substantial difference in the rates of attrition/exclusions between the trial arms and/or &gt; 20% of the baseline sample was lost over a year (&gt; 10% over 6 months). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reporting bias: selective outcome reporting</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have published their trial protocol or trials registry entry before the end of the trial's recruitment period, i.e. prospectively. They needed to have reported on all of the primary and secondary outcomes listed in the protocol/registry entry. We deemed reporting additional secondary outcomes in the results paper(s), although not ideal, to still be low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trial protocol or trials registry entry was found, it was registered retrospectively, or the dates of registration and participant recruitment were unclear. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors did not report at least one primary or secondary outcome listed in the protocol/registry entry or the results paper(s) reported a primary outcome that was not listed at all in the protocol or not listed as a primary outcome in the protocol. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: attention bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have reported that participants in all trial arms received the same amount of attention and time from researchers and clinical teams. For example, "All participants attended the clinic for a baseline assessment which took 2 hours. They were then followed with monthly telephone calls, and finally attended for a 6 month assessment at the clinic which took 1 hour." If the trial only differed by the content of the capsules, and the assessment schedule was not stated to differ between the two arms, we assumed it to be at low risk. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The authors did not state the attention each arm received.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants in different arms received different amounts of attention. For example "the intervention group only attended for additional assessments at months 2, 4, and 6" or "the rates of relapse differed substantially between the groups which led to differing amounts of treatment time and attention," or "the intervention group received a 40 minute dietary education session." </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: limited compliance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The trial authors needed to have reported on the level of compliance in all arms in sufficient detail to determine whether the trial results were robust. We followed a flow chart to make this determination. A statistically significant difference between the intervention and control groups in a body measure of at least 50% of the test fatty acids. Where no body measures were reported then estimated compliance needed to be greater than 64% (proportion complying multiplied by compliance threshold). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compliance not reported or not in a way that could be interpreted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measures of compliance were reported but fell below the appropriate thresholds.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other sources of bias: other</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In the absence of any additional issues this item was coded "low risk of bias"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If fraud concerns had been raised and the paper had been withdrawn, or the author had been found guilty of fraud by a legal or medical entity the paper was excluded from the review. However if fraud concerns were raised, but the journal had not withdrawn the paper, and the author had not been formally sanctioned; then the trial was included in the review, but concerns were raised here, and the risk of bias for this item was high. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CRP</b> : C‐reactive protein; <b>PSA</b>: prostate specific antigen </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment methods in greater detail</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Meta‐regression results for cardiovascular mortalitya </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> <p>+ LCn3 dose</p> <p>+ n6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> <p>0.37</p> <p>0.99</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular mortality. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Meta‐regression results for cardiovascular mortalitya </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Meta‐regression results for cardiovascular eventsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (lower CVD event risk with higher LCn3 dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> <p>+ LCn3 dose</p> <p>+ duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> <p>0.07</p> <p>0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (lower CVD event risk with higher LCn3 dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LCn3 dose ‐ analysis omitting <a href="./references#CD003177-bbs2-0067" title="BhattDL , StegPG , BrintonEA , JacobsonTA , MillerM , TardifJC , et al. REDUCE‐IT Investigators. Rationale and design of REDUCE‐IT: reduction of cardiovascular events with icosapent ethyl‐intervention trial. Clinical Cardiology2017;40(3):138‐48. BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine2019;380:11‐22. [DOI: 10.1056/NEJMoa1812792] BhattDL , StegPG , MillerM , BrintonEA , JacobsonTA , KetchumSB , et al. Effects of icosapent ethyl on total ischemic events: from REDUCE‐IT. Journal of the American College of Cardiology2019;73(22):2791‐802. NCT01492361 . A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE‐IT). clinicaltrials.gov/ct2/show/NCT01492361 (first received 15 December 2011). ">REDUCE‐IT 2019</a> data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on cardiovascular events. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Meta‐regression results for cardiovascular eventsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐regression results for coronary heart disease deathsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> <p>+ Food or capsule</p> <p>+ PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> <p>0.81</p> <p>0.68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on coronary heart disease mortality. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Meta‐regression results for coronary heart disease deathsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metaregression results for coronary heart disease eventsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (risk of CHD events falls as LCn3 dose increases)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> <p>+ duration</p> <p>+ LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> <p>0.35</p> <p>0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Negative (risk of CHD events falls as LCn3 dose increases)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LCn3 dose ‐ analysis omitting REDUCE‐IT data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CHD:</b> coronary heart disease; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on CHD events. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Metaregression results for coronary heart disease eventsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metaregression results for strokea </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (lower risk with higher dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (smaller risk with longer duration)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration</p> <p>+ LCn3 dose</p> <p>+ total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> <p>0.06</p> <p>0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on stroke. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Metaregression results for strokea </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Meta‐regression results for arrhythmiaa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Variable assessed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Coefficient sign where P &lt; 0.10</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Omega‐6 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total PUFA dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration, months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Positive (higher risk with longer duration)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary or secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Negative (greater effect with primary prevention)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Food or capsule</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALA dose</p> <p>+ Primary secondary prevention</p> <p>+ duration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> <p>0.42</p> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ALA</b> : alpha‐linolenic acid; <b>CVD</b> : cardiovascular disease; <b>LCn3</b> : long‐chain omega‐3 fatty acids; <b>PUFA</b>: polyunsaturated fatty acids </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>Random‐effects meta‐regression exploring effects of LCn3 dose, ALA dose, omega‐6 dose, total PUFA dose, trial duration, primary or secondary prevention, food or capsule intervention, and summary risk of bias (low or moderate to high) on arrhythmia. We ran the meta‐regression using all included trials that reported this outcome in this review, and its sister reviews (<a href="./references#CD003177-bbs2-0250" title="HooperL , Al‐KhudairyL , AbdelhamidAS , ReesK , BrainardJS , BrownTJ , et al. Omega‐6 fats for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD011094.pub3] ">Hooper 2018</a> and <a href="./references#CD003177-bbs2-0214" title="AbdelhamidAS , MartinN , BridgesC , BrainardJS , WangX , BrownTJ , et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD012345.pub2] ">Abdelhamid 2018b</a>). For each variable the P value presented represents probability that the relationship was due to chance (as we had limited power we assumed a true relationship when P &lt; 0.10). Meta‐regression was of each variable singly, plus a multivariate meta‐regression of the 3 single variables with lowest P values. See methods for further information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Meta‐regression results for arrhythmiaa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003177-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of the results of long‐chain omega‐3 interventions in this review with other major recent reviewsa </span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Systematic review</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>This review</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of people experiencing events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR (95% CI)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8480</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.92 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,297</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.93 to 1.01)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular deaths</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3799</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.82 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4630</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (0.88 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5658</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.86 to 0.99)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CVD events (MACCEs in Balk 2016)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8085</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.91 to 1.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.93 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97 (0.94 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,619</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.92 to 1.01)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHD deaths</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2695</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93, (0.83 to 1.03)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2934</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92 (0.86 to 0.98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3598</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.90 (0.81 to 1.00)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CHD events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6273</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96, (0.90 to 1.01)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7536</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.91 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8791</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (0.85 to 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Stroke</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.88 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.03 (0.93 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.98 to 1.14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.02 (0.94, 1.12)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Arrhythmia</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not pooled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not assessed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4586</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.99 (0.92 to 1.06)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>CHD:</b> coronary heart disease; <b>CI:</b> confidence interval; <b>CVD:</b> cardiovascular disease; <b>MACCE:</b> major adverse cerebrovascular or cardiovascular event; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Meta‐analysis of effects of long‐chain omega‐3 in three recent systematic reviews, <a href="./references#CD003177-bbs2-0218" title="BalkEM , AdamGP , LangbergV , HalladayC , ChungM , LinL , et al. Omega‐3 fatty acids and cardiovascular disease: an updated systematic review. Rockville (MD): Agency for Healthcare Research and Quality; 2016. Evidence report/technology assessment no. 223. AHRQ Publication No. 16‐E002‐EF. www.effectivehealthcare.ahrq.gov/reports/final.cfm. [DOI: 10.23970/AHRQEPCERTA223] ">Balk 2016</a>, <a href="./references#CD003177-bbs2-0217" title="AungT , HalseyJ , KromhoutD , GersteinHC , MarchioliR , TavazziL , et al. Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77 917 individuals. JAMA Cardiology2018;3(3):225‐34. [DOI: 10.1001/jamacardio.2017.5205] ">Aung 2018</a> and <a href="./references#CD003177-bbs2-0253" title="HuY , HuFB , MansonJ . Marine omega‐3 supplementation and cardiovascular disease: an updated meta‐analysis of 13 randomized controlled trials involving 127477 participants. Journal of the American Heart Association2019;8:e013543. [DOI: 10.1161/JAHA.119.013543] ">Hu 2019</a>, comparing their findings with our findings for our primary outcomes. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of the results of long‐chain omega‐3 interventions in this review with other major recent reviewsa </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/full#CD003177-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (primary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality ‐LCn3 ‐ sensitivity analysis (SA) fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75741</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Moderate or high summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67952</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143437</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.27, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.56, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129505</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.94, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.77, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 LCn3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.56, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 LCn3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 LCn3 replacing N‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.51, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 LCn3 replacing CHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.05, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 LCn3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47844</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 LCn3 replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.77, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5554</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.60, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.84, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.93, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.11, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10981</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.86, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.96, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Primary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Mixed primary &amp; secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.75, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 LCn3 ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 LCn3 &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.58, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.94, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.54, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 All‐cause mortality ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.93, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.92, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Cardiovascular mortality (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 CVD mortality ‐ LCn3 ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.88, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 CVD mortality ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 CVD mortality ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.85, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 CVD mortality ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.53, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 CVD mortality ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.53, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 N‐3 replacing N‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1435</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.41, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.12, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.74, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.13, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 CVD mortality ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.52, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.72, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 CVD mortality ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.64, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.82, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 CVD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.67, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 CVD mortality ‐ LCn3 ‐ subgroup by statin uses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 LCn3‐ Use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.13, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 CVD mortality ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 CVD mortality ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68856</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12817</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Cardiovascular events (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 CVD events ‐ LCn3 ‐ SA fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.94, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 CVD events ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.95, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Moderate or high summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 CVD events ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.92, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 CVD events ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.73, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.65, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 CVD events ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.94, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.86, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 3.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.50, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 CVD events ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.86, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.89, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.90, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 CVD events ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.69, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.95, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.88, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 CVD events ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.93, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.68, 0.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 CVD events ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.92, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71031</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.51, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 CVD events ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.92, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.67, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 CVD events ‐ LCn3 ‐ subgroup by baseline diabetes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.93, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.72, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Coronary heart disease mortality (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 CHD mortality ‐ LCn3 ‐ SA fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.86, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 CHD mortality ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.76, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Moderate or high summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 CHD mortality ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.67, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 CHD mortality ‐ LCn3 ‐ SA omitting cardiac death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.73, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.68, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 CHD mortality ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 LCn3 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.3 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.4 LCn3 &gt; 2.4 ≤ 4.4g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>822</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.49, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.5 LCn3 &gt; 4.4g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 CHD mortality ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.51, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.33, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 CHD mortality ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.50, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.69, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 CHD mortality ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5978</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.58, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.77, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94855</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.83, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 CHD mortality ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.75, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 CHD mortality ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.78, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.77, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 CHD mortality ‐ LCn3 ‐ subgroup by CAD history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 Previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.71, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 No previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 CHD mortality ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 CHD mortality ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.92, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.67, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 Coronary heart disease events (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 CHD events ‐ LCn3 ‐ SA fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.89, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 CHD events ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71578</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.82, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 Moderate or high summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 CHD events ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.84, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 CHD events ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.82, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122081</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.87, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.63, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>422</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.54, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 CHD events ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.16, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.89, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.78, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.72, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.45, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 CHD events ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.67, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.75, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.83, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 CHD events ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.64, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.90, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.74, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 CHD events ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78716</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.75, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.91, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 CHD events ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66679</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.89, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>892</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.11, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 CHD events ‐ LCn3 subgroup by CAD history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 Previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2 No previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3 Mixed ‐ some previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 CHD events ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.89, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.60, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 CHD events ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>134116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.85, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84915</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.88, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.45, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.70, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 Stroke (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 Stroke ‐ LCn3 ‐ SA fixed effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.94, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 Stroke ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73390</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65498</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.87, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Stroke ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48501</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138761</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.93, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68 Stroke ‐ LCn3 ‐ subgroup by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.1 Ischaemic stroke ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69090</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.79, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.2 Haemorrhagic stroke ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.93, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>68.3 Transient ischaemic attack (TIA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.76, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69 Stroke ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.14, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.96, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.57, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.58 [0.78, 55.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70 Stroke ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.19, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.94, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.18, 24.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.61, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71 Stroke ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.42, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.47, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128803</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.93, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72 Stroke ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.86, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28387</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.93, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>103034</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.89, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73 Stroke ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50026</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [1.05, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.57, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74 Stroke ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [1.01, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.38, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75 Stroke ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.96, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 4.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76 Stroke ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.94, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.98, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.80, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.73, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">77 Arrythmia (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">78 Arrythmia ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.98, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">79 Arrhythmia‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.99, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>79.2 Moderate to high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36174</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.86, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">80 Arrhythmia‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.88, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>80.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.91, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">81 Arrhythmia ‐ LCn3 ‐ subgroup by new or recurrent <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.1 New arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [1.01, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>81.2 Recurrent arrhythmia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">82 Arrhythmia ‐ LCn3 ‐ subgroup by fatality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.1 Fatal arrhythmias ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12938</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.95, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>82.2 Non‐fatal arrhythmias ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.57, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">83 Arrhythmia ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.58, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.32, 3.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>83.7 Unclear LCn3 dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.76, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">84 Arrhythmia ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.10, 5.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58652</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.91, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.86, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>84.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">85 Arrhythmia ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>85.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.44, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>85.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5039</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.67, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>85.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.91, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>85.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">86 Arrhythmia ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>86.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>86.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>86.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [1.03, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">87 Arrhythmia ‐ LCn3 ‐ subgroup by primary or secondary prevention3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>87.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.98, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>87.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>87.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.99, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">88 Arrhythmia ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>88.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47438</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>88.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29467</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.85, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>88.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.80, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">89 Arrythmia ‐ LCn3 ‐ subgroup by baseline TG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>89.1 Baseline TG not restricted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69475</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>89.2 Baseline TG raised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.99, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">90 Arrythmia ‐ LCn3 ‐ subgroup by baseline DM <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>90.1 Normal diabetes risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>90.2 Diabetes risk factors at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.93, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>90.3 Diabetes at baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (secondary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MACCEs ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34730</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total MI ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total MI ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.83, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Moderate or high summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61636</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.76, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total MI ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.70, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.80, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total MI ‐ LCn3 ‐ subgroup by fatality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Fatal MI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.52, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Non‐fatal MI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.84, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Sudden cardiac death (overall) ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.77, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Angina ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.88, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Heart failure ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>73303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.87, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.89, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Moderate to high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Revascularisation ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129382</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.86, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.91, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Moderate to high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.78, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Peripheral arterial disease ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 PAD ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 PAD ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.75, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.68, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 PAD ‐ LCn3 ‐ SA compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 SA compliance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.58, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 SA study size 100+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.76, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Acute coronary syndrome ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.71, 2.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.71, 2.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Body weight, kg ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.69, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Weight, kg ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.19, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Weight, kg ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.94, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [‐1.08, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Weight, kg ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐0.52, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.67, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Weight, kg ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐1.14, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐2.58, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.28, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Weight, kg ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐4.30, ‐0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.34, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.3 [‐3.83, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐4.75, ‐0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐1.11, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.23, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Weight, kg ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.69, 0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.5 [0.25, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.82, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐6.47, 5.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Weight, kg ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.54 [‐2.21, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>676</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [‐0.30, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.53, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Weight, kg ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Primary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.87, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐1.24, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Weight, kg ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.42, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [‐0.66, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.51 [‐3.30, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Body mass index, kg/m² ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.14, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 BMI, kg/m² ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.14, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 BMI, kg/m²‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.36, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.12, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 BMI, kg/m²‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1848</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.21, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.12, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 BMI, kg/m² ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14789</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.11, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.07, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 BMI, kg/m² ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.14, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.12, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [‐0.46, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.14, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [‐0.30, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [‐1.17, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 BMI, kg/m² ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.14, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [‐0.10, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14169</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.22, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [‐0.43, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 BMI, kg/m² ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.40, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.06, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12536</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.20, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 BMI, kg/m² ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Primary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.36, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 Secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.07, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 BMI, kg/m² ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.17, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.15, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>678</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.86, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Other measures of adiposity ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Percentage body fat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [‐6.87, 8.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Percentage visceral fat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐15.03, 11.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 Waist circumference, cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [‐0.17, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.4 Waist‐hip ratio</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.01, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.5 Abdominal circumference, cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐8.78, 7.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.6 Hip circumference, cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐9.80, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Total cholesterol, serum, mmoL/L ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.05, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 TC, mmoL/L ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 TC, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15878</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22591</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.08, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 TC, mmoL/L ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3341</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.05, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 TC, mmoL/L ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.01, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.22, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.28, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 TC, mmoL/L ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.01, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.34, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.03, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.07, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.14, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 TC, mmoL/L ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.01, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.09, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.07, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.10, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 TC, mmoL/L ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.16, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.04, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.08, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 TC, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.08, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 TC, mmoL/L ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.06, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.27, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Triglycerides, fasting, serum, mmoL/L ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.31, ‐0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 TG, fasting, mmoL/L ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.26, ‐0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.28, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.35, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 TG, fasting, mmoL/L ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.36, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐0.32, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34388</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.25, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.53, ‐0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.68, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.59, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14634</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.25, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>715</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐0.50, ‐0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.5 [‐1.49, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.51, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>615</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.58, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.36, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.15, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.38, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.28, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1880</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.36, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.31, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.32, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.26, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.44, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 TG, fasting, mmoL/L ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.21, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2414</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.36, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.38, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 High‐density lipoprotein, serum, mmoL/L ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 HDL, mmoL/L ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46604</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 HDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30764</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 HDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.01, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 HDL, mmoL/L ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36920</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9625</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.16, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 HDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.10, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.17, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27924</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.14, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 HDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.10, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 HDL, mmoL/L ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1562</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.01, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 HDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 HDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.00, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.07, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Low‐density lipoprotein, serum, mmoL/L ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">68 LDL, mmoL/L ‐ LCn3 ‐ SA fixed effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">69 LDL, mmoL/L ‐ LCn3 ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.1 Low summary risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14840</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.03, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>69.2 Moderate or high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">70 LDL, mmoL/L ‐ LCn3 ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>70.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">71 LDL, mmoL/L ‐ LCn3 ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.1 LCn3 ≤ 150 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.2 LCn3 &gt; 150 ≤ 250 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.3 LCn3 &gt; 250 ≤ 400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.4 LCn3 &gt; 400 ≤ 2400 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.5 LCn3 &gt; 2.4 ≤ 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.08, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>71.6 LCn3 &gt; 4.4 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [‐0.09, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">72 LDL, mmoL/L ‐ LCn3 ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.14, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.26, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.4 N‐3 replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>258</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.51, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27790</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>72.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.04, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">73 LDL, mmoL/L ‐ LCn3 ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.22, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.10, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>73.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.44, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">74 LDL, mmoL/L ‐ LCn3 ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.03, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>74.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39568</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.04, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">75 LDL, mmoL/L ‐ LCn3 ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.01, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.04, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>75.3 Mixed primary &amp; secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">76 LDL, mmoL/L ‐ LCn3 ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.1 LCn3 ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.02, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.2 LCn3 ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>76.3 LCn3 ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.17, 0.14]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (tertiary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood pressure, mmHg ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systolic BP ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.31, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Diastolic BP ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35626</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.22, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Any serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.94, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.91, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Serious GI events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>774</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.64, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Pulmonary embolus or DVT ‐ LCn3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3546</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.44, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Progression to advanced AMD (age‐related macular degeneration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.90, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Side effects ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropouts due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.99, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Abdominal pain or discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41056</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.91, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.87, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.96, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Any gastrointestinal side effect ‐ LCn3 fats</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89668</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.97, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Skin problems (itching, rashes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36721</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.52, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Headache or worsening migraine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.51, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Reflux</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8916</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.79, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Pain (joint, lumbar, muscle pain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27359</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.74, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 All side effects combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.95, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Dropouts ‐ LCn3 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56089</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">High vs low LCn3 omega‐3 fats (tertiary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High vs low ALA omega‐3 fat (primary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All‐cause mortality (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 All‐cause mortality ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.85, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause mortality ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.72, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.71, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.68, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.77, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.80, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.48, 3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 ALA replacing CHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 ALA replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [0.29, 26.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All cause mortality ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.82, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.70, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.71, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.68, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All‐cause mortality ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Primary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.75, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Secondary CVD prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause mortality ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.81, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.75, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Cardiovascular mortality (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 CVD mortality ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 CVD mortality ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 CVD mortality ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 CVD mortality ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.62, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 CVD mortality ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.69, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.60, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.11, 64.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 CVD mortality ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 CVD mortality ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 CVD mortality ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 CVD mortality ‐ ALA ‐ subgroup by statin uses <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.74, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.60, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Cardiovascular events (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 CVD events ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 CVD events ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.84, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 CVD events ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 CVD events ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.82, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 CVD events ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.24, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.36, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 CVD events ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.85, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 CVD events ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.86, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.79, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 CVD events ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.46, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 CVD events ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.83, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.80, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.46, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Coronary heart disease mortality (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 CHD mortality ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 CHD mortality ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 CHD mortality ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 CHD mortality ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 CHD mortality ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 Coronary heart mortality‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.4 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.5 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.6 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.7 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.11, 64.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 CHD mortality ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 CHD mortality ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 CHD mortality ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 CHD mortality ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.58, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 CHD mortality ‐ ALA ‐ subgroup by CAD history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.72, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.66, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 No previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.61, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Coronary heart disease events (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 CHD events ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 CHD events ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.86, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 CHD events ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 CHD events ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 CHD events ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.85, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.08, 5.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 CHD events ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5655</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.72, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.85, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 CHD events ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.34, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5545</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>49.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 CHD events ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.86, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 CHD events ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.86, 1.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 CHD events ‐ ALA ‐ subgroup by CAD history <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19061</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.82, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 Previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 No previous CAD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.84, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 Stroke (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 Stroke ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.71, 2.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 Stroke ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.45, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.62, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 Stroke ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.39, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 Stroke ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.39, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2 ALA high ≥ 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14490</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.65, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 Stroke ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.1 N‐3 replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.2 N‐3 replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.39, 2.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.3 N‐3 replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.53, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.4 N‐3 replacing carbohydrates/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.5 N‐3 replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>58.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>818</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.31, 10.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 Stroke ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.46, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.3 Supplements (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.62, 3.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>59.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 Stroke ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.56 [0.70, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5811</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.39, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.3 Long duration: ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 Stroke ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.66, 2.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.57, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.47, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 Stroke ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.71, 2.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.56, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14380</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.57, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 Stroke ‐ ALA ‐ subgroup by stroke type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.65, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1 Ischaemic stroke ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.65, 3.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2 Haemorrhagic stroke ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 Arrythmia (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1 ALA ‐ new arrhythmias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.2 ALA ‐ recurrent arrhythmias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 Arrythmia ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 Arrhythmia ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 Arrythmia ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.63, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">High vs low ALA omega‐3 fat (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">High vs low ALA omega‐3 fat (secondary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MACCEs ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.32, 3.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Myocardial infarction (overall) ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>18353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.76, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total MI ‐ ALA ‐ subgroup by fatality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fatal MI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4947</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.62, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Non‐fatal MI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.15, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Angina ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13516</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.75, 2.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Revascularisation ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 CABG ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.01, 5.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Angioplasty ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Any revascularisation ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.07, 7.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Peripheral arterial disease ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Body weight, kg ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐4.17, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Weight, kg ‐ ALA ‐ sensitivity analysis (SA) fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.61, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Weight, kg ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐4.17, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight, kg ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐4.47, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐4.47, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Weight, kg ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐3.31, 1.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐7.61, ‐0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Weight, kg ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>526</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.23 [‐5.27, 2.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐5.89, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Weight, kg ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐5.89, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐10.57, 9.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐6.26, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Weight, kg ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐4.17, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Weight, kg ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐10.57, 9.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐5.89, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐6.26, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Weight, kg ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Low CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐4.47, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Moderate CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐10.57, 9.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 High CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Body mass index, kg/m² ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.53, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 BMI, kg/m² ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.06, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 BMI, kg/m² ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.04, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐2.86, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 BMI, kg/m² ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.53, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.53, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 BMI, kg/m² ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐2.24, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 BMI, kg/m² ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1581</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐1.53, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 BMI, kg/m² ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.3 [‐2.29, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐2.86, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 BMI, kg/m² ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐2.86, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.04, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 BMI, kg/m² ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.3 [‐2.29, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.5 [‐2.86, ‐0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 BMI, kg/m² ‐ ALA ‐ subgroup by primary or secondary preventionA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.12 [‐2.24, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Other measures of adiposity ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Visceral adipose tissue, cm²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>27.0 [‐21.28, 75.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 Subcutaneous adipose tissue, cm²</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 Waist circumference, cm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>629</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐3.10, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Total cholesterol, serum, mmoL/L ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.23, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 TC, mmoL/L ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.17, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 TC, mmoL/L ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.13, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.36, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 TC, mmoL/L ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.25, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2045</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.25, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 TC, mmoL/L ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.24, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.47, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 TC, mmoL/L ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.23, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 TC, mmoL/L ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1210</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.10, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.30, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>777</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.31, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 TC, mmoL/L ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.33, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.12, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 TC, mmoL/L ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.15, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.10, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.30, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 TC, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>870</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.30, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.14, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Triglycerides, fasting, serum, mmoL/L ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.11, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 TG, fasting, mmoL/L ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.11, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 TG, fasting, mmoL/L‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.13, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.18, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 TG, fasting, mmoL/L‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.13, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.16, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.09, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 TG, fasting, mmoL/L‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.33, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 TG, fasting, mmoL/L‐AL ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.17, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.16, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.39, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.15, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 TG, fasting, mmoL/L‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.15, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.17, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 TG, fasting, mmoL/L ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.17, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.26, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.20, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 TG, fasting, mmoL/L‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 Primary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>482</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.14, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 Secondary prevention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.22, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 High‐density lipoprotein, serum, mmoL/L ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.08, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">49 HDL, mmoL/L ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.05, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">50 HDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.06, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>50.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>340</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.14, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">51 HDL, mmoL/L ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.08, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>51.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1657</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.08, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">52 HDL, mmoL/L ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.08, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>52.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.12, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">53 HDL, mmoL/L ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1650</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.06, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>53.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.01, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">54 HDL, mmoL/L ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.11, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.17, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>54.6 Replacement unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.17, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">55 HDL, mmoL/L ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.13, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.05, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>55.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">56 HDL, mmoL/L ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.09, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.14, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>56.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.20, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">57 HDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.1 Low CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.21, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.2 Moderate CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.10, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>57.3 High CVD risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">58 Low‐density lipoprotein, serum, mmoL/L ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.15, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">59 LDL, mmoL/L ‐ ALA ‐ SA fixed‐effect <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.11, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">60 LDL, mmoL/L ‐ ALA ‐ SA by summary risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.1 Low risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.05, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>60.2 Moderate/high risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.22, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">61 LDL, mmoL/L ‐ ALA ‐ SA by compliance and study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.1 SA ‐ low risk of compliance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>61.2 SA ‐ 100+ randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2085</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.16, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">62 LDL, mmoL/L ‐ ALA ‐ subgroup by dose <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.1 ALA low &lt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.17, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>62.2 ALA high &gt; 5 g/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>405</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.28, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">63 LDL, mmoL/L ‐ ALA ‐ subgroup by intervention type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.1 Dietary advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.2 Supplemental foods</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2075</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.17, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.3 Supplement (capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>63.4 Any combination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.25, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">64 LDL, mmoL/L ‐ ALA ‐ subgroup by replacement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.1 ALA replacing SFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.2 ALA replacing MUFA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.07, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.3 ALA replacing n‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.08, 0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.4 ALA replacing carbs/sugars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>64.5 ALA replacing nil/low n‐3 placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.59, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">65 LDL, mmoL/L ‐ ALA ‐ subgroup by duration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.1 Medium duration 1 to &lt; 2 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>935</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.22, ‐0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.2 Medium‐long duration: 2 to &lt; 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.06, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>65.3 Long duration ≥ 4 years in study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">66 LDL, mmoL/L ‐ ALA ‐ subgroup by statin use <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.1 ALA ‐ ≥ 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.08, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.2 ALA ‐ &lt; 50% of control group on statins</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>268</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.09, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>66.3 ALA ‐ use of statins unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.16 [‐0.25, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">67 LDL, mmoL/L ‐ ALA ‐ subgroup by primary or secondary prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.1 Primary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.20, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>67.2 Secondary prevention of CVD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.08, 0.09]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">High vs low ALA omega‐3 fat (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003177-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">High vs low ALA omega‐3 fats (tertiary outcomes)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Blood pressure, mmHg ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systolic BP ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐4.48, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Diastolic BP ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1671</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.42 [‐4.40, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serious adverse events ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Any serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Serious GI effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Pulmonary embolus or DVT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Thrombophleibitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.72, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Urolithiasis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.47, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Side effects ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropouts due to side effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.66, 6.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Abdominal pain or discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [0.82, 17.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.29 [0.33, 118.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Any gastrointestinal side effect ‐ ALA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.06 [0.62, 6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Pain (joint, lumbar, muscle pain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 All side effects combined</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Dropouts ‐ ALA <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3663</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.92, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">High vs low ALA omega‐3 fats (tertiary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003177.pub5/references#CD003177-tbl-0017">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003177.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003177-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003177-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003177-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003177-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003177-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003177-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD003177-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003177-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003177-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD003177-note-0006">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003177-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003177-note-0026">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003177\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003177\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003177\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003177\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003177\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=sogqpCtr&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003177.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003177.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003177.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003177.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003177.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714118513"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003177.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714118519"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003177.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d66d3a8af937d',t:'MTc0MDcxNDExOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 